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Background: Acute kidney injury (AKI) is highly prevalent in hospital inpatient populations, leading to
significant mortality and morbidity, reduced quality of life and high short- and long-term health-care costs
for the NHS. New diagnostic tests may offer an earlier diagnosis or improved care, but evidence of benefit
to patients and of value to the NHS is required before national adoption.
Objectives: To evaluate the potential for AKI in vitro diagnostic tests to enhance the NHS care of patients
admitted to the intensive care unit (ICU) and identify an efficient supporting research strategy.
Data sources: We searched ClinicalTrials.gov, The Cochrane Library databases, Embase, Health Management
Information Consortium, International Clinical Trials Registry Platform, MEDLINE, metaRegister of Current
Controlled Trials, PubMed and Web of Science databases from their inception dates until September 2014
(review 1), November 2015 (review 2) and July 2015 (economic model). Details of databases used for each
review and coverage dates are listed in the main report.
Review methods: The AKI-Diagnostics project included horizon scanning, systematic reviewing,
meta-analysis of sensitivity and specificity, appraisal of analytical validity, care pathway analysis,
model-based lifetime economic evaluation from a UK NHS perspective and value of information
(VOI) analysis.
Results: The horizon-scanning search identified 152 potential tests and biomarkers. Three tests, Nephrocheck®
(Astute Medical, Inc., San Diego, CA, USA), NGAL and cystatin C, were subjected to detailed review. The
meta-analysis was limited by variable reporting standards, study quality and heterogeneity, but sensitivity was
between 0.54 and 0.92 and specificity was between 0.49 and 0.95 depending on the test. A bespoke critical
appraisal framework demonstrated that analytical validity was also poorly reported in many instances. In the
economic model the incremental cost-effectiveness ratios ranged from £11,476 to £19,324 per quality-adjusted
life-year (QALY), with a probability of cost-effectiveness between 48% and 54% when tests were compared
with current standard care.
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Limitations: The major limitation in the evidence on tests was the heterogeneity between studies in the
definitions of AKI and the timing of testing.
Conclusions: Diagnostic tests for AKI in the ICU offer the potential to improve patient care and add
value to the NHS, but cost-effectiveness remains highly uncertain. Further research should focus on the
mechanisms by which a new test might change current care processes in the ICU and the subsequent cost
and QALY implications. The VOI analysis suggested that further observational research to better define the
prevalence of AKI developing in the ICU would be worthwhile. A formal randomised controlled trial of
biomarker use linked to a standardised AKI care pathway is necessary to provide definitive evidence on
whether or not adoption of tests by the NHS would be of value.
Study registration: The systematic review within this study is registered as PROSPERO CRD42014013919.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Acute kidney injury (AKI) occurs in many critically ill patients and leads to poor clinical outcomes andhigh mortality rates, resulting in high costs to the NHS. For these reasons it is important to identify
patients who are at risk or who are developing AKI so that they can be treated earlier or more intensively
to limit subsequent problems as much as possible. The diagnosis of AKI can be difficult; even with the best
test that we currently have (serum creatinine) AKI may not become apparent until several days after
damage to the kidneys has begun. There is currently no single test that can immediately diagnose AKI or
tell us how severe it will become; however, there are several tests in development that offer this potential.
The AKI-Diagnostics project identified > 150 in-development tests. Three of these tests were subjected
to detailed review. Although the quality of much of the published literature did not meet ideal standards,
there was evidence that these tests can help with the early identification of AKI in the intensive care unit
(ICU). All three tests have the potential to be cost-effective, although there is much uncertainty about this
based on the current evidence. It is recommended that further research is carried out to better understand
how common AKI is in the ICU and how a positive test result will change the way that patients are treated.
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Scientific summary
Background
Acute kidney injury (AKI) is highly prevalent in hospital inpatient populations, leading to significant mortality
and morbidity, reduced quality of life and high short- and long-term health-care costs for the NHS. Diagnosis
currently relies on serum creatinine concentrations and anuria, which are imperfect biomarkers, leading to
delayed detection after initial kidney damage. New biomarker-based in vitro diagnostics (IVDs) offer an
opportunity for earlier diagnosis and improved risk stratification, enabling earlier specialist referral, targeted
intervention or intensification of therapy when indicated by the test.
Candidate diagnostic tests have been commercially developed and are being marketed to clinicians and
commissioners. Their evidence base is variable and there is an urgent need to develop evidence for clinical
utility and cost-effectiveness to guide appropriate and suitably informed adoption within routine health
services.
The development of evidence for diagnostic tests has historically been inefficient, resulting in uncertain or
poor-value adoption decisions. There is a time-limited opportunity to propose an efficient research strategy
for AKI diagnostics in the UK.
Aims
l To evaluate the potential for AKI IVD tests to enhance the NHS care of patients admitted to the
intensive care unit (ICU)
l To identify the priorities for further research and development.
Design
The AKI-Diagnostics project included a systematic review, evidence synthesis and meta-analysis, care pathway
analysis, model-based economic evaluation and value of information (VOI) analysis.
Methodological scope and outputs
l Pre-analytical, analytical and biological measurement properties.
l Clinical validity (sensitivity and specificity) for relevant outcomes identified within the care pathway.
l Clinical efficacy, clinical effectiveness and cost-effectiveness of test-directed care compared with
standard care.
l Value of information analysis for research prioritisation.
Methods
The systematic review consisted of three literature searches, prospectively registered on the PROSPERO
database (reference number CRD42014013919):
1. A horizon-scanning search of literature published after 2004 to identify current and future biomarkers
and diagnostic tests for potential use in the identification and management of AKI in critical care.
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A ranking procedure was developed to prioritise tests for further review based on the state of
regulatory approvals, number of citations, combined sample size, biological mechanism and
expert advice.
2. A more detailed systematic review was then undertaken of the analytical and clinical validity, clinical
utility and cost-effectiveness of the highest-priority biomarkers. Two independent reviewers undertook a
search of 12 databases and two trials registers in November 2015 using predefined eligibility criteria,
with quality assessment carried out using the QUADAS-2 (quality assessment of diagnostic accuracy
studies) tool.
3. A third literature review consisted of a series of targeted searches aimed at identifying previous relevant
cost-effectiveness analyses and related research to inform the development of an economic model.
The meta-analysis of diagnostic accuracy used a bivariate model to estimate joint pooled means and
variances of sensitivity and specificity for each of the diagnostic tests considered for the outcome measure
of AKI KDIGO (Kidney Disease: Improving Global Outcomes). Separate meta-analyses were conducted for
each diagnostic test, sample media and the two health service settings of ICU and post-cardiac surgery.
Approximate estimates of the variance of sensitivity and specificity for use in the economic model were
estimated using the delta method.
In the absence of a published tool, a framework for the quality assessment of measurement was
developed through a process of expert consensus and review of the published literature. This was applied
to a single test as proof of concept.
The economic evaluation relied on a de novo decision model constructed to determine the cost-effectiveness
of the biomarkers for the early identification of AKI in the ICU from a NHS and Personal Social Services
perspective. Tests were assumed to be used once on entry to the ICU. The primary analysis concerned the
use of tests on an all-comer ICU population; a secondary analysis was conducted to explore the impact of
the tests in a subgroup of patients in the ICU post cardiac surgery. Costs were reported in 2015 prices and
effectiveness was measured in terms of quality-adjusted life-years (QALYs). All future cost and QALY
outcomes were discounted at an annual rate of 3.5%.
Model parameters were estimated using individual patient clinical trial and registry data, supplemented when
necessary with information from the published literature, which was identified through a series of targeted
systematic literature reviews. Uncertainty around parameter estimates was characterised by assigning
probability distributions to each of the uncertain parameters according to available variance data. Probabilistic
sensitivity analysis was then conducted using 10,000 Monte Carlo simulations. Cost-effectiveness was
assessed in terms of the incremental net (health) benefit (INB) and the incremental cost-effectiveness ratio
(ICER). The cost-effectiveness threshold was taken as £20,000 per QALY unless otherwise stated.
The VOI analysis used the measures expected value of perfect information (EVPI) and expected value
of perfect parameter information (EVPPI), calculated using non-parametric regression meta-modelling
techniques including a generalised additive model and multivariate adaptive regression splines. Individual
patient- and population-level estimates were calculated. The EVPPI was used to rank groups of model
parameters as priorities for further research.
Results
Horizon-scanning search
The scoping search identified 4804 references. After screening by title/abstract, 487 potentially relevant
papers remained, relating to 152 individual biomarkers. Those already used in standard care (n = 11,
including serum creatinine) or with incomplete data related to the dimensions outlined earlier (n = 19)
were excluded. Ten priority biomarkers/tests were shortlisted: brain natriuretic peptide (BNP), cystatin C,
interleukin (IL)-6, IL-18, kidney injury molecule-1 (KIM-1), liver fatty acid-binding protein (L-FABP),
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N-acetyl-beta-D-glucosaminidase (NAG), Nephrocheck® (Astute Medical, Inc., San Diego, CA, USA),
neutrophil gelatinase-associated lipocalin (NGAL) and tumour necrosis factor alpha (TNF-α).
Systematic review and meta-analysis
Detailed review was undertaken for the top three ranked diagnostic tests: Nephrocheck (urine), which
measures a combination of two proteins, tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like
growth factor-binding protein 7 (IGFBP-7); NGAL protein; and cystatin C protein. The different media of
blood serum, blood plasma and urine were considered separately.
Nephrocheck
Ten studies were included in the review and three were included in the meta-analysis in the critical care
setting using urine. The median age of participants in the studies was 64 years and 58% of participants
were male. Using the high sensitivity cut-off value (0.3), pooled sensitivity was estimated as 0.90 [95%
confidence interval (CI) 0.85 to 0.93] and pooled specificity was estimated as 0.49 (95% CI 0.46 to 0.53).
No clinical efficacy, clinical utility or cost-effectiveness studies were identified. One study was included in
the cardiac surgery setting using serum, with a sensitivity of 0.92 (95% CI 0.76 to 0.98) and specificity of
0.67 (95% CI 0.47 to 0.82).
Neutrophil gelatinase-associated lipocalin
Thirty-nine studies were included in the review. There was heterogeneity in the outcome definitions,
assessment period and threshold used to define a positive test. Eight studies were included in the
meta-analysis in the critical care setting using plasma. For plasma, the pooled sensitivity estimate was 0.72
(95% CI 0.65 to 0.79) and the pooled specificity estimate was 0.81 (95% CI 0.75 to 0.86). For serum, one
study was included, with a sensitivity of 0.54 (95% CI 0.43 to 0.65) and a specificity of 0.95 (95% CI 0.88
to 0.98). For urine, six studies were included, with a pooled sensitivity of 0.70 (0.59 to 0.80) and a pooled
specificity of 0.79 (95% CI 0.71 to 0.86). In the cardiac surgery setting eight studies were included for
plasma, with a pooled sensitivity of 0.62 (95% CI 0.49 to 0.74) and a pooled specificity of 0.78 (95% CI
0.75 to 0.81). For serum in the cardiac surgery setting, two studies were included, with a pooled sensitivity
of 0.84 (95% CI 0.43 to 0.97) and a pooled specificity of 0.87 (95% CI 0.59 to 0.97). For urine in the
cardiac surgery setting, 13 studies were included, with a pooled sensitivity of 0.66 (95% CI 0.54 to 0.76)
and a pooled specificity of 0.62 (95% CI 0.41 to 0.79).
Cystatin C
Seventeen studies were included in the review. There was heterogeneity in the outcome definitions,
assessment period and threshold used to define a positive test. In the meta-analysis, in the critical care
setting, for plasma, three studies were included, with a pooled sensitivity of 0.72 (95% CI 0.59 to 0.82)
and a pooled specificity of 0.74 (95% CI 0.65 to 0.81); for serum, four studies were included, with a
pooled sensitivity of 0.76 (95% CI 0.57 to 0.88) and a pooled specificity of 0.91 (95% CI 0.85 to 0.95);
and, for urine, three studies were included, with a pooled sensitivity of 0.68 (95% CI 0.43 to 0.86) and a
pooled specificity of 0.76 (95% CI 0.62 to 0.86). In the cardiac surgery setting there were no suitable
studies for plasma; for serum, two studies were included, with a pooled sensitivity of 0.73 (95% CI 0.65 to
0.80) and a pooled specificity of 0.72 (95% CI 0.63 to 0.79); and, for urine, two studies were included,
with a pooled sensitivity of 0.52 (95% CI 0.27 to 0.76) and a pooled specificity of 0.72 (95% CI 0.36 to
0.92). Estimates of 95% prediction intervals for each test, medium and setting further demonstrated the
heterogeneity in the studies considered.
Quality assessment of measurement
The defining features of ‘quality’ with respect to measurement procedures were agreed as ‘bias’,
‘reproducibility’ and ‘applicability’. Parameters associated with biological within-individual variation,
biological pre-analytical factors, technical pre-analytical variation factors and analytical factors were
included within the quality assessment framework.
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Application of this framework within four Nephrocheck case studies identified several measurement
parameters that present a high risk of irreproducibility, including a failure to exclude samples with known
interferents; a lack of internal and external quality control; and a complete lack of analytical measurement
verification in all studies. It also highlighted several issues that might affect the clinical applicability of
test results, including freeze–thawing of samples in the absence of validation data and against the
recommendations of the manufacturer, potentially biasing clinical cut-off points and overestimating
precision; use of a device in an unvalidated patient population (i.e. aged < 18 years); and reporting the
median value of three measurements from different laboratories. Furthermore, it identified several issues
that made assessment of the risk of bias uncertain.
Economic evaluation
The economic evaluation assessed seven testing strategies: Nephrocheck, cystatin C in urine, plasma and
serum and NGAL in urine, plasma and serum. Based on the mean expected cost and QALY results, lifetime
incremental QALYs ranged from 0.012 (cystatin C, urine) to 0.016 (Nephrocheck) and additional costs
ranged from £149 (cystatin C, urine) to £301 (Nephrocheck). The ICERs ranged from £11,476 to £13,504
per additional QALY for the cystatin C tests and from £13,372 to £13,828 for the NGAL tests and the ICER
was £19,324 for Nephrocheck. For the incremental costs, all of the testing strategies had 95% CIs ranging
from –£1000 to +£1400; for the incremental QALYs, all results ranged from –0.16 to +0.19 or +0.20. The
overall probability that tests are cost-effective compared with standard care was 48% for Nephrocheck,
51–52% for the NGAL tests and 52–54% for the cystatin C tests (with cystatin C in serum performing the
best). Raising the threshold value to £50,000 per QALY only slightly increased these probabilities.
The results of the multiway incremental comparison indicated that, in the base-case analysis, between a
threshold of £11,400 and a threshold of £25,400, cystatin C (serum) has the highest probability of
cost-effectiveness compared with all other tests. Above a £25,400 threshold, NGAL (serum) is expected
to be the most cost-effective strategy. All other strategies are either dominated by cystatin C (serum) or,
in the case of Nephrocheck, have an ICER well above £20,000 per QALY.
Similar results were observed in the post-cardiac surgery subgroup analysis. The incremental QALYs ranged
from 0.007 (cystatin C, urine) to 0.012 (NGA,L serum) and additional costs ranged from £124 (cystatin C,
urine) to £205 (Nephrocheck). The ICERs were £13,051–19,287 per additional QALY for the cystatin C tests,
£15,337–20,435 for the NGAL tests and £18,617 for Nephrocheck, with INB values ranging from 0.000 to
0.004 QALYs. Again, there was substantial uncertainty around these results, with a 48–52% probability that
the tests would be cost-effective. In the multiway incremental analysis, only NGAL (serum) remained after
removal of dominated or extendedly dominated alternatives (ICER £13,051 vs. standard care).
The model results were highly sensitive to changes in key model parameters. Scenarios that led to tests
becoming non-cost-effective included shortening the time horizon of the analysis, reducing the incidence
of AKI in the ICU, decreasing the impact or increasing the cost of early AKI intervention, applying a
mortality risk for patients with false-positive test results, applying a cost saving for patients with negative
test results and increasing the mortality rate for false-negative cases and increasing the cost of Nephrocheck.
Value of information analysis
The EVPI was positive for all analyses of the three tests that were studied in detail, suggesting that the
current burden of uncertainty is high and that further research into all tests and all settings may be
worthwhile. Diagnostic accuracy parameters were not associated with a high EVPPI. The results of the
EVPPI analysis suggested that the highest priority areas for further research include obtaining better
intelligence on the current incidence of AKI in the ICU; the impact of interventions or changes in care and
associated costs in response to test results; and further research on the quality of life experienced by
survivors of ICU. Some of this information (e.g. the incidence and progression of AKI) may be obtainable
from growing national audits. Determining the comparative impact of patient management changes
resulting from different test results, however, is likely to require randomised comparisons.
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Conclusions
It is clear that very large numbers of potential biomarkers and diagnostic tests have the potential to
contribute to better care for patients at risk of AKI in the critical care setting. The two-stage approach
taken in this study – first, horizon scanning and then prioritising biomarkers for in-depth review – proved
to be a feasible and effective strategy for dealing with the volume of literature identified, which far
exceeded that identified in initial scoping searches. Despite a large volume of literature covering the
prioritised tests, the quality of reporting was low, leading to a significant dropout rate between review and
meta-analysis. Further efforts to promote the use of reporting standards for diagnostic tests should be
undertaken.
The Nephrocheck test appeared to be the best-performing test of the three tests subjected to detailed
study. It has high sensitivity and moderate specificity for AKI in adult critical care settings and there was
low heterogeneity between studies in the meta-analysis. The NGAL test using plasma has moderate
sensitivity and high specificity, but showed greater heterogeneity between studies. Other sample types and
the cystatin C test showed evidence of considerable heterogeneity between studies.
As far as we are aware, our study is the first such initiative to attempt a systematic assessment of the
quality of measurement procedures used in clinical studies or trials. Our framework proved feasible and
provides a foundation for further work in this area. A key finding was that the reporting of critical
measurement parameters was very poor in the identified studies and this severely hindered the reviewers’
ability to assess the quality of the studies. The major limitation of the meta-analysis was a lack of
standardisation in the reference standard definition of AKI as an outcome.
Each of the three tests included in the economic evaluation was found to be cost-effective when
compared in two-way analyses against standard care, although the absolute difference in both costs
and QALYs is likely to be small. There is substantial uncertainty around these results, with the probability
of cost-effectiveness being close to 50% for all tests. The VOI analysis highlighted some of the key
parameters that should be the focus of further research in this area. It is apparent that observational
studies that aim to better define the current clinical care pathway for patients at risk of AKI in critical
care should be a priority, as should further work to understand how the care pathway might change in
response to a positive test and the effectiveness of these changes in mitigating against the development
of AKI. Such studies would likely be cheap to perform compared with formal randomised controlled trials
that seek to directly measure the clinical benefit and observed cost-effectiveness of tests and that may not
currently represent good value for research funders. It is also of note that further studies of diagnostic
accuracy for the three tests would be unlikely to change the current estimates of cost-effectiveness.
Study registration
This study is registered as PROSPERO CRD42014013919.
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background and introduction
Introduction
Acute kidney injury (AKI) has been identified as an area of unmet need affecting a sizeable population,
with a health burden that has the potential for significant improvement. A large number of diagnostic tests
and biomarkers feature in the published literature dating back many years but, as yet, they have failed to
translate into clinical practice or meaningfully benefit patients. The AKI Diagnostics project was initiated as
a direct response to this problem following initial attempts to quantify the evidence base for diagnostic
tests in the specific setting of critical care. Its high-level objective was to map out a strategy for further
research and development that will efficiently deliver patient benefits using this technological opportunity.
The clinical problem
The relevance of AKI (also referred to as acute kidney failure) as a major problem for public health has
been recently emphasised in guidance issued by the National Institute for Health and Care Excellence
(NICE).1 NICE estimates that AKI costs the UK NHS £434–620M every year (which is more than the cost of
breast, lung and skin cancer combined2). Moreover, according to NICE, adequate care of AKI could result
in 42,000 deaths being avoided every year.
Acute kidney injury occurs in 30–70% of critically ill patients and is most commonly associated with
multiorgan failure secondary to hypotension and sepsis. Patients who develop AKI have worse clinical
outcomes, with a mortality rate of > 50%, which, despite advances in modern medicine, has remained
unchanged for the last 30 years. Patients who develop severe AKI requiring renal replacement therapy
(RRT) have a further increase in their risk of death.3
The recognition of AKI currently relies on a rise in serum creatinine and/or a decrease in urine output,
both of which are considered relatively poor biomarkers. Serum creatinine remains a non-specific marker
of AKI, being a product of muscle metabolism, and does not indicate the site of the injury or distinguish
between pre-renal (functional process) and intrinsic (damage process) AKI. The generation of creatinine
is dependent on muscle mass and it is therefore a very poor marker of kidney function, particularly in
malnourished patients or patients with liver disease. It is recognised that a person could lose 50% of
their kidney function before the serum creatinine level rises above the normal range. The rise in serum
creatinine is delayed in relation to the onset of the injury and the magnitude of rise does not correlate
with the severity of injury. Likewise, serum creatinine levels do not correlate well with recovery of kidney
function. More specific serum and urinary biomarkers of AKI are urgently needed.4
The need for research
More recently it has been recognised that chronic kidney disease (CKD) occurs in 40% of survivors of AKI in
critical illness and results in significant morbidity and expense. It is estimated that up to 10% of patients will
not recover sufficient kidney function and will remain on RRT.5 CKD in the UK costs £1.45B per year.6 It is
therefore important to identify patients at risk or who are developing AKI to reduce the impact, ameliorate
the severity of the injury and thereby reduce its short- and long-term consequences. It was reported that, in
2009–10, patients who experienced an episode of AKI in the UK stayed in hospital an average of 4.7 days
longer than patients without AKI.2 AKI represents an important patient safety issue, as recognised by NHS
England,7 and results in a significant financial burden on health-care services. There is a great potential to
prevent AKI and reduce its severity and, therefore, the medical and financial burden to the NHS.
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The development of better biomarkers to detect AKI would also benefit patients at risk outside of the
intensive care unit (ICU) setting. Not all hospitals in the UK have renal units and the facility to deliver RRT;
in these hospitals patients who develop severe AKI requiring RRT may have to be transferred to the ICU
for RRT alone, which inappropriately utilises a precious NHS resource. Earlier detection of AKI with the
potential to stratify prognosis would allow for prompt transfer of patients to the correct environment for
their care.
Biomarker-based in vitro diagnostics (IVDs) offer an opportunity for early diagnosis, risk stratification and
monitoring, enabling earlier specialist referral, targeted intervention or intensification of therapy when
indicated by the test. There is some evidence that early RRT can improve outcomes from AKI, including
reducing the duration of RRT, the length of the hospital stay and the rates of CKD and long-term RRT.8
A number of pharmaceutical interventions are in late-phase development, which will increase the
opportunity for targeted intervention in the coming years. Previous therapeutic interventions have been
unsuccessful, in part because of the very crude approach to AKI and the failure to understand its
complexity without the use of appropriate biomarkers.
The management of the majority of cases of AKI in the ICU remains supportive, with no proven
pharmacological intervention for AKI secondary to hypoperfusion and sepsis. Currently, there is no robust
evidence base to guide when to initiate RRT and this is determined empirically, dependent on the clinical
context and utilising serum creatinine as a marker of severity of AKI. There is an ongoing research effort
internationally to discover and develop biomarkers and diagnostics for AKI. The extent to which such tests
can influence the clinical decisions and change the current management of patients admitted to critical
care remains unknown. There is an urgent need to evaluate the extent to which AKI diagnostics have
the potential to influence outcomes through a change in clinical practice. If a model-based analysis
demonstrates that AKI diagnostics can potentially change practice in a way that results in more
cost-effective care, there will be value in further investment in a development programme.
The sizeable waste within the historical research process has recently been highlighted.4,9–14 Academic
and commercial communities are at the start of a new era of diagnostics development for AKI. There is a
time-limited opportunity to design this UK research programme efficiently and with appropriate upfront
prioritisation.
Existing research
A number of different biomarkers have been investigated in small heterogeneous studies in critically ill
patients with AKI, including neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL)-18, kidney
injury molecule-1 (KIM-1), liver fatty acid-binding protein (L-FABP) and, more recently, the cell cycle arrest
markers insulin-like growth factor-binding protein 7 (IGFBP-7) and tissue inhibitor of metalloproteinases 2
(TIMP-2).4 More data are required from well-conducted trials to identify both improved patient outcomes
and economic benefit to the NHS before their routine use can be recommended. It is unlikely that one
biomarker will fit all because of the heterogeneity of causes of AKI and, therefore, a panel of biomarkers
will be required. A number of biomarkers have already been commercialised as IVD test kits and are
subject to active marketing campaigns, including IGFBP-7 and TIMP-2 (Nephrocheck®, Astute Medical,
San Diego, CA, USA); the NGAL test (BioPorto, Hellerup, Denmark/Alpha Laboratories, Eastleigh, UK); urine
NGAL (Abbott Laboratories, Chicago, IL, USA); and the Triage® NGAL Test (Alere, Waltham, MA, USA).
There is therefore a real risk that these biomarkers could be adopted by NHS laboratories and clinicians
prior to the development of robust supporting evidence for clinical effectiveness and cost-effectiveness.
In 2013 a diagnostic test based on the NGAL biomarker was considered by the NICE Diagnostics Advisory
Committee (DAC). It concluded that more research was needed prior to adopting the test but that this was
undoubtedly an area of considerable clinical need.
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Adoption of diagnostic tests in the NHS
Diagnostic tests are the foundation of the new era of personalised medicine and, as such, are critical for
future effective health care. The pipeline of research and development that brings new diagnostic tests
to help patients within the NHS has been criticised for failing to deliver good-quality evidence-based
technologies in a timely manner. It has been highlighted that progress in personalised medicine is slower
than some had expected.15 The reasons for this are likely multifactorial but may include inadequate science
or insufficient economic incentives for investing in molecular diagnostics. What has recently become clear
is that the methods employed in the development of evidence for new diagnostic technologies are
inadequate for the task or are not used appropriately. Work is needed to develop new ways of rapidly
bringing high-quality diagnostics to the front-line care of NHS patients.
The decision to reimburse a new technology on the NHS should require evidence for quality control,
safety, effectiveness and cost-effectiveness; demonstration of these aspects represents the key hurdle in
the process of health technology adoption. In the UK, decision-making for diagnostics may occur at a
local or a national level. The gold standard process, however, is orchestrated by the NICE DAC and its
methodological advisors have identified many problems and a lack of standardisation in the requirements
for evidence on safety, efficacy, effectiveness and cost-effectiveness of diagnostic tests. This contrasts with
the relatively well-defined evidence requirements for pharmaceuticals, which are driven by high financial
stakes and a long history of safety scandals that have prompted a stepwise tightening of licensing and
regulatory requirements.
The National Institute for Health Research Diagnostic Evidence
Co-operatives
In response to these concerns, in 2013 the National Institute for Health Research (NIHR) in England
commissioned a network of infrastructure support organisations called the Diagnostic Evidence
Co-operatives (DECs). Their mission is to engage with commercial stakeholders, academic institutions
and the NHS to bring high-value and high-impact diagnostic tests to patients in an efficient manner.
The two key objectives of the DECs that the AKI-Diagnostics project addressed were (1) to devise and
refine methods in IVD study design, health economics and health informatics to improve and speed up the
way that IVDs can be evaluated for NHS use and (2) to invite, select and prioritise specific IVD candidates
across key clinical areas from partners and interested parties and help them develop and deliver
appropriate evidence.
Technical background for the methodological approach
The DECs aim to promote efficient research design for new technologies within the NHS. They acknowledge
that the gold standard for demonstrating clinical utility and cost-effectiveness (and accepted by NICE) is a
model-based economic evaluation, informed when possible by randomised controlled trials (RCTs). For any
given clinical context, modelling will therefore commence at the very start of technology evaluation, during
the process that selects and prioritises technologies for inclusion within the DEC research pipeline (Figure 1).
By introducing a model early, it is possible to characterise the potential impact of a diagnostic test on the
clinical pathway, clinical decision points and expected clinical end economic outcomes. The optimal case
definition threshold (cut-off point) for tests can be proposed for cost-effectiveness in addition to clinical
validity alone. Models will be maintained and updated as IVD evaluation progresses, populated by
meta-analysis of evidence generated both within and external to the DEC. Probabilistic modelling will be
used to characterise areas of uncertainty in the evolving evidence between each phase of development,
thus enabling iterative research design efficiency. Expected cost-effectiveness and value for the NHS can be
established as well as commercial headroom for relevant manufacturers. It is possible to model the cost of a
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test under different commercialisation scenarios (e.g. large centralised laboratory vs. local hospital laboratory
provision) and its impact on the value of alternative research activities can therefore be estimated. As an
example, the trade-offs between investment in a large RCT and investment in alternative cheaper or quicker
study designs can be described using the modelling process, including through the use of Bayesian decision
modelling and value of information (VOI) analysis.
Project objectives
Based on the DEC methodological approach, the objectives of the AKI-Diagnostics project, focusing on
critical care, were to:
l describe the care pathway followed by patients who are admitted to critical care and who are at risk of
AKI, represented as a decision-analytic model
l identify, through systematic review, candidate diagnostic tests for the early detection, risk stratification
or therapy personalisation of AKI
l systematically review and meta-analyse the evidence on the diagnostic properties, clinical validity and
clinical utility of identified AKI diagnostic tests for AKI
l identify decision points in the care pathway that might be influenced by the diagnostic tests
l evaluate the potential clinical effectiveness and cost-effectiveness of the diagnostic tests, given their
potential to change the care pathway
l characterise uncertainties in the evidence, prioritise tests for development and identify efficient
research designs.
Patient
benefit
IVD developers
• Industry
• Academia
• NHS
Stakeholders
Stage 1:
selection,
modelling and
prioritisation
Stage 2:
qualify
analytical
validity
Stage 3:
qualify 
clinical
validity
Stage 4:
model/
evaluate
clinical utility
Methodological expertise and resources
Pathway and economic modelling, evidence synthesis,
clinical informatics
Stage 5:
disseminate
outputs
• Patient and public
• Commissioners
• NHS/NIHR
• Clinical networks
• Trade associations
Economic
value
* * * *
Clinical expertise and resources
Research sites, biobank samples and data,
databases, registries
FIGURE 1 The NIHR DEC research and development pipeline. *, strategic decision-making points.
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Outline of the project components
To deliver these objectives the AKI-Diagnostics project was structured into five distinct phases:
l phase 1: systematic review
l phase 2: evidence synthesis and meta-analysis
l phase 3: care pathway analysis
l phase 4: decision-analytic model
l phase 5: sensitivity analysis and VOI analysis.
Phase 1: systematic review
Phase 1 consisted of three distinct systematic literature searches and reviews. Review 1 was broad and
inclusive, analogous to a horizon scan, and sought to identify candidate or in-development relevant diagnostic
tests that could be used in critical care to identify AKI. Review 2 employed a focused search that identified
current evidence on the analytical validity, clinical validity, clinical utility and cost-effectiveness of the prioritised
tests identified in search 1. The purpose of review 3, which is reported in the health economics chapter
(see Chapter 5), was primarily to inform the design and parameterisation of the economic model for
assessing cost-effectiveness. Using a series of highly focused literature searches it aimed to identify
information describing the clinical care pathway and standard care for AKI in critical care, including
investigation, clinical management, interventions, health-care resource use, morbidity, mortality, quality of
life and other relevant outcomes descriptors.
Phase 2: evidence synthesis and meta-analysis
Phase 2 aimed to combine the findings from phase 1 and enable summary estimation of the relevant
metrics for the diagnostic properties of tests, predominantly sensitivity and specificity for relevant
outcomes.
Phase 3: care pathway analysis
Phase 3 was conducted in parallel to literature search 3, using formal consultation with relevant experts
and patients with the primary aim of defining standard care for patients at risk of and experiencing AKI in
critical care. This was necessary as part of the economic model development process, including the
identification of key decision points at which tests change the process of care, mechanisms for changing
the process of care, relationships and downstream knock-on effects that may be influenced by tests and
key surrogate end points. In addition to expert consultation and information obtained from literature
search 3, recent UK clinical trial data sets and UK registration study data sets were identified and analysed
to inform the model structure and parameters.
Phase 4: decision-analytic model
Phase 4 consisted of the construction, parameterisation and analysis of a health economic decision model
based on the care pathway developed in phase 3. The model was initially designed to calculate expected
costs and quality-adjusted life-years (QALYs) for the current AKI care pathway. AKI diagnostic tests were
then incorporated into the model at key decision points, as indicated by the current evidence and
recommendations from the specialist advisory group. Divergence in the clinical pathway consequent on
test results was modelled based on the diagnostic properties and decision impact of the tests.
Phase 5: sensitivity analysis and value of information analysis
Phase 5 consisted of a series of sensitivity analyses undertaken to explore the impact of parameter and
structural uncertainties on the expected cost-effectiveness of each test. In addition, VOI analysis was
undertaken in an attempt to quantify the value of further publicly funded research into diagnostic tests.
VOI analysis is a method based on Bayesian decision theory that can be used to characterise the burden of
uncertainty on a NHS reimbursement decision-maker or commissioner.16,17 The results were presented to
guide a future research programme in this area, as needed prior to adoption of any new tests by the NHS.
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Patient and public engagement in the study
Both the study research team and the specialist advisory group contained patient representation and
through these two groups the patient perspective was taken into account in every aspect of the project.
As part of the development of the economic model structure, a focus group was held on 26 February
2015 with two clinicians (nephrologists) and two patient representatives with experience of chronic kidney
failure. The primary aim of this session was to understand the care pathway for patients diagnosed with
AKI in the ICU and the focus of the discussion was on developing a diagrammatic representation of the
patient pathway for someone experiencing AKI in the ICU. The findings from this session were used to
inform the development of the structure of the decision model. In addition to the focus group, the final
structure and parameter estimates used for the decision model were determined via iterative feedback
from the project advisory board, which included a patient representative.
BACKGROUND AND INTRODUCTION
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Chapter 2 Systematic review
Aim
The overall aim of this systematic review was to provide evidence to evaluate the potential for AKI
diagnostics to enhance the NHS care of patients admitted to critical care. The review involved three
searches designed to meet specific project objectives:
1. search 1: to identify candidate or in-development relevant diagnostic tests that could be used in critical
care to identify AKI (horizon scanning)
2. search 2: to identify current evidence on the clinical utility, analytical validity and cost-effectiveness of
diagnostic tests identified in search 1
3. search 3: to gather information to describe the clinical care pathway and standard care for AKI in critical
care, including investigation, clinical management, interventions, health-care resource use, morbidity,
mortality, quality of life and other relevant outcome descriptors (methods and findings reported in
Chapter 5).
Search 1: horizon scanning
Objective
The objective of this search was to identify candidate or in-development relevant diagnostic tests that
could be used in critical care to identify AKI.
Identification of studies
A broad strategy was employed to support a horizon-scanning search for tests and biomarkers that are,
or can be, used for AKI diagnosis but that are not currently used as standard practice in emergency and
critical care. Our search included ongoing studies in trials registers, conference proceedings and recently
published studies in PubMed to ensure that all emerging test and biomarker evidence was identified.
Inclusion of the major databases such as MEDLINE, EMBASE and Science Citation Index (via Web of
Science) enabled comprehensive identification of relevant literature and allowed assessment of the likely
weight of evidence (volume of research) for different tests should they be included in the next stage
(search 2, evidence on candidate tests). Searches were carried out in September 2014 in ClinicalTrials.gov
(US National Institutes of Health) (accessed 29 September 2014), Cochrane Central Register of Controlled
Trials (via Wiley Online Library) (Issue 9 of 12, September 2014), Cochrane Database of Systematic Reviews
(via Wiley Online Library) (Issue 9 of 12, September 2014), Conference Proceedings Citation Index –
Science (Thomson Reuters’ Web of Science) (1990 to September 2014), Database of Abstracts of Reviews
of Effect (via Wiley Online Library) (Issue 3 of 4, July 2014), EMBASE Classic and EMBASE (via Ovid)
(1947 to 25 September 2014), International Clinical Trials Registry Platform (World Health Organization)
[www.who.int/ictrp/en/ (accessed 29 September 2014)], MEDLINE (via Ovid) (1946 to September Week 3
2014), MEDLINE In-Process & Other Non-Indexed Citations (via Ovid) (25 September 2014), metaRegister
of Current Controlled Trials (mRCT) (accessed 29 September 2014), PubMed (US National Library of
Medicine) (1946 to September 2014) and Science Citation Index (Thomson Reuters Web of Science)
(1900 to September 2014).
The search terms included index terms, free-text words, abbreviations and synonyms. Terms for AKI and
specific biomarkers were identified from known relevant papers, database thesauri and suggestions from
clinical members of the team. Searches for diagnostic studies are known to often retrieve very large
numbers of citations. Although the use of diagnostic search filters is cautioned against – because of poor
reporting and indexing – for pragmatic reasons we included some diagnostic terms in these scoping
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searches. We combined our search concept for AKI with a ‘fluid’ search concept as only tests using fluid
samples (rather than tissue samples) could be considered for use in emergency and critical care. A variety
of terms, headings and subheadings were combined to identify ‘tests’. The concepts used were:
1. AKI or conditions that imply AKI (e.g. tubular necrosis)
2. diagnostic tests or biomarkers [generic ‘test’ terms; MeSH terms, e.g. Acute-Phase Proteins/du
(Diagnostic use); specific test terms, e.g. NGAL]
3. plasma, blood, urine and serum samples or specimens
4. evaluation of a test to predict or diagnose (e.g. sensitivity, accuracy, monitor, etc.).
The research team agreed that biomarkers developed and evidence gathered during the previous 10 years
would be most relevant for the scoping review. All sources were searched from 2004 onwards, except for Web
of Science, which was searched from 2008 onwards. The complete search strategies are available in Appendix 1.
Selection of studies
Studies were included if the participants were adults or children with new or existing AKI and (1) they were
based in critical care (or another clinical setting if using a candidate test for future use in clinical care),
(2) they evaluated a fluid biomarker not currently used as part of routine care for AKI, (3) they used the
biomarker for AKI diagnosis, risk stratification or prediction of treatment benefit and (4) they involved at
least 52 subjects. The participant criterion was based on the hypothesis that useful biomarkers in the
literature have been evaluated in underpowered studies. Thus, we made the following assumptions: in
order to be published, markers have a sensitivity and specificity of 0.6; to be inclusive in terms of power
(1 – β) and significance level (α), we assumed power to be 0.7 and the significance level to be 0.2; and
ideally a marker would be most useful if it had a sensitivity and specificity of 0.7 or 0.8 (although 0.8 is
unlikely). To identify the most relevant literature, we anticipated that the majority of early-stage clinical
validation studies would have equal numbers of cases and controls. In addition, to include studies with
some chance of identifying markers with a sensitivity/specificity of > 0.8, we selected papers that studied
at least 52 patients (26 per arm in trials) (Table 1).
Studies were excluded if the participants had CKD only, if they used a tissue biomarker or imaging
technology for AKI diagnosis, or if the biomarker was used only for monitoring events subsequent to an
AKI diagnosis (e.g. post discharge). Biomarker discovery and preclinical studies were also excluded, along
with those evaluating the stability and/or storage of biomarker samples. No restrictions on language or
study design were applied (Table 2).
Literature yield
Scoping searches conducted at the project proposal stage suggested a pool of around 2500 references;
however, the final search identified 6329 articles, which was reduced to 4804 following exclusion of
duplicates. Given this almost twofold increase in the volume of literature, and in a change to the protocol,
the decision was taken to appraise articles in a single stage (title and abstract screen) rather than in two
TABLE 1 Patients numbers for a range of sensitivities and specificities
Sensitivity and specificity Number (non-AKI) Number (AKI) Number (total)
0.65 467 467 934
0.70 113 113 226
0.75 48 48 96
0.80 26 26 52
0.85 15 15 30
0.90 10 10 20
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stages (title and abstract screen followed by full-text review). At the outset of the process, a training
session was held to facilitate standardisation in screening and selection and ensure that each reviewer was
aware of and understood the explicit inclusion and exclusion criteria. Abstracts were then screened for
relevance by individual reviewers (with independent double assessment of 25% of articles), with 487
relevant articles identified.
Identification of candidate biomarkers
Data from each of the 487 studies were extracted by one reviewer (EDM) and used to produce a longlist
of potential biomarkers. In total, 153 individual biomarkers (excluding serum creatinine) were identified.
Non-novel biomarkers, that is, those that were already used as part of standard care in the diagnosis of
kidney function, were excluded (n = 11), as were those for which the citation did not report complete
details of the population studied (n = 19). The remainder (see Appendix 2) were then tabulated on four
dimensions: volume of evidence, currency of evidence, total population included and biological or
mechanistic plausibility (inflammatory marker, function marker, damage marker and cell cycle marker).
Pragmatic limits were then set on each of the dimensions to enable the longlist to be reduced while trying
to ensure that the focus of search 2 would be on those tests that would be likely to produce the most
evidence. The limits and their rationales were as follows:
l the biomarker must have been considered in six or more studies – to try to ensure that there were
sufficient data to allow appropriate synthesis for each test
l studies must have been published in the previous 5 years – to try to ensure that only the most
promising biomarkers with recent evidence were included
l the biomarker must have been used with ≥ 1500 subjects in total (i.e. across studies) – to try to ensure
that the biomarker had wide clinical use and would provide sufficient data for synthesis
l biomarkers from all four plausibility dimensions should be represented – to ensure that the focus did
not exclude biomarkers with a specific biological or mechanistic function.
Application of these limits provided a shortlist of 10 candidate tests (Table 3), which, following review by
the Project Delivery Board and ratification by the specialist advisory group, were used in search 2.
TABLE 2 PICOS (population, interventions, comparator, outcomes, study design) criteria for search 1:
horizon scanning
PICOS
criteria Inclusion criteria Exclusion criteria
Population l Adults and children with new or existing AKI
l Critical care (or other clinical setting if the test
is a future candidate for critical care)
l Participant group ≥ 52 (≥ 26 per arm if a trial)
l Animal-only studies
l Adults and children with CKD only
l Participant group < 52 (< 26 per arm if a trial)
Interventions l Fluid biomarker (e.g. urine, plasma, blood)
l Not currently used in routine care (for AKI)
l Utilised for diagnosis or decision-making
related to AKI
l Evaluated to determine clinical validity
l Tissue biomarker or imaging technology
l Designed or used only for monitoring of events
subsequent to a diagnosis of AKI (e.g. post
discharge from hospital)
l Biomarker discovery and preclinical studies
l Evaluation of stability and/or storage of samples
for biomarkers
Comparator l None or an alternative biomarker l None
Outcomes l Diagnosis of new-onset AKI
l Risk stratification in diagnosed AKI
l Treatment benefit prediction in diagnosed AKI
l None
Study design l Systematic review, RCT, clinical trial,
observational, qualitative or acceptability
study, economic evaluation
l Published abstract if sufficient clinical, cost or
outcome data presented in lieu of a full paper
l Commentary
l Editorial
l Letter (unless research letter reporting data)
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Search 2: identification of evidence for candidate tests
Objective
The objective of this search was to identify current evidence on the analytical validity, clinical validity,
clinical utility and cost-effectiveness of the diagnostic tests identified in search 1.
Identification of studies
The world literature from 2004 to November 2015 was reviewed to identify existing research describing
the diagnostic accuracy, analytical validity or cost-effectiveness of the 10 candidate biomarkers. It became
clear when developing our search strategy that we would identify considerably more literature than
suggested by our prestudy scoping searches. We therefore took the decision to carry out a more sensitive
search over a shorter time period rather than a precise search covering the full duration of the databases.
As our aim was to identify novel tests, we believed that this approach would be more inclusive, identifying
the diversity of newer biomarkers and reducing the identification of older, established biomarkers. We
searched the following databases for published and unpublished literature: ClinicalTrials.gov (US National
Institutes of Health) (accessed 30 November 2015), Cochrane Central Register of Controlled Trials
(via Wiley Online Library) (Issue 10 of 12, October 2015), Cochrane Database of Systematic Reviews
(via Wiley Online Library) (Issue 11 of 12, November 2015), Conference Proceedings Citation Index –
Science (Thomson Reuters Web of Science) (1990 to November 2015), Database of Abstracts of Reviews
of Effect (via Wiley Online Library) (Issue 2 of 4, April 2015), EMBASE Classic and EMBASE (via Ovid)
(1947 to 24 November 2015), Health Technology Assessment database (via Wiley Online Library) (Issue 4
of 4, October 2015), Health Management Information Consortium database (1983 to November 2015),
International Clinical Trials Registry Platform (World Health Organization) (accessed 30 November 2015),
MEDLINE (via Ovid) (1946 to November Week 2 2015), MEDLINE In-Process & Other Non-Indexed Citations
(via Ovid) (24 November 2015), NHS Economic Evaluation Database (via Wiley Online Library) (Issue 2 of 4,
April 2015), PubMed (US National Library of Medicine) (1946 to November 2015) and Science Citation
Index (Thomson Reuters Web of Science) (1900 to November 2015).
The search consisted of index terms and text words for AKI, AKI synonyms and name variants for the
10 biomarkers: brain natriuretic peptide (BNP), cystatin C, IL-18, IL-6, KIM-1, L-FABP, N-acetyl-beta-D-
glucosaminidase (NAG), Nephrocheck, NGAL and tumour necrosis factor alpha (TNF-α). The searches were
limited by date of publication (from 2004) but no restrictions on language were applied (non-English-language
papers were included at this stage but would be included for full-text assessment only if translation of the
TABLE 3 Candidate biomarkers for inclusion in search 2
Biomarker Studies (n) Subjects (n) Biology/mechanism
BNP 6 3402 Functional marker
Cystatin C 73 21,180 Functional marker
IL-6 8 33,224 Inflammatory marker
IL-18 40 15,965 Inflammatory marker
KIM-1 40 12,959 Damage marker
L-FABP 28 7865 Functional marker
NAG 20 2982 Cell cycle marker
Nephrocheck (TIMP-2 and IGFBP-7) 6 1817 Cell cycle marker
NGAL 173 52,763 Inflammatory/damage marker
TNF-α 6 31,090 Inflammatory marker
BNP, brain natriuretic peptide; NAG, N-acetyl-beta-D-glucosaminidase; TNF-α, tumour necrosis factor alpha.
SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
study data would be possible within the project timescale). All study designs except for single case studies
were included. A diagnostic search filter was tested but not used in the final searches as it excluded potentially
relevant abstracts. Search strategies for each database are provided in Appendix 3.
Selection of studies
Studies were included if they evaluated at least one of the outcome areas of clinical validity (including
utility), analytical validity or cost-effectiveness and:
l the participants were adults or children with new or existing AKI
l they were based in critical care or the emergency department or included patients undergoing
cardiac surgery
l they evaluated one or more of the 10 candidate biomarkers (fluid only)
l they included serum creatinine or another candidate biomarker as a comparator
l they assessed use of the biomarker for AKI-related decision-making
l they involved at least 50 subjects (unless reporting an aspect of analytical validity or cost-effectiveness).
The emergency department and cardiac surgery (including presurgery) were included as the most important
alternative settings to consider when trying to capture relevant tests used outside ICUs/high-dependency
units that might be transferable to the critical care setting. A cut-off point of ≥ 50 participants was used to
include studies with some chance of identifying markers with a sensitivity/specificity of > 0.75 (see Table 1).
This threshold was lowered slightly from search 1 to be as inclusive as possible when obtaining evidence
relevant to the candidate biomarkers.
Studies were excluded if they involved kidney transplant patients only, studied a tissue biomarker or imaging
technology for AKI diagnosis or used the biomarker only for predicting transplant rejection. Studies
considering risk factors for AKI itself or combining the results for individual tests (with the exception of
algorithmic biomarkers) were also excluded, as were case studies and descriptive or commentary pieces
(Table 4).
Identified citations were stratified according to the test under study and in relation to whether they
considered single or multiple biomarkers and were reviewed on a group-by-group basis. Titles and abstracts
were screened for eligibility by one reviewer, with a random sample (15%) of articles independently
screened by a second reviewer. Full-text articles of potentially relevant studies were then obtained and
independently assessed by two reviewers to determine their inclusion status. Differences of opinion were
discussed until a consensus was reached. To facilitate consistency in appraisal, the three main reviewers
(EDM, NC and NW) initially assessed a batch of 14 papers independently and then met to discuss outcomes
and to ensure clarity around the inclusion and exclusion criteria.
Data extraction
Data extraction was carried out by a single reviewer using a bespoke proforma (see Appendix 4). Data
extracted included study methodology, country of study, study duration, setting and patient population
(including baseline characteristics), type of candidate test and parameters, details of the diagnostic ‘gold
standard’ and AKI classification system used, outcome measure(s) studied and findings. Analytical and
validation factors associated with the physical measurement of a biomarker [including sensitivity, specificity,
precision, parallelism, recovery, selectivity, limit of quantitation (LOQ) and vulnerability to interferences]
were also sought for review in line with current US Food and Drug Administration (FDA) best practice
guidelines18 and Clinical and Laboratory Standards Institute (CLSI) principles (see Table 38).29 Pre-analytical
variables that might influence the quality, integrity or composition of samples, including biological factors
(such as within-patient variability, sample timing, medical history and diet and lifestyle) and technical
factors (such as sample collection, processing, shipping and storage conditions), were also obtained. Prior
to use, the data extraction proforma was piloted by the reviewers and team statisticians on a small number
of studies and refined where necessary. Once the process of data extraction began, the statisticians then
reviewed a sample of completed proformas to ensure that the relevant data were being extracted.
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Quality assessment
Quality assessment for the evidence synthesis was carried out by one main reviewer (EDM) using the
QUADAS-2 (quality assessment of diagnostic accuracy studies) tool,30 a diagnostic test-specific approach
to determine potential study bias. In this system, papers are evaluated on the basis of patient selection,
interpretation of the index test, appropriateness and interpretation of the reference standard and flow of
patients and timing of tests. The applicability of each study to the question under review is also assessed
(see Appendix 5). In keeping with good practice, studies at risk of bias were not excluded from the
meta-analysis. Instead, an appraisal of the strength of the existing evidence has been reported and the
findings are interpreted in light of this.
Results of the systematic review
As was the case with search 1, broadening the search strategy to include tests used following cardiac
surgery impacted significantly on the volume of literature identified compared with that anticipated by the
original scoping strategy, with a total of 5045 articles identified. Given the time implications associated
with assessment and data extraction in a complex review such as this, we took the decision to focus
initially on three of the candidates: a recently developed test that is receiving considerable marketing and
is the only FDA-licensed test for AKI (Nephrocheck, which detects two biomarkers, TIMP-2 and IGFBP-7)
and the two biomarkers for which there was the greatest amount of evidence (cystatin C and NGAL).
TABLE 4 PICOS (population, interventions, comparator, outcomes, study design) criteria for search 2: evidence for
candidate tests
PICOS
criteria Inclusion criteria Exclusion criteria
Population l Adults and children with new or existing AKI
l Participant group ≥ 50 (≥ 25 per arm if a trial)
l Critical care setting
l Cardiac surgery setting (including presurgery)
l Any setting (analytical only)
l Any participant number (analytical only)
l Animal-only studies
l Transplant patients only
l Participant group < 50 (< 25 per arm if a trial)
Interventions l Fluid biomarker
l Used for diagnosis of AKI
l Used for decision-making in AKI (treatment,
prognosis etc.)
l Biomarker not specified in detail
l Used to predict transplant rejection only
Comparator l Creatinine
l Alternative candidate biomarker
l None (analytical or costs only)
l None
Outcomes Primary:
l diagnosis of AKI (plus one or more of a–d):
(a) clinical validity
(b) clinical utility
(c) cost-effectiveness
(d) analytical validity
Secondary:
l length of stay
l readmission
l recovery of kidney function
l CKD
l RRT
l mortality
l Risk factors for AKI only
l Combines results for individual biomarkers
[does not include algorithmic biomarkers
(e.g. Nephrocheck)]
Study design l Systematic review, RCT, clinical trial,
observational, qualitative or acceptability
study, economic evaluation
l Published abstract if sufficient clinical, cost or
outcome data presented in lieu of a full paper
l Duplicate study
l Case study
l Editorial
l Commentary (including non-systematic review)
l Letter (unless research letter reporting data)
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The choice of these three tests as the focus for study was ultimately a pragmatic one, determined with
advice from the specialist advisory group. Although fewer studies have used Nephrocheck than some of
the other shortlisted tests, it is one of the most recent biomarkers that has shown enough promise to be
approved by the FDA and so there is much interest in its clinical utility. We were aware that there would
be more publications on the older biomarkers; however, our approach seemed an intelligent approach that
avoided ignoring a new and potentially novel biomarker. Between them, these markers were considered in
3260 of the identified citations (65%), with 605 articles meeting the inclusion criteria for detailed review
(Figure 2). We were unable to locate three papers and 23 non-English-language papers were set aside.
Most of the excluded studies were either conference abstracts with no subsequent publication or studies
that did not focus on the population or setting under review (Table 5). In total, 207 eligible papers31–237
were included in the review (see Appendix 6).
Citations
identified from
database
searches
(n = 5045)
Synthesis:
Nephrocheck
(n = 5)
Synthesis:
NGAL
(n = 39)
Eligible
articles
(n = 207)
Articles
retrieved for
detailed review
(n = 605)
Articles
excluded after
title/abstract
screen
(n = 2655)
Abstracts
not included
(BNP, IL-6, IL-18,
KIM-1, L-FABP,
NAG, TNF-α)
(n = 1785)
Inclusion/
exclusion criteria
applied
Inclusion/
exclusion criteria
applied
Articles
excluded after
full-text screen
(n = 398)
Non-English
papers set aside
(n = 23)
Unable to
locate three
articles
Synthesis:
cystatin C
(n = 17)
FIGURE 2 Flow of studies into the review.
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
Location and setting
The majority of the eligible studies were carried out in Europe (n = 114, 55%) and North America (n = 63,
30%), with the USA being the single most prolific country (Table 6). Fifteen studies involved centres in
multiple countries. The most commonly reported clinical setting was cardiac care (n = 86, 42%) – including
11 studies on contrast-induced nephropathy – followed by critical care (n = 85; 41%), the emergency
department (n = 20; 10%) and the laboratory (n = 11, 5%). The setting of five studies was unclear. Less
than one-quarter of studies (n = 46, 22%) reported the involvement of multiple centres (median 3, range
2–35) (see Appendix 6). Study duration ranged from 1 month to 7 years and most papers were published
between 2012 and 2015 (70%).
Population
Most studies were small in scale (mean 227, median 112 participants), with the smallest being an
analytical validity study involving 17 patients undergoing surgery for congenital heart disease and the
largest being a study of 1635 adults admitted to the emergency department (see Appendix 6). Two studies
TABLE 5 Reasons for study exclusion (N= 398)
Reason for exclusion Number of studies
Abstract only (no full text available) 184
Outside the review setting 73
Not used for AKI diagnosis or decision-making 35
Participant group < 50 27
Non-English language 23
No discrete biomarker data 12
Duplicate paper or study 10
Review or meta-analysis (references checked) 9
No candidate biomarker studied 4
Editorial, commentary or letter 3
No comparator test included 3
Ongoing trial with full text identified 3
Study of transplant patients 3
Unable to obtain article 3
Animal study 2
Erratum only 2
Poster only (no full text available) 1
Study of patients with CKD 1
TABLE 6 Included papers by country under study
Country Number of papers (%)
Argentina 1 (0.5)
Australia 9 (4.3)
Austria 3 (1.4)
Belgium 6 (2.9)
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TABLE 6 Included papers by country under study (continued )
Country Number of papers (%)
Bosnia and Herzegovina 1 (0.5)
Brazil 3 (1.4)
Canada 9 (4.3)
China 14 (6.8)
Curaçao 1 (0.5)
Denmark 3 (1.4)
Egypt 5 (2.4)
Finland 5 (2.4)
France 11 (5.3)
Germany 17 (8.2)
Greece 4 (1.9)
Hungary 1 (0.5)
India 2 (1.0)
Iran 4 (1.9)
Ireland 1 (0.5)
Italy 12 (5.8)
Japan 5 (2.4)
Republic of Korea 10 (4.8)
Malaysia 1 (0.5)
The Netherlands 8 (3.9)
New Zealand 5 (2.4)
Pakistan 1 (0.5)
Poland 3 (1.4)
Portugal 3 (1.4)
Saudi Arabia 1 (0.5)
Serbia 3 (1.4)
Spain 8 (3.9)
Sri Lanka 1 (0.5)
Sweden 10 (4.8)
Switzerland 1 (0.5)
Taiwan 2 (1.0)
Thailand 1 (0.5)
Turkey 7 (3.4)
UK 7 (3.4)
USA 54 (26.1)
Fifteen studies involved multiple locations and have been listed under each included country: Austria, Belgium, Canada,
France, Germany, Spain, Sweden, the UK and the USA (n= 1); Austria, Belgium, France, Germany, Spain, Sweden, the UK
and the USA (n= 2); Belgium, France (n= 1); Belgium and the USA (n = 1); Canada, the Netherlands and the USA (n = 1);
Canada and the USA (n= 5); France, Italy and the USA (n= 1); Germany and the USA (n= 1); Italy and the USA (n= 1);
Sri Lanka and the USA (n= 1).
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did not specify population size: one on the analytical validity of NGAL and the other using decision analysis
to model the cost-effectiveness of NGAL following cardiac surgery. In more than three-quarters of studies
the population was adult patients (n = 166, 80%), with three studies including both adults and children.
The source of the samples was not specified in two studies on the analytical validity of NGAL.
Biomarkers and outcome areas
The most commonly studied biomarker was NGAL (n = 145, 70%) followed by cystatin C (n = 91, 44%)
and Nephrocheck (n = 10, 5%). One study evaluated all three tests, 35 evaluated cystatin C and NGAL and
three evaluated Nephrocheck and NGAL. The Nephrocheck test is carried out using urine only, but cystatin
C and NGAL were evaluated on a range of sample matrices, most commonly serum for cystatin C and
urine for NGAL (Table 7). Forty-one studies evaluated two different matrices for the same or multiple
biomarkers (n = 14 for cystatin C, n = 35 for NGAL). Although there is a standard definition for the
diagnosis of AKI, various classifications can be used in clinical practice to grade the level of injury (Table 8).
In this review, the most commonly used criteria in studies determining clinical validity were the RIFLE
(Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease) criteria,241 either alone or in
conjunction with the Acute Kidney Injury Network (AKIN) criteria242 (n = 80, 42%). Almost one-fifth of
studies did not report using one of the standard classifications.
Of the outcomes areas evaluated in this review, the most commonly considered was clinical validity (i.e.
diagnostic accuracy; n = 193, 93%). A smaller number of studies focused on analytical validity (n = 12,
6%), with only two studies focusing on the cost-effectiveness of biomarker use (both in cardiac surgery,
one looking at NGAL use in adults and the other looking at the use of cystatin C and NGAL in children).
Almost one-quarter of studies (n = 46, 22%) reported on clinical validity alongside some aspect of
analytical validity, usually related to brief details on limits of detection or inter-/intra-assay variation.
In most of the studies dealing with clinical validity, the purpose of the use of the biomarker was AKI
diagnosis, either solely (n = 126; 65%) or alongside risk prediction (n = 34, 18%) or prognosis (n = 21, 11%).
Quality assessment
With few exceptions, a cohort study design was the most frequently used study design in biomarker
evaluation (n = 181, 87%), perhaps unsurprisingly given the topic under review. There were four RCTs,
all of them relatively small scale (n = 71–204 adult patients), one in critical care and three involving cardiac
surgery. One paper reported subgroup analysis from a larger trial but did not provide details of the parent
study; the focus of two others was on the use of therapeutic drug treatment to prevent renal damage
[Probucol (Sanofi Aventis, Paris, France) and erythropoietin].
Only 14% of studies (n = 29) reported a power calculation to justify the included sample size and less than
half provided details of patient throughout [n = 88, 43%; Consolidated Standards of Reporting Trials
(CONSORT) diagram, n = 38; written statement, n = 50]. For the most part, the reporting of methodology
was poor and few studies stated that they had adhered to a quality standard when describing their study
[Standards for Reporting Diagnostic Accuracy (STARD) guidance,243 n = 4; Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guidance,244 n = 3; both STARD and STROBE, n = 1].
TABLE 7 Biomarker evaluation by sample matrix used
Sample matrix
Biomarker
Cystatin C Nephrocheck NGAL
Plasma 23 – 51
Serum 54 – 23
Urine 27 10 105
Whole blood – – 2
Not specified 1 – 1
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Fewer than two-thirds of clinical validity studies provided sensitivity and specificity data for a given
biomarker cut-off threshold (n = 113, 59%). Only 42 eligible studies (20%) provided sufficient data to
allow population of a confusion matrix and, therefore, their inclusion in meta-analysis: four studies
evaluating Nephrocheck, 17 studies evaluating cystatin C and 35 studies evaluating NGAL (see Chapter 3).
Risk of bias among studies included in the evidence synthesis
When considered across the four domains – patient selection, index test, reference standard and flow and
timing – only six45,48,50,54,58,66 of the studies included in the evidence synthesis had a low risk of bias for all;
two studies49,72 did not report enough information to be able to allocate a level of bias for any of the
domains (Table 9). Three studies had a high risk of bias for one domain: one36 that used a prespecified
threshold for the biomarker cut-off point (potential index test bias), one in which the analysis did not
include all patients39 and one that had a prolonged interval between the tests (both flow and timing
bias).57 In all of the remaining studies (n = 31, 74%), the level of bias was unclear in at least one of the
domains. This was especially true for bias related to the reference standard, for which just over half of
TABLE 8 Classifications for staging AKI in clinical validity studies (N = 193)
First author
and year Criteria
Studies,a
n (%)
Definition of AKI Absolute increase in SCr of ≥ 0.3 mg/dl (≥ 26.5 µmol/l) within 48 hours or a
percentage increase of at least 50% (1.5 times the baseline value) or reduced urine
output for > 6 hours (< 0.5 ml/kg/hour)
–
RIFLE241 R: ≥ 1.5- and < 2-fold increase from baseline SCr or ≥ 25% fall in GFR from baseline
or urine output < 0.5 ml/kg/hour for ≥ 6 and < 12 hours
80 (41.5)
I: ≥ 2- and < 3-fold increase from baseline SCr or ≥ 50% fall in GFR from baseline or
urine output < 0.5 ml/kg/hour for ≥ 12 hours and < 24 hours
F: ≥ 3-fold increase from baseline SCr or ≥ 75% fall in GFR from baseline or SCr
≥ 4 mg/dl with an acute rise of ≥ 0.5 mg/dl or urine output < 0.3 ml/kg/hour for
≥ 24 hours or anuria for ≥ 12 hours
L: complete loss of renal function for > 4 weeks
E: end-stage renal disease
AKIN242 Stage 1: increase in SCr of ≥ 0.3 mg/dl (≥ 26.4 µmol/l) or increase in SCr to
≥ 150–200% (1.5- to 2-fold) of baseline value or urine output < 0.5 ml/kg/hour for
≥ 6 and < 12 hours
62 (32.1)
Stage 2: increase in SCr to > 200–300% (> 2- to 3-fold) of baseline value or urine
output < 0.5 ml/kg/hour for ≥ 12 hours and < 24 hours
Stage 3: increase in SCr to > 300% (3-fold) of baseline value or SCr ≥ 4.0 mg/dl
(≥ 354 µmol/l) with an absolute increase of ≥ 0.5 mg/dl (≥ 44 µmol/l) or initiation of
RRT or urine output < 0.3 ml/kg/hour for ≥ 24 hours or anuria for ≥ 12 hours
KDIGO (Kidney
Disease: Improving
Global Outcomes)238
Stage 1: 1.5–1.9 × baseline SCr or ≥ 0.3 mg/dl (≥ 26.5 µmol/l) increase in SCr or urine
output < 0.5 ml/kg/hour for ≥ 6 and < 12 hours
26 (13.5)
Stage 2: 2.0–2.9 × baseline SCr or urine output < 0.5 ml/kg/hour for ≥ 12 hours and
< 24 hours
Stage 3: 3.0 × baseline SCr or increase in SCr of ≥ 4.0 mg/dl (≥ 353.6 µmol/l)
or initiation of RRT or, in patients aged < 18 years, decrease in eGFR to
< 35 ml/minute/1.73 m2 or urine output < 0.3 ml/kg/hour for ≥ 24 hours or
anuria for ≥ 12 hours
Otherb – 35 (18.1)
Not reported – 4 (2.1)
eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; SCr, serum creatinine.
a 12 studies used the RIFLE and AKIN criteria and one study used the AKIN, KDIGO and RIFLE criteria.
b Includes the Acute Dialysis Quality Initiative Group consensus (n = 4),239 the Kidney Disease Outcomes Quality Initiative
guidelines240 (n= 1) and the National Kidney Foundation guideline240 (n = 1).
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TABLE 9 Risk of bias among studies included in the evidence synthesis
First author and year
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Ayodogdu 201332 ✓ ? ✓ ✓ ✓ ✓ ✓
Bihorac 201433 ? ✓ ✓ ✓ ✓ ✓ ✓
Chen 201234 ✓ ? ✓ ✓ ✓ ✓ ✓
Cho 201335 ✓ ? ✓ ✓ ✓ ✓ ✓
Constantin 201036 ✓ ✗ ✓ ✓ ✓ ✓ ✓
de Geus 201137 ✓ ? ✓ ✓ ✓ ✓ ✓
Ghonemy 201438 ? ? ✓ ✓ ✓ ? ✓
Haase 200931 ? ? ? ✓ ? ? ✓
Haase-Fielitz 200939 ? ✓ ? ✗ ? ✓ ?
Haase-Fielitz 200940 ? ? ✓ ✓ ✓ ✓ ✓
Han 200941 ✓ ? ? ✓ ✓ ? ✓
Herget-Rosenthal 200442 ✓ ? ? ✓ ✓ ✓ ✓
Hjortrup 201543 ? ✓ ? ? ✓ ✓ ✓
Hoste 201444 ✓ ✓ ? ✓ ✓ ✓ ✓
Kashani 201345 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Kato 200846 ✓ ? ? ✓ ✓ ? ✓
Kidher 201447 ? ? ✓ ✓ ✓ ✓ ✓
Kokkoris 201248 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Legrand 201549 ? ? ? ? ? ? ?
Liangos 200950 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Linko 201351 ✓ ? ? ? ✓ ✓ ?
Liu 201352 ? ✓ ✓ ✓ ✓ ✓ ✓
McIlroy 201053 ? ? ✓ ✓ ✓ ✓ ✓
Meersch 201454 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Meersch 201455 ✓ ? ✓ ✓ ✓ ✓ ✓
Munir 201356 ✓ ? ✓ ✓ ✓ ✓ ✓
Nejat 201057 ✓ ? ? ✗ ✓ ✓ ✓
Oh 201258 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Palazzuoli 201559 ✓ ? ? ✓ ✓ ✓ ✓
Parikh 201160 ? ✓ ✓ ✓ ✓ ✓ ✓
Park 201561 ✓ ? ✓ ✓ ✓ ✓ ✓
Perrotti 201562 ✓ ? ? ? ✓ ✓ ✓
Perry 201063 ? ✓ ✓ ✓ ✓ ✓ ✓
Prowle 201564 ? ✓ ✓ ✓ ✓ ✓ ✓
Sargentini 201265 ? ? ? ✓ ✓ ✓ ✓
Shum 201566 ✓ ✓ ✓ ✓ ✓ ✓ ✓
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studies (n = 22, 52%) did not provide information on blinding, that is, whether or not the index test results
were interpreted without knowledge of the results of the reference standard. There was little concern that
the included studies were not applicable to this review.
Discussion
This review was undertaken to provide a comprehensive picture of the current evidence around the clinical
and analytical validity and cost-effectiveness of novel biomarkers for the diagnosis of AKI in critical care.
There is undoubtedly a considerable amount of research in this area; however, issues related to the quality
of reporting meant that less than one-quarter of the eligible studies identified were able to be included in
meta-analysis. In addition, this made it difficult to determine the levels of potential bias across studies.
Several key issues were encountered when carrying out this piece of work. First, in the absence of
published guidance, the test shortlisting criteria were developed by expert consultation and, as such, may
not have captured all of the promising in-development tests because of the pragmatic focus on objective
criteria (such as volume of evidence). Second, the literature yield was substantially greater than originally
indicated by the prestudy scoping searches, largely because of the decision to broaden the final scope to
include tests developed outside the critical care setting. This, combined with the number of candidate tests
identified (including multiple tests evaluated in the same study) and the complexity of data extraction
(which sought to determine both clinical and analytical validity), resulted in extended study timelines and
an inability to complete the review for all 10 candidate biomarkers. Furthermore, differences in inclusion
and exclusion criteria depending on whether the focus was on clinical or analytical validity made it more
difficult to exclude potentially irrelevant studies at the abstract screening stage as this could not easily be
achieved using sample size or the presence of a comparator (see Table 4). The decision to include an
eligibility criterion based on sample size for studies with equal numbers of cases and controls could have
been improved by stating that the group of interest (AKI in this case) had to be at least this size and the
other group (no AKI) could have been larger.
As the number of biomarkers entering the health-care market continues to expand rapidly, the role of
reviews to inform future research priorities is increasingly important. The two-stage search process outlined
here represents a novel approach in this area; however, it is clear that further work is required to establish
efficient and optimal search strategies and shortlisting criteria for such reviews.
TABLE 9 Risk of bias among studies included in the evidence synthesis (continued )
First author and year
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Tuladhar 200967 ✓ ? ? ? ✓ ✓ ✓
Tung 201568 ✓ ? ? ✓ ✓ ✓ ✓
Tziakas 201569 ✓ ? ? ? ✓ ✓ ✓
Varela 201570 ? ? ? ✓ ✓ ✓ ✓
Villa 200571 ? ? ? ✓ ✓ ✓ ✓
Wagener 200872 ? ? ? ? ✓ ✓ ✓
✓, low risk of bias; ✗, high risk of bias; ?, unclear risk of bias.
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Chapter 3 Meta-analysis of diagnostic tests for
acute kidney injury
Introduction
In this chapter a meta-analysis of diagnostic accuracy studies is provided to evaluate the body of evidence
available for three diagnostic tests of AKI and to provide input into the decision analysis in subsequent
chapters. The primary health-care setting considered in the use of these tests was the critical care unit and
the secondary health-care setting considered was cardiac surgery (pre and/or post intervention). The three
diagnostic tests considered were the Nephrocheck test (which uses a combination of two proteins: TIMP-2
and IGFBP-7) and the biomarkers NGAL and cystatin C. The NGAL and cystatin C tests have been used in
this setting for measurement of their concentration in samples of blood serum, blood plasma and urine
and these media were considered separately. The pooled estimates of sensitivity and specificity and their
variance from the meta-analyses directly informed the decision analysis in Chapter 5. In our searches we
identified no previous reviews or meta-analyses considering Nephrocheck or cystatin C in this setting, but
we did identify two relevant reviews of NGAL.40,245
Methods
Primary objective
The primary objective was to estimate pooled means and variances of sensitivity and specificity for each of
the diagnostic tests considered. When appropriate data were available, these estimates were obtained
separately for each of the health-care settings considered and for each of the sample media considered.
When only one study was available, no meta-analysis was undertaken.
Identification of studies
Details on the search strategies used to identify studies and the process for study screening and evaluation,
data extraction and quality assessment are presented in Chapter 2.
Full papers were retrieved for studies of all patients (< 18 years, ≥ 18 years) in which AKI diagnosis had
been evaluated using any one or multiples of the three diagnostic tests considered (Nephrocheck, NGAL,
cystatin C), in any of the sample media considered (blood serum, blood plasma or urine), in either of the
health-care settings considered (critical care unit or cardiac surgery). Studies were excluded if they were
not primarily located in either of these health-care settings.
Study methods
The gold standard for determining AKI diagnosis was defined as diagnosis according to the RIFLE,241
AKIN242 or KDIGO (Kidney Disease: Improving Global Outcomes)238 diagnostic and classification system,
based on an assessment of serum creatinine levels and urine output (see Chapter 2).
Outcome measurements
The primary outcomes were sensitivity (the probability of the test being positive given that the true
diagnosis is positive) and specificity (the probability of the test being negative given that the true diagnosis
is negative), which are determined by comparison of the results of the experimental diagnostic test with
the results of the gold standard method used in the study. Studies were excluded if the gold standard
method used to determine the outcome was not described in sufficient detail. Studies were not excluded
if the cut-off point used to assess the positive and negative status of the outcome in the experimental
diagnostic test was not reported.
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
Diagnostic and staging systems for acute kidney injury
A number of diagnostic and staging systems for AKI have been used in diagnostic accuracy studies. The
most commonly used make use of repeated serum creatinine measurements and measurement of urine
output to diagnose and stage AKI. Three commonly used systems are the RIFLE, AKIN and KDIGO systems.
RIFLE classification of acute kidney injury
The Acute Dialysis Outcome Initiative group proposed the RIFLE classification, which defines five categories
of AKI,241 as shown in Table 8. AKI is staged for severity according to the criteria listed in Table 8, with any
classification of risk or above being a diagnosis of AKI.
Acute Kidney Injury Network classification of acute kidney injury
The AKIN has defined diagnostic criteria for AKI and provided a staging system for the severity of AKI,242
as shown in Table 8. AKI is staged for severity according to the criteria listed in Table 8, with any classification
of stage 1 or above being a diagnosis of AKI. In particular, in contrast to the RIFLE criteria, the absolute
change in serum creatinine defining AKI is defined as an abrupt (within 48 hours) reduction in kidney
function as defined by stage 1 or above.
KDIGO classification of acute kidney injury
The 2011 KDIGO Clinical Practice Guideline for AKI (Summary of Recommendation Statements, 2012)246
defined diagnostic criteria for AKI and provided a staging system for the severity of AKI, as shown in Table 8.
AKI is staged for severity according to the criteria listed in Table 8, with any classification of stage 1 or above
being a diagnosis of AKI. This classification system uses the same time frame for absolute changes as the
AKIN criteria and clarifies that for the relative changes the baseline values should be known or presumed to
have occurred within the previous 7 days.
Summary of staging methods
There is a similarity between the staging and diagnostic criteria proposed for AKI, which is demonstrated in
Table 10. It has been shown that the AKIN criteria can diagnose more patients correctly with AKI than the
RIFLE criteria (not unexpected given the additional criterion – the absolute change in serum creatinine
level), but it has not been shown to have a better predictive ability for in-hospital mortality.247 It has also
been shown that the AKIN criteria do not improve the sensitivity of AKI diagnosis compared with the RIFLE
criteria in the first 24 hours after admission to the critical care unit.248 Similarly, it has been shown than a
higher incidence of AKI can be diagnosed using the KDIGO criteria than using the RIFLE criteria and that
the KDIGO criteria are more predictive for in-hospital mortality, but there was no significant difference
between the AKIN criteria and the KDIGO criteria.249 Other studies have suggested that the RIFLE, AKIN
and KDIGO criteria are good tools for predicting mortality in critically ill patients and observe no evidence
of a difference between them.250
Based on the definitions used in the different diagnostic and staging/classification systems and the
evidence above we believe that there are broad similarities between the RIFLE, AKIN and KDIGO criteria
TABLE 10 Comparison of common AKI diagnostic and staging/classification systems based on serum creatinine
levels and urine output
Staging system Stage or classification
RIFLE R I F L E
AKIN 1 2 3
KDIGO 1 2 3
RRT
AKI ‘diagnosis’ AKI ‘failure’
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and, for the purposes of this study, we defined a diagnosis of AKI, following the KDIGO criteria, as any of
the following:
l increase in serum creatinine of ≥ 0.3 mg/dl (≥ 26.5 µmol/l) within 48 hours
l increase in serum creatinine to ≥ 1.5 × baseline, which is known or presumed to have occurred within
the previous 7 days
l urine volume < 0.5 ml/kg/hour for at least 6 hours.
Furthermore, in the studies identified for inclusion in the meta-analysis, studies that used either of the
outcomes indicated by the shaded areas in Table 10 (RIFLE R, AKIN 1 or KDIGO 1 – a diagnostic-type
outcome; RIFLE F, AKIN 3, KDIGO 3 or RRT – a failure-type outcome) were considered homogeneous for
the purposes of the meta-analysis.
Key data extracted
The primary data extracted for inclusion in the meta-analysis are shown in Table 11. It is recommended
in the STARD statement that a cross-tabulation of the index test results by the results of the reference
standard is included in any study report,251,252 but it was anticipated that this information would not be
present in all study reports. In this situation the elements of the confusion matrix were calculated using
information describing the diagnostic outcomes and estimates of sensitivity and specificity. For example,
if the sensitivity (s) and number of true diagnoses [given by the sum of the number of true positives (TPs)
and the number of false negatives (FNs), i.e. (TP + FN)] were reported in the study then the number of
TPs could be calculated as s.(TP + FN). A similar calculation for specificity (p) allowed the estimation of the
number of true negatives (TNs): p.(FP + TN), where FP represents the number of false positives. Finally,
given these estimates for TP and TN and the numbers of true outcomes [(TP + FN) and (FP + TN)], simple
subtraction provided estimates for FN and FP.
Study exclusion
Studies were excluded from the meta-analysis if it was not possible to estimate values for the elements of
the confusion matrix or if other key data could not be extracted. Further reasons for the exclusion of
studies were if diagnosis was carried out in the emergency department rather than in the critical care unit
and if the biomarker was measured on a relative scale rather than an absolute scale, for example unit of
biomarker per unit of serum creatinine.
Data analysis
Simple diagnostic accuracy summaries [sensitivity, specificity and the diagnostic odds ratio (DOR) and its
components – positive likelihood ratio (LR+) and negative likelihood ratio (LR–)] were produced for each
study included in the meta-analysis. The sensitivity of a diagnostic test (T) is defined formally as the
probability that the test will give a positive result if the patient has the disease (D+), in this case AKI. This is
often referred to as the TP rate for a diagnostic test and can be expressed as a conditional probability:
s = Sensitivity = P(test = positive j status = diseased) = P(T + j D + ). (1)
TABLE 11 Confusion matrix
True outcome
Test outcome
Diagnostic property True outcomeTest+ Test–
Disease+ (D+) TP FN Sensitivity = TP/(TP + FN) TP + FN
Disease– (D–) FP TN Specificity = TN/(TN + FP) FP + TN
TP+ FP FN + TN
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The specificity of a diagnostic test is the probability that the test will give a negative result if the patient
does not have the disease (D–), which is equivalent to 1 minus the FP rate for the test and can be
expressed as the conditional probability:
p = Specificity = P(test = negative j status = not diseased) = P(T− j D−). (2)
Confidence intervals (CIs) were estimated for sensitivity and specificity based on the Wilson score interval
method.253
The LR+ of a diagnostic test is the probability of a patient with disease (D+) having a positive test result
divided by the probability of a patient without disease (D–) having a positive test result:
LR+ = P(T+ j D+ ) /P(T + j D−). (3)
Similarly, the LR– of a diagnostic test is the probability of a patient with disease having a negative test
result divided by the probability of a patient without disease having a negative test result:
LR− = P(T− j D+ ) /P(T− j D−). (4)
Confidence intervals for the LR+ and LR– were estimated using the method of Koopman.254
The DOR for a test is the ratio of the odds of a positive test result for a patient with disease relative to the
odds of a positive test result for a patient without disease:
DOR = LR+ / LR−. (5)
Confidence intervals for log(DOR) were estimated based on the assumption that, as an odds ratio, the DOR
is normally distributed. Estimates for DOR were then obtained by back-transformation.
The method of meta-analysis for diagnostic accuracy studies used here was the bivariate meta-analysis
proposed by Reitsma et al.,255 based on the methodology of van Houwelingen et al.256 Briefly, if logit
sensitivity (µsi) and logit specificity (µpi) are
µSi = logit(si) = log(
s
1− s
) (6)
and
µPi = logit(pi) = log(
p
1−p
), i = 1, . . ., k. (7)
for each study i (with k studies included in the meta-analysis), the true logit sensitivity and logit specificity
are then assumed to have a bivariate normal distribution across studies:

µSi
µPi

∽N
 µS
µP

,ΣSP

, (8)
where ΣSP =

σ2S σ
n
SP
σnSP σ
2
P

.
where σnSP is the covariance between logit sensitivity and logit specificity. This model is extended by
incorporating the variability due to sampling through the variance of sensitivity (s2S,i) and specificity (s
2
P,i),
as measured in each study:
s2S,i =
1
nS,ipS,i(1−p)S,i
(9)
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and
s2P, i =
1
nP, ipP, i(1−p)P, i
, (10)
assuming that 0 < p and s < 1 and that the number of subjects used to estimate sensitivity and specificity is
large.256 The final model is then a bivariate random-effects model of the form:
µSi
µPi
 
∼N
 µS
µP

,ΣSP + Ci
 
, (11)
where Ci =
s2S, i 0
0 s2P, i
 
.
This model was estimated using likelihood-based methods using the mada package257 in the R
Environment for Statistical Computing (The R Foundation for Statistical Computing, Vienna, Austria). It has
been shown that this method is equivalent to the hierarchical regression meta-analysis proposed by and
further developed by Rutter and Gatsonis when there are no study-level covariates.258–260
Separate meta-analyses were conducted for each diagnostic test, sample media and health service setting.
Pooled estimates of sensitivity, specificity, LR+, LR– and DOR can be estimated from back-transformed
parameter estimates. Estimates from each study and pooled estimates from the meta-analysis are
presented in forest plots. A summary receiver operating characteristic (SROC) curve was estimated, with
estimates of the confidence and prediction region.255,259 Approximate estimates of the variance of
sensitivity and specificity for use in the economic model were determined using the delta method.261
Tests of heterogeneity were not used, as such statistical methods (Cochran’s Q, I2) do not account for
heterogeneity explained by phenomena such as positivity threshold effects and are not recommended by
the Cochrane Diagnostic Test Accuracy Group.262 Estimating the prediction region in the SROC curve is one
way of examining the extent of heterogeneity by depicting a region within which, assuming that the model
is correct, we have 95% confidence that the true sensitivity and specificity of a future study would lie.260
Results
Papers selected for inclusion in the meta-analysis are described briefly in tabular summaries followed by a
summary of diagnostic accuracy for each study. Pooled estimates of sensitivity and specificity and the
SROC curve are also provided for each diagnostic test, health-care setting and sample type. A Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram that depicts the flow of
information through the different phases of the systematic review to data extraction and final inclusion in
the meta-analysis is shown in Chapter 2 (see Figure 2).
Nephrocheck
Critical care unit: plasma and serum
The searches identified no studies suitable for data extraction for this diagnostic test in either health-care
setting for either plasma or serum.
Critical care unit: urine
Summaries of the baseline characteristics and test parameters for the included urinary Nephrocheck studies
are shown in Table 12. Three studies were included,33,44,45 with a total of 1289 patients [199 patients
(15.4%) with a diagnosis of AKI and 1090 patients (84.6%) without a diagnosis of AKI]. The sample for
use in the test was taken on enrolment in all of the included studies. The outcome used to define the
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presence of AKI was consistent across each of the three studies (KDIGO stage 2 or 3). Similarly, the
threshold used to define a positive test was consistent in all included studies [(TIMP-2) × (IGFBP-7) = 0.3].
Diagnostic accuracy summaries for the included studies are shown in Table 13.
Figure 3 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for Nephrocheck in the critical care unit using patient urine samples. The pooled sensitivity
estimate was 0.90 (95% CI 0.85 to 0.93) and the pooled specificity estimate was 0.49 (95% CI 0.46 to
0.53). Figure 4 shows an estimate of the SROC curve with the 95% confidence region and 95% prediction
region. The prediction and confidence regions are small, suggesting limited heterogeneity. This is to be
expected given the highly controlled similarity in these studies.
Cardiac surgery: urine
One study including 50 patients [26 patients (52.0%) with a diagnosis of AKI and 24 patients (48.0%)
without a diagnosis AKI] was identified for the use of Nephrocheck in the cardiac surgery setting using urine
samples.54 A summary of the baseline characteristics and test parameters for the included study is shown in
Table 14. The outcome used to define a diagnosis of AKI was a RIFLE classification of ≥ R within 72 hours of
surgery. The threshold used to define a positive test was whether the maximum (TIMP-2) × (IGFBP-7) value
in the 24 hours post cardiopulmonary bypass (CPB) was > 0.3. A diagnostic accuracy summary for the
included study is shown in Table 15. No meta-analysis was performed for this single study.
TABLE 12 Characteristics of studies included in meta-analysis for Nephrocheck in the critical care unit health-care
setting using urine
First author
and year
Patient
group Age (years)
Timing of test
sample Threshold Outcome
Outcome
+ –
Kashani
201345
Patients
admitted to
the critical
care unit
Median (IQR):
± 64 (53, 73)
Within 18 hours
of enrolment
0.3 KDIGO (2 or 3)
within 12 hours
101 627
Bihorac
201433
Patients
admitted to
the critical
care unit
Mean (SD):
± 63 (17)
On enrolment
(median 15 hours
from admission)
0.3 KDIGO (2 or 3)
within 12 hours
71 337
Hoste
201444
Patients
admitted to
the critical
care unit
Median (IQR):
+ 64 (54, 75);
– 65 (54, 78)
On enrolment
(within 24 hours
of admission)
0.3 KDIGO (2 or 3)
within 12 hours
27 126
+, with a diagnosis of AKI; –, without a diagnosis of AKI; IQR, interquartile range (quartile 1, quartile 3); SD, standard deviation.
TABLE 13 Diagnostic accuracy summaries for studies included in meta-analysis for Nephrocheck in the critical care
unit health-care setting using urine
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Kashani
201345
90 313 11 314 0.891
(0.815 to 0.938)
0.501
(0.462 to 0.540)
1.785
(1.609 to 1.980)
0.217
(0.124 to 0.382)
8.21
(4.305 to 15.7)
Bihorac
201433
65 182 6 155 0.915
(0.828 to 0.961)
0.460
(0.407 to 0.513)
1.695
(1.502 to 1.914)
0.184
(0.085 to 0.399)
9.21
(3.891 to 21.9)
Hoste
201444
24 59 3 67 0.889
(0.719 to 0.961)
0.532
(0.445 to 0.617)
1.898
(1.510 to 2.387)
0.209
(0.071 to 0.615)
9.09
(2.602 to 31.7)
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Study
Kashani et al. 201345
Bihorac et al. 201433
Hoste et al. 201444
Summary
Sensitivity (95% CI)
0.89 (0.82 to 0.94)
0.92 (0.83 to 0.96)
0.89 (0.72 to 0.96)
0.90 (0.85 to 0.93)
Specificity (95% CI)
0.50 (0.46 to 0.54)
0.46 (0.41 to 0.51)
0.53 (0.44 to 0.62)
0.49 (0.46 to 0.53)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 3 Forest plot for studies included in the meta-analysis and pooled estimates for sensitivity and specificity Nephrocheck in the critical care unit health-care setting
using urine.
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Neutrophil gelatinase-associated lipocalin
Critical care unit: plasma
Summaries of the baseline characteristics and test parameters for the included studies are shown in Table 16.
Eight studies were included,35,43,48,49,51,59,66,100 with a total of 1670 patients [381 patients (22.8%) with a
diagnosis of AKI and 1289 patients (77.2%) without a diagnosis of AKI]. The outcome used to define the
presence of AKI was not consistent across the studies, with six studies35,43,49,59,66,100 using a diagnostic outcome
and two studies48,51 using a failure-type outcome. There was also heterogeneity in the time at which the
outcome assessment occurred (unclear, 48 hours and 7 days). Similarly, the threshold used to define a positive
test was not consistent across the studies, ranging from 242 pg/ml49 to 558 ng/ml.43 Diagnostic accuracy
summaries for the included studies are provided in Table 17.
TABLE 14 Characteristics of the study included for Nephrocheck in the cardiac surgery health-care setting
using urine
First author and year
Patient
group Age (years)
Timing of test
sample Threshold Outcome
Outcome
+ –
Meersch 201454 Patients
undergoing
CPB
Mean (SD):
± 72 (11)
Maximum (TIMP-2)
× (IGFBP7) in
24 hours post CPB
0.3 RIFLE (≥ R)
within 72 hours
of surgery
26 24
+, with a diagnosis of AKI; –, without a diagnosis of AKI; SD, standard deviation.
0.0 0.2 0.4 0.6 0.8 1.0
False-positive rate
Se
n
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
SROC
95% confidence region
95% prediction region
Individual study estimates
Pooled summary estimate
FIGURE 4 Summary receiver operating characteristic curve for studies included in the meta-analysis for
Nephrocheck in the critical care unit health-care setting using urine.
TABLE 15 Diagnostic accuracy summary for the study included for Nephrocheck in the cardiac surgery health-care
setting using urine
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Meersch
201454
24 8 2 16 0.923
(0.759 to 0.979)
0.667
(0.467 to 0.820)
2.769
(1.556 to 4.929)
0.115
(0.030 to 0.450)
24.00
(4.502 to 128.0)
META-ANALYSIS OF DIAGNOSTIC TESTS FOR ACUTE KIDNEY INJURY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
TABLE 16 Characteristics of studies included in meta-analysis for NGAL in the critical care unit health-care setting
using plasma
First author and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml)a Outcome
Outcome
+ –
Constantin 201036 Patients
admitted to the
critical care unit
Mean (SD):
± 57 (16)
Within 2 hours
of admission
303 RIFLE (≥ R)
within 7 days
of admission
7 81
de Geus 2011100 Patients
admitted to the
critical care unit
Median (IQR):
+ 62 (50, 68);
– 58 (43, 68)
On admission 417 RIFLE (≥ F)
within 7 days
of admission
56 461
Kokkoris 201248 Patients
admitted to the
critical care unit
Median (IQR):
+ 63 (50.3,
80.8); – 49
(35.0, 66.3)
Within
13 hours of
admission
62 RIFLE (≥ R)
within 7 days
of admission
36 64
Linko 201351 Critically ill
patients
receiving
ventilator
support
Median (SD):
± 61 (51, 73)
Enrolment (at
least 6 hours’
ventilator
support)
304 RRT (AKIN 3,
KDIGO 3)
87 282
Hjortrup 201543 Patients
admitted to the
critical care unit
with severe
sepsis and in
need of fluid
resuscitation
Median (IQR):
± 66 (63, 85)
Enrolment 558 KDIGO (≥ 1)
within
48 hours of
enrolment
31 100
Legrand 201549 Patients
admitted to the
critical care unit
with oliguria
(diuresis
< 0.5 ml/hour/kg
for > 6
consecutive
hours)
Median (IQR):
+ 55 (41, 70);
– 55 (41, 70)
At time of
oliguria
diagnosis
242 pg/ml KDIGO (≥ 1)
within 7 days
of admission
41 70
Palazzuoli 201559 Acute heart
failure (evidence
of volume
overload,
pulmonary
congestion or
BNP greater
than the ULN for
age)
Mean (SD):
+ 78 (9);
– 80 (8)
Within
24 hours of
admission
134 AKIN (≥ 1)
during the
hospitalisation
period
78 125
Shum 201566 Patients
admitted to the
critical care unit
and expected
to stay for
> 24 hours
Median (IQR):
+ 74 (60, 83);
– 64 (54, 78)
6 hours after
admission
230 AKIN (≥ 1)
within
48 hours of
admission
45 106
+, with a diagnosis of AKI; –, without a diagnosis of AKI; IQR, interquartile range (quartile 1, quartile 3); SD, standard
deviation; ULN, upper-limit of normal.
a Threshold measured in ng/ml unless stated otherwise.
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Figure 5 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for NGAL in the critical care unit using patient plasma samples. The pooled sensitivity estimate
was 0.72 (95% CI 0.65 to 0.79) and the pooled specificity estimate was 0.81 (95% CI 0.75 to 0.86).
Figure 6 shows an estimate of the SROC curve with the 95% confidence region and 95% prediction
region. The prediction interval shows that there is a degree of heterogeneity in sensitivity and specificity,
probably reflecting the variability in outcome measures and cut-off points, as well as other unidentified
sources of heterogeneity.
Critical care unit: serum
One study including 150 patients [43 patients (28.7%) with a diagnosis of AKI and 107 patients (71.3%)
without a diagnosis of AKI] was identified for NGAL in the critical care unit setting using serum.34 A
summary of the baseline characteristics and test parameters for the included study is provided in Table 18.
A diagnostic-type outcome was used to define the presence of AKI (AKIN stage 1 or above within 48 hours
of admission). The threshold used to define a positive test was 110 ng/ml. A diagnostic accuracy summary
for the included study is provided in Table 19. No meta-analysis was performed for this single study.
Critical care unit: urine
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 20. Six studies were included,32,34,35,43,48,100 with a total of 1194 patients [283 patients (23.7%) with a
diagnosis of AKI and 911 patients (76.3%) without a diagnosis of AKI]. The outcome used to define the
presence of AKI was not consistent across the studies. Of the studies included, five had a similar end
point,32,34,35,43,48 being at least the least severe stage of the RIFLE, AKIN or KDIGO classification system.
There was heterogeneity in the time up to which the outcome assessment occurred (from 28 hours up to
the end of the hospital stay). Similarly, the threshold used to define a positive test was not consistent
across the studies, ranging from 29.5 ng/ml32 to 1310 ng/ml.100 Diagnostic accuracy summaries for the
included studies are shown in Table 21.
TABLE 17 Diagnostic accuracy summaries for studies included in meta-analysis for NGAL in the critical care unit
health-care setting using plasma
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Constantin
201036
43 1 9 35 0.827
(0.703 to 0.906)
0.972
(0.858 to 0.995)
29.7
(4.29 to 206.4)
0.178
(0.098 to 0.323)
167.2
(20.20 to 1384)
de Geus
2011100
39 46 17 415 0.696
(0.567 to 0.801)
0.9
(0.869 to 0.924)
6.98
(5.04 to 9.65)
0.337
(0.227 to 0.502)
20.70
(10.85 to 39.49)
Kokkoris
201248
26 14 10 50 0.722
(0.560 to 0.842)
0.781
(0.666 to 0.865)
3.302
(1.992 to 5.473)
0.356
(0.207 to 0.612)
9.286
(3.628 to 23.77)
Linko 201351 59 73 28 209 0.678
(0.574 to 0.767)
0.741
(0.687 to 0.789)
2.62
(2.05 to 1.60)
0.434
(0.318 to 0.594)
6.033
(3.577 to 10.18)
Hjortrup
201543
18 24 13 76 0.581
(0.408 to 0.736)
0.76
(0.668 to 0.833)
2.42
(1.53 to 3.83)
0.552
(0.359 to 0.847)
4.385
(1.877 to 10.24)
Legrand
201549
33 14 8 56 0.805
(0.660 to 0.898)
0.8
(0.692 to 0.877)
4.024
(2.460 to 6.583)
0.244
(0.130 to 0.459)
16.50
(6.259 to 43.50)
Palazzuoli
201559
66 25 12 100 0.846
(0.750 to 0.910)
0.8
(0.721 to 0.861)
4.231
(2.942 to 6.083)
0.192
(0.113 to 0.326)
22.00
(10.34 to 46.82)
Shum 201566 26 25 19 81 0.578
(0.433 to 0.710)
0.764
(0.675 to 0.835)
2.45
(1.60 to 3.74)
0.553
(0.386 to 0.790)
4.434
(2.111 to 9.134)
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Study
Constantin et al. 201036
de Geus et al. 2011100
Kokkoris et al. 201248
Linko et al. 201351
Hjortrup et al. 201543
Legrand et al. 201549
Palazzuoli et al. 201559
Shum et al. 201566
Summary
Sensitivity (95% CI)
0.83 (0.70 to 0.91)
0.70 (0.57 to 0.80)
0.72 (0.56 to 0.84)
0.68 (0.57 to 0.77)
0.58 (0.41 to 0.74)
0.80 (0.66 to 0.90)
0.85 (0.75 to 0.91)
0.58 (0.43 to 0.71)
0.72 (0.65 to 0.79)
Specificity (95% CI)
0.97 (0.86 to 1.00)
0.90 (0.87 to 0.92)
0.78 (0.67 to 0.86)
0.74 (0.69 to 0.79)
0.76 (0.67 to 0.83)
0.80 (0.69 to 0.88)
0.80 (0.72 to 0.86)
0.76 (0.67 to 0.83)
0.81 (0.75 to 0.86)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 5 Forest plot for studies included in the meta-analysis and pooled estimates for NGAL in the critical care unit health-care setting using plasma.
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Figure 7 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for NGAL in the critical care unit using patient urine samples. The pooled sensitivity estimate was
0.70 (95% CI 0.59 to 0.80) and the pooled specificity estimate was 0.79 (95% CI 0.71 to 0.86). Figure 8
shows an estimate of the SROC curve with the 95% confidence region and 95% prediction region. The
prediction region shows that there is a degree of heterogeneity in sensitivity and specificity, probably
reflecting the variability in outcome measures and cut-off points, as well as other unidentified sources of
heterogeneity.
TABLE 18 Characteristics of the study included for NGAL in the critical care unit health-care setting using serum
First author
and year Patient group
Age
(years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Chen 201234 Patients admitted
to the critical
care unit
Mean (SE):
66 (1)
Admission 110 AKIN (≥ 1) within
48 hours of
admission
43 107
+, with a diagnosis of AKI; –, without a diagnosis of AKI; SE, standard error of the mean.
TABLE 19 Diagnostic accuracy summary for the study included for NGAL in the critical care unit health-care setting
using serum
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Chen 201234 39 4 33 74 0.542
(0.427 to 0.652)
0.949
(0.875 to 0.98)
10.562
(3.973 to 28.084)
0.483
(0.374 to 0.624)
21.864
(7.221 to 66.195)
0.0 0.2 0.4 0.6 0.8 1.0
False-positive rate
Se
n
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
SROC
95% confidence region
95% prediction region
Individual study estimates
Pooled summary estimate
FIGURE 6 Summary receiver operating characteristic curve for studies included in the meta-analysis for NGAL in the
critical care unit health-care setting using plasma.
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TABLE 20 Characteristics of studies included in meta-analysis for NGAL in the critical care unit health-care setting
using urine
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
de Geus
2011100
Patients admitted to the critical
care unit
Median (IQR):
+ 62 (50, 68);
– 58 (43, 68)
On admission 1310 RIFLE (≥ F)
within 7 days
of admission
56 461
Chen 201234 Patients admitted to the critical
care unit
Mean (SE):
66 (1)
On admission 110 AKIN (≥ 1)
within 48 hours
of admission
43 107
Kokkoris
201248
Patients admitted to the ICU Median (IQR):
+ 63 (50.3,
80.8); – 49
(35.0, 66.3)
Within
13 hours of
admission
58.5 RIFLE (≥ R)
within 7 days
of admission
36 64
Aydogdu
201332
Patients admitted to the ICU
(without previous history of
renal disease)
Mean (SD):
+ 70 (13)
(sepsis); – 66
(10) (no sepsis);
– 67 (15)
(sepsis)
Daily
throughout
hospital stay
29.5 RIFLE (≥ R)
during hospital
stay
63 88
Cho 201335 Patients admitted to the medical
or surgical ICU
Mean (SD):
+ 65.4 (14.8);
– 60.4 (17.4)
On admission
to the ICU
251 AKIN (≥ 1)
within 5 days
of admission
54 91
Hjortrup
201543
Patients admitted to the critical
care unit with severe sepsis and
in need of fluid resuscitation
Median (IQR):
± 66 (63, 85)
Enrolment 558 KDIGO (≥ 1)
within 48 hours
of enrolment
31 100
+, with a diagnosis of AKI; –, without a diagnosis of AKI; IQR, interquartile range (quartile 1, quartile 3); SD, standard
deviation; SE, standard error of the mean.
TABLE 21 Diagnostic accuracy summaries for studies included in meta-analysis for NGAL in the critical care unit
health-care setting using urine
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
de Geus
2011100
31 46 25 415 0.554
(0.424 to 0.676)
0.900
(0.869 to 0.924)
5.55
(3.87 to 7.96)
0.496
(0.370 to 0.665)
11.2
(6.09 to 20.6)
Chen 201234 28 17 15 90 0.651
(0.502 to 0.776)
0.841
(0.760 to 0.898)
4.098
(2.516 to 6.675)
0.415
(0.273 to 0.629)
9.882
(4.380 to 22.295)
Kokkoris
201234
28 18 8 46 0.778
(0.619 to 0.883)
0.719
(0.599 to 0.814)
2.765
(1.801 to 4.246)
0.309
(0.165 to 0.581)
8.944
(3.438 to 23.271)
Aydogdu
201332
55 24 8 64 0.873
(0.769 to 0.934)
0.727
(0.626 to 0.809)
3.201
(2.247 to 4.560)
0.175
(0.090 to 0.338)
18.333
(7.623 to 44.092)
Cho 201335 40 27 14 64 0.741
(0.611 to 0.839)
0.703
(0.603 to 0.787)
2.497
(1.753 to 3.555)
0.369
(0.230 to 0.590)
6.772
(3.177 to 14.435)
Hjortrup
201543
17 23 14 77 0.548
(0.378 to 0.708)
0.770
(0.678 to 0.842)
2.38
(1.48 to 3.85)
0.587
(0.392 to 0.877)
4.07
(1.74 to 9.48)
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et al. 2011100
Chen et al. 201234
Kokkoris et al. 201248
Aydogdu et al. 201332
Cho et al. 201335
Hjortrup et al. 201543
Summary
Sensitivity (95% CI)
0.55 (0.42 to 0.68)
0.65 (0.50 to 0.78)
0.78 (0.62 to 0.88)
0.87 (0.77 to 0.93)
0.74 (0.61 to 0.84)
0.55 (0.38 to 0.71)
0.70 (0.59 to 0.80)
Specificity (95% CI)
0.90 (0.87 to 0.92)
0.84 (0.76 to 0.90)
0.72 (0.60 to 0.81)
0.73 (0.63 to 0.81)
0.70 (0.60 to 0.79)
0.77 (0.68 to 0.84)
0.79 (0.71 to 0.86)
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de Geus 
FIGURE 7 Forest plot for studies included in the meta-analysis and pooled estimates for NGAL in the critical care unit health-care setting using urine.
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Cardiac surgery: plasma
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 22. Eight studies were included,31,40,47,60–63,67 with a total of 2644 patients [286 patients (10.8%) with
a diagnosis of AKI and 2358 patients (89.2%) without a diagnosis of AKI]. The outcome used to define a
diagnosis of AKI was largely consistent across the studies, although there was some heterogeneity in the
time period in which the outcome was assessed. However, one study, used an end point that could not
easily be mapped to the considered criteria.67 Each of these could be considered to be somewhere
between the least two severe categories of the RIFLE, AKN or KDIGO classification system. Similarly, the
threshold used to define a positive test was not consistent across the studies, ranging from 150 ng/ml31 to
426 ng/ml.67 Diagnostic accuracy summaries for the included studies are shown in Table 23.
Figure 9 shows point estimates of the sensitivity and specificity from individual studies and the pooled estimates
for NGAL in the cardiac surgery setting using patient plasma samples. The pooled sensitivity estimate was 0.62
(95% CI 0.49 to 0.74) and the pooled specificity estimate was 0.78 (95% CI 0.75 to 0.81). Figure 10 shows an
estimate of the SROC curve with the 95% confidence region and 95% prediction region. The prediction region
suggests limited heterogeneity when considering specificity, with far greater heterogeneity when considering
sensitivity, confirming the observations that can be made from the forest plot (see Figure 9).
Cardiac surgery: serum
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 24. Two studies were included,38,68 with a total of 239 patients [53 patients (22.2%) with a diagnosis
of AKI and 186 patients (77.8%) without a diagnosis of AKI]. The outcome used to define the presence
of AKI was not consistent across the studies, with one study38 using a less stringent version of the AKIN
stage 1 classification without justification. Similarly, the threshold used to define a positive test was not
consistent, being 0.62 ng/ml in one study38 and 133.7 ng/ml in the other study.68 Diagnostic accuracy
summaries for the included studies are shown in Table 25.
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FIGURE 8 Summary receiver operating characteristic curve for studies included in the meta-analysis for NGAL in the
critical care unit health-care setting using urine.
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TABLE 22 Characteristics of studies included in meta-analysis for NGAL in the cardiac surgery health-care setting
using plasma
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Haase
200931
Patients undergoing cardiac
surgery
Mean (SD):
+ 74.2 (6.9);
– 68.3 (10.3)
6 hours post
CPB surgery
150 AKIN (≥ 1)
within 5 days
of admission
46 54
Haase-Fielitz
200940
Patients undergoing cardiac
surgery with CPB
Mean (SD):
+ 75.9 (4.8);
– 67.6 (9.9)
On arrival in the
ICU (6 hours)
150 AKIN (≥ 1)
within 5 days
of admission
23 77
Tuladhar
200967
Patients undergoing cardiac
surgery
Median (IQR):
+ 70 (57–78);
– 66 (41, 81)
2 hours post
surgery
426 An increase in
SCr in the
postoperative
period by
> 0.5 mg/dl
from baseline
9 41
Perry 201063 Patients undergoing CABG
surgery
Mean (SD):
+ 65 (12);
– 65 (10)
At CPB 353.5 AKIN (≥ 1)
within 4 days
postoperatively
75 804
Parikh
201160
Patients undergoing cardiac
surgery (CABG or valve
surgery)
Mean (SD):
± 71 (10)
Soon after
arrival in the ICU
293 AKIN (≥ 2)
within 4 days
postoperatively
60 1159
Kidher
201447
Patients undergoing aortic
valve replacement
Mean (SD):
± 71 (9)
3 hours post
surgery
150 RIFLE (≥ R)
within 2 days
postoperatively
16 37
Park 201561 Patients undergoing
cardiovascular surgery with
CPB
Median (IQR):
+ 65 (50, 74);
– 54 (40, 61)
On admission 168.5 RIFLE (≥ R)
within 3 days
postoperatively
5 72
Perrotti
201562
Patients undergoing cardiac
surgery
Mean (SD):
± 77 (6)
15 minutes after
interruption of
extracorporeal
circulation
178 RIFLE (≥ R)
within 2 days
postoperatively
52 114
+, with a diagnosis of AKI; –, without a diagnosis of AKI; CABG, coronary artery bypass graft; IQR, interquartile range
(quartile 1, quartile 3); SCr, serum creatinine; SD, standard deviation.
TABLE 23 Diagnostic accuracy summaries for studies included in meta-analysis for NGAL in the cardiac surgery
health-care setting using plasma
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Haase
200931
34 14 12 40 0.739
(0.597 to 0.844)
0.741
(0.611 to 0.839)
2.851
(1.760 to 4.618)
0.352
(0.211 to 0.587)
8.095
(3.303 to 19.84)
Haase-Fielitz
200940
18 17 5 60 0.783
(0.581 to 0.903)
0.779
(0.675 to 0.857)
3.545
(2.212 to 5.681)
0.279
(0.127 to 0.611)
12.706
(4.114 to 39.24)
Tuladhar
200967
7 14 2 27 0.778
(0.453 to 0.937)
0.659
(0.505 to 0.784)
2.278
(1.314 to 3.948)
0.337
(0.097 to 1.168)
6.750
(1.235 to 36.91)
Perry 201063 29 149 46 655 0.387
(0.285 to 0.500)
0.815
(0.786 to 0.840)
2.086
(1.515 to 2.873)
0.753
(0.627 to 0.904)
2.771
(1.685 to 4.558)
Parikh
201160
28 220 32 939 0.467
(0.346 to 0.591)
0.810
(0.787 to 0.832)
2.458
(1.830 to 3.304)
0.658
(0.519 to 0.835)
3.735
(2.203 to 6.332)
Kidher
201447
13 4 3 33 0.812
(0.570 to 0.934)
0.892
(0.753 to 0.957)
7.516
(2.892 to 19.53)
0.210
(0.075 to 0.587)
35.750
(7.013 to 182.23)
Park 201561 4 8 1 64 0.800
(0.376 to 0.964)
0.889
(0.796 to 0.943)
7.200
(3.278 to 15.81)
0.225
(0.039 to 1.301)
32.000
(3.172 to 322.8)
Perrotti
201562
28 33 24 81 0.538
(0.405 to 0.667)
0.711
(0.621 to 0.786)
1.860
(1.269 to 2.726)
0.650
(0.474 to 0.891)
2.864
(1.452 to 5.647)
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Haase-Fielitz et al. 200940
Haase et al. 200931
Tuladhar et al. 200967
Perry et al. 201063
Parikh et al. 201160
Kidher et al. 201447
Park et al. 201561
Perrotti et al. 201562
Summary
Sensitivity (95% CI)
0.78 (0.58 to 0.90)
0.74 (0.60 to 0.84)
0.78 (0.45 to 0.94)
0.39 (0.28 to 0.50)
0.47 (0.35 to 0.59)
0.81 (0.57 to 0.93)
0.80 (0.38 to 0.96)
0.54 (0.41 to 0.67)
0.62 (0.49 to 0.74)
Specificity (95% CI)
0.78 (0.67 to 0.86)
0.74 (0.61 to 0.84)
0.66 (0.51 to 0.78)
0.81 (0.79 to 0.84)
0.81 (0.79 to 0.83)
0.89 (0.75 to 0.96)
0.89 (0.80 to 0.94)
0.71 (0.62 to 0.79)
0.78 (0.75 to 0.81)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
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FIGURE 9 Forest plot for studies included in the meta-analysis and pooled estimates for NGAL in the cardiac surgery health-care setting using plasma.
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Figure 11 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for NGAL in the cardiac surgery setting using patient serum samples. The pooled sensitivity
estimate was 0.84 (95% CI 0.43 to 0.97) and the pooled specificity estimate was 0.87 (95% CI 0.59 to
0.97). Figure 12 shows an estimate of the SROC curve with the 95% confidence region and 95%
prediction region. There appears to be considerable heterogeneity in both sensitivity and specificity.
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FIGURE 10 Summary receiver operating characteristic curve for studies included in the meta-analysis for NGAL in
the cardiac surgery health-care setting using plasma.
TABLE 24 Characteristics of studies included in meta-analysis for NGAL in the cardiac surgery health-care setting
using serum
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Ghonemy
201438
Patients
undergoing
CABG surgery
or valve
replacement
Range:+ 39–56;
– 32–53
3 hours
postoperatively
0.62 An increase in SCr
either by 25% of
the baseline or by
0.3 mg/dl above
the baseline level
within 24 hours
postoperatively
17 33
Tung 201568 Patients with
STEMI
receiving PCI
Mean (SD):
+ 68.14 (12.6);
– 61.33 (13.9)
At
presentation
133.7 AKIN (≥ 1) within
48 hours of
admission
36 153
+, with a diagnosis of AKI; –, without a diagnosis of AKI; CABG, coronary artery bypass graft; PCI, percutaneous coronary
intervention; SCr, serum creatinine; SD, standard deviation; STEMI, ST elevation myocardial infarction.
TABLE 25 Diagnostic accuracy summaries for studies included in meta-analysis for NGAL in the cardiac surgery
health-care setting using serum
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Ghonemy
201438
16 2 1 31 0.941
(0.730 to 0.990)
0.939
(0.804 to 0.983)
15.529
(4.032 to 59.81)
0.063
(0.009 to 0.420)
248.0
(20.87 to 2947)
Tung 201568 25 35 11 118 0.694
(0.531 to 0.820)
0.771
(0.699 to 0.831)
3.036
(2.112 to 4.363)
0.396
(0.240 to 0.653)
7.66
(3.432 to 17.12)
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Ghonemy and Amro 201438
Tung et al. 201568
Summary
Sensitivity (95% CI)
0.94 (0.73 to 0.99)
0.69 (0.53 to 0.82)
0.84 (0.43 to 0.97)
Specificity (95% CI)
0.94 (0.80 to 0.98)
0.77 (0.70 to 0.83)
0.87 (0.59 to 0.97)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
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FIGURE 11 Forest plot for studies included in the meta-analysis and pooled estimates for NGAL in the cardiac surgery health-care setting using serum.
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Cardiac surgery: urine
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 26. Thirteen studies were included,41,50,52,53,56,58,60,64,65,67,69,70,72 with a total of 3226 patients [444
patients (13.8%) with a diagnosis of AKI and 2782 patients (86.2%) without a diagnosis of AKI]. The
outcome used to define the presence of AKI was largely consistent across the studies, with one study67
using a non-standard definition and one study41 using only the serum creatinine assessment tool of the
AKIN criteria. However, there was heterogeneity in the time to outcome assessment across the studies.
The threshold used to define a positive test was not consistent across all of the studies, with some studies
using raw concentration values and concentrations normalised by units of urine creatinine. Diagnostic
accuracy summaries for the included studies are shown in Table 27.
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FIGURE 12 Summary receiver operating characteristic curve for studies included in the meta-analysis for NGAL in
the cardiac surgery health-care setting using serum.
TABLE 26 Characteristics of studies included in meta-analysis for NGAL in the cardiac surgery health-care setting
using urine
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml)a Outcome
Outcome
+ –
Wagener
200872
Patients undergoing
cardiovascular surgery
Mean (SD):
+ 69.5 (13.1);
– 61.7 (14.9)
Immediately
post surgery
23.5 AKIN (≥ 1)
within 48 hours
postoperatively
85 341
Han 200941 Patients undergoing
cardiovascular surgery
Mean (SD):
+ 68.3 (2.3);
– 60.4 (1.98)
Immediately
post surgery
456.0 ng/mg
of creatinine
Modified AKIN
stages 1 and 2
within 72 hours
postoperativelyb
36 54
Liangos
200950
Patients undergoing
on-pump cardiovascular
surgery
Mean (SD):
+ 73 (9);
– 67 (12)
2 hours post
surgery
166 ng/mg of
creatinine
RIFLE (≥ R)
within 72 hours
postoperatively
13 90
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TABLE 26 Characteristics of studies included in meta-analysis for NGAL in the cardiac surgery health-care setting
using urine (continued )
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml)a Outcome
Outcome
+ –
Tuladhar
200967
Patients undergoing
cardiac surgery
Median (IQR):
+ 70 (57, 78);
– 66 (41, 81)
2 hours post
surgery
393 ng/mmol
of creatinine
An increase in
SCr in the
postoperative
period by
> 0.5 mg/dl
from baseline
9 41
McIlroy
201053
Hospitalised patients
undergoing contrast-
enhanced CT
– Immediately
post surgery
8 AKIN (≥ 1)
within 48 hours
postoperatively
8 45
Parikh
201160
Patients undergoing
cardiac surgery (CABG or
valve surgery)
Mean (SD):
± 71 (10)
Soon after
arrival in the
ICU
102 AKIN (≥ 2)
within 4 days
postoperatively
60 1159
Oh 201258 Patients undergoing
CABG surgery
Median (IQR):
placebo: + 73
(69, 77.5),
– 68 (62, 72);
EPO: + 70
(62, 75), – 62
(56.5, 72.5)
Immediately
post surgery
5 AKIN (≥ 1)
within 72 hours
postoperatively
21 50
Sargentini
201265
Patients undergoing
cardiovascular surgery
Mean (SD):
+ 74 (6);
– 67 (11)
4 hours post
ICU admission
55.2 mg/g of
creatinine
AKIN (≥ 1)
within 48 hours
postoperatively
15 37
Liu 201352 Patients undergoing
cardiovascular surgery
Mean (SD):
± 63.0 (11.3)
Immediately
postoperatively
131.1 AKIN (≥ 1)
within 48 hours
postoperatively
excluding urine
output
26 83
Munir
201356
Patients undergoing
cardiovascular surgery
Median (IQR):
+ 56 (47–64);
– 51 (45–61)
4 hours post
CPB
109 AKIN (≥ 1)
within 48 hours
postoperatively
11 77
Prowle
201564
Patients undergoing
cardiovascular surgery
Median (IQR):
± 70 (61–76)
Immediately
postoperatively
195 RIFLE (≥ R)
within 5 days
postoperatively
25 68
Tziakas
201569
Patients admitted with
acute, spontaneous
(type 1) AMI undergoing
cardiovascular surgery
Mean (SD):
± 62 (13)
During
admission
Unclear AKIN (≥ 1)
within 48 hours
postoperatively
118 687
Varela
201570
Patients undergoing
cardiovascular surgery
Mean (SD):
± 68 (11)
6 hours Unclear AKIN (≥ 1)
within 48 hours
postoperatively
16 50
+, with a diagnosis of AKI; –, without a diagnosis of AKI; AMI, acute myocardial infarction; CABG, coronary artery bypass
graft; CT, computerised tomography; EPO, erythropoietin; IQR, interquartile range (quartile 1, quartile 3); SCr, serum
creatinine; SD, standard deviation.
a Threshold measured in ng/ml unless stated otherwise.
b Only absolute creatinine level used from stage 1 and all of stage 2 criterion.
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Figure 13 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for NGAL in the cardiac surgery setting using patient urine samples. The pooled sensitivity
estimate was 0.66 (95% CI 0.54 to 0.76) and the pooled specificity estimate was 0.62 (95% CI 0.41 to
0.79). Figure 14 shows an estimate of the SROC with the 95% confidence region and 95% prediction
region. The prediction interval covers almost all of the SROC space, suggesting that there is considerable
heterogeneity between the studies included in this meta-analysis.
Cystatin C
Critical care unit: plasma
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 28. Three studies were included,32,48,49 with a total of 362 patients [140 patients (38.7%) with a
diagnosis of AKI and 222 patients (61.3%) without a diagnosis of AKI]. The outcome used to define the
presence of AKI was not consistent across the studies. All of the studies can be considered to have used a
similar end point, but there was heterogeneity in the time up to which the outcome assessment occurred
(7 days post study entry up to during the hospital stay). Similarly, the threshold used to define a positive
test was not consistent across the studies, ranging from 1040 ng/ml48 to 1500 ng/ml.32 Diagnostic accuracy
summaries for the included studies are shown in Table 29.
Figure 15 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for cystatin C in the critical care unit using patient plasma samples. The pooled sensitivity
TABLE 27 Diagnostic accuracy summaries for studies included in meta-analysis for NGAL in the cardiac surgery
health-care setting using urine
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Wagener
200872
26 65 59 276 0.306
(0.218 to 0.410)
0.809
(0.764 to 0.848)
1.605
(1.089 to 2.365)
0.858
(0.738 to 0.997)
1.871
(1.096 to 3.194)
Han 200941 26 33 10 21 0.722
(0.560 to 0.842)
0.389
(0.270 to 0.522)
1.182
(0.881 to 1.585)
0.714
(0.383 to 1.333)
1.655
(0.665 to 4.117)
Liangos
200950
9 80 4 10 0.692
(0.424 to 0.873)
0.111
(0.061 to 0.193)
0.779
(0.538 to 1.127)
2.769
(1.016 to 7.551)
0.281
(0.073 to 1.084)
Tuladhar
200967
8 9 1 32 0.889
(0.565 to 0.980)
0.780
(0.633 to 0.880)
4.049
(2.175 to 7.540)
0.142
(0.022 to 0.910)
28.444
(3.131 to 258.4)
McIlroy
201053
2 41 6 4 0.250
(0.071 to 0.591)
0.089
(0.035 to 0.207)
0.274
(0.082 to 0.914)
8.437
(3.051 to 23.34)
0.033
(0.005 to 0.218)
Parikh
201160
30 209 30 950 0.500
(0.377 to 0.623)
0.820
(0.796 to 0.841)
2.773
(2.093 to 3.673)
0.610
(0.473 to 0.787)
4.545
(2.682 to 7.705)
Oh 201258 19 26 2 24 0.905
(0.711 to 0.973)
0.480
(0.348 to 0.615)
1.740
(1.289 to 2.35)
0.198
(0.051 to 0.765)
8.769
(1.844 to 41.693)
Sargentini
201265
8 10 7 27 0.533
(0.301 to 0.752)
0.730
(0.570 to 0.846)
1.973
(0.970 to 4.020)
0.640
(0.360 to 1.137)
3.086
(0.887 to 10.74)
Liu 201352 20 15 6 68 0.769
(0.579 to 0.890)
0.819
(0.723 to 0.887)
4.256
(2.571 to 7.047)
0.282
(0.139 to 0.572)
15.111
(5.183 to 44.055)
Munir
201356
6 1 5 76 0.545
(0.280 to 0.787)
0.987
(0.930 to 0.998)
42.000
(5.57 to 316. 8)
0.461
(0.241 to 0.880)
91.200
(9.123 to 911.7)
Prowle
201564
19 27 6 41 0.760
(0.566 to 0.885)
0.603
(0.484 to 0.711)
1.914
(1.327 to 2.761)
0.398
(0.193 to 0.821)
4.809
(1.702 to 13.584)
Tziakas
201569
14 17 2 33 0.875
(0.640 to 0.965)
0.660
(0.522 to 0.776)
2.574
(1.677 to 3.949)
0.189
(0.051 to 0.703)
13.588
(2.763 to 66.830)
Varela
201570
89 378 30 309 0.748
(0.663 to 0.817)
0.450
(0.413 to 0.487)
1.359
(1.200 to 1.539)
0.560
(0.407 to 0.772)
2.425
(1.562 to 3.766)
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Wagener et al. 200872
Han et al. 200941
Liangos et al. 200950
Tuladhar et al. 200967
McIlroy et al. 201053
Parikh et al. 201160
Oh et al. 201258
Sargentini et al. 201265
Liu et al. 201352
Munir et al. 201356
Prowle et al. 201564
Tziakas et al. 201569
Varela et al. 201570
Summary
Sensitivity (95% CI)
0.31 (0.22 to 0.41)
0.72 (0.56 to 0.84)
0.69 (0.42 to 0.87)
0.89 (0.57 to 0.98)
0.25 (0.07 to 0.59)
0.50 (0.38 to 0.62)
0.90 (0.71 to 0.97)
0.53 (0.30 to 0.75)
0.77 (0.58 to 0.89)
0.55 (0.28 to 0.79)
0.76 (0.57 to 0.89)
0.75 (0.66 to 0.82)
0.88 (0.64 to 0.97)
0.66 (0.54 to 0.76)
Specificity (95% CI)
0.81 (0.76 to 0.85)
0.39 (0.27 to 0.52)
0.11 (0.06 to 0.19)
0.78 (0.63 to 0.88)
0.09 (0.04 to 0.21)
0.82 (0.80 to 0.84)
0.48 (0.35 to 0.61)
0.73 (0.57 to 0.85)
0.82 (0.72 to 0.89)
0.99 (0.93 to 1.00)
0.60 (0.48 to 0.71)
0.45 (0.41 to 0.49)
0.66 (0.52 to 0.78)
0.62 (0.41 to 0.79)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 13 Forest plot for studies included in the meta-analysis and pooled estimates for NGAL in the cardiac surgery health-care setting using urine.
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TABLE 28 Characteristics of studies included in meta-analysis for cystatin C in the critical care unit health-care
setting using plasma
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Kokkoris
201248
Patients admitted to
the critical care unit
Median (IQR):
+ 63 (50.3, 80.8);
– 49 (35.0, 66.3)
Within
13 hours of
admission
1040 RIFLE (≥ R)
within 7 days
of admission
36 64
Aydogdu
201332
Patients admitted to
the ICU (without
previous history of
renal disease)
Mean (SD):
+ 70 (13) (sepsis);
– 66 (10) (no
sepsis); – 67 (15)
(sepsis)
Daily
throughout
hospital stay
1500 RIFLE (≥ R)
during the
hospital stay
63 88
Legrand
201549
Patients admitted to
the critical care unit
with oliguria (diuresis
< 0.5 ml/hour/kg for
> 6 consecutive
hours)
Median (IQR):
+ 55 (41, 70);
– 55 (41, 70)
At the time
of oliguria
diagnosis
1375 KDIGO (≥ 1)
within 7 days
of admission
41 70
+, with a diagnosis of AKI; –, without a diagnosis of AKI; IQR, interquartile range (quartile 1, quartile 3); SD, standard deviation.
0.0 0.2 0.4 0.6 0.8 1.0
False-positive rate
Se
n
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
SROC
95% confidence region
95% prediction region
Individual study estimates
Pooled summary estimate
FIGURE 14 Summary receiver operating characteristic curve for studies included in the meta-analysis for NGAL in
the cardiac surgery health-care setting using urine.
TABLE 29 Diagnostic accuracy summaries for studies included in meta-analysis for cystatin C in the critical care unit
health-care setting using plasma
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Kokkoris
201248
22 12 14 52 0.611
(0.449 to 0.752)
0.812
(0.700 to 0.889)
3.259
(1.838 to 5.779)
0.479
(0.313 to 0.733)
6.810
(2.719 to 17.055)
Aydogdu
201332
46 28 17 60 0.730
(0.610 to 0.824)
0.682
(0.579 to 0.770)
2.295
(1.632 to 3.226)
0.396
(0.257 to 0.609)
5.798
(2.838 to 11.848)
Legrand
201549
34 19 7 51 0.829
(0.687 to 0.915)
0.729
(0.615 to 0.819)
3.055
(2.031 to 4.595)
0.234
(0.118 to 0.467)
13.038
(4.946 to 34.364)
META-ANALYSIS OF DIAGNOSTIC TESTS FOR ACUTE KIDNEY INJURY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
Study
Kokkoris et al. 201248
Aydogdu et al. 201332
Legrand et al. 201549
Summary
Sensitivity (95% CI)
0.61 (0.45 to 0.75)
0.73 (0.61 to 0.82)
0.83 (0.69 to 0.91)
0.72 (0.59 to 0.82)
Specificity (95% CI)
0.81 (0.70 to 0.89)
0.68 (0.58 to 0.77)
0.73 (0.61 to 0.82)
0.74 (0.65 to 0.81)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 15 Forest plot for studies included in the meta-analysis and pooled estimates for cystatin C in the critical care unit health-care setting using plasma.
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estimate was 0.72 (95% CI 0.59 to 0.82) and the pooled specificity estimate was 0.74 (95% CI 0.65 to
0.81). Figure 16 shows an estimate of the SROC curve with the 95% confidence region and 95%
prediction region. Examining the forest plot and prediction region suggests that there is greater
heterogeneity in sensitivity than in specificity.
Critical care unit: serum
Summaries of the baseline characteristics and test parameters for the included studies are shown in Table 30.
Four studies were included,34,42,46,71 with a total of 372 patients [110 patients (29.6%) with a diagnosis of AKI
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95% confidence region
95% prediction region
Individual study estimates
Pooled summary estimate
FIGURE 16 Summary receiver operating characteristic curve for studies included in the meta-analysis for cystatin C
in the critical care unit health-care setting using plasma.
TABLE 30 Characteristics of studies included in meta-analysis for cystatin C in the critical care unit health-care
setting using serum
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Herget-
Rosenthal
200442
Patients predisposed
to acute renal failure
in the critical care
unit
Mean (SD):
+ 70 (8);
– 63 (11)
On
admission
– RIFLE (≥ R) within 48 hours 24 61
Villa 200571 Risk of renal failure Range
21–86
In the
morning
Elevated
(no specific
information)
Renal dysfunction
(SCr < 80ml/minute/1.73m2 –
based on 24-hour urine sample)
25 25
Kato 200846 All patients
scheduled for
elective CAG
returning to the
critical care unit
Range
43–86
Prior to
CAG
1200 An increase of > 25% from the
baseline SCr value or an
absolute increase of at least
0.5 mg/dl within 48 hours
18 69
Chen 201234 Patients admitted to
the critical care unit
Mean (SE):
66 (1)
On
admission
1800 AKIN (≥ 1) within 48 hours of
admission
43 107
+, with a diagnosis of AKI; –, without a diagnosis of AKI; CAG, coronary angiography; SCr, serum creatinine; SD, standard
deviation; SE, standard error of the mean.
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and 262 patients (70.4%) without a diagnosis of AKI]. The outcome used to define the presence of AKI was
not consistent across the studies, with one study using a definition that was less serious than the least serious
stage of the RIFLE, AKIN or KDIGO classification system46 and one study basing the outcome on continuous
urine collection.71 Similarly, the threshold used to define a positive test was not consistent across all of the
studies, ranging from absolute values of 1200 ng/ml46 to 1800 ng/ml34 and with other patient-specific relative
thresholds used. Diagnostic accuracy summaries for the included studies are shown in Table 31.
Figure 17 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for cystatin C in the critical care unit using patient serum samples. The pooled sensitivity estimate
was 0.76 (95% CI 0.57 to 0.88) and the pooled specificity estimate was 0.91 (95% CI 0.85 to 0.95).
Figure 18 shows an estimate of the SROC curve with the 95% confidence region and 95% prediction
region, which again shows greater heterogeneity in sensitivity than in specificity.
Critical care unit: urine
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 32. Three studies were included,32,34,175 with a total of 745 patients [231 patients (31.0%) with a
diagnosis of AKI and 514 patients (69.0%) without a diagnosis of AKI]. The definition of AKI used was
fairly consistent across the studies, but the time period within which the outcome was assessed varied
from 48 hours to the entire length of the hospital stay. Similarly, the threshold used to define a positive
test was not consistent across the studies, ranging from 106 ng/ml32 to 200 ng/ml.34 Diagnostic accuracy
summaries for the included studies are shown in Table 33.
Figure 19 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for cystatin C in the critical care unit using patient urine samples. The pooled sensitivity estimate
was 0.68 (95% CI 0.43 to 0.86) and the pooled specificity estimate was 0.76 (95% CI 0.62 to 0.86).
Figure 20 shows an estimate of the SROC curve with the 95% confidence region and 95% prediction
region. Heterogeneity appears to be considerable and greater in terms of sensitivity than specificity.
Cardiac surgery: plasma
The searches identified no studies suitable for data extraction for this diagnostic test, setting and
sample type.
TABLE 31 Diagnostic accuracy summaries for studies included in meta-analysis for cystatin C in the critical care unit
health-care setting using serum
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Herget-
Rosenthal
200442
13 3 11 58 0.542
(0.351 to 0.721)
0.951
(0.865 to 0.983)
11.014
(3.442 to 35.25)
0.482
(0.311 to 0.747)
22.848
(5.572 to 93.70)
Villa 200571 19 2 6 23 0.760
(0.566 to 0.885)
0.920
(0.750 to 0.978)
9.500
(2.469 to 36.55)
0.261
(0.129 to 0.529)
36.417
(6.575 to 201.7)
Kato 200846 17 10 1 59 0.944
(0.742 to 0.990)
0.855
(0.753 to 0.919)
6.517
(3.634 to 11.69)
0.065
(0.010 to 0.438)
100.300
(11.976 to 840.0)
Chen 201234 33 10 10 97 0.767
(0.623 to 0.868)
0.907
(0.836 to 0.948)
8.212
(4.450 to 15.15)
0.257
(0.149 to 0.443)
32.010
(12.239 to 83.72)
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Study
Herget-Rosenthal et al. 200442
Villa et al. 200571
Kato et al. 200846
Chen et al. 201234
Summary
Sensitivity (95% CI)
0.54 (0.35 to 0.72)
0.76 (0.57 to 0.89)
0.94 (0.74 to 0.99)
0.77 (0.62 to 0.87)
0.76 (0.57 to 0.88)
Specificity (95% CI)
0.95 (0.87 to 0.98)
0.92 (0.75 to 0.98)
0.86 (0.75 to 0.92)
0.91 (0.84 to 0.95)
0.91 (0.85 to 0.95)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 17 Forest plot for studies included in the meta-analysis and pooled estimates for cystatin C in the critical care unit health-care setting using serum.
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TABLE 32 Characteristics of studies included in meta-analysis for cystatin C in the critical care unit health-care
setting using urine
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Nejat
2010175
Patients admitted to the
critical care unit
Mean (SD):
+ 62 (15);
– 58 (18)
On admission 120 AKIN (≥ 1)
within 7 days
of admission
125 319
Chen 201234 Patients admitted to the
critical care unit
Mean (SE): 66 (1) On admission 200 AKIN (≥ 1)
within 48 hours
of admission
43 107
Aydogdu
201332
Patients admitted to the ICU
(without a previous history of
renal disease)
Mean (SD):
+ 70 (13) (sepsis);
– 66 (10)
(no sepsis);
– 67 (15) (sepsis)
Daily
throughout
the hospital
stay
106 RIFLE (≥ R)
during the
hospital stay
63 88
+, with a diagnosis of AKI; –, without a diagnosis of AKI; SD, standard deviation; SE, standard error of the mean.
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FIGURE 18 Summary receiver operating characteristic curve for studies included in the meta-analysis for cystatin C
in the critical care unit health-care setting using serum.
TABLE 33 Diagnostic accuracy summaries for studies included in meta-analysis for cystatin C in the critical care unit
health-care setting using urine
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Nejat 2010175 84 115 41 204 0.672
(0.586 to 0.748)
0.639
(0.585 to 0.690)
1.864
(1.540 to 2.256)
0.513
(0.394 to 0.668)
3.634
(2.346 to 5.631)
Chen 201234 20 17 23 90 0.465
(0.325 to 0.611)
0.841
(0.760 to 0.898)
2.927
(1.704 to 5.029)
0.636
(0.476 to 0.850)
4.604
(2.085 to 10.17)
Aydogdu
201332
54 18 9 70 0.857
(0.750 to 0.923)
0.795
(0.700 to 0.867)
4.190
(2.742 to 6.404)
0.180
(0.097 to 0.332)
23.333
(9.723 to 55.99)
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Nejat et al. 2010175
Chen et al. 201234
Aydogdu et al. 201332
Summary
Sensitivity (95% CI)
0.67 (0.59 to 0.75)
0.47 (0.33 to 0.61)
0.86 (0.75 to 0.92)
0.68 (0.43 to 0.86)
Specificity (95% CI)
0.64 (0.59 to 0.69)
0.84 (0.76 to 0.90)
0.80 (0.70 to 0.87)
0.76 (0.62 to 0.86)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 19 Forest plot for studies included in the meta-analysis and pooled estimates for cystatin C in the critical care unit health-care setting using urine.
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Cardiac surgery: serum
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 34. Five studies were included,31,38,39,64,68 with a total of 532 patients [147 patients (27.6%) with a
diagnosis of AKI and 385 patients (72.4%) without a diagnosis of AKI]. The outcome used to define the
presence of AKI was not consistent across the studies, with one study38 using a definition that was less
serious than the least serious stage of the RIFLE, AKIN or KDIGO classification system17 and one study basing
the outcome on continuous urine collection (from 48 hours up to 4 days post study entry). Similarly, the
threshold used to define a positive test was not consistent across the studies, ranging from 0.0265 ng/ml
(26.5 pg/ml) to 1100 ng/ml. Diagnostic accuracy summaries for the included studies are shown in Table 35.
Figure 21 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for cystatin C in the cardiac surgery setting using patient serum samples. The pooled sensitivity
estimate was 0.73 (95% CI 0.65 to 0.80) and the pooled specificity estimate was 0.72 (95% CI 0.63 to
0.79). Figure 22 shows an estimate of the SROC curve with the 95% confidence region and 95%
prediction region. The studies show limited evidence of heterogeneity, with a greater degree of
heterogeneity with respect to specificity than sensitivity.
Cardiac surgery: urine
Summaries of the baseline characteristics and test parameters for the included studies are shown in
Table 36. Two studies were included,50,69 with a total of 908 patients [131 patients (14.4%) with a diagnosis
of AKI and 777 patients (85.6%) without a diagnosis of AKI]. The outcome used to define the presence of
AKI was similar in both studies, although the time frame over which the outcome was assessed varied by
24 hours. The threshold used to define a positive test was not consistent across the studies, with one
study69 not clearly reporting the threshold used. Diagnostic accuracy summaries for the included studies
are shown in Table 37.
Figure 23 shows point estimates of the sensitivity and specificity from individual studies and the pooled
estimates for cystatin C in the cardiac surgery setting using patient serum samples. The pooled sensitivity
estimate was 0.52 (95% CI 0.27 to 0.76) and the pooled specificity estimate was 0.72 (95% CI 0.36 to
0.92). Figure 24 shows an estimate of the SROC curve with the 95% confidence region and 95%
prediction region. Examining the forest plot and prediction region in the SROC curve suggests that there is
considerable heterogeneity between the studies in terms of sensitivity and specificity.
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FIGURE 20 Summary receiver operating characteristic curve for studies included in the meta-analysis for cystatin C
in the critical care unit health-care setting using urine.
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TABLE 35 Diagnostic accuracy summaries for studies included in meta-analysis for cystatin C in the cardiac surgery
health-care setting using serum
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Haase 200931 34 18 12 36 0.739
(0.597 to 0.844)
0.667
(0.534 to 0.778)
2.217
(1.465 to 3.356)
0.391
(0.232 to 0.659)
5.667
(2.379 to 13.50)
Haase-Fielitz
200939
18 11 5 66 0.783
(0.581 to 0.903)
0.857
(0.762 to 0.918)
5.478
(3.043 to 9.863)
0.254
(0.116 to 0.554)
21.600
(6.646 to 70.20)
Ghonemy
201438
9 9 8 24 0.529
(0.310 to 0.738)
0.727
(0.558 to 0.849)
1.941
(0.950 to 3.968)
0.647
(0.375 to 1.117)
3.000
(0.884 to 10.18)
Prowle
201564
19 25 6 43 0.760
(0.566 to 0.885)
0.632
(0.514 to 0.737)
2.067
(1.411 to 3.028)
0.380
(0.185 to 0.780)
5.447
(1.922 to 15.44)
Tung 201568 28 47 8 106 0.778
(0.619 to 0.883)
0.693
(0.616 to 0.760)
2.532
(1.885 to 3.401)
0.321
(0.173 to 0.596)
7.894
(3.349 to 18.61)
TABLE 34 Characteristics of studies included in meta-analysis for cystatin C in the cardiac surgery health-care
setting using serum
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Haase
200931
Patients undergoing
cardiac surgery in a
tertiary hospital
Mean (SD):
+ 74.2 (6.9);
– 68.3 (10.3)
On arrival in
the ICU
(6 hours)
1.1 AKIN (≥ 1) within
5 days of
admission
46 54
Haase-Fielitz
200939
Patients undergoing
cardiac surgery with CPB
Mean (SD):
+ 75.9 (4.8);
– 67.6 (9.9)
On arrival in
the ICU
(6 hours)
1100 AKIN (≥ 1) within
5 days of
admission
23 77
Ghonemy
201438
Patients undergoing
CABG surgery or valve
replacement
Range:+ 39–56;
– 32–53
3 hours
postoperatively
0.0265 An increase in
SCr either by
25% of the
baseline value or
by 0.3 mg/dl
above the
baseline level
within 24 hours
postoperatively
17 33
Prowle
201564
Patients undergoing
cardiovascular surgery
Median (IQR):
± 70 (61–76)
Immediately
postoperatively
1.24 RIFLE (≥ R)
within 5 days
postoperatively
25 68
Tung 201568 Patients with STEMI
receiving PCI
Mean (SD):
+ 68.14 (12.6);
– 61.33 (13.9)
At
presentation
1.6 AKIN (≥ 1) within
48 hours of
admission
36 153
+, with a diagnosis of AKI; –, without a diagnosis of AKI; CABG, coronary artery bypass graft; IQR, interquartile range
(quartile 1, quartile 3); PCI, percutaneous coronary intervention; SCr, serum creatinine; SD, standard deviation; STEMI, ST
elevation myocardial infarction.
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Study
Haase-Fielitz et al. 200939
Haase et al. 200931
Ghonemy and Amro 201438
Prowle et al. 201564
Tung et al. 201568
Summary
Sensitivity (95% CI)
0.78 (0.58 to 0.90)
0.74 (0.60 to 0.84)
0.53 (0.31 to 0.74)
0.76 (0.57 to 0.89)
0.78 (0.62 to 0.88)
0.73 (0.65 to 0.80)
Specificity (95% CI)
0.86 (0.76 to 0.92)
0.67 (0.53 to 0.78)
0.73 (0.56 to 0.85)
0.63 (0.51 to 0.74)
0.69 (0.62 to 0.76)
0.72 (0.63 to 0.79)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 21 Forest plot for studies included in the meta-analysis and pooled estimates for cystatin C in the cardiac surgery health-care setting using serum.
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Limitations
A limitation of this work is the use of a number of similar criteria for diagnosing AKI based on the
measurement of serum creatinine and urine output rather than a more direct and accurate determination
of kidney function and injury. Criteria based on serum creatinine lack real-time sensitivity for kidney injury,
as creatinine concentration has a slow rate of change and is affected by other factors such as sex and
muscle mass. Current standard AKI criteria based on serum creatinine and urine output measures therefore
TABLE 37 Diagnostic accuracy summaries for studies included in meta-analysis for cystatin C in the cardiac surgery
health-care setting using urine
First author
and year
TP,
n
FP,
n
FN,
n
TN,
n
Sensitivity
(95% CI)
Specificity
(95% CI) LR+ (95% CI) LR– (95% CI) DOR (95% CI)
Liangos
200950
5 13 8 77 0.385
(0.177 to 0.645)
0.856
(0.768 to 0.914)
2.663
(1.136 to 6.241)
0.719
(0.464 to 1.115)
3.702
(1.047 to 13.083)
Tziakas
201569
76 309 42 378 0.644
(0.554 to 0.725)
0.550
(0.513 to 0.587)
1.432
(1.223 to 1.676)
0.647
(0.503 to 0.832)
2.214
(1.475 to 3.321)
0.0 0.2 0.4 0.6 0.8 1.0
False-positive rate
Se
n
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
SROC
95% confidence region
95% prediction region
Individual study estimates
Pooled summary estimate
FIGURE 22 Summary receiver operating characteristic curve for studies included in the meta-analysis for cystatin C
in the cardiac surgery health-care setting using serum.
TABLE 36 Characteristics of studies included in meta-analysis for cystatin C in the cardiac surgery health-care
setting using urine
First author
and year Patient group Age (years)
Timing of
sample
Threshold
(ng/ml) Outcome
Outcome
+ –
Liangos
200950
Patients undergoing
on-pump cardiovascular surgery
Mean (SD):
+ 73 (9);
– 67 (12)
2 hours
post surgery
192 ng/mg
of creatinine
RIFLE (≥ R)
within 72 hours
postoperatively
13 90
Tziakas
201569
Patients admitted with
spontaneous (type 1) AMI
undergoing cardiovascular
surgery
Mean (SD):
± 62 (13)
During
admission
Unclear AKIN (≥ 1)
within 48 hours
postoperatively
118 687
+, with a diagnosis of AKI; –, without a diagnosis of AKI; AMI, acute myocardial infarction; SD, standard deviation.
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Study
Liangos et al. 200950
Tziakas et al. 201569
Summary
Sensitivity (95% CI)
0.38 (0.18 to 0.64)
0.64 (0.55 to 0.72)
0.52 (0.27 to 0.76)
Specificity (95% CI)
0.86 (0.77 to 0.91)
0.55 (0.51 to 0.59)
0.72 (0.36 to 0.92)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Sensitivity
Specificity
FIGURE 23 Forest plot for studies included in the meta-analysis and pooled estimate for cystatin C in the cardiac surgery health-care setting using urine.
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represent an imperfect reference test for the early detection of AKI. Each of the studies considered in these
meta-analyses used criteria based on changes in serum creatinine concentrations and is therefore affected
equally by this limitation.
The method of meta-analysis used in this analysis is recommended by the Cochrane Screening and
Diagnostic Tests Methods Group.262 However, a similar method in the Bayesian paradigm, which has
shown to be equivalent in simple cases, may have been a reasonable alternative.259 Furthermore, this fully
Bayesian approach has the advantage of potentially unifying the sensitivity analyses (assessment of
uncertainty in the estimates in decision analysis) with the modelling step and of allowing predictions of test
accuracies in future trials through a posterior predictive distribution. The hierarchical model approach may
also have been flexible enough to include further modelling aspects related to analytical and biological
variance of the diagnostic tests considered in this work, if enough studies were included to reasonably
estimate models. This is not possible using the simple bivariate random-effects meta-analysis method and
is a possible limitation of this work. Further work will consider in more detail the possibility of extending
the hierarchical model to include these aspects and investigate if the hierarchical model can be estimated
in meta-analyses of this size. Extension of this model that allows for imperfect gold reference standards
may also be worthy of further investigation.263
There is evidence of considerable heterogeneity in some of the included studies, which is clearly observed
in the large prediction regions in the SROC space. Two of the sources of heterogeneity are the outcome
measures used and the time within which the outcome is assessed. As mentioned earlier, a limitation of
this work is the use of criteria based on measurement of serum creatinine and urine output rather than a
more direct determination of kidney function. If more studies had provided data, meta-regression may
have been useful for isolating and quantifying some of these sources of heterogeneity further. Further
investigations may be conducted into modelling these sources of heterogeneity as part of future work
described above related to investigating the possible extension of the hierarchical regression models.
0.0 0.2 0.4 0.6 0.8 1.0
False-positive rate
Se
n
si
ti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
SROC
95% confidence region
95% prediction region
Individual study estimates
Pooled summary estimate
FIGURE 24 Summary receiver operating characteristic curve for studies included in the meta-analysis for cystatin C
in the cardiac surgery health-care setting using urine.
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Summary
A number of the diagnostic tests for AKI considered in these meta-analyses may have a role to play in
certain health-care settings and using particular sample media. The Nephrocheck test using urine in the
critical care unit setting appears overall to have the best sensitivity, albeit with low specificity. The
estimates of sensitivity are high and there is low heterogeneity. The NGAL test using plasma shows
moderate sensitivity and high specificity, but greater heterogeneity. Other health-care settings and sample
types show evidence of considerable heterogeneity between studies. Two studies that were included in
previously published NGAL meta-analyses were excluded here as they included patients who originated in
the emergency room and who were subsequently released to other hospital departments.245,264
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Chapter 4 Measurement performance: a
framework for the Quality Assessment of
Measurement Procedures using in vitro diagnostic
medical devices in clinical research
Introduction
It is generally accepted that between 60% and 80% of clinical decisions are influenced by the results of
laboratory testing using IVDs.265 A large proportion, although not all, of this testing is focused on the
quantitative or semiquantitative measurement of biomarkers in patient samples. The accuracy and
associated uncertainty of these measurements can have a major impact on the overall quality of clinical
decisions and their subsequent clinical effectiveness and cost-effectiveness.266,267
The main factors affecting measurement uncertainty are shown in Figure 25. Laboratories and regulators
have historically focused on analytical factors associated with the measurement system, including analytical
imprecision and trueness (accuracy). However, it is increasingly accepted that the major sources of error
(uncertainty) associated with biomarker measurements are derived from either the patients themselves or
the acquisition of their samples, referred to respectively as biological and pre-analytical factors.268,269 The
uncertainty introduced by these factors accumulates throughout the measurement system, eventually
affecting test performance, such as diagnostic accuracy (Figure 26).
Although there has been significant progress in characterising and controlling for measurement factors in
clinical care, they are almost always poorly accounted for in clinical research.271 This has led to recent
criticisms and calls for more rigorous methodology in the field.272
Pre-analytical: biological Analytical: imprecision
Analytical: truenessPre-analytical: technicalBiological: within-individual
Patient preparation
Time
Operator
EnvironmentSite of sampling
Patient state
Week–week
Diurnal Collection
Processing Bias
UM
Day–day
Months or years Storage
SelectivityHandling and
transport
Time of sampling Equipment
Calibration
FIGURE 25 Feather diagram depicting sources of uncertainty contributing towards the measurement
uncertainty (UM).
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Measurement factors can impact negatively on clinical studies and trials as follows:
l Risk of bias. Subtle differences in measurement procedures between study arms can introduce
systematic errors between groups of patients, which may be mistakenly interpreted as clinically relevant
differences.273 For example, a 2002 Lancet publication described a mass spectrometry-based proteomic
signature for diagnosing ovarian cancer, with almost 100% sensitivity and specificity.274 However,
after the results proved difficult to reproduce, an independent analysis concluded that ‘procedural
differences’ between the groups was the most likely explanation for the results.275 Later studies have
confirmed that mass spectrometry-based proteomic signatures are profoundly affected by pre-analytical
sample-handling conditions, potentially leading to significant experimental bias.276
l Concerns regarding reproducibility. Differences in measurement procedures can introduce excessive
variability between studies. This is a particular issue for systematic reviews and meta-analysis, in which
reviewers do not generally take into account the robustness of measurement procedures or differences
between studies. For example, evidence on the clinical validity and utility of the biomarker vascular
endothelial growth factor (VEGF) has been complicated by differences in pre-analytical procedures
between studies.277,278
l Concerns regarding the applicability of research findings to clinical practice. Often for reasons of
pragmatism or cost, measurement procedures performed within a clinical study may differ substantially
from those employed in clinical care. For example, it is not uncommon for trial samples to be frozen
and analysed within a single batch. Although this reduces the study variance and makes a significant
finding more likely, the results may not translate to clinical practice, where variability is usually higher
as samples are measured over many days and using different batches of reagents. The effect of
freeze–thawing may also introduce a systematic increase or decrease in biomarker concentration,
invalidating clinical cut-off points and leading to a higher FP/FN rate in the clinic.
Although the updated STARD 2015251 and QUADAS-230 documents both address important
methodological issues concerning studies of diagnostic accuracy, neither of them address the issues
associated with measurement. Furthermore, although several reporting guidelines have been produced in
specific areas of the field,279–281 we are not aware of any methods in use for evaluating the quality of
measurement procedures within clinical studies. We suggest that this is limiting the ability of systematic
reviewers and health technology assessors to fully evaluate risk and to model uncertainty within
assessments. This has been highlighted in several recent NICE diagnostic assessment reports.282–284
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FIGURE 26 Gaussian bell curves illustrating the interdependency of analytical uncertainty (UA), pre-analytical
uncertainty (UPA), within-individual biological variation (CVwi) and within-group variation (CVG1 and CVG2).
As previously illustrated by Rorass et al.270
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Development of a framework for the Quality Assessment of
Measurement Procedures
A framework for the Quality Assessment of Measurement Procedures (QAMPs) was developed within this
study. An initial framework was constructed through consultation with experts and this was subsequently
tested and refined. The final framework was then validated and its utility explored by applying it to the
literature included in the meta-analysis for Nephrocheck (see Chapter 3).
Three medical laboratory professionals (Rebecca Kift, Leeds Teaching Hospitals NHS Trust; Ashley Garner,
Leeds Teaching Hospitals NHS Trust; Catherine Sturgeon, NHS Lothian) were consulted concerning the scope
and parameters for inclusion. The group agreed that the scope should be limited to ‘in vitro diagnostic
medical devices’ as the requirements for non-IVDs (e.g. imaging devices or devices for taking physical or
clinical measurements) may differ. The defining features of ‘quality’ with respect to measurement procedures
were agreed as ‘bias’, ‘reproducibility’ and ‘applicability’. It was agreed that parameters associated with
biological within-individual variation, biological pre-analytical factors (also known as pre-pre-analytical
factors), technical pre-analytical variation factors (also known simply as pre-analytical factors) and analytical
factors would be included within the quality assessment framework. Existing standards and reviews in these
areas were collated and reviewed to identify best practice in the field of IVD metrology. Once parameters
had been identified, data extraction fields were created to capture the information required by a reviewer to
quality assess each parameter within a research publication. The standards and guidelines identified and
used are shown in Table 38.
TABLE 38 Standards and guidance documents used to develop the QAMPs framework
Organisation Standard or guidance document Type of uncertainty
ISO BS EN ISO 15189:2012 Medical laboratories. Requirements for quality
and competence285
Pre-analytical and analytical
IFCC Quality indicators in laboratory medicine: a fundamental tool for quality
and patient safety286
Pre-analytical and analytical
NIHR RIPOSTE287 Pre-analytical and analytical
EQUATOR Biospecimen Reporting for Improved Study Quality (BRISQ)280 Pre-analytical
EFLM Standardization of collection requirements for fasting samples288 Pre-analytical
EFLM Preanalytical quality improvement. In pursuit of harmony289 Pre-analytical
CLSI H3-A6 Procedures for the Collection of diagnostic blood specimens by
venepuncture290
Pre-analytical
CLSI H18-A4 Procedures for the handling and processing of blood samples291 Pre-analytical
CLSI GP16-A3 Urinalysis292 Pre-analytical
ISBER Pre-Analytical variables affecting the integrity of human biospecimens in
biobanking293
Pre-analytical
EQUATOR STROBE-ME281 Biological, pre-analytical and
analytical
NACB Tumor Marker Quality Requirements Guidelines294 Biological, pre-analytical and
analytical
EFLM A checklist for critical appraisal of studies of biological variation279 Biological
ISO 17511:2003 In vitro diagnostic medical devices295 Analytical
ISO 13612:2002 Performance evaluation of in vitro diagnostic medical
devices296
Analytical
continued
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The initial framework for assessing the quality of measurement procedures was developed and further
refined through an iterative process of testing, consultation and updating. Additional fields were included
by the group if they were thought to be beneficial to the process. The nomenclature ‘low risk’, ‘high risk’
and ‘unclear’ was adopted for rating quality criteria, as used by The Cochrane Collaboration303 and in the
QUADAS-2 tool.30 The QAMPs data extraction and quality assessment framework is shown in Table 39.
To initially validate the QAMPs template and demonstrate its utility, two reviewers extracted and quality
appraised the literature included in the meta-analysis for Nephrocheck from Chapter 2.
Testing the Quality Assessment of Measurement Procedures framework
using Nephrocheck as a case study
In total, four studies were included in the quality assessment, as identified from the searches reported in
Chapter 2. Studies were first data extracted and then supporting evidence was collated while answering
the signalling questions. Finally, a quality judgement was reached using the supporting evidence as the
TABLE 38 Standards and guidance documents used to develop the QAMPs framework (continued )
Organisation Standard or guidance document Type of uncertainty
ISO BS ISO 5725:1994 Accuracy (trueness and precision) of measurement
methods and results297
Analytical
ACB Measurement verification in the clinical laboratory298 Analytical
CLSI EP32-R Metrological Traceability and Its Implementation19 Analytical
CLSI EP26-A User Evaluation of Between-Reagent Lot Variation20 Analytical
CLSI EP25-A Evaluation of Stability of In Vitro Diagnostic Reagents21 Analytical
CLSI EP21-A Estimation of Total Analytical Error for Clinical Laboratory
Methods22
Analytical
CLSI EP15-A3 User Verification of Precision and Estimation of Bias23 Analytical
CLSI EP09-A3 Measurement Procedure Comparison and Bias Estimation Using
Patient Samples24
Analytical
CLSI EP07-A2 Interference Testing in Clinical Chemistry25 Analytical
CLSI EP05-A3 Evaluation of Precision of Quantitative Measurement
Procedures26
Analytical
CLSI I/LA30-A Immunoassay Interference by Endogenous Antibodies27 Analytical
CLSI EP14-A2 Evaluation of Matrix Effects28 Analytical
FDA Bioanalytical Method Validation18,299 Analytical
LGC Evaluating measurement uncertainty in clinical chemistry300 Analytical
CLSI Expression of Measurement Uncertainty in Laboratory Medicine29 Analytical
AAPS Fit-for-Purpose Method Development and Validation for Successful
Biomarker Measurement301
Analytical
AAPS Recommendations for the Bioanalytical Method Validation of
Ligand-binding Assays302
Analytical
AAPS, American Association of Pharmaceutical Scientists; ACB, Association of Clinical Biochemistry; EFLM, European
Federation of Laboratory Medicine; EQUATOR, Enhancing the QUAlity and Transparency Of health Research Network;
IFCC, International Federation of Clinical Chemistry; ISBER, International Society for Biological and Environmental
Repositories; ISO, International Standards Organisation; LGC, Laboratory of the Government Chemist; NACB, National
Academy of Clinical Biochemistry.
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TABLE 39 The QAMPs framework
Citation
Authors:
Title:
Journal: Year: Pages:
Vol.:
Description of the measurement procedure
Features Index Reference
Name of analyte
Test name
Test platform/method used
Manufacturer
Sample matrix used [e.g. urine, serum, plasma (including type)]
Pre-analytical biological
Patient state (e.g. fed/fasted, sitting/standing, rested)
Patient preparation
Anatomical site and/or mechanism
Time of sampling (e.g. before 0900, within 1 hour of reference test)
Pre-analytical technical
Sample collection (mechanism and use of stabilisation)
Preprocessing handling, temperature, transport and time
Sample processing (e.g. preservation, centrifugation conditions, timings and temperature)
Storage (e.g. volume, temperature, duration, freeze–thaw cycles)
Postprocessing handling and transport
Consideration of differences between groups
Standard operating procedures or quality assurance
Other
Analytical factors
Sample blinding procedure
Sample randomisation procedure
Batching procedure
Reference control materials
Quality assurance procedures
Patient inclusion/exclusion criteria
Test failure rate and reasons for test failure
Technical replication
Performance evaluation
Performance goals for:
Precision
Bias
(method of calculation)
continued
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TABLE 39 The QAMPs framework (continued )
Performance evaluation
Within-individual biological variation
Pre-analytical factors
Total measurement uncertainty
Analytical validation
Full validation or verification
Analytical sensitivity:
Method (brief description)
Limit of blank (LOB)
Limit of detection (LOD)
Limit of quantitation (LOQ)
Analytical selectivity:
Method (brief description)
Cross-reactivity
Interference
Carry-over
Trueness:
Method (brief description)
Bias
Precision:
Method (brief description including M-Factors: time, calibration, operator and equipment)
Repeatability (range), CV%
Intermediate Imprecision (range), CV%
Reproducibility (range), CV%
Linearity and working range:
Method (brief description)
Other (e.g. lot to lot, antibody validation profile)
Signalling questions
Were measurement procedures different between groups?
Were measurement procedures described in enough detail to be repeated?
Were measurement factors appropriately controlled for?
Were measurement procedures applicable to the final clinical setting?
Risk of bias (high, low, unclear)
Risk of irreproducibility (high, low, unclear)
Risk of inapplicability (high, low, unclear)
CV%, coefficient of variation.
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basis for transparency and discussion. When evidence was identified, risk was judged as being either high
or low; only when there was insufficient evidence was risk judged as being uncertain. The results of the
signalling questions are presented in Box 1 and the quality assessment is summarised in Table 40. Full
results from the data extraction are presented in Appendix 7.
Discussion
Quality assessment is now recognised as an essential component of systematic review and health
technology assessment because of the marked heterogeneity between studies. Initiatives such as
QUADAS305 and QUADAS-230 have been routinely adopted into these processes and have proven useful in
identifying studies that are at high risk of bias or inapplicability. Similarly, the introduction of reporting
guidelines such as STARD243 and STARD 2015251 have improved reporting in the areas covered, assisting
reviewers to assess quality and differences between studies, while helping researchers to accurately report
BOX 1 Results of the signalling questions
Meersch et al.54
Were measurement procedures different between groups?
l Uncertain. Pre-analytical and analytical study procedures were not reported in enough detail to be
confident that bias had been avoided, for example no details were reported concerning sample blinding,
randomisation and batching.
l In some patients, baseline creatinine level was used rather than creatinine level at time of enrolment; it is
not clear if this was systematically different between patient groups.
Were measurement procedures described in enough detail to be repeated?
l Limited details were provided concerning the Nephrocheck test; not enough details were provided to
repeat the study.
l Almost all parameters required to repeat the serum creatinine reference test were not described, even the
name and manufacturer of the assay.
Were measurement factors appropriately controlled for?
l No. Albumin, bilirubin and methylene blue are known Nephrocheck interferents, which were not controlled
for in the urine samples.
l Quality control procedures were not reported for the Nephrocheck test or for the creatinine reference test.
l The method and traceability of the reference test were not described.
l Performance characteristics of the reference test and index test were not described.
l It is unclear whether the measurement systems were performing as specified by the manufacturer as no
internal verification was reported.
l No performance goals were reported.
Were measurement procedures applicable to the final clinical setting?
l Unclear as the study procedures not described in enough detail.
l Samples were frozen and thawed prior to measurement in the study, whereas samples are likely to be
analysed immediately (fresh) in the acute clinical context. No data were available on freeze–thaw cycles, but
the manufacturer suggests avoiding repeated freezing and thawing.
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Bihorac et al.33
Were measurement procedures different between groups?
l No, but it is not clear whether samples were measured randomly and/or in batches, which may have
introduced a systematic bias.
Were measurement procedures described in enough detail to be repeated?
l The urinary Nephrocheck test was generally reported in enough detail to be repeated.
l Several parameters required to repeat the serum creatinine reference test were not described.
Were measurement factors appropriately controlled for?
l No, the manufacturer’s kit insert identifies albumin and bilirubin as interferents and recommends ‘caution
in interpreting Nephrocheck® results in patients with significant proteinuria or severe hyperbilirubinuria’.304
Albumin (proteinuria and haematuria) and bilirubin (to a lesser extent) are associated with AKI. No attempt
was made to identify and exclude these samples.
l Quality control procedures were not reported for the creatinine reference test.
l No validation or verification of the measurement systems was reported.
l No performance goals were reported.
Were measurement procedures applicable to the final clinical setting?
l No, measurements were conducted at three sites and the median of three measurements was used to
determine diagnostic accuracy. Only a single measurement at a single site would be used in clinical
practice, which may lead to less precise measurements.
l Samples were freeze–thawed prior to measurement in the study, whereas samples are likely to be analysed
immediately (fresh) in the acute clinical context. No data were available on freeze–thaw cycles, but the
manufacturer suggests avoiding repeated freezing and thawing.
Meersch et al.55
Were measurement procedures different between groups?
l Uncertain. Pre-analytical and analytical study procedures were not reported in enough detail to be
confident that systematic bias between groups had been avoided, for example no details were reported
concerning sample randomisation and batching, although laboratory investigators were blinded to
clinical outcomes.
l Index and reference test samples were collected at different times; it was unclear whether this might
introduce bias.
Were measurement procedures described in enough detail to be repeated?
l No, very limited data were provided concerning Nephrocheck and only the analyte name, matrix and time
points were provided for creatinine.
Were measurement factors appropriately controlled for?
l No. Albumin, bilirubin and methylene blue are known Nephrocheck interferents, which were not controlled
for in the urine samples.
BOX 1 Results of the signalling questions (continued)
MEASUREMENT PERFORMANCE: A FRAMEWORK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
66
l Quality control procedures were not reported for either the index or the reference test.
l The method and traceability of the reference test were not described.
l Performance characteristics of the index test and reference test were not described.
l It is unclear whether the measurement systems were performing as specified by the manufacturer as no
internal verification was performed.
l No performance goals were reported.
Were measurement procedures applicable to the final clinical setting?
l No. Test was performed in patients aged < 18 years, which contradicts the instructions for use.
l Samples were frozen and thawed prior to measurement in the study, whereas samples are likely to be
analysed immediately (fresh) in the acute clinical context. No data were available on freeze–thaw cycles,
but the manufacturer suggests avoiding repeated freezing and thawing.
Hoste et al.44
Were measurement procedures different between groups?
l Pre-analytical procedures were described in adequate detail and did not appear to differ between
patient groups.
l Although laboratory investigators were blinded to clinical outcomes, it is unclear whether samples were
batched or randomised for analysis.
l Index and reference test samples were collected at different times; it was unclear whether this might
introduce bias.
Were measurement procedures described in enough detail to be repeated?
l The urinary Nephrocheck test was reported in enough detail to be repeated, although it is not clear
whether the measurements were performed in a single batch and randomised.
l In addition, it is not clear how long samples were frozen for.
l Several parameters required to repeat the serum creatinine reference test were not described.
Were measurement factors appropriately controlled for?
l No; albumin, bilirubin and methylene blue are known Nephrocheck interferents, which were not controlled
for in the urine samples. The manufacturer’s kit insert recommends ‘caution in interpreting Nephrocheck®
results in patients with significant proteinuria or severe hyperbilirubinuria’.304
l Quality control procedures were not reported for the creatinine reference test. The method and traceability
of the reference test were not described.
l It is unclear whether the measurement systems were performing as specified by the manufacturer as no
internal verification was performed.
l It is also not clear whether the samples were processed within 1 hour of collection.
l Performance characteristics and goals of the reference test and index test were not described.
Were measurement procedures applicable to the final clinical setting?
l Unclear; samples were freeze–thawed prior to measurement in the study, whereas samples are likely to be
analysed immediately (fresh) in the acute clinical context. No data were available on freeze–thaw cycles,
but the manufacturer suggests avoiding repeated freezing and thawing.
BOX 1 Results of the signalling questions (continued)
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their findings.306 However, factors associated with measurement have so far been excluded from such
quality assessments, even though they are known to be a major source of bias, irreproducibility and
inapplicability in clinical practice and increasingly in research studies. This could compromise patients’
health if inappropriate test adoption decisions are made based on biased or inaccurate results. As far as
we are aware, this is the first such initiative to assess the quality of measurement procedures used in
clinical studies or trials.
Application of this framework within the four Nephrocheck case studies identified several measurement
parameters that present a high risk of irreproducibility, including a failure to exclude samples with known
interferents, a lack of internal and external quality control and a complete lack of analytical measurement
verification in all studies. It also highlighted several issues that might affect the clinical applicability of
test results, including freeze–thawing of samples in the absence of validation data and against the
recommendations of the manufacturer, potentially biasing clinical cut-off points and overestimating
precision; use of a device in an unvalidated patient population (i.e. aged < 18 years); and reporting the
median value of three measurements from different laboratories. Furthermore, it identified several issues
that made assessment of the risk of bias uncertain.
A key finding of this assessment was that the reporting of critical measurement parameters was very
poor in the majority of studies and this severely hindered the reviewers’ ability to assess their quality.
Interestingly, all of the studies claimed to comply with the STARD reporting guidelines. In the absence
of better reporting this framework will have limited utility, so this is an area that needs addressing.
Unfortunately, the reporting guidelines already in existence [Biospecimen Reporting for Improved Study
Quality (BRISQ)307 and (STPROBE-ME)308] have not been widely adopted or promoted by journals. It is
important to note that the issues pertaining to poor measurement procedures and the application of the
QAMPs framework apply not only to diagnostic, prognostic or predictive accuracy studies of IVDs but also
to any clinical trial or study using IVDs as end points or inclusion criteria. This includes Clinical Trials of an
Investigational Medicinal Product (CTIMPs), especially in the era of precision medicine, with an increasing
number of CTIMPs basing their eligibility criteria and end points on molecular biomarkers measured using IVDs.
Because of the complexity and scale of the subject matter, it might be tempting to create a long and
highly detailed data extraction template and include more signalling questions. However, in the interests
of pragmatism and user friendliness we attempted to keep the number of fields and signalling questions
to a minimum. We believe that this will probably change over time as experience of using the framework
develops and our understanding of the requirements and knowledge of reviewers and the critical ‘at risk’
parameters develops. For example, following the review of the results we identified that it might prove
useful in future to include a specific field for ‘sample exclusion’ procedures.
Although the work presented here demonstrates the value of such an approach to quality assessment, the
authors accept that this is only the first step towards developing such a framework and that further work
is required. Potential areas for future research include refining the parameters and signalling questions,
TABLE 40 Summary of the QAMPs results for Nephrocheck studies
First author and year Risk of bias Risk of irreproducibility Risk of inapplicability
Bihorac 201433 Unclear High High
Meersch 201455 Unclear High High
Hoste 201444 Unclear High Unclear
Meersch 201454 Unclear High High
MEASUREMENT PERFORMANCE: A FRAMEWORK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
validating the utility more widely and developing guidance for users. We have identified the following
limitations that we hope to address in future work:
l The framework has had limited input from the wider IVD community. To address this we plan to set up
a workshop with key external stakeholders and apply a more systematic approach to development of
the framework.
l Interpretation is limited by prior knowledge of the measurement factors affecting an IVD. The
instructions for use of IVDs must, by law, contain certain information on the analytical procedures and
performance of a test. A formal data extraction process for instructions for use may provide a useful
and pragmatic starting point against which to benchmark studies. However, additional parameters are
often identifiable from the literature, perhaps requiring systematic review methods to be developed.
l Limited evidence of utility. Further validation of the approach is required across diagnostic, prognostic,
predictive and monitoring contexts in addition to investigating its application in RCTs of CTIMPs.
l The framework is currently limited to quantitative measurements. There is a need to consider how to
apply the framework to semiquantitative or qualitative measurements, for example next-generation
sequencing.
l Limited to IVDs. There are similar issues with all diagnostics including imaging, physical measurements
and clinical support algorithms.
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Chapter 5 Economic evaluation
Introduction
There is currently growing interest in the use of decision modelling earlier in the research and development
process for new health-care technologies.309–311 This is, in part, a response to the high costs and failure
rates of pre-regulatory Phase III trials, which is a key issue for tests, in particular, because of the difficult
and often financially prohibitive task of linking test outcomes with subsequent treatment pathways. A
decision model can be used in the early phases of the research pathway to synthesise current evidence on
the effectiveness and cost-effectiveness of emerging technologies. For tests, models are a key resource to
enable linkage of diagnostic accuracy evidence with downstream health and cost impacts. Furthermore,
models can be used to identify key uncertainties in the evidence base that pose the most risk for clinical,
regulatory and reimbursement decision-makers; this information can then be used to tailor the ongoing
trajectory and design of research to target and reduce critical uncertainties and to avoid unnecessary and
expensive large-scale trials when possible. This approach thereby enables both optimisation of future
research resources and maximisation of research outputs.
The objective of the economic evaluation in the AKI-Diagnostics study was to (1) assess the potential
cost-effectiveness of AKI biomarkers in an acute care setting, based on an evaluation of the current
evidence base, and (2) determine the value of conducting further research into such biomarkers. The focus
of this chapter is on the development of a decision model to determine the expected cost-effectiveness of
AKI biomarkers; the implications for future research are explored further in Chapter 6.
Overview of the economic evaluation
A de novo decision-analytic model was constructed to evaluate the potential impact of AKI biomarkers
within a hospital critical care setting. The model structure was developed using the findings from a model
literature review, a focus group and expert consultation; model parameters were subsequently derived
using data from the literature, analysis of individual patient clinical trial data and expert opinion. The
model adopts a UK NHS and Personal Social Services (PSS) perspective, with all costs reported in 2015
prices and patient health measured in terms of QALYs. Future cost and health outcomes were discounted
at an annual rate of 3.5%, as per current NICE guidance.312
Each of the tests included in the meta-analysis in Chapter 3 (Nephrocheck, NGAL and cystatin C) was
compared both individually against standard care monitoring and in a multiway incremental analysis.
Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER) and incremental net
(health) benefit (INB) values and a range of sensitivity analyses was conducted to explore the impact of key
model assumptions and parameter uncertainty on the results. The model was developed in line with
current best practice standards312–314 and was built and analysed using R software version 3.0.3.
Methods
Population and perspective
The base-case primary evaluation focused on the assessment of AKI biomarkers for a population of adult
all-comers (aged ≥ 18 years) admitted to the hospital critical care unit. A secondary analysis was also
conducted to assess outcomes in a subgroup of patients admitted to critical care post cardiac surgery.
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These patients are known to be at particular risk of post-surgery renal failure and form a relatively
homogeneous group who are managed in a controlled environment; they therefore represent a subgroup
for whom there is a strong potential for management adjustments to lead to measurable changes in
outcomes.
All analyses were conducted from a NHS and PSS perspective, as per the NICE reference case.312 This aims
to incorporate costs relating to NHS primary care, secondary care, community care and social care.
Testing strategies
Tests evaluated in the meta-analysis in Chapter 3 (Nephrocheck, cystatin C and NGAL) were included in
the economic evaluation. Cystatin C and NGAL are currently available across three alternative media
(plasma, urine and serum); each of these was considered separately in the analysis, which, together with
the Nephrocheck test, resulted in a total of seven testing strategies.
All tests were assumed to be used once on entry to the critical care unit in addition to standard care,
consisting of daily serum creatinine and urine output testing. Although these new tests could also be used
sequentially or in a monitoring context, the majority of evidence on the diagnostic accuracy of these tests
relates to single-time usage and this was the focus of the current systematic review. Assessment of
sequential and monitoring testing strategies was therefore deemed beyond the scope of this analysis but
remains a key area for future research.
Costs and health outcomes
All costs are reported in 2015 prices (Great British pounds) and were inflated when necessary using an
online converter.315
Health outcomes were measured in terms of QALYs. QALYs provide a generic measure of patient overall
health and are a composite measure of patient survival weighted by quality of life (utility) over time, for
example 1 year in full health is equivalent to 1 QALY, whereas 1 year at half-full health is equivalent to
0.5 QALYs. Expression of health benefit in terms of QALYs allows decision-makers to make a direct
comparison between the cost-effectiveness of interventions across different disease areas and indications;
NICE312 currently recommends the use of QALYs in cost-effectiveness analyses.
Literature review of acute kidney injury economic models
A literature search was conducted in February 2015 and updated in March 2016 to identify economic
models of AKI to help inform the model structure and parameters.
The following databases were searched: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
EMBASE, Cochrane Central register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of
Effects (DARE) and NHS EED (NHS Economic Evaluation Database). Search strategies included concepts for
AKI and economic models (see Appendix 8 for the full database details and an example search strategy).
All search results were screened by one health economist using a two-stage process: initial abstract
screening to identify potentially relevant references followed by full-text screening to determine final
inclusion.
The initial inclusion criteria aimed to identify any models including AKI health states, regardless of setting.
For the updated search only economic models assessing AKI biomarker testing strategies were included,
as these were deemed to be of most use to the project at that stage.
The original search identified 235 references (179 after removal of duplicates), which increased to 296
(48 after removal of duplicates) references in the update search. In total, 11 studies were included in the
review,187,205,316–324 two of which were economic evaluations of AKI biomarkers187,205 (Figure 27).
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Details of the included models are presented in Table 41. The majority of studies not looking at biomarkers
were concerned with assessing different dialysis modalities or contrast media to prevent or treat renal
injury. These studies incorporated a range of health states, including within-hospital states such as dialysis/
no dialysis, AKI/no AKI, AKI severity levels and hospital death, and post-discharge states, such as alive
with/without dialysis, CKD, end-stage renal disease (ESRD), transplant and death.
Two studies assessed the cost-effectiveness of biomarkers for the early diagnosis of AKI in a critical care
setting and are of greatest relevance to this study.
Shaw et al.205
This study assessed the lifetime cost-effectiveness of urinary NGAL for the early diagnosis of AKI after
cardiac surgery compared with standard care testing of blood urea nitrogen, blood creatinine and urine
output. The base case considered a 67-year-old man after coronary artery bypass graft surgery. The
authors stated that they adopted a UK societal perspective; however, it was subsequently acknowledged
that they could not include indirect costs because of difficulties in estimating them and the final analysis
appears to have been restricted to a NHS perspective, with costs reported in 2008 Great British pounds.
The authors presented a simplified decision tree diagram of their model, in which patients in the testing
arm were monitored using NGAL on four occasions (2 hours after surgery and then every 6 hours), with a
single elevated result leading to early treatment for AKI. AKI severity was defined in terms of the RIFLE
criteria, with each severity level being associated with a specific mortality risk, critical care length of stay
and long-term CKD risk. The authors assumed a non-specific treatment modality for AKI including various
dialysis modalities, avoidance of nephrotoxic agents, fluid management and an additional nephrologist
Economic model search
February 2015
Search hits
(deduplicated)
(n = 179)
Search hits
(deduplicated)
(n = 48)
Items shortlisted
(n = 16)
Inclusions
(n = 10)
AKI models
(n = 9)
AKI models
including biomarkers
(n = 2)
Inclusions
(n = 1)
Excluded at
abstract review
(n = 163)
Excluded at
abstract review
(n = 47)
(screening only for
models including
biomarkers)Excluded at
full-text stage
(n = 6)
• No decision
   model, n = 3
• Not AKI, n = 3
Updated model search
March 2016
FIGURE 27 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the
AKI economic decision model search.
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TABLE 41 Acute kidney injury economic decision model review: included studies
First author
and year Country Intervention(s) AKI status Perspective Time horizon Model type Health states included Main result
Chicaiza-
Becerra
2012316
Colombia Iso- and
low-osmolality
contrast media
Outpatients at
high risk of
renal injury
National
Health System
Lifetime Decision tree Treatment + no AKI + death/
no death; treatment + AKI +
dialysis/no dialysis + death/
no death
Lopamidol and lodixanol
dominated all other alternatives.
Lodixanol vs. lopamidol =
US$14,660/life-year gained
De Smedt
2012317
Belgium CRRT, IRRT and
conservative
(CONS) treatment
AKI in the ICU Payer
perspective
2 years Area under the
curve analysis
NA CRRT was the most effective and
costly strategy. CONS dominated
IRRT. ICERs: CRRT vs. IRRT=
€114,012 per QALY; CRRT vs.
CONS = €590,410 per QALY
Desai
2008318
USA Daily vs. alternate-
day haemodialysis
60-year-old
man in ICU
with AKI
Societal Lifetime Markov model
(annual cycle
length)
Hospital death,
post-discharge CKD ±
haemodialysis, no CKD,
transplant waiting list
(± dialysis), transplant failure/
success
ICER for daily vs alternate-day
haemodialysis: US$5084 per QALY
Erstad
1999319
USA Albumin–furosemide
complex vs.
sequential therapy
Acute oliguric
renal
insufficiency
Teaching
hospital
Short
(approximately
6 months)
Decision tree Treatment + successful
(no dialysis); treatment +
unsuccessful (dialysis)
Cost per averted dialysis:
albumin–furosemide complex =
US$28,807; sequential therapy =
US$109,350
Ethgen
2015320
USA CRRT vs. IRRT AKI in the ICU Third-party
public payer
Lifetime Markov model
(daily cycle first
5 years; yearly
thereafter)
CRRT in ICU, IRRT in ICU,
post discharge ± dialysis,
death
CRRT dominated IRRT (based on
ICER)
He 2010321 USA Nesiritide Natrecor;
Johnson &
Johnson, New
Brunswick, NJ,
USA) vs. placebo
for prevention of
AKI
Post cardiac
surgery
NA (no costs
included)
NR Decision tree Hospital death ± dialysis,
discharged alive ± dialysis
Absolute risk reductions for dialysis
and hospital death for nesiritide
vs. placebo = 1.3% and 3.3%
respectively
Iannazzo
2014322
Italy Iodixanol vs.
low-osmolar
contrast media
Patients with
intravenous
contrast media
CT
Health-care
provider
Lifetime Markov model
(1-month cycle)
AKI free, AKI, myocardial
infarction, death
Incremental cost per life-year
gained: iodixanol dominated
low-osmolar contrast media
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First author
and year Country Intervention(s) AKI status Perspective Time horizon Model type Health states included Main result
Kerr 2014323 UK NA (assessment of
costs and QALYs)
72-year-old
patients with
AKI in hospital
English NHS 2 years post
discharge
Markov model
(annual cycle)
Normal kidney function, AKI,
CKD, ESRD± RRT, transplant
for ESRD, death
Lifetime cost for all AKI inpatients
post-discharge care = £179M;
lifetime QALY loss= 1.4 per person
Klarenbach
2009324
Canada Standard- or high-
dose CRRT vs. IHD
≈60-year-old
requiring RRT
in ICU
Health-care
provider
Lifetime Mixed decision
tree and
Markov model
Tree (hospital): dead,
treatment ± recovery.
Markov model (discharged):
alive± dialysis, dead
CRRT resulted in equivalent QALYs
but was C$3679 more costly than
IHD
Shaw
2011205
UK NGAL vs. standard
care
67-year-old
man
undergoing
CABG surgery
Societal Lifetime Decision tree AKI/no AKI, NGAL elevated/
normal, AKI failure/injury,
CKD/no CKD, treatment/
no treatment, CKD/no CKD
post discharge, death
NGAL dominated standard care
Petrovic
2015187
USA Cystatin C, urine
NGAL and uL-FABP
vs. standard care
Children with
congenital
heart disease
post cardiac
surgery
Health-care
payer
Lifetime Markov model AKI/noAKI, AKI risk/injury/
failure, discharged, death,
long term no CKD, CKD,
ESRD, transplantation, death
ICERs vs. standard care: US$5959
(uL-FABP), US$7077 (cystatin C),
US$9315 (NGAL urine)
CABG, coronary artery bypass graft; CRRT, continuous renal replacement therapy; CT, computerised tomography; dominated, less costly and more effective than the next best alternative;
IHD, intermittent haemodialysis; IRRT, intermittent renal replacement therapy; NA, not applicable; NR, not reported; uL-FABP, urine liver fatty acid-binding protein.
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visit. NGAL sensitivity (0.379) and specificity (0.812) were derived from two diagnostic studies of 72 and
426 patients (smaller studies were not considered) and, in the absence of data, the accuracy of sequential
tests was assumed to be equivalent. Instigation of early AKI treatment in the risk stage was assumed to
result in a 25% reduction in progression to the injury or failure state.72,140 The cost of each NGAL test was
£25. Discounting of future costs and outcomes was not reported.
The expected lifetime costs and QALYs were £4244 and 11.86 for urine NGAL and £4672 and 11.79
for usual diagnosis. NGAL dominated usual care, being more effective and less costly, and had a 100%
probability of being cost-effective at a willingness-to-pay threshold of £30,000. NGAL remained the
preferred strategy even in a ‘conservative scenario’ in which the treatment effect was halved from 25% to
12.5%. The most influential inputs identified from sensitivity analyses were the previous probability of AKI
and the probability of developing CKD.
This study was funded by a grant from Abbott Diagnostics (Lake Forest, IL, USA), the manufacturer of an
assay kit for the measurement of NGAL in urine.
Petrovic et al.187
This study assessed the lifetime cost-effectiveness of cystatin C (serum), NGAL (urine) and urine liver fatty
acid-binding protein (uL-FABP) for the diagnosis of AKI in children (aged < 18 years) after cardiac surgery
compared with standard care of serum creatinine monitoring. The analysis adopted a US third-party payer
perspective (price year not reported).
The model consisted of an initial decision tree in which patients were divided into no AKI and AKI RIFLE
severity groups. Patients in the testing arms were assumed to be tested 2 hours after surgery and were
subsequently separated into TP/FP and TN/FN groups according to the test accuracies. Patients could then
either die in hospital (with mortality dependent on AKI stage) or survive to discharge and then die or
survive post discharge. A Markov model was used to capture the long-term risks of CKD (stages 1–4),
ESRD, renal transplant and mortality for patients experiencing AKI. All cost and health outcomes were
discounted by 3% per annum.
Sensitivity (cystatin C = 0.54; NGAL = 0.63; uL-FABP = 1) and specificity (cystatin C = 0.54; NGAL = 0.63;
uL-FABP = 1) values were derived from a single study including 112 paediatric subjects.184 Therapy as a
result of early AKI diagnosis was assumed to result in a 25% improved outcome for AKI patients. Test
costs were US$18.94 for cystatin C, US$17.81 for NGAL and US$24.38 for uL-FABP. Probabilistic sensitivity
analysis was conducted; however, no variance data were presented for the parameter distributions.
The testing strategies were all more effective and more costly than standard care, with expected lifetime
costs of US$18,463 for cystatin C, US$15,304 for NGAL and US$14,126 for uL-FABP compared with
US$5608 for standard care and QALYs of 5.15, 5.16, 5.21 and 3.78 respectively. Cystatin C and NGAL
were both dominated by uL-FABP, which produced an ICER of US$5959 per QALY compared with
standard care and had a 100% probability of being cost-effective at a willingness-to-pay threshold of
US$50,000 per QALY. The authors declared no conflicts of interest for this study.
Focus group
A focus group was held on 26 February 2015 with two clinicians (nephrologists) and two patient
representatives with experience of chronic kidney failure. The primary aim was to understand the care
pathway for patients diagnosed with AKI in a critical care setting, with secondary aims of understanding
the impact of AKI and its treatments on patient outcomes and quality of life. The session was co-ordinated
by two qualitative research officers (NW and KVC) and two health economists (DM and AS). The group
discussion followed a topic guide, which was focused on developing a diagrammatic representation of
the patient pathway for someone experiencing AKI in critical care. Interviews were audio recorded and
transcribed verbatim by a third party and framework analysis was undertaken to systematically sift, chart
and sort material by key themes.
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The findings were outlined according to four subsections, briefly outlined below:
1. People at risk of developing AKI. There are many triggers for AKI and there are multiple groups at risk,
including patients with long-term conditions (CKD/heart failure), patients with comorbidities and the
elderly. In the hospital patients on any ward may develop AKI and may have previously had normal
renal function.
2. Diagnosing AKI. Multiple tests and assessments can be used to diagnose AKI in hospital. Some hospitals
now use electronic alert systems but there is currently a lack of standardised practice in this area.
3. Treating AKI. After diagnosis, treatment generally consists of a non-specific care bundle including fluid
assessment, medication review and additional investigations and monitoring. Treatment procedures may
vary depending on the cause of the AKI, individual patient characteristics and hospital procedures.
4. Long-term health consequences of AKI. Post treatment some patients completely recover whereas
others may go on to develop CKD and require dialysis or renal transplantation.
The themes identified in the focus group generally support NICE-identified pathways for AKI.1,325–327
Particular issues identified that were pertinent to the development of the decision model included (1) the
multiple aetiologies of AKI and the associated heterogeneity of the AKI population, (2) the non-specific
nature of AKI treatment and (3) the need to capture downstream risks of CKD.
Model structure
The model structure was developed using the findings from the literature review and focus group,
NICE guidelines1,325–327 and expert feedback. A simplified representation of the model is presented in
Figures 28 and 29.
The model is split into an initial decision tree (see Figure 28) and a subsequent modified Markov model
(see Figure 29). The decision tree separates patients into cohorts depending on their AKI status and test
results; patients then enter the main Markov model, which describes patients’ health-care pathway over
the duration of their hospital stay and post-discharge follow-up. In the Markov model patients occupy
different health states and may move between those states over time, with movement triggered by events
such as AKI onset, AKI progression, development of CKD and mortality. Each health state is associated
with a specific cost and quality of life (utility) value such that over time patients accumulate costs and
health benefits over model cycles of a defined length of time. The model is run separately for each of the
specified cohorts within each of the arms (standard care and testing arms) to obtain an average cost and
average QALYs (quality of life + survival), from which cost-effectiveness is calculated.
Initial decision tree model
The initial decision tree separates patients into cohorts depending on their AKI status and (for the
intervention arms) their additional test results. In the standard care arm, patients are split into ‘AKI’ and
‘no AKI’ cohorts. Patients in the AKI cohort either arrive in the critical care unit (also hereafter referred to
as the ICU) with pre-existing AKI or are destined to develop AKI at some point during their stay; patients
in the no AKI cohort are those who maintain normal renal function throughout their critical care stay.
Standard care testing is assumed to be perfect, such that all patients in the baseline model are correctly
identified as either having or not having AKI.
Patients in the testing arms of the model are assumed to receive an additional test on admission to the
critical care unit alongside standard care testing. It is expected that patients arriving in critical care with
known moderate or severe AKI (KDIGO stages ≥ 2) would not receive additional testing; these patients
follow the baseline AKI cohort pathway. All other patients are assumed to be tested and are separated
into four cohorts according to the accuracy of the test results, that is, TPs, FNs, TNs and FPs.
Main Markov model
The Markov model consists of two periods: a hospital period, to assess patients’ short-term outcomes, and
a follow-up period, to assess patients’ long-term outcomes post hospital discharge.
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All-comers to
ICU
Standard care arm
Test arm
Test
Pre-admission AKI (no test) Baseline model (AKI cohort)
Baseline model (AKI cohort)
Baseline model (AKI cohort)
Baseline model (no AKI cohort)
AKI
No AKI
TP
TN
FN
FP
Baseline model (no AKI cohort)
Baseline model (no AKI cohort) + early treatment costs
Baseline model (AKI cohort) + reduced AKI risks + early treatment costs
M
M
M
M
M
M
M
FIGURE 28 Model structure: initial decision tree. M, Markov model.
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Hospital period
Start: patients
admitted to ICU
Follow-up period (no AKI cohort)
Follow-up period (AKI cohort)
Death
CKD
[KDIGO] AKI in ICU
ICU with
normal kidney
function
Hospital ward Discharged
Hospital ward
+ RRT
Discharged
+ RRT
Hospital ward Discharged
Outpatient
follow-up
Outpatient
follow-up
CKD
(stages 1– 4)
ESRD
(CKD stage 5)
ESRD +
dialysis
ESRD +
transplant
S0
S1
S2
S3
S3 + RRT
FIGURE 29 Model structure: main Markov model.
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Hospital period (days 1–90)
The hospital period adopts daily cycles and runs from day 1 (entry to critical care unit) to day 90 to capture
rapid changes in patients’ health during their critical care stay.
The model is separated into no AKI and AKI cohort states. Patients with no AKI start in the ‘ICU with
normal kidney function’ state and over time may remain in critical care, be discharged directly into the
community or be transferred to a general ward before being discharged. Patients in the AKI cohort are
classified into one of five health states according to the severity of their AKI on entry to the critical care
unit: current normal kidney function (but destined to get AKI) (stage 0; S0) and the four KDIGO AKI
classifications – stage 1 (S1), stage 2 (S2), stage 3 (S3) and stage 3 plus RRT (S3 + RRT). Patients may
deteriorate or improve over time (moving to higher or lower severity states). From the ICU health states,
patients may be transferred to a hospital ward (with or without RRT) or be discharged home (with or
without RRT). Post-discharge patients are assumed to remain in their discharged state for the remainder of
the hospital period. By definition, the onset of CKD requires a minimum of 3 months of persistent renal
failure;328 CKD is therefore not included within the hospital period, but is captured in the follow-up model.
Follow-up period
The follow-up period aimed to capture patients’ long-term outcomes post hospital discharge. It was run
from 90 days post critical care admission for the patients’ lifetime (capped at 100 years) using annual
cycles. A half-cycle correction was applied in the follow-up period of the Markov model to account for
the continuous flow of patients between Markov states (i.e. in reality not all patients transition at the
beginning/end of a year).
All patients in the no AKI cohort who are still alive at the end of the hospital period model are assumed to
move to the ‘outpatient follow-up’ state in the follow-up model, where they remain, subject to an annual
mortality risk.
Patients in the AKI cohort who are still alive and not on RRT at the end of the hospital period similarly
move to a separate ‘outpatient follow-up’ state, where they experience elevated mortality and CKD risks
compared with the no AKI cohort. Patients receiving RRT at the end of the hospital period (in the ICU,
hospital ward or discharged plus RRT states) are assumed to have CKD and move to the ‘CKD (stages 1–4)’
state. From the CKD state, patients may go on to develop ESRD, with or without maintenance dialysis,
or require a renal transplant. If the transplant is successful patients remain in the transplant state; if the
transplant is unsuccessful patients are assumed to return to the ‘ESRD + dialysis’ state, but may go on to
receive a subsequent transplant.
In all states for both cohorts, patients experience a mortality risk that is dependent on their current health state.
Impact of the tests
All patients in the testing arms without known pre-existing AKI (KDIGO stage ≥ 2) are assumed to be
tested and, therefore, receive an additional cost of testing. Other baseline risks and costs in the model are
adjusted according to the test result, as described in the following sections.
True positives
Patients with a TP test result are split into two subgroups. Patients with no or mild AKI (KDIGO stages ≤ 1)
according to concurrent standard care test results are assumed to be able to benefit from early AKI
intervention as a result of the positive test result. These patients follow the baseline AKI cohort but with an
additional cost of early treatment and reduced risks of future AKI progressions [i.e. from (S0 or S1) to (S2, S3
or S3 +RRT)] and AKI-associated mortality (mortality in state S3 + RRT). Patients with moderate or severe AKI
(KDIGO stages ≥ 2) according to concurrent standard care tests are assumed to not be able to benefit from
early intervention. These patients follow the baseline AKI cohort model with no changes to risks or costs.
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False positives
Patients with a FP result incur an unnecessary additional cost of early AKI intervention; however, in the
base case this is assumed to have no detrimental impact on patients’ health. These patients follow the
baseline no AKI cohort with no risk changes applied.
True negatives
Patients with a TN result follow the baseline no AKI cohort with no additional changes applied to the
baseline risks or costs.
False negatives
Patients with a FN result receive a concurrent or eventual AKI diagnosis through standard care daily
testing. In the base case these patients are assumed to incur no harm from the inaccurate test result and
follow the baseline AKI cohort.
A range of alternative assumptions regarding the impact of testing are explored in the sensitivity analysis
reported later in this chapter.
Model parameter literature review
Primary searches
To help inform model parameter estimation, a literature review was conducted in July and August 2015
across the following databases: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE
and The Cochrane Library. Six search strategies were devised to identify evidence on (1) AKI costs, (2) AKI
utilities, (3) AKI risks, (4) CKD costs, (5) CKD utilities and (6) CKD risks. Date limits and UK filters were used
in some searches to target studies with recent, UK-based data (i.e. of most relevance to the model). Full
details are reported in Appendix 9.
For AKI searches, studies were included if they reported on relevant outcomes for adult patients with or
recovering from AKI, or on dialysis, and had a hospital critical care or post-critical care setting. For CKD
searches, studies were included if they reported on relevant outcomes for adult patients with a primary
condition of CKD, who were on chronic dialysis or who had undergone a renal transplant, across any
setting. Relevant outcomes were defined as follows:
l cost searches: UK patient or health-care costs
l utility searches: direct utilities reported on multiattribute utility indexes or through direct valuation
exercises [i.e. EuroQol-5 Dimensions (EQ-5D),329 Short Form questionnaire-6 Dimensions (SF-6D)330 or
time trade-off (TTO)/standard gamble (SG) utilities]
l AKI risk searches: AKI incidence or progression, mortality, dialysis dependence, progression to CKD or
ICU/hospital length of stay
l CKD risk searches: incidence of CKD, ESRD or transplants post AKI, progression or recovery rates for
these conditions, dialysis dependence, transplant success and mortality.
All screening and data extraction was conducted by one health economist (AS). Citations were initially
screened by title and abstract, followed by full-text screening to determine inclusion. In cases in which the
reviewer was unsure about study inclusion a second reviewer (DM or PH) was consulted. All papers
screened at the full-text stage were hand-searched for additional relevant references. Search results were
stored in six EndNote version X12 libraries [Clarivate Analytics (formerly Thomson Reuters), Philadelphia,
PA, USA] and data extraction was conducted using a standard extraction form in Microsoft Excel® 2010
(Microsoft Corporation, Redmond, WA, USA).
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Across the six searches, 1153 potentially relevant citations were identified after removal of duplicates
(Figure 30). In total, 129 references were included in the review: four for AKI costs,323,331–333 none for AKI
utilities, 40 for AKI risks,323,331–369 33 for CKD costs,323,370–401 eight for CKD utilities402–409 and 44 for CKD
risks.370,373,410–451
AKI utilities
(n = 4)
Included via
secondary
screening of
non-UK studies
(n = 4)
AKI utilities
(n = 0)
CKD utilities
(n = 8)
AKI risks
(n = 40)
CKD risks
(n = 44)
AKI costs
(n = 4)
CKD costs
(n = 33)
Inclusions
(n = 129)
Parameters search
July and August 2015
Search hits (deduplicated)
(n = 1153)
• AKI costs, n = 169
• AKI utilities, n = 25
• AKI risks, n = 148
• CKD costs, n = 273
• CKD utilities, n = 230
• CKD risks, n = 308
Items shortlisted
(n = 208)
• AKI costs, n = 22
• AKI utilities, n = 10
• AKI risks, n = 52
• CKD costs, n = 40
• CKD utilities, n = 33
• CKD risks, n = 51
Included via reference searching
(n = 36)
• AKI costs, n = 0
• AKI utilities, n = 0
• AKI risks, n = 14
• CKD costs, n = 9
• CKD utilities, n = 0
• CKD risks, n = 13
Excluded at full-text review
(n = 115)
• AKI costs, n = 18 (15A, 3B)
• AKI utilities, n = 10 (4A, 6C)
• AKI risks, n = 26 (9A, 8B, 7C, 2D)
• CKD costs, n = 16 (9A, 7C)
• CKD utilities, n = 25 (14A, 10C, 1D)
• CKD risks, n = 20 (14A, 3B, 3C)
Excluded at abstract review
(n = 945)
• AKI costs, n = 147
• AKI utilities, n = 15
• AKI risks, n = 96
• CKD costs, n = 233
• CKD utilities, n = 197
• CKD risks, n = 257
FIGURE 30 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the
model parameter searches. Reasons for exclusion: A = no relevant outcome reported; B= non-UK study (when this
was applied as an additional exclusion criteria); C= inappropriate study type (e.g. editorial); D = date (when date
restrictions were applied).
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For the AKI utilities search, no UK studies or international evidence syntheses were identified according to
the original scope of the search. Secondary screening and citation tracking of the search results was
therefore conducted to identify any relevant non-UK studies, with no date restrictions, leading to four
non-UK-relevant papers being included.317,452–454
Tables 42–44 provide a summary of the included studies. The majority of evidence identified related to
studies reporting outcomes for patients with CKD. Of these studies, the following were identified as being
of particular use for model parameter estimation: (1) a comprehensive worldwide meta-analysis reporting
CKD, dialysis and transplant health state utilities;402 (2) a large (n = 7246) UK randomised multicentre
clinical trial reporting CKD, dialysis and transplant costs, as well as the probabilities of transition between
CKD, dialysis and death;370 and (3) the UK Renal Registry annual report, which reports key data on annual
transitions between ESRD, dialysis, transplant and mortality states410 (note that model parameters were
derived from the subsequently published 2015 version of this report).455
Limited evidence on costs and utilities for AKI was identified: no UK utility studies were identified (compared
with nine in the CKD search) and only three UK cost studies were identified (compared with 33 for CKD),
none of which reported disaggregated or per-patient critical care costs that could be used to inform the
model health state costs. For AKI risks, a worldwide systematic review334 was identified that reported an ICU
KDIGO AKI incidence of 31.7% (95% CI 28.6 to 35.0) in an all-comer population and 24.3% (20.4 to 28.8)
in a post-cardiac surgery population.456 This was deemed to be the most reliable study to inform the
estimates of AKI incidence. It was noted, however, that other clinical studies reported incidences both above
and below the reported 95% CIs;334–342 this parameter was therefore included in the sensitivity analysis.
Additional searches
Two additional searches were conducted in an attempt to identify data on (1) cost and quality of life
outcomes for patients treated in the ICU (AKI and no AKI cohorts) and (2) the impact of early AKI
intervention.
Costs and utilities
Subsequent searching of BioMed Central Critical Care journal publications identified a high-quality recent
publication reporting follow-up costs and mortality for a large cohort of all-comer patients (n = 5259)
treated in ICUs across Scotland (published after the date of the review).457 No further searches were
therefore conducted for ICU/follow-up costs.
To help inform ICU utility estimates, an additional search was undertaken using the Cost-effectiveness
Analysis (CEA) Registry458 and School of Health and Related Research Health Utilities Database (ScHARRHUD)
databases,459 which provide specific health state utility search functions. Key terms relating to hospital wards
and the ICU were searched to identify UK papers reporting direct utilities on multiattribute utility indexes or
through direct valuation exercises (i.e. SF-6D or TTO/SG utilities). Three relevant studies were identified460–462
and are summarised in Table 45. The studies by Hernández et al.460 and Cuthbertson et al.461 measured
EQ-5D outcomes for all-comer ICU populations and were deemed to be of most relevance for the model.
Impact of early acute kidney injury intervention
A key parameter in the model concerns the impact of early AKI intervention on patient health outcomes,
that is, the ‘treatment effect’ parameter linked to tests resulting from early identification of AKI. Two
previous economic evaluations of AKI biomarkers187,205 identified in the model review assumed a uniform
25% reduction in subsequent AKI risks as a result of early diagnosis. However, in both studies no evidence
base was cited to support this key parameter estimate.
A literature search was conducted in March 2015 to identify reviews of early treatment/preventative
strategies for AKI in the ICU across the following databases: MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations, EMBASE and The Cochrane Library. The search aimed to identify UK reviews
including early treatment/preventative strategies for adults with AKI in the ICU, published in the last 5 years.
Search strategies included the search concepts acute kidney injury, critical care, early treatment and
treatment effectiveness (see Appendix 10 for full details).
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TABLE 42 Included studies from the AKI and CKD utility searches
First author
and year Country n Age (years)
Sex
male (%) AKI/CKD status Utility measure Reported utilities
AKI utilitiesa
Johansen
2010452
USA 377 Mean 58 70.6 AKI in ICU as a result
of necrosis plus sepsis
or organ failure,
requiring RRT
HUI Mean utility at 60 days post randomisation: 0.40
(SD 0.37)
De Smedt
2012317
Belgium 203 Adults NR AKI in ICU requiring
RRT with serum
creatinine > 2mg/dl
SF-36 Mean utility at 20.1 months post hospital
admission: 0.69 (SE 0.15, 95% CI 0.67 to 0.71)
Åhlström
2005453
Finland 153 Mean 56 69 AKI in ICU or ward
requiring RRT
EQ-5D Median utility at median follow-up of 2.4 years:
0.68 (IQR 0.53–0.85) for ICU patients vs. 0.86
(IQR 0.83–0.88) in matched general population
Hamel 1997454 USA 57 Median 61 42 AKI in ICU or ward
requiring RRT with an
average expected
6-month survival of 50%
TTO Mean utility at 6 months follow-up: 0.84 (SD 0.25)
CKD utilities (all UK studies or reviews)
Neri 2012403 UK and USA 144 (UK patients) Mean 52 61 Kidney transplant
patients. Mean time
since transplant
5.3 years
EQ-5D Median: 0.73 (IQR 0.23). Mean utility: transplant
with CKD stages 1–2: 0.64; CKD stage 3: 0.58;
CKD stage 4: 0.49; CKD stage 5: 0.28. Mean
disutility of CKD stage 5 vs. CKD stages 1–2: –0.38
Neri 2010404 UK and USA 209 (UK patients) Mean 53 NR Kidney transplant
patients. Mean time
since transplant
5.6 years
EQ-5D (Kidney transplant patients) Mean utility: transplant
with CKD stages 1–2: 0.74; CKD stage 3: 0.69;
CKD stage 4: 0.61; CKD stage 5: 0.39
Wyld 2012402 USA= 99,
Europe = 151,
other = 76
Number of utility
estimates: CKD
pretreatment = 25,
dialysis = 226,
transplant = 66,
conservative care= 3
NR NR CKD, dialysis and
transplant
Utilities on 0–1
scale (review)
Pretreatment CKD stages 3–5: 0.79 (95% CI 0.70
to 0.89); conservative care: 0.62 (95% CI 0.43 to
0.82); CKD stages 3–5 dialysis: 0.70 (95% CI 0.62
to 0.78); utility decrement vs. transplant: –0.02,
–0.2 and –0.11 respectively; transplant: 0.85
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First author
and year Country n Age (years)
Sex
male (%) AKI/CKD status Utility measure Reported utilities
Wyld 2010405 NR (170 studies
included)
> 56,000 NR NR CKD, dialysis and
transplant
Utilities on 0–1
scale (review)
Pretreatment CKD: 0.56 (95% CI 0.52 to 0.60);
conservative care: 0.66 (95% CI 0.30 to 1.00);
CKD stages 3–5 dialysis: 0.52 (95% CI 0.50 to
0.53); home dialysis 0.57 (95% CI 0.53 to 0.61)
vs. hospital 0.50 (95% CI 0.57–0.63); transplant:
0.60 (95% CI 0.57 to 0.63)
Blakeman
2014406
UK 436 Mean 72.1 42 CKD stage 3 EQ-5D Mean baseline utility CKD stage 3: 0.67 (SD 0.3)
Liem 2008407 NR (27 studies
included)
27 studies included Mean range
42.1–60
Range
50–63
ESRD requiring dialysis
or transplant patients
TTO, SG or
EQ-5D (review)
(ESRD dialysis) TTO values: HD: 0.61 (95% CI 0.54
to 0.68); PD: 0.73 (95% CI 0.61 to 0.85). EQ-5D
values: HD: 0.56 (95% CI 0.49 to 0.62); PD: 0.58
(95% CI 0.50 to 0.67). SG values: HD: 0.75
(95% CI 0.57 to 0.92). TTO transplant: 0.78
(95% CI 0.63 to 0.93). EQ-5D transplant: 0.81
(95% CI 0.72 to 0.90)
Lung 2011408 USA= 2,
UK = 1,
Japan= 1
Mean of included
studies = 184.6
NR NR Diabetic patients with
ESRD
Preference-based
measures (review)
Diabetes + ESRD: 0.48 (95% CI 0.25 to 0.71)
Nafees
2014409
UK 100 general public NR NR Patients with CHF and
CKD (post hospital
discharge)
TTO CHF + CKD: 0.78 (SD 0.21)
CHF, chronic heart failure; HD, haemodialysis; HUI, Health Utilities Index; IQR, interquartile range; NR, not reported; PD, peritoneal dialysis; SD, standard deviation; SE, standard error;
SF-36, Short Form Questionnaire-36 items.
a All non-UK studies identified after secondary screening; not part of the original search.
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TABLE 43 Included studies from the AKI and CKD cost searches (all UK studies)
First author
and year n Age (years)
Sex male
(%) AKI/CKD status Methods Reported costs
AKI costs
Kerr 2014323 148,226
admissions
Adults NR AKI in critical care/
general ward
Retrospective analysis of hospital records/database;
economic Markov model. NHS perspective; 2010/11
prices
Annual inpatient cost (England) £380M (excluding
critical care), £1.02B (including critical care). Cost
of post-discharge care £179M
Kolhe 2014331 576 Mean 76 57 AKI in ICU/ward Retrospective analysis of hospital records/database Inpatient cost of AKI: overall £3748, AKIN 1
£3233, AKIN 2 £3206, AKIN 3 £4287, requiring
RRT £8405, no RRT £3504
Paterson
2013332 and
2014333
366 Median 64 56 AKI requiring dialysis
in ICU
Retrospective single-centre before-and-after study Low-volume RRT resulted in an annual 12% cost
saving of £27,000 vs. high-volume RRT
CKD costs
Baboolal
2008371
NA NR NR Patients requiring
dialysis
Multicentre retrospective cost analysis comparing
dialysis modalities. NHS perspective; 2006 prices
Annual costs: automated PD £21,655, CAPD
£15,570, hospital HD £35,023, satellite HD
£32,669, home HD £20,746
Black 2010372 NA Mean 72 44 CKD (KDOQI)
stages 1–4,
excluding diabetes
Economic model comparing CKD referral
strategies. NHS perspective; 35-year time horizon;
2006/7 prices
Annual CKD costs: CKD £344–492 (stage 3a–4),
CKD + CVD £572–93. 35-year costs from £11,798
(current care) to £13,487 (referral at CKD stage 3a)
Chamberlain
2014373
370 Mean 47–53 62–66 Renal transplant
recipients
Retrospective multicentre study of 3-year
post-transplant costs. NHS perspective; 2010 euros
(£1= €1.16)
3-year costs: GFR < 15: €19,230; 15≤GFR ≥ 30:
€16,215; 30≤GFR ≥ 45: €13,943; 45≤GFR ≥ 60:
€9169; GFR ≥ 60: €8475
Grün 2003374 171 Mean 77 67 Patients requiring
dialysis
Prospective cohort study of post-transplant costs.
Societal perspective; 1995 prices
Annual cost £22,740 (95% CI £21,467 to
£24,015). Cost to social services £522 (2.3% of
overall cost)
aIqbal 2014375 NR NR NR Patients requiring
dialysis
Budget impact model to assess early cannulation
arteriovenous grafts (ecAVGs) vs. tunnelled central
venous catheters (TCVSs). Hospital perspective;
price year NR
6-month treatment costs: £5882 (TCVS) vs. £4954
(ecAVG) per patient
aJoseph 2010376 NA NR NR Patients requiring
dialysis
Economic model to assess increasing the
percentage of patients receiving home dialysis.
NHS perspective; price year NR
Projected annual cost of current care in 2013
£35,048 vs. £31,584 for increased percentage of
patients receiving home dialysis
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First author
and year n Age (years)
Sex male
(%) AKI/CKD status Methods Reported costs
Kadam 2013377 60,660 All ≥ 40 36–39 CKD + diabetes and
CHF
Retrospective database analysis to assess the cost
of CKD. NHS secondary care perspective; price
year NR
3-year A&E costs: CKD no diabetes £80,
CKD + diabetes £105, CKD no CHF £75,
CKD + CHF £164. Hospital costs: £2559, £3642,
£2477 and £5344 respectively
Kent 2015370 7246 Mean 63 64 CKD stages
1–5 ± CVD and
diabetes
Randomised multicentre clinical trial to assess the
cost of CKD. Median follow-up 4.9 years; NHS
perspective; 2011 prices
Annual hospital costs: CKD stages 1–3B £403,
CKD stage 4 £393, CKD stage 5 £525,
maintenance dialysis (year 1) £18,986, dialysis
ongoing £23,326, kidney transplant (year 1)
£24,602, transplant (ongoing) £1148
Kerr 2014323 NA (national
databases)
NR NR CKD stages 3–5 Retrospective database analysis and economic
model to assess the cost of CKD. NHS perspective;
2009/10 prices
Annual cost £1.44–1.45B. Mean cost £27,000 on
dialysis, £235 not on dialysis, £12,000 transplant
recipients. Excess strokes and myocardial
infarctions cost £174–8M per annum
Kirby 2001378 NA NR NR Patients requiring
dialysis (with ESRD)
Economic Markov model to assess the cost-
effectiveness of HD vs. CAPD strategies. Lifetime
horizon; hospital perspective; 1999 prices
Monthly costs: HD £827–923, CAPD £905, minor
complications £2.50 (HD) and £8 (CAPD), major
complications £1799 (HD) and £2111 (CAPD).
Total cost: HD £63,370–79,478 (depending on
scenario), CAPD £65,061–76,426
Komenda
2012379
NA NR NR Patients requiring
dialysis
Economic model to assess the home HD service.
Payer perspective; 2010 US dollars
Home HD year 1: in-centre HD US$45,374,
conventional home HD US$46,218, frequent home
HD US$57,898. Subsequent years: US$45,034,
US$37,762 and US$49,442 respectively
aLiu 2013380 NA NR NR Patients requiring
dialysis
Budget impact model to assess dialysis modalities.
NHS perspective; 5 year horizon; price year NR
Current 5-year cost: £4,380,678,000. Increasing
prevalence of PD by 1.5% or 3% per year
projected to save £18.5–63.6M
Liu 2014381 NA NR NR Patients requiring
dialysis (with ESRD)
Budget impact model to assess increasing the
percentage of patients receiving home dialysis.
NHS perspective; 5-year horizon; 2013/14 prices
Base-case 5-year per-patient cost: £23,187. In
scenarios 5-year budget impact of increasing the
percentage of patients receiving home dialysis
ranged from a saving of £572 (£2.5%) to an
increase in costs of £1043 (4.5%)
Liu 2015382 NA NR NR Patients requiring
dialysis (with ESRD)
Economic model to assess high-dose HD vs.
conventional in-centre HD. Lifetime horizon; UK
NHS perspective; 2013/14 prices
Lifetime discounted cost: base case (100%
in-centre HD) £191,207; 100% high-dose
in-centre HD £299,920
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TABLE 43 Included studies from the AKI and CKD cost searches (all UK studies) (continued )
First author
and year n Age (years)
Sex male
(%) AKI/CKD status Methods Reported costs
McEwan
2006383
NA NR NR Renal transplant
recipients
Economic model to assess sirolimus vs. tacrolimus
for the prevention of graft failure. 20-year post-
transplant horizon; NHS perspective; 2003 prices
Sirolimus £62,120, tacrolimus £75,265–81,972
(depending on data profiles used)
aMcEwan
2010384
879 NR NR Renal transplant
recipients
Retrospective single-centre study of post-transplant
costs. NHS perspective; price year NR
3-year costs: > 60ml/minute/1.73 m2 group
£497, 30–60ml/minute/1.73 m2 group £1323,
< 30ml/minute/1.73 m2 group £1448
aMcEwan
2012385
NA NR NR CKD requiring
dialysis or
transplantation
Economic model to assess the impact of graft
survival time on transplantation cost-effectiveness.
NHS perspective; 10-year time horizon
10-year cost: remain on dialysis £394,379,
functioning graft £118,049. 4-year graft survival
was cost saving
Mowatt 2003386 NA NR NR Patients requiring
dialysis (with ESRD)
Economic model of home vs. in-centre HD. 5-year
horizon; NHS perspective; 2001/2 prices
Annual costs: hospital HD £22,246, satellite HD
21,264, home HD 19,470. 5-year costs: £42,722,
£46,001 and £41,250 respectively
Muduma
2014387
Hypothetical
n= 100
NR NR Renal transplant
recipients
Budget impact model of Prograf vs. Advagraf to
prevent graft failure. 5-year horizon; NHS
perspective; 2012/13 prices
5-year cost: Advagraf £29,328, Prograf £33,061.
Cost saving of £375,000 for 100 patients
Muduma
2014388
NA Model
starting
age= 45
NR Renal transplant
recipients
Economic model of immunosuppressents to
prevent graft failure. 25-year horizon; NHS
perspective; 2012/13 prices
25-year costs: Prograf £127,661, Advagraf
£116,733, belatacept £116,733, ciclosporin
£127,187, sirolimus I £103,896, sirolimus II
£103,896
Muduma
2014389
NA NR NR Renal transplant
recipients
Budget impact model to assess Adgraf vs. Prograf
for graft failure. NHS perspective; 5-year horizon;
2012/13 prices
5-year costs: Advagraf £26,941, Prograf £30,356
aMuduma
2015390
Hypothetical
n= 100
NR NR Renal transplant
recipients
Economic model of Prograf vs. Advagraf to
prevent graft failure. NHS perspective; 2014 prices
Mean 5-year costs: Prograf £40,974, Advagraf
£45,836 (cost saving of £4862)
Neil 2009391 NA NR NR Patients requiring
dialysis (with ESRD)
Budget impact model of dialysis costs. NHS
perspective; 2007 prices
Projected 5-year cost of shift to HD : PD ratio of
70 : 30: £133M
NICE 2011392 NA NR NR Patients requiring
dialysis (with ESRD)
Economic model of dialysis settings and modalities.
NHS perspective; 2008/9 prices
Monthly costs: hospital HD £2919, satellite HD
£2722, home HD £1439, transplantation
£10,250–13,627, transplant maintenance £583.
10-year costs: base £130,681, HD centred
£136,146, PD £120,752
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First author
and year n Age (years)
Sex male
(%) AKI/CKD status Methods Reported costs
NICE 2011393 NA NR NR Patients requiring
dialysis (with ESRD)
Budget impact model of dialysis modalities. NHS
perspective; 2011/12 prices
Unit costs: home HD £23,271, hospital HD
£22,916, satellite HD £22,916, CAPD 17,411, APD
21,071. 5-year impact (1% PD increase per year):
saving of £4,087,000
Oates 2012394 78 Mean 68 55 Patients requiring
dialysis
Prospective costing study to assess online haemo-
diafiltration (OL-HDF) vs. high-flux HD. Perspective
and price year NR
Dialysis session costs: high-flux HD £25.56, OL-HDF
£24.78. Weekly drug costs 3 months prior to
starting and 12 months post starting: high-flux HD
£21 and £24 respectively, OL-HDF £16 and £21
respectively
aPollock 2013395 NA NR NR Renal transplant
recipients
Budget impact model to assess Prograf vs.
Advagraf to prevent graft failure. 5-year horizon;
perspective NR; 2012/13 prices
5-year cost per patient: Advagraf £29,290, Prograf
£33,032. Total cost saving of £3742
aPollock 2013396 NA NR NR Renal transplant
recipients
Budget impact model of Prograf vs. Advagraf to
prevent graft failure. Perspective NR; 5-year
horizon; 2012/13 prices
5-year cost per patient: Advagraf £26,958, Prograf
£30,379. Total cost saving £3421
Popat 2014397 45 Mean 48–54 38–71 Renal transplant
recipients
Prospective single-centre study to assess the cost
of IL2Mab vs. antithymocyte globulin (ATG) to
prevent graft failure. Perspective and price year NR
Average cost in year after transplant: IL2Mab
£18,929, ATG £14,904 (p = 0.002)
Roderick
2005398
736 Mean 56–67 53–66 Patients requiring
dialysis
Cost study to assess renal satellite units (RSUs) vs.
main renal units (MRUs). Health service and patient
perspective; 2000/1 prices
Total annual (or since starting dialysis) cost of all
hospitalisations: MRU mean range £31–138
(depending on assumptions), RSU £35–125
aSun 2010399 NA NR NR Renal transplant
recipients
Economic model to assess the cost of renal graft
failure post transplant. Investment perspective
1-year cost of renal graft failure approximately
£58,847. Post graft failure cost £28,179
Thompson
2013400
Hypothetical
n= 1000
Mean 58 61 CKD (stages 3–4)
not on dialysis
Economic model to assess sevelamer vs. calcium
carbonate. NHS perspective: lifetime horizon: 2011
prices
Model costs: HD session £161, PD session £53.15.
Lifetime costs: calcium carbonate £46,117,
sevelamer £83,399
Treharne
2014401
Hypothetical
n= 100
NR NR Patients requiring
dialysis (with newly
diagnosed ESRD)
Economic model to assess the cost-effectiveness of
increasing the percentage of patients receiving PD.
NHS perspective; 5- and 10-year horizon; 2013/14
prices
Current care (22% PD): 5-year horizon £96,307,
10-year horizon £133,339. Cost savings for
increasing uptake to 39% PD: £3180 and £4102
respectively; cost savings for increasing uptake to
50% PD: £5238 and £6758 respectively
A&E, accident and emergency; CAPD, continuous ambulatory peritoneal dialysis; CHF, congestive heart failure; CVD, cardiovascular disease; GFR, glomerular filtration rate; HD, haemodialysis;
KDOQI, Kidney Disease Outcomes Quality Initiative; NA, not applicable; NR, not reported; PD, peritoneal dialysis.
a Abstract only.
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TABLE 44 Included studies for the AKI and CKD risk searches
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
AKI studies
Abosaif 2005343 UK 183 Mean 65 68 AKI in ICU on first day.
Excluded patients with
CKD or renal transplant
Retrospective review of
medical notes. AKI
patients compared
with a randomly
selected control group
with decrease in eGFR
of < 25%
AKI incidence: risk 60/183 (33%),
injury 56/183 (31%), failure 43/183
(23%), control group 24 (13%).
CVVH in ICU (percentage requiring):
39%, 28%, 50%, 58%, 4%. ICU
mortality: 38%, 50%, 75% and 17%
respectively. 6-month mortality: 43%,
54%, 86% and 25% respectively
Alassar
2012344,345
UK 79 Mean 84 59 AKI (Valve Academic
Research Consortium
criteria) after transcatheter
aortic valve implantation.
Excluded patients with
CKD or on dialysis
Single-centre
observational study
ICU AKI incidence: stage 1 9/79, stage 2
1/79. AKI resolved in 9/10 patients
before hospital discharge. No patients
required RRT in hospital and LOS was
not affected by AKI; 3/10 patients died
within 1 year vs. 13/79 for the total
cohort
Ali 2007346 UK 5321 (37
received RRT)
NR NR Patients receiving RRT in
hospital
Retrospective analysis
of population hospital
records
37 (8%) AKI patients received RRT;
23 (62%) had first RRT in the ICU,
13 (35%) in the renal unit and one in
a surgical high-dependency unit; 21
(57%) patients died within 6 months
vs. 5 (45%) of patients with AKI on
CKD who received RRT
aBarnes 2014347 UK 169 NR 83 AKI (AKIN criteria) in ICU
within 48 hours after
off-pump CABG surgery
Retrospective analysis
of hospital records
Incidence 46/169 (27.2%); 50% AKIN
stage 1, 30% stage 2, 20% stage 3.
Mean ICU LOS was 2.3 days for all
patients and 4 days for patients
requiring CRRT
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Bastin 2013348 UK 1881 > 16; mean 68 71 AKI (AKIN, RIFLE, KDIGO)
after cardiac surgery with
CPB. Excluded patients on
chronic dialysis or who died
within 24 hours of surgery
Retrospective analysis
of hospital records
(AKIN and KDIGO) no AKI 1394
(74.1%), stage 1 317 (16.9%), stage 2
34 (1.8%), stage 3 136 (7.2%);
122/1881 (6.5%) required RRT in
hospital. ICU LOS (median): no AKI
1 day, stage 1 2 days, stage 2 4 days,
stage 3 13 days; hospital LOS
(median): 7, 9, 14 and 24 days
respectively; hospital mortality:
4 (0.3%), 1 (0.3%), 0, 19 (14%)
respectively
Baudouin
1993367
UK 35 Mean 56 74 Patients requiring RRT
(continuous venovenous
haemofiltration) after CPB
surgery
Retrospective database/
records review
35/1300 (2.7%) patients required RRT
in the ICU. Mean time from surgery to
RRT was 8 days and mean time spent
on RRT was 8 days; 3/9 ICU survivors
died in hospital after ICU discharge
Bedford 2014349 UK 19,940 Mean 62–76 45–52 AKI (AKIN) in hospital.
Excluded patients receiving
chronic dialysis, maternity
patients and day-case
admissions
Retrospective analysis
of hospital database
Mean ICU LOS: no AKI 3.0 days, AKIN
1 4.4 days, AKIN 2 4.5 days, AKIN 3
7.3 days; 77/588 (13.1%) patients
with stage 3 AKI received RRT in
hospital; 16/77 RRT patients remained
on RRT 90 days post discharge
Bhandari
1996366
UK 1095
(cardiac 139)
NR NR AKI (acute uraemic
emergency with serum
creatinine ≥ 600 µmol/l
and/or requiring dialysis)
post cardiac surgery
Retrospective review of
medical notes
Post-cardiac surgery severe AKI
subgroup: 90-day survival 54 (38.8%),
90-day dialysis dependence 2 (1.4%)
aBrown 2014350 UK 2297
(306 with AKI)
NR 58 AKI requiring diffusive
haemodialysis (CRRT) in
ICU. Mixed non-surgical
and surgical patients
Analysis of hospital
records
319/2297 (13.9%) patients admitted
to the ICU required CRRT. Mean LOS
(days): RRT patients 13, all patients
8.2. Mortality at hospital discharge
was 56% for RRT patients and 20%
for all patients
continued
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
aChakkalakal
2013338
UK 71 NR 70–81 Patients in ICU with
creatine kinase > 5000 w/l
Retrospective analysis
of hospital records
AKI incidence: 39/71 (55%); 19 (27%)
patients required RRT. Hospital
mortality: no AKI 9%, AKI stages 1–3
25%, RRT 79%. ICU mortality: RRT
79%, no RRT 15%
Challiner
2014351
UK 745 NR 55 AKI (RIFLE, AKIN, AKIB) in
ICU. Excluded maternity
patients, admissions of
< 24 hours, and patients
on chronic dialysis
Retrospective audit AKI incidence: RIFLE: risk 3 (2.9%),
injury 5 (10.4%), fail 4 (20%); AKIN:
stage 1 5 (4.3%), stage 2 4 (11.8%),
stage 3 5 (23.8%). ICU AKI mortality
6/26
de Mendonça
2000352
16 countries
including the UK
1411 > 12; median
63–57
AKI (serum creatinine
≥ 300 µmol/l and/or urine
output < 500ml/day) in
ICU. Excluded patients with
ICU stay of < 48 hours, a
history of RRT or had had
an elective operation
Prospective,
multicentre,
observational cohort
analysis
AKI incidence: 348/1411 (24.7%).
Median ICU LOS (days): AKI 7, no AKI 4.
ICU LOS was the same for survivors
and non-survivors. ICU mortality: AKI
149/348 (42.8%), no AKI 199/1068
(18.6%); hospital mortality: AKI 49.1%,
no AKI 17.7%
Grayson
2003353
UK 5132 50% < 65; 39%
65–74; 11%
> 75
75 AKI after cardiac operation
involving CPB. Excluded
patients with pre-existing
significant renal
impairment (serum
creatinine > 200mol/l)
Retrospective cohort
analysis
AKI hospital incidence: 151 (2.9%);
105/151 patients with ARF did not
require dialysis
aHurtado-Doce
2014354
UK 512 Median 54 71 AKI after cardiac surgery
and requiring CRRT
Retrospective analysis
of hospital records
60/512 (12%) patients required CRRT
for AKI. Mortality: all 23/512, no RRT
17/452, RRT 6/60
aKarmali
2015355
UK 262 NR NR AKI after CABG surgery
using CPB (ONCAB,
n= 131) or off-pump
(OPCAB, n= 131).
Excluded dialysed patients
Retrospective analysis
of hospital records
AKI incidence: all 20/262 (7.6%),
OPCAB 14/131 (10.7%), ONCAB
19/131 (14.5%). RRT in ICU: all
15/262 (5.7%), OPCAB 6/131 (4.6%),
ONCAB 9/131 (6.9%). Mean ICU LOS
(days): OPCAB 1.96, ONCAB 2.49
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Kerr 2014323 UK NR Adults (age NR) NR AKI in hospital with ICU
subgroup. Chronic RRT
patients excluded from
hospital data but not
identifiable in HES
Retrospective database
(HES) and records
analysis and economic
decision model
Mean LOS: no AKI 0.05 days, stage 1
0.17 days, stage 2 0.31 days, stage 3
1.57 days, all AKI 0.35 days. Ratio vs.
no AKI: stage 1 2.60 days, stage 2
5.61 days, stage 3 18.2 days, all AKI
4.32 days
aKhawaja
2012337
UK 249 Mean 83–82 62 AKI (modified RIFLE score
≥ 2) after transcatheter
aortic valve implantation.
Excluded patients with
history of RRT
Retrospective review of
medical records
AKI in ICU: 89 (35.7%); 30-day
mortality: AKI 13.5%, no AKI 3.8%.
Mortality at mean follow-up (338
days): AKI 40.4%, no AKI 19.4%
(p< 0.001)
Kirwan 2015356 UK 5544 Median 64–66 78–82 AKI in ICU requiring RRT.
Excluded patients with
known CKD, ESRD or
transplant in the last
10 years
Retrospective review of
hospital records
781/5544 (14%) ICU admissions
received RRT; 22/261 (8.4%) RRT
survivors died within 3 months post
hospital discharge; 7/261 commenced
RRT within 3 months post discharge
Kolhe 2008341 UK 276,731 (17,326
with severe AKI)
Mean 63.2 66 Severe AKI (serum
creatinine ≥ 300 µmol/l
and/or urea ≥ 40mmol/l)
in first 24 hours of ICU
admission. Excluded
patients with a history of
RRT or an ICU stay of
< 8 hours
Retrospective review of
hospital records
AKI incidence: 6.3% (17,326/276,731).
Median ICU LOS (days): AKI survivors
4.1, AKI non-survivors 2.0, whole
cohort survivors 1.7, whole cohort
non-survivors 2.0; median hospital LOS
(days): 31, 8, 16 and 9 respectively
Kolhe 2014331 UK 576 Mean 76 57 Primary or secondary
diagnosis of AKI in hospital
according to International
Classification of Diseases,
10th Edition (ICD-10) codes
Retrospective database
and activity records
analysis
26 (4.5%) AKIN stage 3 patients
required RRT in the ICU. AKI patients
who needed RRT had a longer
hospital LOS stay than those who did
not need RRT: 16.7 vs. 10.3 days
aKolic 2013336 UK 282 Median 50 68 AKI and CKD in the ICU
with an ICU stay of
> 5 days
Retrospective review of
hospital records
180/282 (64%) patients had AKI in
the ICU; 36/282 (12.8%) to 25/282
(8.9%) had CKD depending on the
definition of CKD used
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
aKourliouros
2009342
UK 1072 NR NR AKI after CABG surgery Retrospective cohort
study
Incidence of AKI in the ICU: 175/1072
(16%)
Metcalfe
2002357
UK 51 Median 71.4 65 Patients requiring RRT in
hospital (either AKI or AKI
on CKD)
Prospective
observational study
23/34 (67.6%) patients with AKI had
RRT in the ICU. Hospital LOS: median
19 days. At 90 days: recovered: AKI
cohort 8 (23.5%), AKI on CKD 3
(16.5%). Mortality: AKI 25 (73.5%),
AKI on CKD 12 (67%), CKD 4 (11%),
all 41 (46%)
Noble 2001363 UK 612 Mean 57 61 AKI requiring RRT and
mechanical ventilation for
respiratory failure in the
ICU
Retrospective database
review and telephone
interviews
ICU median LOS: AKI 9.6 days, no AKI
2 days, AKI survivors 12 days, AKI
non-survivors 8.3 days. Hospital
mortality: 64.1% (392/612)
Ostermann
2000361
UK 2337 Mean 65 Female-to-
male ratio
from 4 : 14 to
5 : 16
AKI (urine output
≤ 479ml/24 hours or
≤ 159ml/8 hours, serum
urea ≥ 35mmol/l, serum
creatinine ≥ 300mmol/l)
after surgery with CPB
Prospective
observational study
compared with
historical control
subjects
47/2337 (2.0%) patients needed
CVVH vs. 2.7% from historical data;
21/39 (53.8%) patients vs. 74% in
the historical data died in the ICU.
Hospital mortality: current, 53.8% vs.
historical, 83%. Hospital mean LOS:
survivors 53 days vs. non-survivors
17.3 days. Duration of CVVH (days):
survivors 11 vs. non-survivors 12.7
Ostermann
2007362
UK and Germany 41,972 Mean 61 64 AKI (RIFLE) in the ICU.
Excluded patients on
dialysis at baseline
Retrospective database
analysis
AKI incidence: risk 17.2%, injury
11%, failure 7.6%. ICU mortality: no
AKI 5%, risk 14.7%, injury 36.5%,
failure 47.6%. Hospital mortality:
8.4%, 20.9%, 45.6% and 56.8%
respectively. Mortality odds ratio: risk
1.40, injury 1.96, failure 1.59
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Paterson
2013332 and
2014333
UK 366 Mean 64–66 56–66 Patients receiving RRT in
the ICU. Excluded patients
receiving dialysis for
CKD at baseline and
interhospital ICU transfers
Retrospective before-
and-after study of
high-volume vs. low
volume RRT
Days on RRT for survivors: high-
volume RRT 12, low-volume RRT 8.
ICU RRT mortality: high-volume RRT
55 (29%), low-volume RRT 61 (34%).
Hospital mortality: high-volume RRT
77 (41%), low-volume RRT 75 (42%).
Death post-ICU discharge: high-
volume RRT 22 (12%), low-volume
RRT 14 (8%)
Prescott 2007358 UK 809 > 15; median
65–72
61 Patients requiring RRT
(either AKI or AKI on CKD)
in the ICU or renal ward.
Excluded patients requiring
RRT for ESRD or with renal
transplants
Prospective
observational study
600 patients had AKI, 209 had AKI
on CKD. Median days of RRT: AKI 5,
AKI on CKD 8; 30% of AKI and 20%
of AKI on CKD patients died within
10 days of starting RRT. Mortality at
90 days: AKI 50%, AKI on CKD 43%
Prowle 2014335
and 2014359
UK 700 Median 46–51 Range 62–70 AKI (KDIGO) in the ICU
with an ICU stay of > 5
days and patient surviving
to hospital discharge.
Excluded patients with new
or pre-existing ESRD and
transplant recipients
Retrospective analysis
of hospital records
AKI incidence: 66% (459/700); stage 1
218 (31%), stage 2 75 (11%), stage 3
166 (24%). 121/700 (17.3%) patients
received RRT. ICU median LOS (days):
all 12, no AKI 8, stage 1 11.5, stage 2
11, stage 3 12. Hospital median LOS
(days): no AKI 28, AKI 22
Ricci 2008369 Worldwide
including the UK
71,000 (8398
with relevant
outcome)
NR NR AKI (RIFLE) in the ICU Systematic review with
meta-analysis
RR (vs. no AKI) for mortality in the
ICU: risk 1.77, injury 2.35, failure
4.63. RR (vs. risk): injury 1.32, failure
2.33. RR (vs. injury): failure 1.74
Saratzis 2015339 UK 149 Mean 69 89 AKI (AKIN and KDIGO)
≤ 48 hours post cardiac
surgery (elective
endovascular abdominal
aneurysm repair). Excluded
patients with ESRD or on
dialysis at baseline
Prospective cohort
study
AKI incidence: 28 (18.8%); stage 1
25, stage 2 3. Post-discharge
mortality: AKI 32.1%, no AKI 1.7%.
AKI hazard ratios: mortality 0.035,
cardiovascular morbidity 0.021
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Susantitaphong
2013334
Worldwide 888,604 (ICU),
164,333 (cardiac)
Mean 23–80 NR AKI (KDIGO) in ICU or post
cardiac surgery
Literature review of
large cohort studies
with meta-analysis
AKI incidence in the ICU: 31.7%
(95% CI 28.6% to 35.0%), post
cardiac surgery: 24.3% (95% CI
20.4% to 28.8%). AKI ICU mortality:
33.1% (95% CI 29.8% to 36.6%),
post cardiac surgery: 8.3% (95% CI
6.6% to 10.4%)
aSyed 2011360 UK 373 Adults (age NR) NR AKI stage 1 (AKIN) in ICU Retrospective review of
medical records to
assess the impact of
early oxygen delivery
ICU mortality for AKI stage 1 23.8%;
hospital mortality for all 31.6%. No
significant difference in hospital
mortality between high and low
oxygen monitoring groups. 48/249
(19.3%) patients with no monitoring
progressed to AKI stage 3
Thomson
2014340
UK 264 Mean 70 Female-to-
male ratio
1 : 3
AKI after CABG surgery
and/or aortic valve surgery
in cardiothoracic ICU
Prospective
observational study to
assess the impact of
goal-directed therapy
(GDT)
AKI incidence at day 3: GDT group
6.5%, control group 19.9%
Tsang 1996368 UK 48 Mean 65 71 AKI requiring continuous
hemofiltration after cardiac
surgery
Retrospective database/
records review plus
telephone interviews
319/2297 (13.89%) patients admitted
to the ICU required CRRT. Mean LOS:
RRT patients 13, all patients 8.2.
Mortality at hospital discharge: RRT
patients 56%, all patients 20%
Uchino 2005364 23 countries
including the UK
29,269 (1738
with AKI; 52 UK
patients)
Median 67 64 Patients with AKI [urine
output < 200 ml/12 hours
and/or a marked blood
urea nitrogen level
> 84mg/dl (30 mmol/l)] or
treated with RRT in the ICU
Prospective
observational study
AKI incidence: 1738/29,269 (5.8%),
UK subgroup 20.6%; 1260 (4.2%)
were treated with RRT in the ICU,
52% died in the ICU, 60.3% died in
hospital (73.1% in the UK subgroup).
Dialysis dependence at hospital
discharge: 13.8% for AKI survivors
Uchino 2007365 23 countries
including the UK
1006 Median 66 66 Patients with AKI requiring
CRRT in the ICU. Excluded
patients on dialysis
Prospective
observational study
ICU mortality: 555/1003 (55.3%).
Hospital mortality: 641/999 (64.2%);
85.5% were dialysis independent at
hospital discharge
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
CKD studies
aAnwar 2012411 UK 548 NR NR Renal transplant recipients
with at least 3 years of
follow-up data
Single-centre
observational study
56/548 (10.2%) patients were on
dialysis within 5 years post
transplantation
aBabu 2014412 UK 155 (80 in CKD
group)
Mean 61–69 NR Patients with CKD and
primary prevention cardiac
resynchronisation therapy
devices
Single-centre
observational study
Mean survival time: CKD 59.7 months,
no CKD 81.2 months. CKD was an
independent predictor of sustained
ventricular arrhythmia
Balupuri
2000442
UK 47 16–60 NR Renal transplant recipients
either from heart-beating
donors (HBDs) or non-
heart-beating donors
(NHBDs)
Single-centre
prospective study
In phase I, 19/21 (90.5%) HBD
transplants were successful; in phase II
(including non-HBDs), 5/11 (45.5%)
transplants were successful; in
phase III (non-HBDs including other
departments), 12/13 (92.3%)
transplants were successful
aBevins 2013413 UK 201 NR NR CKD stage 4 Retrospective analysis Over a median follow-up of 1483
days, 60/201 patients progressed to
RRT (i.e. ESRD)
Chamberlain
2014373
Europe 3181
(370 in the UK)
Mean 47–53 62–66 Renal transplant recipients.
Excluded multiorgan
transplants
Retrospective
multicentre study
Database results: over 3 years post-
transplant outcomes for UK: delayed
graft function 22.4%, acute rejection
37%, graft failure 10%, stroke 0%,
death 1.9%. Questionnaire results:
29.9%, 20.6%, 11.5%, 2% and
2.7% respectively
aChan 2011414 UK 1288 Mean 46 62 Renal transplant recipients Cohort analysis 15-year patient and allograft survival
was 84.6% and 66.8% respectively;
13/70 deaths were from malignancy
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
aCherukuri
2014415
UK 504 NR NR Renal transplant recipients Prospective cohort
analysis
Transplant recipients who were
vitamin D deficient had worse overall
survival (77% vs. 92%) and death
censored graft survival (89% vs. 96%)
than those with normal vitamin D
levels
Cherukuri
2010416
UK 94 Mean 63 69 Incident patients starting
dialysis and on dialysis for
at least 90 days
Prospective
observational cohort
study
39/94 (41%) patients died during the
study period, mostly from vascular
disease (39%) or sepsis/infection
(33%); 56% (n= 22) of deaths
occurred in the first year
CKD Prognosis
Consortium
2010444
International
including the UK
105,872 NR NR General population cohorts Systematic review and
meta-analysis
Compared with an eGFR of 95 ml/
minute/1.73 m2, adjusted hazard ratios
for all-cause mortality were 1.18 for
60 ml/minute/1.73 m2), 1.57 for 45 ml/
minute/1.73 m2 and 3.14 for 15 ml/
minute/1.73 m2). Similar findings were
recorded for cardiovascular mortality
CKD Prognosis
Consortium
2011445
International
including the UK
21,688 NR NR Kidney disease cohorts Systematic review and
meta-analysis
Below an eGFR of 45 ml/minute/
1.73 m2, a 15-ml/minute/1.73 m2 drop
in eGFR was significantly associated
with mortality (hazard ratio 1.47) and
ESRD (hazard ratio 6.24)
Coresh 2014417 International 1.7 million Mean 51–74 49–80 Mixed cohorts with and
without CKD. Excluded
patients with ESRD at
baseline
Meta-analysis of
studies from an
international
consortium consisting
of 50 cohorts with
> 1000 participants
A change of −57% in estimated GFR
over 2 years was associated with
adjusted hazard ratios for ESRD of
32.1 at lower eGFRs (< 60ml/minute/
1.73 m2) and 57.2 at higher eGFRs
(≥ 60ml/minute/1.73 m2). Mortality
HRs were 3.7 and 3.8 respectively
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Drey 2003451 UK 405,000 NR NR Detected CKD in a general
population cohort
Retrospective cohort
study
Annual incidence of CKD: 1701 per
million population with a median age
of 77 years and male-to-female ratio
of 1.6. CVD was the most common
cause of death (46%); 4% were
accepted for RRT
Ekberg 2009448 International
including the UK
1645 Median 47 65 Renal transplant recipients
with low-to-normal
immunological risk
Randomised trial Biopsy-proven acute rejection: 25% at
12 months, 26% at 24 months, 27%
at 36 months; death censored graft
survival: 94%, 92% and 91%
respectively; uncensored graft survival:
92%, 89% and 88% respectively;
patient survival: 97%, 96% and 95%
respectively
aFarrugia
2013418
UK 19,103 NR NR Renal transplant recipients Retrospective database
analysis
2085/19,103 of patients died, 376
(18.0%) because of malignancy
aFavi 2015419 UK 639 NR NR Renal transplant recipients Single-centre
observational study to
assess polyomavirus-
associated nephropathy
(PVAN)
Death-censored graft loss rates: PVAN
42%, no viraemia 14%
Fellstrom
2005420
International
including the UK
1052 Mean 50 65.2 Renal transplant recipients RCT (but assessed
placebo arm only in
this analysis)
Over 5–6 years of follow-up: 54/1052
patients experienced cardiac death
and 65/1052 experienced non-cardiac
death and 66/1052 had definite
myocardial infarction
Gansevoort
2011443
International
including the UK
845,125 general
population and
173,892 high risk
Mean 26.4–66.9 39.5–100 General population and
CKD high-risk cohorts
Systematic review and
meta-analysis
Hazard ratios for ESRD at eGFRs of
60, 45 and 15ml/minute/1.73 m2
(vs. 95 ml/minute/1.73 m2) in the
general population cohort analysis:
3.69, 29.3 and 454.9 respectively
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Ghazanfar
2010449
UK 201 Mean 37.4 Male-to-
female ratio
6 : 1
Renal transplant recipients
(living donors)
Retrospective analysis Graft survival at 1, 2 and 5 years post
transplant: 93%, 89% and 87%,
respectively, for multiple arteries;
94%, 91% and 89%, respectively, for
single arteries. Patient survival rates at
1, 2 and 5 years post transplant: 97%,
93% and 92%, respectively, for
multiple arteries; 95%, 94% and
91%, respectively, for single arteries.
Mean graft and patient survival rates
at 10 years were 71% and 79%,
respectively, for multiple arteries and
77% and 83%, respectively, for single
arteries
Hamed a2013421
and a2014422
UK 1090 NR NR Renal transplant recipients Single-centre
observational study
52/1090 (4.8%) patients experienced
early graft loss and had an 8.5 times
increased risk of death, with 1-year
survival less than that for those on
the waiting list (76.9% vs. 88.8%);
5-year survival in the early graft loss
group was better than that for waiting
list patients (69.3% vs. 51.4%).
Retransplantation after early graft loss
resulted in 1-year graft survival of
86.7%
Humar a2009423
and a2010424
UK 318 NR NR High-risk renal transplant
recipients
International RCT 1-year rates of acute rejection (17.2%
vs. 11%) and graft loss (1.8% vs.
1.9%) were comparable between the
100-day and the 200-day prophylaxis
groups respectively. Patient survival
was 100% and 97% respectively
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Jardine 2005425 UK 1052 Mean 50 65.2 Low-risk renal transplant
recipients
RCT (but assessed
placebo arm only in
this analysis)
Over a mean 65.3-month follow-up,
54/1052 patients experienced cardiac
death and 65/1052 experienced
non-cardiac death and 66/1052 had a
definite myocardial infarction
Karim 2014426 UK 19,103 Median 45 61 Renal transplant recipients,
excluding multiorgan
transplants
Retrospective database
linkage and review
(population cohort
analysis)
2085/19,103 patients died over a
median follow-up of 4.4 years. Repeat
transplantations occurred in 635
recipients over the 11-year period
Kent 2015370 International
including the UK
7246 Mean 63 64 CKD ± CVD; CKD stages
1–3: 1494; CKD stage 4:
2228; CKD stage 5 no
dialysis: 1017; on dialysis:
2498
Randomised
prospective trial
Vascular deaths per patient-year: CKD
stages 1–3b 36 (0.6%), CKD stage 4
92 (1%), CKD stage 5 86 (2.2%),
CKD stage 5+ dialysis 235 (2.5%);
non-vascular deaths per patient-year:
1.6%, 2.5%, 3.8% and 4.9%
respectively; kidney transplant in
current period: 0.2%, 1.6%, 5.4%
and 6.7% respectively; kidney
transplant in earlier period: 0.1%,
1.4%, 8.5% and 2.5% respectively;
dialysis initiated in current period:
1.3%, 6.2%, 18.2% and 0.2%
respectively; dialysis from earlier
period: 0.7%, 6.9%, 33.8% and
80.6% respectively
aKrishnan
2013427
UK 13,167 NR 64 Renal transplant recipients Retrospective database
analysis
857 (18%) patients suffered rejection
and 205 (3%) patients died
aMark 2010428 UK 199 NR NR Patients with CKD stage 5,
with contrast cardiovascular
magnetic resonance
imaging and assessed for
renal transplant
Cohort analysis Over a median follow-up of 61.6
months there were 61 (30.7%)
deaths, of which 36 (59%) were
cardiovascular deaths
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Marks 2012447 UK 3414 Median 78.6 44.2 CKD (67% stage 3, 30%
stage 4, 2% stage 5),
excluded patients receiving
RRT
Retrospective cohort
study (case note
review)
At 6 years’ follow-up, 170 (5%)
patients had initiated RRT (with 77
subsequently dying), 59% died
without initiating RRT and 36% were
alive without RRT. Adjusted incident
rate ratios for initiating RRT: CKD
stage 4 vs. 3: 5.60, stage 5 vs. 3:
38.10; adjusted incident rate ratios for
all-cause mortality: 1.41 and 1.55
respectively
Moore 2011429 UK 2763 Mean 46 60 Renal transplant recipients
surviving at least 12 months
post transplant and all
treated with ciclosporin
mircroemulsion
Retrospective database
analysis
In a development data set, 196/2763
(7%) patients died and 225 (8%)
experienced transplant failure. In a
validation data set, 44/731 (6%)
patients died and 101 (14%)
experienced transplant failure
Nath 2015430 UK 1095 Mean 27–48 40–66 Obese patients receiving
single organ renal
transplantation with
multiple renal arteries
Retrospective single-
centre analysis
1-year graft survival: all 996/1095
(91%), underweight 30/33 (91%),
normal weight 378/403 (94%),
overweight 358/394 (91%), obese
230/265 (87%). Patient 1-year
survival: survival for all 99%, all 97%,
underweight 99%, normal weight
99%, overweight 98% and obese
99% respectively
NHS Blood and
Transplant
2015450
UK 8608 NR NR Renal transplant recipients/
patients on transplant
waiting list
Kidney Activity Report
(registry analysis)
Over 1 year (2014/15), of 8608
patients on the kidney transplant
waiting list, 5713 (66%) remained
on the list, 2183 (25%) were
transplanted, 491 (6%) were removed
from the list and 221 (3%) died. For
patients transplanted in 2010–13,
1-year graft survival was 94% and
1-year patient survival was 96%
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Raymond
2007431
UK 106,366 Mean 58 44.5 Community population
with at least one serum
creatinine measurement,
retrospectively assigned to
CKD stages
Retrospective database
analysis
Annual mortality increased with CKD
stage: stages 1 and 2 1.9%, stage 3A
6.4%, stage 3B 11.1%, stage 4 16.5%,
stage 5 20.6%. RR for mortality: 4.0,
8.3, 16.2 and 43.5 for CKD stage 3A,
3B, 4 and 5 respectively. This impact
reduced with age
Renal
Association
2014410
UK 6680 NR NR RRT patients Analysis of registry
data
After 5 years’ follow-up, of 5034
patients on HD, 31% remained on
dialysis, 16% had a transplant and
51% died. Of 1297 patients on PD,
29% remained on dialysis, 37% had a
transplant and 33% died. Of 349
patients on the transplant waiting list,
4% were on dialysis, 92% remained
on the transplant waiting list and 5%
died
Robinson
2012432
International
including the UK
24,525 Mean 61–63 54–58 Patients with ESRD for
> 180 days, receiving
haemodialysis
Prospective cohort
study
5849/24,525 patients died over
42,174 patient-years of follow-up
(rate 0.14 per year)
Roderick
2009433
UK 15,336 Median 80.2 39 Older patients (75+ years)
with CKD in the community
Clinical trial In the first 2 years of follow-up,
adjusted hazard ratios for all-cause
mortality for eGFR bands 45–49,
30–44 and < 30ml/minute/1.73 m2 vs.
> 60ml/minute/1.73 m2 were 1.13,
1.69 and 3.87, respectively, for males
and 1.14, 1.33 and 2.44, respectively,
for females
aSeitz 2015434 UK 14,027 NR NR First-time renal transplant
recipients
Retrospective database
analysis
Median time to rejection was
126 days in the alemtuzumab group
and 35 days in the non-alemtuzumab
group
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TABLE 44 Included studies for the AKI and CKD risk searches (continued )
First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Shabir 2014435 UK 651 Mean 44.2–52.4 60–63 Renal transplant recipients
alive at 12 months post
transplantation
Cohort analysis Development cohort: for patients alive
at 12 months post transplant, 31/651
died from 1–5 years post transplant
and 91/651 had transplant failure.
Validation cohort: for patients alive at
12 months post transplant, 58/787
(7.4%) died from 1–5 years post
transplant and 62/787 (7.9%) had
transplant failure
Taal 2007436 UK 35 Median 63.8 60 CKD stages 4 and 5 not
yet on dialysis. Excluded
patients with renal
transplantation or on
dialysis
Retrospective analysis
of longitudinal study
After a median of 12.4 months,
22/35 (63%) patients with stage 4/5
CKD had commenced dialysis
Thomson
2007437
UK 263 Median 66.7 51.3 Patients receiving
haemodialysis in a renal
unit
Retrospective analysis Over an 18-month follow-up period,
65/263 (24.7%) patients had died;
15 underwent renal transplantation
and one recovered renal function
Udayaraj
2009438
UK 2770 Median 58 58 Patients with ESRD
receiving PD therapy at
180 days from start of RRT
Retrospective analysis
of UK Renal Registry
1104/2770 patients died over a
median follow-up of 3.7 years
van der Velde
2011446
International
including the UK
266,975 NR NR High-risk cohorts Systematic review and
meta-analysis
Risk for all-cause mortality was not
associated with an eGFR between
60 and 105ml/minute/1.73 m2 but
increased at lower levels. Hazard ratios
at eGFRs of 60, 45 and 15ml/minute/
1.73 m2 were 1.03, 1.38 and 3.11,
respectively, compared with an eGFR
of 95 ml/minute/1.73 m2. There were
similar findings for cardiovascular
mortality
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First author
and year Country n Age (years)
Sex male
(%) AKI/CKD status Methods Key risk results
Vivek 2010439 UK 126 Mean 46–55 Male-to-
female ratio
from 16 : 16
to 56 : 38
Renal transplant recipients Retrospective cross-
sectional study
Over a mean of 91 months’ follow-up,
35 (27.8%) patients died. Cardiac
deaths accounted for 12% of all
deaths
Wen 2014440 UK 1,130,472 NR NR General population cohort Meta-analysis In Asian, whites and black patients,
compared with an eGFR of
90–104ml/minute/1.73 m2, the hazard
ratios for eGFR 45–59ml/minute/
1.73 m2 were 1.25, 1.09 and 1.33 for
all-cause mortality, 1.59, 1.40 and
1.44 for cardiovascular mortality and
27.6, 11.2 and 4.05 for ESRD
respectively
Woo 2002441 UK 434 NR 62.9 Renal transplant recipients Longitudinal cohort
study
Age (hazard ratio 1.03), diabetes
(hazard ratio 2.72), smoking (hazard
ratio 1.81) and family history of
premature CVD (hazard ratio 2.17)
were independent risk factors for
patient survival. Acute rejection
(hazard ratio 2.38), smoking (hazard
ratio 1.48) and age (hazard ratio 1.04)
were independent predictors of graft
failure
AKIB, acute kidney injury biomarkers; ARF, acute renal failure; CRRT, continuous renal replacement therapy; CVD, cardiovascular disease; CVVH, continuous venovenous haemodialysis;
eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; HD, haemodialysis; HES, Hospital Episode Statistics; LOS, length of stay; NR, not reported; PD, peritoneal dialysis;
RR, relative risk.
a Abstract only.
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TABLE 45 UK AKI utility studies identified from additional searches of utility databases
First author
and year n Age (years) Sex male (%) Methods Utility
Latimer 2013462 123 All > 80 0–32 RCT of shock-absorbing floor for hospital falls.
EQ-5D data collected 3 months post discharge
for patients treated on a general ward
Mean utility for the ‘no fall’ group 0.38
(vs. 0.27–0.36 for fall categories)
Hernández 2014460 286 Median
59–60
60 Trial assessing ICU follow-up programmes.
EQ-5D data collected at baseline (shortly after
ICU discharge) and 6 and 12 months post
discharge
Mean utility: baseline: 0.44 standard care vs.
0.49 for increased follow-up; 6 months:
0.62 vs. 0.63 respectively; 12 months: 0.60
vs. 0.58 respectively
Cuthbertson 2010461 300 Median 61 59 Prospective cohort study to assess long-term
quality of life post ICU admission. EQ-5D data
were collected at 1, 2.5 and 5 years after ICU
admission. Scores were compared with those
of hypothetical age- and sex-matched control
subjects
Mean utility: 12 months post ICU admission:
0.666 vs. 0.82 in matched cohort; 2.5 years’
follow-up: 0.701 vs. 0.818 in matched
cohort; 5 years’ follow-up: 0.677 vs. 0.817
in matched cohort
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The database searches identified 689 records, with 496 remaining after removal of duplicates (Figure 31).
In total, 37 relevant reviews and papers were initially identified. Within these 37 studies, four key recurring
interventions were identified: early RRT, early nephrologist involvement, AKI e-alert systems and intravenous
administration of alkaline phosphatase. Based on a review of the literature findings and expert consultation,
evidence on the impact of early RRT was deemed to be currently contentious and this intervention was
therefore not explored further. For the remaining interventions citation tracking was conducted to identify
UK primary ICU studies. In total, eight primary studies463–470 were included for data extraction and are
summarised in Table 46.
Evidence on the impact of e-alert systems was mixed, with the largest identified study finding no impact.463
Alkaline phosphatase appears to be a potentially effective treatment for AKI but as of yet there are limited
data to support use of this intervention in practice. The evidence on the impact of early nephrologist
consultation was deemed to be of most relevance for this study as this can reasonably be assumed to
represent a proxy for the non-specific bundle of early AKI treatments that patients would access as a result
of biomarker-led early diagnosis. All of the four identified studies in this area reported some impact of
early consultation on patient mortality and the largest study (n = 1096) reported a significant impact of
early consultation on the incidence of AKI, with an adjusted odds ratio of 0.71 (95% CI 0.53 to 0.95;
p = 0.02).464
AKI early intervention search
March 2015
Search hits
(deduplicated)
(n = 496)
Excluded at abstract
review
(n = 432)
Excluded at full-text review
(n = 27)
Excluded from database extraction
(n = 32)
Items shortlisted
(n = 64)
Review inclusions
(n = 37)
Primary studies included
for data extraction
(n = 8)
Primary studies
identified from
citation tracking
(n = 3)
• Not a relevant intervention, n = 20
• Not in English, n = 4
• Paediatric, n = 1
• Full text unable to be retrieved,
   n = 2
• Not a primary study or an
   appropriate intervention, n = 32
FIGURE 31 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the
AKI early intervention search.
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TABLE 46 Summary of early AKI intervention studies in the ICU in the last 5 years
First author
and year Country n AKI status Methods Key results
Early nephrologist involvement
Flores-Gama
2013464
Mexico 1096 AKI (RIFLE/AKIN)
within 7 days of
cardiac surgery in the
cardiac ICU
Retrospective time series
analysis of impact of
nephrology on-demand
vs. nephrology on-site
(i.e. integrated into the
daily ICU team) on renal
recovery
Patients treated with
nephrology on-site had a
lower incidence of AKI
(25.7% vs. 31.9%;
adjusted OR 0.71) and
in-hospital mortality for
severe AKI (34.1% vs.
55.9%; adjusted OR 0.33)
and higher renal recovery
at hospital discharge
(61.0% vs. 35.3%;
adjusted OR 3.57) than
patients treated with
nephrology on-demand.
No differences in ICU stay
or mechanical ventilation
Costa e Silva
2013465
Brazil 366 AKI (increase of
≥ 50% in baseline
serum creatinine level
according to the
RIFLE risk stage) in
the ICU and length of
ICU stay > 48 hours
Prospective observational
study to assess the
impact of early
(< 48 hours from AKI
diagnosis day) vs.
delayed (≥ 48 hours
after AKI diagnosis)
nephrology consultation
Of 53.6% who had a
nephrologist consultation,
those with a delayed
consultation had a higher
rate of hospital mortality
(adjusted OR 3.39),
increased dialysis
dependence (adjusted OR
3.25), a longer ICU stay
(19 vs. 13.5 days), a longer
time on mechanical
ventilation support (16.5
vs. 10 days) and a longer
time from diagnosis to
dialysis (7 vs. 2 days)
Ponce
2011466
Brazil 148 AKI (AKIN) in the ICU Prospective observational
study of the impact of
delayed nephrologist
consultation (≥ 48 hours
after AKI diagnosis)
Of patients who received a
consultation, 29 received
an early consultation and
48 received a late
consultation. Delayed
consultation was
associated with increased
ICU mortality (65.4% vs.
88.2%, adjusted OR 1.32)
Mehta
2002467
USA 215 AKI in the ICU and
hospital. AKI defined
according to blood
urea nitrogen and
serum creatinine
criteria
Prospective observational
study to assess the
impact of delayed
(≥ 48 hours) nephrology
consultation
Delayed consultation was
associated with increased
in-hospital mortality
(adjusted OR 2.0), length
of hospital stay (median 19
vs. 16 days) and length of
ICU stay (17 vs. 6 days)
Electronic e-alerts
Wilson
2015463
USA 1393 Patients in hospital
(including ICU) with
stage 1 or above
KDIGO AKI
Single-blind,
parallel-group RCT of a
text-based e-alert system.
Patients were stratified
by medical vs. surgical
admission and ICU vs.
non-ICU location
The e-alert system did not
affect patient clinical
outcomes (change in
creatinine level, dialysis and
death at 7 days post
randomisation)
Colpaert
2012468
Belgium 951 AKI (RIFLE) in the ICU Prospective time series
analysis of a telephone
alert system. Three
More patients in the alert
group received intervention
within 60 minutes of alert
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Acute kidney injury registry data
The Epidemiology of AKI in ICU study471 is an ongoing prospective observational international study with
the primary aim of identifying the incidence and prevalence of AKI among critically ill patients. The study
includes in the first instance an initial ‘screening period’ during which data on patient age, sex, weight,
baseline creatinine level, daily creatinine level and urine output are collected over 7 days from patient
admission to ICUs across participating sites. As a result this study provides a registry of daily individual
patient data for patients experiencing AKI in the ICU. If a patient is found to meet AKI criteria within the
screening period, informed consent is pursued to enable further research-specific activity. All patients
admitted to the ICU are eligible for inclusion, with the exception of patients on chronic haemodialysis or
peritoneal dialysis within the past 12 months, those with a functioning kidney transplant and prisoners.
Currently, six hospitals in England have enrolled or begun enrolling patients, with the highest number of
enrolled patients to date coming from the Leeds Teaching Hospitals NHS Trust (LTHT).
TABLE 46 Summary of early AKI intervention studies in the ICU in the last 5 years (continued )
First author
and year Country n AKI status Methods Key results
consecutive study
phases: a 1.5-month
pre-alert control phase,
a 3-month intervention
phase and a 1.5-month
post-alert control phase
(28.7% vs. 7.9% and
10.4% in the pre- and
post-alert control groups
respectively) and received
fluid therapy, diuretics and
vasopressors (p< 0.001)
and more patients in the
alert group returned to a
baseline kidney function
within 8 hours of a ‘risk’
alert (p= 0.048). There was
no impact on ICU length of
stay, use of RRT or mortality
Alkaline phosphatase
Pickkers
2012469
The
Netherlands
36 Patients with severe
sepsis or septic shock
and AKI (AKIN) in the
ICU
Prospective RCT to assess
the impact of intravenous
infusion of alkaline
phosphatase within
48 hours of AKI onset
Creatinine clearance
(baseline to day 28) was
significantly higher in the
treated group (from a
mean of 50± 27 to
108 ± 73ml/minute vs.
from a mean of 40± 37 to
65± 30ml/minute for
placebo). Reductions in RRT
requirement and duration
were not significant
Heemskerk
2009470
The
Netherlands
36 Patients with
bacterial infection,
more than two
systemic inflammatory
response syndrome
criteria and < 12 hours
end-organ dysfunction
onset in the ICU
A multicentre RCT to
assess treatment with an
initial bolus intravenous
injection of alkaline
phosphatase followed by
continuous infusion over
the following 23 hours
and 50 minutes
Over 28 days, mortality
was 24% in the alkaline
phosphatase group vs. 36%
in the placebo group; RRT
use was 24% in the alkaline
phosphatase group vs. 36%
in the placebo group. In
patients with AKI, serum
creatinine levels tended to
decrease over the 2 days
after the start of alkaline
phosphatase treatment
(p= 0.12), whereas there
was a non-significant
increase in the placebo
group (p= 0.49)
OR, odds ratio.
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For the AKI-Diagnostics study, in July 2015 data were requested from the AKI registry on patients treated
at LTHT. Data were provided on 60 patients who experienced AKI in the ICU, 13 of whom were in the ICU
post cardiac surgery. An overview of the baseline characteristics of these patients is provided in Table 47.
A summary of patients’ ICU and hospital length of stay and mortality is provided in Table 48.
Data on these patients were used to determine patient ICU daily status across the 10 possible AKI hospital
period health states: AKI KDIGO S0, S1, S2, S3 and S3 + RRT, discharged to hospital ward, discharged to
hospital ward + RRT, discharged home, discharged home + RRT and mortality. The daily statuses were
used to derive daily Dirichlet transition probabilities between the health states for the model baseline AKI
cohort. When AKI status could not be determined because of missing serum creatinine or urine output
data, the closest observed AKI status value was carried forwards or backwards, as required. An adjustment
of +0.01 was applied to all values to enable Dirichlet estimation in the presence of zero values.
TABLE 47 Leeds Teaching Hospitals NHS Trust AKI registry data: patient characteristics
Characteristic AKI cohort (n= 60) AKI post cardiac surgery (n= 13)
Mean (SD) age (years) 68 (13) 71 (7)
Male (%) 77 92
Type of ICU (%)
General 71.7 0.0
Cardiac 21.7 69.2
Surgical 6.7 30.7
Admission diagnosis (%)
Trauma 1.7 –
Cardiac surgery 21.7 100
Vascular surgery 3.3 –
Other surgery 10.0 –
Sepsis/septic shock 13.3 –
Intoxication 0.0 –
Neurological diagnosis 3.3 –
Cardiac diagnosis 18.3 –
Respiratory diagnosis 18.3 –
Nephrological diagnosis 0.0 –
Gastrointestinal diagnosis 10.0 –
Haematological diagnosis 0.0 –
Oncological diagnosis 0.0 –
Endocrine diagnosis 0.0 –
Not reported 0.0 –
Surgery status (%)
Emergency 18.3 7.7
Elective 35.0 92.3
None 46.7 0.0
Not reported 0.0 0.0
SD, standard deviation.
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A summary of the patients’ maximum ICU AKI status is provided in Table 49 and a summary of patients’
daily AKI status is provided in Figure 32 [note that, because of the size of the daily Dirichlet transition
matrices (10 × 10 × 90), these are not reported].
Intensive care unit and hospital discharge and mortality data were also used to derive Kaplan–Meier
survival curves for ICU length of stay (Figure 33) and survival (Figure 34), which were used to calculate daily
discharge and mortality probabilities for the no AKI cohort by applying a relative risk (RR) (RR 0.30 for ICU
and hospital mortality and RR 0.54 for ICU length of stay) to the AKI cohort survival curves (see Model
parameters for more details).
TABLE 48 Leeds Teaching Hospitals NHS Trust AKI registry data: length of ICU and hospital stay and mortality
Variable ICU Hospital (from ICU admission)
AKI cohort (n = 60)
LOS < 30 days, % (n) 92 (55) 80 (48)
LOS < 60 days, % (n) 98 (59) 92 (55)
LOS < 90 days, % (n) 100 (60) 95 (57)
LOS (days), minimum, maximum 0, 65 0, 175
Mean LOS (days) 8 19
Median LOS (days) 4 10
Mortality, % (n) 53 (32) 59 (35/59a)
AKI cohort post cardiac surgery (n = 13)
LOS < 30 days, n/N (%) 11/13 (85) 10/13 (77)
LOS < 60 days, n/N (%) 13/13 (100) 11/13 (85)
LOS < 90 days, n/N (%) 13/13 (100) 12/13 (92)
LOS (days), minimum, maximum 2, 39 4, 123
Mean LOS (days) 10 25
Median LOS (days) 6 11
Mortality, % (n) 8 (n = 1) 15 (2)
LOS, length of stay.
a One patient had missing hospital discharge data, and was excluded from the hospital mortality calculation. For the
hospital LOS, the last known date of contact in the hospital (the patient consent date) was used as a proxy for the
hospital discharge date.
TABLE 49 Leeds Teaching Hospitals NHS Trust AKI registry: maximum AKI status over first 7 days in the ICU
Maximum ICU AKI status % (n)
AKI S1 50 (30)
AKI S2 20 (12)
AKI S3 7 (4)
AKI S3+ RRT 23 (14)
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FIGURE 33 Leeds Teaching Hospitals NHS Trust AKI registry: Kaplan–Meier survival curve for AKI cohort ICU length
of stay.
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FIGURE 34 Leeds Teaching Hospitals NHS Trust AKI registry: Kaplan–Meier survival curve for AKI cohort
ICU survival.
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FIGURE 32 Leeds Teaching Hospitals NHS Trust AKI registry: daily ICU AKI status over 7 days from admission.
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Model parameters
A summary of the model base-case parameters is provided in Table 50.
Hospital period parameters
For the hospital period of the model, the proportion of patients expected to experience AKI in the ICU
(either on arrival or after) was derived from the worldwide systematic review (2004–12) of large cohort
studies334 identified from the AKI risks literature search (see Model parameter literature review), which
reported a pooled incidence rate across 41 studies (n = 888,604) for KDIGO AKI of 31.7% (95% CI 28.6%
TABLE 50 Economic model base-case parameters
Parameter
Base-case
value SD Distribution Source
Patient characteristics
Starting age (years) of ICU cohort 61 – Fixed LTHT AKI registry data471
Proportion male 0.70 – Fixed LTHT AKI registry data471
Risks: hospital period
Proportion who have or develop AKI
in the ICU (AKI cohort)
0.317 0.018 Beta Susantitaphong et al.334
Proportion who have or develop AKI
in the ICU post cardiac surgery
(secondary analysis)
0.243 0.021 Beta Susantitaphong et al.334
AKI cohort: end day 1 with normal
kidney function (as proportion of
total ICU population)
0.095 0.019 Dirichlet LTHT AKI registry data471
AKI cohort: end day 1 with AKI S1 0.132 0.021 Dirichlet LTHT AKI registry data471
AKI cohort: end day 1 with AKI S2 0.042 0.014 Dirichlet LTHT AKI registry data471
AKI cohort: end day 1 with AKI S3 0.037 0.013 Dirichlet LTHT AKI registry data471
AKI cohort: end day 1 on RRT 0.011 0.007 Dirichlet LTHT AKI registry data471
AKI cohort: daily transition
probabilities for AKI cohort states
(days 1–90)
– – Multiple Dirichlet LTHT AKI registry data471
AKI cohort: ICU mortality (used to
inform no AKI cohort mortality only)
Survival curve – NA (10,000 curve
simulations)
LTHT AKI registry data471
AKI cohort: hospital ward (post ICU)
daily mortality
0.009 0.003 Beta LTHT AKI registry data471
No AKI cohort: RR for ICU and
hospital mortality in no AKI cohort
vs. AKI cohort
0.30 0.10 Log-normal Model calibration using
LTHT AKI registry data,471
Susantiphong et al.,334
Chakkalakal et al.,338
de Mendonça et al.352 and
Ostermann and Chang362
AKI cohort: ICU length of stay (used
to inform no AKI cohort discharge
rates only)
Survival curve – NA (10,000 curve
simulations)
LTHT AKI registry data471
No AKI cohort: RR for ICU stay in no
AKI cohort vs. AKI cohort
0.542 0.15 Log-normal de Mendonça et al.,352
Prowle et al.,335 Ostermann
and Chang362 and LTHT
AKI registry data471
continued
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TABLE 50 Economic model base-case parameters (continued )
Parameter
Base-case
value SD Distribution Source
No AKI cohort: probability
discharged from ICU to hospital
ward vs. home
0.484 0.06 Beta LTHT AKI registry data471
No AKI cohort: daily probability
discharged from hospital
0.089 0.03 Beta LTHT AKI registry data471
and Prowle et al.359
Post-discharge mortality 0.0003 1.33 × 10–5 Beta Lone et al.457
On RRT post-discharge mortality 0.0004 1.83 × 10–5 Beta Renal Association472
Utilities: hospital period
In ICU –0.402 0.20 Normal Kind et al.473 (Appendix B)
In hospital ward (post ICU) 0.44 0.31 1 – gamma Hernández et al.460
Discharged (post ICU) 0.62 0.32 1 – gamma Hernández et al.460
Decrement for dialysis dependence
(any time point post ICU discharge)
0.11 0.02 Normal Wyld et al.402
Daily costs: hospital period (£)
Daily cost of ICU 1306 290 Log-normal Department of Health474
Daily cost of hospital ward 304 111 Log-normal Curtis and Burns (p. 111)475
Daily excess cost of AKI in hospital
(any setting)
265 77 Log-normal Department of Health474
Daily excess cost of dialysis in
hospital (any setting)
691 1154 Log-normal Department of Health474
Daily cost of discharged patient
dialysis independent
17 0.52 Log-normal Lone et al.457
Daily cost of discharged patient
dialysis dependent (excess cost)
69 0.24 Log-normal Kent et al.370
Utilities: follow-up period
Post-discharge recovery (year 1) 0.67 0.28 1 – gamma Cuthbertson et al.461
Post-discharge recovery (years 2–4) 0.70 0.281 1 – gamma Cuthbertson et al.461
Post-discharge recovery (year 5
onwards, i.e. ‘recovered’)
0.68 0.301 1 – gamma Cuthbertson et al.461
Successful kidney transplant 0.68 0.301 1 – gamma Assumed equivalent to
‘recovered’
CKD stages 1–4 (decrement from
‘recovered’)
0.02 0.03 1 – gamma Wyld et al.402
ESRD no dialysis (decrement from
‘recovered’)
0.20 0.09 1 – gamma Wyld et al.402
ESRD maintenance dialysis
(decrement from ‘recovered’)
0.11 0.02 Normal Wyld et al.402
Annual costs: follow-up period (£)
Post-discharge follow-up (annual)
year 1
6230 190 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 2
4010 156 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 3
3811 169 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 4
3618 182 Log-normal Lone et al.457
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TABLE 50 Economic model base-case parameters (continued )
Parameter
Base-case
value SD Distribution Source
Post-discharge follow-up (annual)
year 5
3178 165 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 6
2739 165 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 7
2299 165 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 8
1860 165 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 9
1421 165 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 10
981 165 Log-normal Lone et al.457
Post-discharge follow-up (annual)
year 11+
542 165 Log-normal Lone et al.457
Ratio for impact of AKI on follow-up
costs
1.15 0.074 Log-normal Lone et al.457
CKD stages 1–4 (additional cost) 579 56 Log-normal Kent et al.370
ESRD no dialysis (additional cost) 760 69 Log-normal Kent et al.370
ESRD maintenance dialysis year 1
(additional cost)
20,440 234 Log-normal Kent et al.370
ESRD maintenance dialysis year 2+
(additional cost)
25,035 87 Log-normal Kent et al.370
Functioning transplant year 1
(additional cost)
26,301 341 Log-normal Kent et al.370
Functioning transplant follow-up
years (additional cost)
1467 122 Log-normal Kent et al.370
Annual risks: follow-up period
Starting distributions From hospital
model end
states
– – From end state
distributions from
hospital period model
(10,000 simulations)
Follow-up period mortality year 1
(AKI and no AKI)
0.109 0.004 Beta Lone et al.457
Follow-up period mortality years 2–5
(AKI and no AKI)
0.066 0.002 Beta Lone et al.457
Background age- and sex-
standardised mortality (applied in
year 6 onwards)
Mortality
table
– Fixed Office for National
Statistics476
Baseline rate of CKD in post-ICU
population
0.0044 – – Rimes-Stigare et al.477
RR of CKD in AKI cohort vs. no AKI
cohort
7.6 1.25 Log-normal Rimes-Stigare et al.477
CKD mortality (stages 1–4) 0.03 0.002 Beta Kent et al.370
CKD to ESRD + dialysis 0.04 0.002 Beta Kent et al.370
CKD to ESRD no dialysis 0.01 0.001 Beta Kent et al.370
ESRD (CKD stage 5) no dialysis
mortality
0.12 0.005 Beta Kent et al.370
continued
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TABLE 50 Economic model base-case parameters (continued )
Parameter
Base-case
value SD Distribution Source
ESRD no dialysis to transplant 0.09 0.004 Beta Kent et al.370
ESRD no dialysis to ESRD + dialysis 0.18 0.006 Beta Kent et al.370
ESRD remain on dialysis 0.784 0.006 Dirichlet Renal Association472
ESRD+ dialysis to transplant 0.062 0.004 Dirichlet Renal Association472
ESRD+ dialysis to death 0.154 0.006 Dirichlet Renal Association472
Transplant success 0.979 0.008 Dirichlet Renal Association472
Transplant failure (move to dialysis) 0.014 0.007 Dirichlet Renal Association472
Transplant to death 0.007 0.004 Dirichlet Renal Association472
Test parameters
Proportion who arrive in the ICU
with pre-existing AKI (S2 and above)
and who are therefore not tested
0.066 0.017 Beta Communication with LTHT
(January 2015)
Cost of the Nephrocheck test (£) 71.27 – Fixed Communication with
manufacturer and LTHT
(January 2015)
Cost of the NGAL test 14.98 – Fixed Communication with
manufacturer and LTHT
(January 2015)
Cost of the cystatin C test 4.26 – Fixed Communication with
manufacturer and LTHT
(January 2015)
Cost of early AKI intervention as a
result of a positive test result (£)
205 279 Log-normal Department of Health474
RR for AKI risks as a result of early
treatment
0.782 0.255 Log-normal Flores-Gama et al.464
Nephrocheck test: sensitivity 0.90 – Multivariate normal Meta-analysis
Nephrocheck test: specificity 0.49 – Multivariate normal Meta-analysis
NGAL test (plasma): sensitivity 0.72 – Multivariate normal Meta-analysis
NGAL test (plasma): specificity 0.81 – Multivariate normal Meta-analysis
NGAL test (urine): sensitivity 0.70 – Multivariate normal Meta-analysis
NGAL test (urine): specificity 0.79 – Multivariate normal Meta-analysis
NGAL test (serum): sensitivity 0.92 – Multivariate normal Chen et al.34
NGAL test (serum): specificity 0.69 – Multivariate normal Chen et al.34
Cystatin C test (plasma): sensitivity 0.72 – Multivariate normal Meta-analysis
Cystatin C test (plasma): specificity 0.74 – Multivariate normal Meta-analysis
Cystatin C test (urine): sensitivity 0.68 – Multivariate normal Meta-analysis
Cystatin C test (urine): specificity 0.76 – Multivariate normal Meta-analysis
Cystatin C test (serum): sensitivity 0.76 – Multivariate normal Meta-analysis
Cystatin C test (serum): specificity 0.88 – Multivariate normal Meta-analysis
SD, standard deviation.
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to 35.0%). For patients who experienced AKI in the ICU, the daily distribution and movement of patients
between the AKI health states was derived using individual patient data obtained from the LTHT AKI
registry (see Acute kidney injury registry data).
To determine the probability of ICU discharge and mortality in the no AKI cohort, RRs were applied to
10,000 simulations of the relevant survival curves from the AKI registry for the AKI cohort. For the
probability of ICU discharge, the RR was determined by taking the mean ratio (0.542) of the median ICU
length of stay for the no AKI group compared with the AKI group observed across three studies identified
from the review, assuming a constant ratio over time.349,352,359,362 The RR for ICU and hospital ward
mortality was determined by model calibration, by setting the RR value such that the observed ratio of
death for the AKI cohort compared with the no AKI cohort at day 10 in the model was equivalent to the
mean ratio of ICU mortality (3.92) observed across three studies identified from the literature.343,352,362
Daily hospital costs were derived from published NHS Reference Costs 2014 to 2015474 and Personal Social
Services Research Unit (PSSRU) costs.475 The daily cost of ICU (£1306) was determined by taking a weighted
average of reported reference costs for critical care ‘Non-specific general adult critical care patients
predominate’, across 0 to 6 organs supported (service code CCU01; Currency codes XC0[1–7]Z). The daily
cost of the hospital ward was derived from the reported PSSRU cost for a non-elective inpatient short stay
(£608), assuming that an average ‘short stay’ would be 2 days (i.e. daily cost £304). The daily excess cost of
AKI in hospital (ICU or ward) was derived by taking the weighted average of reference costs for (long-stay)
excess bed-days for non-elective inpatients with AKI either with or without interventions (service codes LA07
[H/J/K/L/M/N/P]). This cost was assumed to be independent of the stage of AKI (for S1–S3 without RRT). A
further excess cost of RRT was applied to all RRT states, which was taken as the weighted mean of reported
reference costs for critical care ‘Renal Dialysis for Acute Kidney Injury’ using either haemodialysis or
peritoneal dialysis for patients aged 19 years and over (service code RENALAKI; currency codes LE0[1/2]A).
In the absence of any identified data on patient utilities while in the ICU, patient utility was assumed to be
equivalent to the utility of an unconscious patient reported in the EQ-5D scoring manual (–0.402)473 and to
be independent of AKI status. As a result of the significant uncertainty around this parameter, it was
included in the planned sensitivity analysis.
The utility of patients in the hospital ward and post-hospital discharge states was derived from a RCT460
identified from the review of utility databases (see Model parameter literature review), which evaluated a
nurse-led ICU follow-up programme compared with standard care for 286 patients treated across three UK
hospitals between 2006 and 2007. In the model, hospital ward utility is assumed to be equivalent to the
reported baseline standard care arm utility (0.44) and post-discharge utility is assumed to be equivalent to
the reported 6-month post-discharge utility (0.62). As for the ICU health states, because of a paucity of
data, health state utilities for those on the general ward and those discharged were assumed to be
independent of AKI status. However, a utility decrement was applied for anyone receiving RRT (–0.11),
assuming a value equivalent to the reported disutility associated with chronic dialysis from a recent
meta-analysis, which pooled data from 226 studies reporting dialysis utilities.402
Follow-up period parameters
The starting distribution of patients across health states in the follow-up period of the model was taken
from the end-state distribution of patients in the hospital period model. All patients in non-RRT health
states were assumed to enter the relevant ‘follow-up’ state in the AKI or no AKI cohort follow-up model,
whereas patients in the AKI cohort occupying a RRT health state at the end of the hospital period were
assumed to transition to the CKD health state in the follow-up model. All patients who died in the hospital
period transitioned to the corresponding ‘dead’ states in the follow-up period.
Post-discharge follow-up mortality and costs were derived from a recent large cohort study that provided
5-year follow-up mortality and hospital resource use data on 5259 patients surviving to hospital discharge
after an ICU admission in Scotland.457 After 5 years, mortality was assumed to return to population norm
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levels, which were sourced from UK Office for National Statistics data.476 From year 6 to year 10, follow-up
costs were assumed to continue to decrease at the same annual rate observed in the Lone et al.,457 study
with a constant value of standard deviation (SD); for year 11 onwards, costs were assumed to remain at
the level calculated in year 11. For follow-up costs in the AKI cohort, a factor of 1.15 was applied to the
baseline follow-up costs for the first 5 years. This value was derived from the Lone et al.457 study, using the
reported RR of 5-year follow-up hospital admission rates (used to derive costs in the study) for patients
who required RRT during their ICU stay. This was assumed to be an appropriate proxy for the expected
additional follow-up costs in the AKI cohort compared with the no AKI cohort as a result of renal injury in
the first 5 years. Beyond 5 years, costs were assumed to be equal between the two cohorts.
The risk of progressing to the CKD state from the AKI cohort follow-up state was derived from a recent
cohort study of 97,782 patients from the Swedish intensive care register (2005–11),370 which reported
the incidence of CKD at 1 year post ICU discharge for AKI (6%) and no AKI (0.44%) survivors and the
associated incident rate ratio (7.6). This additional risk was assumed to apply for the duration of the
follow-up model (i.e. until death). Subsequent probabilities relating to progression from CKD to ESRD,
renal transplantation and mortality were derived from the Renal Association472 and the study by Kent
et al.,370 which reported information on kidney disease progression and costs for 7246 patients included in
the Study of Heart and Renal Protection (SHARP) international randomised trial. This study was also used to
derive the annual costs of the CKD, ESRD and transplant health states.
Follow-up utility was derived from a prospective longitudinal cohort study that reported patient EQ-5D
scores at 12 months (0.66), 2.5 years (0.701) and 5 years (0.677) post ICU admission for 300 patients
treated within a UK university hospital ICU. Follow-up utility in year 1 of the follow-up model was assumed
to be equivalent to the reported 12-month utility; utilities in years 2–4 were assumed to be equivalent to
the reported 2.5-year utility; and utility in year 5 onwards was assumed to be equivalent to the reported
5-year utility. The utility for someone with a successful kidney transplant was assumed to be equivalent to
the follow-up utility for year 5 onwards. Utility decrements for CKD, ESRD and chronic dialysis were
applied to the successful transplant state value, using decrement values reported in a previous systematic
review and meta-analysis of quality of life measures relating to CKD treatment modalities.402
Test parameters
Test accuracy
Each test was assumed to be conducted on all patients arriving in the ICU without known AKI (KDIGO
stages 2 and above). The proportion of patients arriving in the ICU with known AKI stage 2 or above
(0.066) was estimated by communication with the LTHT (January 2015), who had previously requested
these data from the Intensive Care National Audit & Research Centre (ICNARC) database.
Test accuracy (sensitivity and specificity) was based on the results of the AKI-Diagnostics systematic
review and meta-analysis including papers on adult patients only (see Chapter 3). Using the pooled mean
sensitivity and specificity values and variance–covariance matrices, test accuracies were determined by
drawing from multivariate normal distributions to maintain parameter correlation, using the ‘mvrnorm’
function in the R ‘MASS’ package (version 3).478 This effectively specifies that the logit sensitivity and
specificity were generated from a bivariate normal distribution. When fewer than two papers were
available to conduct a meta-analysis [i.e. for NGAL (serum) in the primary base-case analysis and
Nephrocheck and cystatin C (plasma) in the post-cardiac surgery secondary analysis], sensitivity and
specificity values were derived using the individual papers from the review (all tests had at least one paper
for both the primary and the secondary analyses). For these three cases, because of a lack of reported
data, variance–covariance values were assumed to be equivalent to the variance–covariance matrix from
the meta-analysis of that specific test in the corresponding primary/secondary analysis. For example, for
NGAL (serum) in the base case, the values for the test sensitivity and specificity variance–covariance matrix
were assumed to be equivalent to those observed in the meta-analysis of NGAL (serum) in the post-cardiac
surgery secondary analysis.
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Using the multivariate normal distribution for test accuracy parameters can result in values > 1 (which are
invalid) when the mean values are close to 1 and/or the variance around these parameters is large. In these
cases, in the absence of any alternative methodology, affected distributions were truncated at 1. For most
of the tests for which this occurred, the proportion of points on the distribution lying above 1 was
minimal, with the exception of NGAL (serum) (Table 51). This is a limitation of the analysis and an area
requiring future methodological research.
Test costs
Direct test costs were derived by personal communication with each of the test manufacturers (January 2015).
Laboratory staff and hospital overhead costs were derived by consultation with laboratory scientists and
managers at LTHT (January 2015). The number of tests required to be conducted per year per hospital
laboratory (n = 1253) was estimated based on the total number of ICU admission at St James’s University
Hospital, Leeds, in 2015 (n = 1341) minus the proportion of patients expected to arrive with pre-existing
moderate-to-severe AKI who would not be tested (6.5% of 1341 = 88). This was assumed to be broadly
representative of the expected workload for a typical medium-sized NHS hospital laboratory.
A breakdown of each of the test costs is provided in the following sections.
Nephrocheck
Nephrocheck tests are currently provided by Astute Medical and Ortho Clinical Diagnostics (Raritan, NJ,
USA; in partnership with Astute Medical). Nephrocheck can be run both on the Astute 140® Meter or
using a high-throughput VITROS® platform. Currently, the evidence on the diagnostic accuracy of this test
relates to its use on the Astute 140 Meter. In addition, there may be adoption barriers to using the VITROS
platform because of the relative rarity of this platform in UK clinical laboratories; in particular, the recent
trend in UK laboratories towards participation in managed service contracts is expected to result in limited
opportunities for the utilisation of alternative platforms outside these contracts. It was therefore assumed in
the model that the Astute 140 Meter would be used. Manufacturer-estimated costs, quoted in euros, were
converted into pounds using an exchange rate of 0.84.315
The cost of the Nephrocheck test consists of the:
l kit cost:
¢ kit cost = €1250 for 25 tests = €50 per test = £42 per test
¢ liquid control kit = €120 (assumed one per kit) = €4.80 per test = £4.03 per test
¢ kit paper roll = €2.90 (assumed one per kit) = €0.116 per test = £0.0974 per test
¢ kit quality control and shipping costs included in the kit cost
¢ total kit cost = £46.13
TABLE 51 Proportion of model test sensitivity and specificity values lying above 1 when using the multivariate
normal distribution
Test
Population
(primary/secondary analysis)
Proportion of points > 1 (%)
Sensitivity distribution Specificity distribution
Cystatin C (urine) ICU all-comers 00.42 00.01
Post cardiac surgery 00.07 03.55
Cystatin C (serum) ICU all-comers 00.15 00.00
NGAL (serum) ICU all-comers 26.35 00.02
Post cardiac surgery 11.35 07.10
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l platform cost:
¢ Astute 140 Meter platform acquisition cost (assumed one per laboratory) = €10,000 = £8400
¢ platform maintenance for 5 years (assumed lifetime of platform) = €900 × 2 + €600 (cost of two
2-year warranties plus one 1-year warranty) = €2400 = £2016
¢ platform external quality control device (assuming manufacturer-recommended four devices per
year for 5 years) = €97 × 4 × 5 = €1940 = £1629.6
¢ total platform cost (per test over 5-year lifetime) = £12,045.6/(5 × 1253) = £1.92 per test
l indirect costs:
¢ staff cost per test [assumed 30 minutes (top of the band) band 6 biomedical scientist time for
non-automated test (£9.03) + 20% for headroom] = £10.85
¢ trust overheads per test (assumed to be 21% of the total test cost) = (£46.13 + £1.92 + £10.85) ×
0.21 = £12.37
l total cost per Nephrocheck test = £46.13 + £1.92 + £10.85 + £12.37 = £71.26.
Neutrophil gelatinase-associated lipocalin
Neutrophil gelatinase-associated lipocalin tests are provided by two companies, BioPorto and Abbott
Architect. Abbott Architect provides a specific platform for its test, whereas the BioPorto test can be run
on several testing platforms. The BioPorto NGAL test kit is currently the cheaper option of the two and was
therefore used in the cost calculation (assuming that the NHS would generally opt for the cheaper test). It
was assumed that the test would be run using a Siemens ADVIA® 1800 platform (Siemens, Camberley, UK)
as this is already used within several NHS laboratories (as are the Abbott Architect platforms). As these
platforms are already in place and provide a significant turnover of tests under existing maintenance
contracts, no additional platform maintenance or external quality control costs were included. In the
absence of any data to indicate otherwise, costs for NGAL urine, plasma and serum tests were assumed to
be equivalent. The cost of the NGAL tests consists of the:
l kit cost:
¢ kit cost = £3600 for 300 tests = £12.00 per test
¢ kit quality control and calibration costs included in kit cost
¢ shipping cost = £18.50 for 300 tests = £0.06 per test
l platform cost:
¢ not applicable
l indirect costs:
¢ staff cost per test [estimated cost of running automated assay using Genesys laboratory
software (Daly City, CA, USA)] = £0.32
¢ trust overheads per test (assumed to be 21% of the total cost) = (£12.06 + £0.32) × 0.21 = £2.60
l total cost per NGAL test = £12.00 + £0.06 + £0.32 + £2.60 = £14.98.
Cystatin C
Several companies provide cystatin C test kits and the test may be run on several platforms. For this cost
calculation, we assumed that the Siemens test and the ADVIA® Chemistry XPT Platform would be adopted,
as this is currently used at the LTHT. As for the NGAL test, no platform maintenance or external quality
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control costs were applied and costs across the plasma, urine and serum tests were assumed to be
equivalent. The cost of the cystatin C test consists of the:
l kit cost:
¢ kit cost = £250.63 for 400 tests = £0.63 per test
¢ kit quality control costs per test (assuming 12 kits per year) = (£63.89 × 12)/1253 = £0.61
¢ kit calibration costs per test (assuming six kits per year) = (£400 × 6)/1253 = £1.92
¢ shipping cost assumed to be included in the kit cost
l platform cost:
¢ not applicable
l indirect costs:
¢ staff cost (estimated using Genesys laboratory software) = £0.32
¢ trust overheads (assumed to be 21% of the total cost) = (£0.63 + £0.61 + £1.92 + £0.32) ×
0.21 = £0.73
l total cost per cystatin C test = £0.63 + £0.61 + £1.92 + £0.32 + £0.73 = £4.21.
Impact of early acute kidney injury Intervention
The impact of early AKI intervention [applied to patients with a TP test result and currently no AKI or early
AKI (KDIGO stage ≤ 1) according to concurrent standard care tests] was derived from a Mexican study
identified in the literature review of early AKI interventions.464 This study assessed the impact of early
nephrologist consultation in a group of 1096 patients within 7 days of cardiac surgery. The reported
adjusted odds ratio (0.71) for AKI incidence was used to derive a RR, which was applied to all upwards AKI
progressions from the S0 and S1 states and for mortality in the S3 + RRT state. This value was supported
by independent consultation with the specialist advisory group.
Post-cardiac surgery subgroup population parameters
In the secondary analysis, alternative parameters specific to the post-cardiac surgery subgroup were
adopted when possible (Table 52). When no post-cardiac surgery-specific evidence could be identified,
parameter values were assumed to be equivalent to those used in the base-case analysis. It was assumed
that the same patient pathway as adopted in the base case would apply for this subgroup.
For the estimation of AKI incidence, the same worldwide meta-analysis was used as in the base case,334
which reported a pooled KDIGO AKI incidence across 42 studies (n = 164,333 patients) in post-cardiac
surgery populations of 24.3% (95% CI 20.4% to 28.8%). To inform the relative rate of ICU mortality and
ICU and hospital discharge between the AKI cohort and the no AKI cohort, a single retrospective study
was identified from the review that reported mortality and length of stay outcomes by AKI status for 1881
patients undergoing cardiac surgery necessitating CPB.348 Daily ICU costs were derived as a weighted mean of
critical care NHS Reference Costs 2014 to 2015 for ‘Cardiac surgical adult patients predominate’ services.474
For test accuracies, sensitivity and specificity values for NGAL and cystatin C were derived from the
post-cardiac surgery meta-analysis results, using the same methodology as outlined in the base case. For
Nephrocheck, only one relevant paper was identified from the review, which did not report information on
the parameter correlation. For this case we assumed the same variance–covariance matrix as observed in
the meta-analysis of Nephrocheck studies conducted in all-comer ICU populations.
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
Summary of model assumptions
As with any economic evaluation, this study has limitations. Various simplifying assumptions were adopted
in the analysis to produce an efficient and workable model. In particular:
l The model is limited to an evaluation of the three tests judged currently to be of the highest priority.
Many other tests are available and may represent cost-effective alternatives. The results of the multiway
incremental analysis should therefore be interpreted with caution, as not all relevant comparators have
been included.
l The model considers only the use of one-off testing on entry to the ICU. Use of tests in a sequential or
monitoring context have not been considered.
l The model considers adult all-comers to the ICU only; paediatric populations were excluded from
the analysis.
l The model does not directly consider the case of AKI on top of CKD. The majority of evidence on the
accuracy of the tests excludes patients with existing CKD and we have therefore not attempted to
model these patients.
TABLE 52 Economic model post-cardiac surgery population secondary analysis parameters
Parameter
Base-case
value SD Distribution Source
Risks: hospital period
Proportion who have or develop
AKI in the ICU
0.243 0.021 Beta Susantitaphong et al.334
No AKI cohort: RR for ICU and
hospital mortality in the no AKI
cohort vs. AKI cohort
0.12 0.04 Log-normal Model calibration using
LTHT AKI registry data471
and Bastin et al.348
No AKI cohort: RR for ICU stay in
the no AKI cohort vs. AKI cohort
0.216 0.07 Log-normal Bastin et al.348
No AKI cohort: daily probability
discharged from hospital
0.117 0.04 Beta LTHT AKI registry data471
and Bastin et al.348
Daily costs: hospital period
Daily cost of ICU (generic) £1275 get Log-normal Department of Health474
Test parameters
Nephrocheck: sensitivity 0.80 – Multivariate normal Meersch et al.54
Nephrocheck: specificity 0.83 – Multivariate normal Meersch et al.55
NGAL (plasma): sensitivity 0.61 – Multivariate normal Meta-analysis
NGAL (plasma): specificity 0.77 – Multivariate normal Meta-analysis
NGAL (urine): sensitivity 0.66 – Multivariate normal Meta-analysis
NGAL (urine): specificity 0.62 – Multivariate normal Meta-analysis
NGAL (serum): sensitivity 0.84 – Multivariate normal Meta-analysis
NGAL (serum): specificity 0.87 – Multivariate normal Meta-analysis
Cystatin C (plasma): sensitivity 0.61 – Multivariate normal Tziakas et al.69
Cystatin C (plasma): specificity 0.56 – Multivariate normal Tziakas et al.69
Cystatin C (urine): sensitivity 0.52 – Multivariate normal Meta-analysis
Cystatin C (urine): specificity 0.72 – Multivariate normal Meta-analysis
Cystatin C (serum): sensitivity 0.73 – Multivariate normal Meta-analysis
Cystatin C (serum): specificity 0.72 – Multivariate normal Meta-analysis
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l The model does not allow for re-entry to the ICU or hospital once a patient has been discharged. In reality,
it is expected that in the short term a (potentially significant) proportion of patients would re-enter the ICU
or hospital because of worsening health post discharge. This would be expected to have a noticeable
impact on the results only if the biomarkers are expected to have an impact on the rate of re-admission.
l The model does not allow for a hospital length of stay of > 90 days. Based on an analysis of the LTHT
AKI registry data,471 it is expected that up to 5% of patients with AKI may stay in hospital for > 90 days
(but 0% in the ICU).
l Any difference between arms in the model in the downstream incidence of CKD is dictated by the
proportion of patients ending the hospital period model in RRT states. As such, the model does not
pick up the impact on CKD related to a reduced severity of AKI in terms of reduced rates of KDIGO
S1–S3, or from a reduced duration of AKI. The impact of the tests on long-term CKD rates may be
underestimated in this case.
l The impact of early AKI intervention on patients’ risks of developing worse AKI in the model lasts for
the whole hospital period (i.e. 90 days).
l It was assumed that if patients are dialysis independent/dependent on hospital discharge, then they
remain dialysis independent/dependent for the remainder of the hospital period of the model.
l For the NGAL and cystatin C tests, diagnostic accuracy was determined by pooling data from studies
using different cut-off point thresholds, because of the limited availability of data and reporting on
alternative cut-off points. It is unclear, therefore, if these tests were to be adopted in practice, which
cut-off point(s) should be used.
l The analysis does not include societal costs because of the limited availability of data. Both the length
of the ICU/hospital stay and the risk of CKD may have significant impacts on patient costs and
productivity losses. This is therefore a key area for future research.
l The secondary analysis of the subgroup of patients in the ICU post cardiac surgery is limited; only a few
parameters were updated for this analysis based on data available from the literature reviews. In
particular, the same ICU daily transition probabilities were applied for the AKI cohort, because of a
limited number of data from the LTHT AKI registry on patients post cardiac surgery. Similarly, other key
parameters in this analysis are not specific to this patient subgroup, for example early AKI treatment
costs and impact, follow-up costs, mortality and utility and follow-up risk of CKD.
l We have been unable to externally validate the model (i.e. compare the estimated model outputs to
real-world data) because of a paucity of data with which to externally validate against. As a result,
although we have conducted extensive internal validation and cross-validation (comparing the model
outputs with those of other economic evaluations), the model results should be interpreted with caution.
Cost-effectiveness analysis
Cost-effectiveness is measured in terms of the ICER and the INB.
The ICER is calculated by dividing the difference in mean costs between two arms by the difference in
mean health effects (QALYs) between the two arms:
ICER =
CT − CSC
ET − ESC
=
ΔC
ΔE
, (12)
where CT and ET are the expected cost and effectiveness of the intervention (i.e. test arm), CSC and ESC are
the expected cost and effectiveness of the standard care arm and ΔC and ΔE are the incremental cost and
effect, respectively, of the test arm compared with the standard care arm.
Assuming that the intervention is more costly and more effective than standard care, the ICER represents
the additional cost required to be spent on the intervention to gain an additional unit of health. The
cost-effectiveness of an intervention is determined by whether or not this ICER falls above or below the
decision-maker’s willingness-to-pay per additional QALY (i.e. ‘threshold’). In the UK, NICE currently adopts
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a threshold value of £20,000 per QALY; if a new intervention has an ICER of < £20,000 per additional
QALY then it is likely to be considered a cost-effective use of NHS resources, whereas an ICER of
> £20,000 indicates that the intervention is not expected to be a cost-effective use of resources or is
required to meet additional criteria. This decision rule is expressed using the following formula:
ΔC
ΔE
< λ, (13)
where λ is the adopted willingness-to-pay threshold.
When the threshold is known, we can divide the incremental cost by the threshold value to convert this
value onto the QALY scale (or, conversely, multiply the QALYs by the threshold to express QALYs on the
monetary scale). For example, if the threshold is £20,000 and the intervention has an additional cost of
£10,000, we can calculate that this cost is equivalent to 0.5 QALYs. This allows us to rearrange the ICER
formula to express the overall INB on the QALY scale or the incremental net monetary benefit (INMB) on
the monetary scale:
INB = ΔE−
ΔC
λ
(14)
INMB = ΔE  λ−ΔC. (15)
Unlike the ICER, for which the exact interpretation of cost-effectiveness depends on whether or not the
incremental cost and QALYs are positive or negative, the interpretation of the INB is straightforward:
for any given set of strategies, the strategy with the greatest INB (or INMB) is the most cost-effective
alternative. In addition, the favourable mathematical properties of the INB allow for more straightforward
computation of the cost-effectiveness probabilities and, therefore, the INBs are presented alongside the
ICERs for each of the analyses.
Cost-effectiveness was assessed by comparing each testing strategy with standard care in turn. In addition,
a full incremental analysis, including all of the available tests within one evaluation, was conducted.
In this approach testing strategies are ranked in order of increasing cost and any options that are either
dominated (i.e. produce fewer QALYs for a greater cost than the next best alternative) or extendedly
dominated (i.e. produce fewer QALYs for a greater cost than a linear combination of two alternatives) are
removed. ICERs for the remaining strategies (now ordered in terms of increasing cost and QALYs) are then
recalculated by comparing each strategy in turn to the next best alternative (i.e. the next most costly and
effective strategy).479
Sensitivity analysis
All model base-case analyses were run using probabilistic sensitivity analysis using 10,000 Monte Carlo
simulations of the model. This accounts for joint parameter uncertainty in non-linear models by assigning
probability distributions to each of the input parameters (using available variance data) and randomly drawing
from these probabilities over the 10,000 simulations. The results are presented as a scatterplot on the
cost-effectiveness plane (which presents incremental costs and QALYs for each intervention compared with
standard care), with all base-case analyses assuming a willingness-to-pay threshold of £20,000. In addition,
the results are presented using cost-effectiveness acceptability frontiers (CEAFs) to show (1) the probability
that an intervention is cost-effective across different willingness-to-pay thresholds (range £0–150,000) and
(2) which strategy is optimal based on having the highest mean net benefit (i.e. the ‘frontier’).
For each testing strategy a series of one-way sensitivity analyses was conducted, using 5000 simulations of
the model. In the case of NGAL and cystatin C, for which multiple tests are available (i.e. plasma, urine and
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serum), the one-way sensitivity analyses were run only for the test found to have the highest probability of
being cost-effective in the primary CEA.
The following one-way sensitivity analyses were conducted:
1. SA1: time horizon (base case: lifetime). A range of alternative time horizons were considered: 90 days
(i.e. hospital period), 1 year (+90 days), 5 years (+90 days), 10 years (+90 days) and 20 years (+90 days).
2. SA2: test costs (base-case fixed costs: Nephrocheck £71.27, NGAL £14.99, cystatin C £4.62). A range of
low and high test costs were explored, equal to 0.25, 0.5, 1.5, 2 and 5 times the base-case values.
3. SA3: AKI incidence (base case: mean 0.317, SD 0.018). A sensitivity analysis was conducted using a
range of alternative values for the incidence of AKI in the ICU: 10%, 20%, 40% and 50%.
4. SA4: impact of the early AKI Intervention RR parameter (base case: mean RR 0.78, SD 0.25). Two
sensitivity analyses were conducted around this key parameter:
i. Low-/high-impact scenarios – A sensitivity analysis was conducted assuming alternative values for the
RR (0.2, 0.4, 0.6, 0.7, 0.9 and 0.95) to explore the possibility that early AKI intervention may be
more or less effective than estimated in the base case.
ii. Distribution adjustments – Ideally, a beta distribution would have been adopted for this parameter to
ensure that the value was between 0 and 1 (i.e. that appropriate early intervention always resulted in
improved outcomes). However, because of the high uncertainty around this parameter the beta
distribution could not be used. In the base case this parameter was therefore drawn from a
log-normal distribution, which maintains the expected ‘bell’ shape at the cost of allowing values > 1
(meaning that in some cases early AKI intervention leads to increased AKI risks). Two alternative
parameterisations were explored: (1) truncating the distribution at 1 (i.e. recoding values > 1 to = 1)
and (2) reducing the parameter uncertainty to allow beta estimation (SD 0.06).
5. SA5: cost of early AKI intervention (base case: mean £205, SD £279). A sensitivity analysis was
conducted assuming alternative costs for early AKI intervention (£50, £100, £500, £800).
6. SA6: ICU utility (base case: mean –0.402, SD 0.201). A sensitivity analysis was conducted assuming
alternative mean values of 0 and 0.2 for ICU utility, as there was a paucity of data for this value.
7. SA7: test accuracy adjustment (FP cases reset to TPs and overall incidence of AKI increased). The
diagnostic accuracy studies informing the base-case sensitivity and specificity estimates for each of the
tests were conducted using standard care testing as the reference standard, assuming that standard care
perfectly identifies patients with and without AKI. However, standard care tests are known to be imperfect
and, in particular, are expected to currently fail to identify many patients with early renal injury. An
exploratory sensitivity analysis was conducted for each testing strategy assuming that 10%, 25%, 50% or
100% of test FP results are actually TP results (i.e. cases of early AKI that standard care testing failed to
identify), with the associated reduced risks of AKI progression as a result of early AKI intervention. For
simplicity, in the testing arms all of these extra cases of AKI were assumed to have a KDIGO AKI stage of
S1. This analysis results in the overall incidence of AKI increasing by the proportion of FP results that have
been recoded to TP results and the incidence of AKI is increased in the baseline arm to reflect this change.
8. SA8: negative impact of FP test results (increased mortality). The base-case analysis assumes no negative
health consequences for patients falsely identified as having AKI. It is possible that these patients could
suffer if, for example, access to required nephrotoxic agents, scans or other treatments is delayed.
A sensitivity analysis was conducted assuming that, on average, patients with FP test results would
experience a 5%, 10%, 30% or 50% increased risk of mortality while in the ICU.
9. SA9: impact of negative test results (reduction in monitoring leading to cost saving plus mortality risk
for FNs). The focus of the base-case analysis was on the impact of testing on patients correctly
diagnosed early. Testing may also enable reduced intensity of treatment or monitoring for patients
with negative test results, at the expense of potentially worse outcomes for patients with FN results
(as above). A sensitivity analysis was conducted, assuming that all patients with negative test results
with early AKI (KDIGO ≤ S1) would have a reduced cost of ICU care (–£100) and that patients with FN
results with early AKI would incur an increased mortality risk of 10%.
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
Cost-effectiveness results
Nephrocheck compared with standard care
Base case (adult intensive care unit all-comers)
The results for the base-case CEA of Nephrocheck testing compared with standard care are presented in
Table 53. The addition of Nephrocheck testing on admission to the ICU for an all-comer adult population
is expected to have a lifetime additional cost of £301 and an additional health benefit of 0.016 QALYs per
patient. This results in an ICER of £19,324 per additional QALY, with a mean positive INB of 0.001 QALYs
(equivalent to £20 in terms of INMB).
The uncertainty around the model results can be seen in Figure 35. Although the mean ICER (£19,324) lies
below the threshold line (indicating cost-effectiveness), the expected incremental cost and QALY results vary
widely, with a significant proportion of points lying in non-cost-effective regions (i.e. above the threshold line).
The uncertainty around the test cost-effectiveness over alternative thresholds is presented in the CEAF in
Figure 36. Above a threshold of £19,400 per QALY, Nephrocheck testing is expected to be the most
cost-effective strategy. The test has a 48% probability of being cost-effective at a £20,000 per QALY
threshold, increasing to 54% at a £50,000 per QALY threshold.
Secondary analysis (post-cardiac surgery subgroup)
The results of the secondary analysis are presented in Table 54. The addition of Nephrocheck testing in this
setting is expected to have a lifetime additional cost of £205 and produce an additional 0.011 QALYs per
patient. This results in an ICER of £18,617 per QALY, with a mean INB of 0.001 QALYs (equivalent to £20
in terms of INMB). At a £20,000 per QALY threshold there is a 50% probability that Nephrocheck testing
is cost-effective in this subgroup, rising to 54% at a threshold of £50,000 (CEAF not shown).
Sensitivity analyses
The results of the one-way sensitivity analyses conducted for Nephrocheck testing compared with standard
care are provided in Table 55. Nephrocheck testing is no longer cost-effective (i.e. has an ICER of
> £20,000 per QALY) when (1) the time horizon is reduced to ≤ 20 years (SA1), (2) the test cost is
increased by ≥ 50% (i.e. to ≥ £106.91) (SA2), (3) the incidence of AKI in the ICU is reduced to ≤ 20%
(from 31.7% in the base case) (SA3), (4) the impact of early AKI intervention is limited to a ≤ 10%
reduction in AKI risks (from 22% in the base case) (SA4), (5) the cost of early AKI intervention is increased
to £500 or £800 (£205 in the base case) (SA5), (6) FP test results are assumed to lead to a ≥ 5% increased
risk of ICU mortality (SA8) and (7) negative test results are assumed to lead to a £100 cost saving (because
of diminished monitoring) and a simultaneous 10% increased mortality rate for FPs (SA9). In contrast, the
only instances when the probability that Nephrocheck testing is cost-effective rises above 60% are when
25%, 50% or 100% of FP test results are assumed to have actually been TP results (with the incidence
of AKI increasing to 40%, 49% and 66% respectively). In these cases the ICER falls below £10,000 per
QALY (SA7).
Neutrophil gelatinase-associated lipocalin compared with standard care
Base case (adult intensive care unit all-comers)
The results for the base-case CEA of NGAL testing compared with standard care are shown in Table 56.
NGAL testing is associated with a lifetime additional cost of £164–215 (depending on the specific test) and
an additional health benefit of 0.012–0.016 QALYs. This results in ICERs of £13,372–13,828 per additional
QALY, with mean INBs of 0.004–0.005 (equivalent to £80–100 in terms of INMB). At a threshold value of
£20,000 per additional QALY, NGAL (plasma) testing has the highest probability of being cost-effective
(51.9%) and is therefore explored in the sensitivity analysis.
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TABLE 53 Results of the primary CEA (ICU all-comer population): Nephrocheck vs. standard care
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI)
Incremental
cost (95% CI) (£)
Incremental
QALYs (95% CI) ICER (£)
Net benefit
(QALYs) (95% CI) INB (95% CI)
P(more
effective)
P(cost
saving)
P(cost-
effective)
Standard care 32,596
(24,320 to 43,145)
5.61
(0.46 to 9.09)
3.979
(–1.14 to 7.34)
Nephrocheck 32,897
(24,662 to 43,484)
5.62
(0.46 to 9.12)
301
(–1087 to 1713)
0.016
(–0.16 to 0.20)
19,324 3.985
(–1.15 to 7.33)
0.001
(–0.12 to 0.13)
0.57 0.32 0.48
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The uncertainty around the results for NGAL (plasma) testing is shown in Figures 37 and 38 [the results
for NGAL (urine) and (serum) testing have a very similar distribution and are not presented]. As for
Nephrocheck testing, although the mean ICER for NGAL (plasma) testing (£13,372) lies below the
threshold line, the individual simulation points vary widely. Above a threshold of £13,400 per QALY, NGAL
(plasma) testing is expected to be the most cost-effective strategy. The test has a 52% probability of being
cost-effective at a £20,000 per QALY threshold, increasing to and levelling out at 56% at a £50,000 per
QALY threshold.
Secondary analysis (post-cardiac surgery subgroup)
The results of the secondary analysis conducted in a subgroup of patients after cardiac surgery are
presented in Table 57. In this subgroup, NGAL testing is expected to have a lifetime additional cost of
£137–172 and produce an additional health benefit of 0.008–0.012 QALYs per patient. This results in
ICERs ranging from £13,051 to £19,287 per additional QALY, with mean INBs of 0.001–0.004 QALYs.
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FIGURE 36 Cost-effectiveness acceptability frontier: Nephrocheck vs. standard care (base case).
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FIGURE 35 Scatterplot: incremental costs and QALYs for Nephrocheck vs. standard care (base case).
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TABLE 54 Results of the secondary CEA (post-cardiac surgery subgroup): Nephrocheck vs. standard care
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI)
Incremental
cost (95% CI) (£)
Incremental
QALYs (95% CI) ICER (£)
Net benefit
(QALYs) (95% CI) INB (95% CI)
P(more
effective)
P(cost
saving)
P(cost-
effective)
Standard care 29,959
(22,738 to 37,726)
6.50
(0.56 to 10.20)
5.01
(–0.90 to 8.60)
Nephrocheck 30,163
(22,893 to 37,942)
6.52
(0.56 to 10.20)
205
(–850 to 1249)
0.011
(–0.13 to 0.15)
18,617 5.01
(–0.91 to 8.60)
0.001
(–0.09 to 0.10)
0.57 0.34 0.50
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TABLE 55 Sensitivity analyses: Nephrocheck vs. standard care
Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
Base-case analysis (for comparison)
Nephrocheck base case 32,897 5.62 301 0.016 19,323 3.99 0.001 0.57 0.32 0.48
SA1: time horizon (base case: lifetime, i.e. approximately 40 years)
90 days 13,928 0.05 210 0.000 1,679,292 –0.64 –0.010 0.54 0.26 0.25
1 year (+90 days) 17,626 0.52 232 0.002 150,509 –0.36 –0.010 0.57 0.26 0.23
5 years (+90 days) 25,732 2.02 264 0.006 43,783 0.73 –0.007 0.57 0.29 0.30
10 years (+90 days) 29,626 3.38 283 0.010 27,816 1.90 –0.004 0.58 0.31 0.41
20 years (+90 days) 31,859 5.04 302 0.015 20,163 3.45 0.000 0.57 0.32 0.47
SA2: Nephrocheck test cost (base-case cost £71.27)
Test cost × 0.25= £17.82 32,901 5.62 263 0.017 15,648 3.98 0.004 0.57 0.35 0.50
Test cost × 0.50= £35.64 32,918 5.62 279 0.017 16,640 3.98 0.003 0.57 0.34 0.49
Test cost × 1.50= £106.91 32,985 5.62 346 0.017 20,608 3.97 –0.001 0.57 0.30 0.46
Test cost × 2.0 = £142.54 33,018 5.62 379 0.017 22,591 3.97 –0.002 0.57 0.29 0.45
Test cost × 5.0 = £365.35 33,226 5.62 588 0.017 34,995 3.96 –0.013 0.57 0.19 0.36
SA3: ICU AKI incidence (base case: mean 0.317, SD 0.018)
AKI incidence= 0.10 32,558 6.26 237 0.005 45,241 4.63 –0.007 0.59 0.16 0.33
AKI incidence= 0.20 32,768 5.97 273 0.010 26,096 4.33 –0.003 0.59 0.26 0.44
AKI incidence= 0.40 33,187 5.39 346 0.021 16,523 3.73 0.004 0.59 0.33 0.50
AKI incidence= 0.50 33,397 5.10 383 0.026 14,609 3.43 0.007 0.59 0.35 0.52
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Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
SA4: impact of early AKI intervention on AKI risks (base case: RR 0.78, SD 0.25)
RR= 0.20 (i.e. 80% reduced risks) 33,171 5.66 532 0.051 10,347 3.997 0.025 0.68 0.26 0.59
RR= 0.40 (60% reduced risks) 33,125 5.65 487 0.044 11,026 3.992 0.020 0.68 0.26 0.59
RR= 0.60 (40% reduced risks) 33,052 5.64 413 0.033 12,702 3.984 0.012 0.65 0.28 0.55
RR= 0.70 (30% reduced risks) 33,006 5.63 367 0.025 14,471 3.980 0.007 0.63 0.29 0.52
RR= 0.90 (10% reduced risks) 32,898 5.61 260 0.009 29,199 3.969 –0.004 0.55 0.34 0.43
RR= 0.95 (5% reduced risks) 32,868 5.61 230 0.004 52,500 3.965 –0.007 0.52 0.35 0.41
RR values > 1 reset to 1 32,973 5.62 335 0.020 16,406 3.976 0.004 0.59 0.31 0.49
RR SD reduced to 0.06 32,963 5.62 325 0.019 17,249 3.975 0.003 0.60 0.30 0.49
SA5: cost of early AKI intervention (base case: mean cost £205, SD £279)
Cost of early AKI treatment = £50 32,843 5.62 205 0.017 12,180 3.979 0.007 0.57 0.38 0.53
Cost of early AKI treatment = £100 32,871 5.62 232 0.017 13,824 3.978 0.005 0.57 0.37 0.51
Cost of early AKI treatment = £500 33,092 5.62 453 0.017 26,975 3.967 –0.006 0.57 0.24 0.41
Cost of early AKI treatment = £800 33,257 5.62 619 0.017 36,839 3.958 –0.014 0.57 0.17 0.34
SA6: ICU utility (base case: mean –0.402, SD 0.201)
ICU utility = 0.00 32,947 5.63 309 0.017 18,704 3.982 0.001 0.57 0.33 0.47
ICU utility = 0.20 32,947 5.63 309 0.017 18,690 3.987 0.001 0.57 0.33 0.47
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TABLE 55 Sensitivity analyses: Nephrocheck vs. standard care (continued )
Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
SA7: test accuracy adjustment (FPs reset to TPs and overall incidence of AKI increased)
10% of FP results recoded as TPs (AKI S1) and
overall incidence of AKI increased to 35.2%
33,161 5.54 418 0.035 11,857 3.882 0.014 0.65 0.28 0.56
25% of FP results recoded as TPs (AKI S1) and
overall incidence of AKI increased to 40.4%
33,326 5.41 559 0.061 9228 3.740 0.033 0.72 0.24 0.66
50% of FP results recoded as TPs (AKI S1) and
overall incidence of AKI increased to 49%
33,751 5.20 774 0.102 7620 3.508 0.063 0.80 0.21 0.76
100% of FP results recoded as TPs (AKI S1)
and overall incidence of AKI increased to
66.4%
34,489 4.76 1217 0.184 6606 3.039 0.123 0.87 0.18 0.84
SA8: increased mortality for FP results
5% increased ICU mortality for FPs 32,877 5.61 £238 0.004 63,268 3.964 –0.008 0.50 0.36 0.41
10% increased ICU mortality for FPs 32,803 5.60 £165 –0.009 Dominated 3.955 –0.017 0.44 0.41 0.34
30% increased ICU mortality for FPs 32,517 5.54 –121 –0.060 2035a 3.919 –0.053 0.25 0.57 0.18
50% increased ICU mortality for FPs 32,244 5.50 –394 –0.108 3646a 3.884 –0.088 0.15 0.69 0.11
SA9: impact of negative test results (reduction in monitoring leading to cost saving + increased mortality risk for FNs)
One-off cost saving (–£100) + 10% increased
ICU mortality for FNs
32,558 5.58 –80 –0.020 4100a 3.957 –0.016 0.40 0.55 0.38
a Cost saved per QALY lost: in these cases the ICER must be > £20,000 (i.e. > £20,000 saved per QALY lost) to be considered cost-effective. In these instances Nephrocheck testing is
therefore not cost-effective.
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TABLE 56 Results of the primary CEA (ICU all-comer population): NGAL vs. standard care
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI)
Incremental
cost (95% CI) (£)
Incremental
QALYs (95% CI)
ICER
(£)
Net benefit
(QALYs) (95% CI) INB (95% CI)
P(more
effective)
P(cost
saving)
P(cost-
effective)
Standard care 32,596
(24,320 to 43,145)
5.61
(0.46 to 9.09)
3.979
(–1.14 to 7.34)
NGAL (urine) 32,759
(24,521 to 43,351)
5.62
(0.46 to 9.11)
164
(–1179 to 1517)
0.0119
(–0.16 to 0.19)
13,742 3.985
(–1.15 to 7.33)
0.004
(–0.11 to 0.13)
0.56 0.40 0.514
NGAL
(plasma)
32,759
(24,516 to 43,339)
5.62
(0.46 to 9.11)
164
(–1180 to 1510)
0.0122
(–0.16 to 0.19)
13,372 3.983
(–1.15 to 7.33)
0.004
(–0.11 to 0.13)
0.56 0.40 0.519
NGAL (serum) 32,811
(24,587 to 43,427)
5.62
(0.46 to 9.11)
215
(–1167 to 1619)
0.0156
(–0.16 to 0.20)
13,828 3.987
(–1.15 to 7.33)
0.005
(–0.11 to 0.14)
0.57 0.37 0.517
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Sensitivity analyses
The results of the one-way sensitivity analyses conducted for NGAL (plasma) testing compared with
standard care are provided in Table 58. NGAL testing is no longer cost-effective (i.e. has an ICER of
> £20,000 per QALY) when (1) the time horizon is ≤ 5 years (SA1), (2) the incidence of AKI in the ICU is
reduced to 10%, (from 31.7% in the base case) (SA3), (3) the impact of early AKI intervention is limited to
a 5% reduction in AKI risks (from 22%) (SA4), (4) the cost of early AKI intervention is increased to £800
(from £205) (SA5), (5) FP test results result in a ≥ 10% increase in ICU mortality for those patients (SA8)
and (6) negative test results are assumed to lead to a £100 cost saving (because of diminished monitoring)
and a 10% increased mortality rate for FPs. In contrast, the only instances when the probability that NGAL
testing is cost-effective rises above 60% are when the impact of early AKI intervention is increased to a
≥ 60% reduction in AKI risks (SA4) and when 25%, 50% or 100% of FP test results are assumed to have
actually been TP test results (with corresponding increases in AKI incidence of 35%, 38% and 45%) (SA7).
Cystatin C compared with standard care
Base case (adult intensive care unit all-comers)
The results for the base-case CEA of cystatin C testing compared with standard care are shown in Table 59.
Cystatin C testing is expected to have a lifetime additional cost of £149–166 (depending on the specific
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FIGURE 38 Cost-effectiveness acceptability frontier: NGAL (plasma) vs. standard care (base case).
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FIGURE 37 Scatterplot: incremental costs and QALYs for NGAL (plasma) vs. standard care (base case).
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TABLE 57 Results of the secondary CEA (post-cardiac surgery subgroup): NGAL vs. standard care
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI)
Incremental
cost (95% CI) (£)
Incremental
QALYs (95% CI) ICER (£)
Net benefit
(QALYs) (95% CI) INB (95% CI)
P(more
effective)
P(cost
saving)
P(cost-
effective)
Standard care 29,959
(22,738 to 37,726)
6.50
(0.56 to 10.20)
5.007
(–0.90 to 8.60)
NGAL
(plasma)
30,096
(22,836 to 37,867)
6.51
(0.56 to 10.21)
137
(–895 to 1178)
0.008
(–0.13 to 0.14)
16,709 5.008
(–0.90 to 8.60)
0.001
(–0.09 to 0.09)
0.56 0.39 0.50
NGAL (urine) 30,131
(22,885 to 37,900)
6.51
(0.56 to 10.21)
172
(–875 to 1225)
0.009
(–0.13 to 0.14)
19,287 5.007
(–0.90 to 8.60)
0.003
(–0.09 to 0.09)
0.56 0.36 0.48
NGAL
(serum)
30,108
(22,845 to 37,892)
6.52
(0.56 to 10.22)
149
(–905 to 1204)
0.012
(–0.13 to 0.15)
13,051 5.011
(–0.90 to 8.60)
0.004
(–0.09 to 0.10)
0.57 0.38 0.52
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TABLE 58 One-way sensitivity analyses: NGAL (plasma) vs. standard care
Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
Base-case analysis (for comparison)
NGAL (plasma) base case 32,759 5.62 164 0.0122 13,372 3.983 0.004 0.56 0.40 0.52
SA1: time horizon (base case: lifetime, i.e. approximately 40 years)
90 days 13,808 0.05 90 0.000 978,005 –0.64 –0.004 0.53 0.38 0.37
1 year (+90 days) 17,504 0.52 110 0.001 89,683 –0.35 –0.004 0.56 0.37 0.35
5 years (+90 days) 25,603 2.02 135 0.005 28,191 0.74 –0.002 0.56 0.38 0.42
10 years (+90 days) 29,493 3.38 150 0.008 18,517 1.90 0.001 0.56 0.39 0.49
20 years (+90 days) 31,723 5.04 165 0.012 13,819 3.45 0.004 0.56 0.39 0.52
SA2: NGAL test cost (base-case cost £14.98)
Test cost × 0.25= £3.745 32,802 5.62 163 0.013 12,180 3.98 0.005 0.56 0.40 0.52
Test cost × 0.50= £7.49 32,805 5.62 167 0.013 12,442 3.98 0.005 0.56 0.40 0.52
Test cost × 1.50= £22.47 32,819 5.62 181 0.013 13,487 3.98 0.004 0.56 0.39 0.52
Test cost × 2.0 = £29.96 32,826 5.62 188 0.013 14,010 3.98 0.004 0.56 0.38 0.51
Test cost × 5.0 = £74.90 32,868 5.62 230 0.013 17,145 3.97 0.002 0.56 0.36 0.49
SA3: ICU AKI incidence (base case: mean 0.317, SD 0.018)
AKI incidence= 0.10 32,420 6.26 98 0.004 23,909 4.63 –0.001 0.58 0.31 0.46
AKI incidence= 0.20 32,628 5.96 133 0.008 16,211 4.33 0.002 0.58 0.36 0.51
AKI incidence= 0.40 33,045 5.38 204 0.016 12,363 3.73 0.006 0.58 0.39 0.53
AKI incidence= 0.50 33,253 5.09 239 0.021 11,593 3.43 0.009 0.58 0.40 0.54
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Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
SA4: impact of early AKI intervention on AKI risks (base case: RR 0.78, SD 0.25)
RR= 0.20 (i.e. 80% reduced risks) 32,988 5.65 349 0.041 8497 3.996 0.024 0.66 0.33 0.61
RR= 0.40 (60% reduced risks) 32,951 5.64 313 0.035 8871 3.992 0.020 0.66 0.33 0.61
RR= 0.60 (40% reduced risks) 32,892 5.63 254 0.026 9780 3.986 0.013 0.62 0.35 0.58
RR= 0.70 (30% reduced risks) 32,856 5.62 217 0.020 10,729 3.982 0.009 0.60 0.36 0.56
RR= 0.90 (10% reduced risks) 32,770 5.61 131 0.007 18,587 3.973 0.000 0.54 0.41 0.49
RR= 0.95 (5% reduced risks) 32,746 5.61 107 0.003 31,140 3.971 –0.002 0.52 0.43 0.46
RR values > 1 reset to 1 32,830 5.62 191 0.016 11,762 3.979 0.007 0.58 0.38 0.53
RR SD reduced to 0.06 32,822 5.62 183 0.015 12,208 3.978 0.006 0.58 0.38 0.53
SA5: cost of early AKI intervention (base case: mean cost £205, SD £279)
Cost of early AKI treatment = £50 32,755 5.62 116 0.013 8669 3.980 0.008 0.56 0.43 0.55
Cost of early AKI treatment = £100 32,769 5.62 131 0.013 9763 3.979 0.007 0.56 0.42 0.54
Cost of early AKI treatment = £500 32,887 5.62 248 0.013 18,519 3.974 0.001 0.56 0.35 0.48
Cost of early AKI treatment = £800 32,975 5.62 336 0.013 25,085 3.969 –0.003 0.56 0.30 0.43
SA6: ICU utility (base case: mean –0.402, SD 0.201)
ICU utility = 0.00 32,809 5.63 170 0.013 12,983 3.986 0.005 0.56 0.40 0.52
ICU utility = 0.20 32,810 5.63 171 0.014 12,654 3.991 0.005 0.56 0.39 0.52
SA7: test accuracy adjustment (FPs reset to TPs and overall incidence of AKI increased)
10% of FP results recoded as TPs (AKI S1) and
overall incidence of AKI increased to 33.0%
32,926 5.59 221 0.021 10,335 3.945 0.010 0.61 0.37 0.56
25% of FP results recoded as TPs and overall
incidence of AKI increased to 34.9%
32,952 5.54 280 0.031 8932 3.890 0.017 0.64 0.34 0.60
continued
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TABLE 58 One-way sensitivity analyses: NGAL (plasma) vs. standard care (continued )
Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
50% of FP results recoded as TPs and overall
incidence of AKI increased to 38.2%
33,149 5.46 354 0.046 7678 3.804 0.028 0.69 0.32 0.66
100% of FP results recoded as TPs and overall
incidence of AKI increased to 44.7%
33,423 5.30 521 0.077 6752 3.629 0.051 0.77 0.27 0.75
SA8: increased mortality for FP results
5% increased ICU mortality for FPs 32,784 5.61 146 0.009 17,108 3.974 0.001 0.53 0.41 0.49
10% increased ICU mortality for FPs 32,757 5.61 118 0.004 32,218 3.970 –0.002 0.51 0.43 0.46
30% increased ICU mortality for FPs 32,647 5.59 8 –0.016 Dominated 3.957 –0.016 0.41 0.50 0.36
50% increased ICU mortality for FPs 32,539 5.57 –100 –0.035 2884a 3.943 –0.030 0.32 0.56 0.27
SA9: impact of negative test results (reduction in monitoring leading to cost saving + increased mortality risk for FNs)
One-off cost saving (–£100) + 10% increased
ICU mortality for FNs
31,753 5.52 –885 –0.088 10,064a 3.929 –0.044 0.15 0.91 0.25
a Cost saved per QALY lost: in these cases the ICER must be > £20,000 (i.e. > £20,000 saved per QALY lost) to be considered cost-effective. In these instances Nephrocheck testing is
therefore not cost-effective.
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TABLE 59 Results of the primary CEA (ICU all-comer population): cystatin C vs. standard care
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI)
Incremental
cost (95% CI) (£)
Incremental
QALYs (95% CI) ICER (£)
Net benefit
(QALYs) (95% CI) INB (95% CI)
P(more
effective)
P(cost
saving)
P(cost-
effective)
Standard care 32,596
(24,320 to 43,145)
5.61
(0.46 to 9.09)
3.979
(–1.14 to 7.34)
Cystatin C
(urine)
32,751
(24,524 to 43,347)
5.62
(0.46 to 9.11)
155
(–1187 to 1500)
0.0115
(–0.16 to 0.19)
13,449 3.985
(–1.15 to 7.33)
0.004
(–0.11 to 0.13)
0.56 0.40 0.52
Cystatin C
(plasma)
32,761
(24,546 to 43,355)
5.62
(0.46 to 9.11)
166
(–1183 to 1524)
0.0123
(–0.16 to 0.20)
13,504 3.983
(–1.15 to 7.32)
0.004
(–0.11 to 0.13)
0.56 0.40 0.52
Cystatin C
(serum)
32,744
(24,320 to 43,340)
5.62
(0.46 to 9.11)
149
(–1201 to 1496)
0.0130
(–0.16 to 0.19)
11,476 3.986
(–1.15 to 7.33)
0.006
(–0.11 to 0.13)
0.56 0.42 0.54
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test) and produce an additional 0.012–0.013 QALYs. This results in ICERs ranging from £11,476 to £13,504
per additional QALY, with INBs of 0.004–0.006 QALYs (equivalent to £80–120 in terms of INMB). At a
threshold of £20,000 per QALY, cystatin C (serum) testing has the highest probability of being cost-effective
(54%) and was explored in the sensitivity analysis.
The uncertainty around the cost-effectiveness of cystatin C (serum) testing is illustrated in Figures 39 and 40
[the results for cystatin C (urine) and cystatin C (plasma) testing have a very similar distribution and are not
presented]. Above a threshold of £11,500 per QALY, cystatin C (serum) testing is expected to be the most
cost-effective strategy. The test has a 54% probability of being cost-effective at a £20,000 per QALY
threshold, increasing to and levelling out at 56% at a £50,000 per QALY threshold.
Secondary analysis (post-cardiac surgery subgroup)
The results of the secondary analysis conducted within a subgroup of patients after cardiac surgery in the
ICU are presented in Table 60. In this subgroup, the addition of cystatin C testing is expected to have a
lifetime additional cost of £124–166 and produce an additional health benefit of 0.007–0.01 QALYs per
patient. This results in ICERs ranging from £15,337 to £20,435 per additional QALY, with mean INBs of
–0.0002 to +0.002 QALYs.
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FIGURE 39 Scatterplot: incremental costs and QALYs for cystatin C (serum) vs. standard care (base case).
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FIGURE 40 Cost-effectiveness acceptability frontier: cystatin C (serum) vs. standard care (base case).
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TABLE 60 Results of the secondary CEA (post-cardiac surgery subgroup): cystatin C vs. standard care
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI)
Incremental
cost (95% CI) (£)
Incremental
QALYs (95% CI) ICER (£)
Net benefit
(QALYs) (95% CI) INB (95% CI)
P(more
effective)
P(cost
saving)
P(cost-
effective)
Standard care 29,959
(22,738 to 37,726)
6.50
(0.56 to 10.19)
5.007
(–0.90 to 8.60)
Cystatin C
(plasma)
32,125
(22,879 to 37,889)
6.51
(0.56 to 10.21)
166
(–881 to 1229)
0.008
(–0.13 to 0.14)
20,435 5.007
(–0.90 to 8.60)
–0.0002
(–0.09 to 0.09)
0.56 0.37 0.48
Cystatin C
(urine)
30,082
(22,816 to 37,856)
6.51
(0.56 to 10.21)
124
(–908 to 1162)
0.007
(–0.13 to 0.14)
18,076 5.008
(–0.90 to 8.59)
0.0007
(–0.09 to 0.09)
0.55 0.40 0.49
Cystatin C
(serum)
30,111
(22,847 to 37,869)
6.51
(0.56 to 10.21)
153
(–900 to 1204)
0.010
(–0.13 to 0.15)
15,337 5.009
(–0.90 to 8.60)
0.0023
(–0.09 to 0.10)
0.57 0.38 0.51
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Sensitivity analyses
The results of the one-way sensitivity analyses conducted for cystatin C (serum) testing compared with
standard care are provided in Table 61. Based on the mean expected cost and QALY results, cystatin C is
no longer cost-effective (i.e. has an ICER of > £20,000 per QALY) when (1) the time horizon is ≤ 5 years
(SA1), (2) the impact of early AKI intervention is limited to a 5% reduction in AKI risks (from 22% in the
base case) (SA4), (3) the cost of early AKI intervention is increased to £800 (from £205) (SA5), (4) patients
with a FP test result have a ≥ 30% increased ICU mortality rate (SA8) and (5) negative test results are
assumed to lead to a £100 cost saving (because of diminished monitoring) and a 10% increased mortality
rate for FPs (SA9). In contrast, the only instances in which the probability that cystatin C is cost-effective
rises above 60% are when the impact of early AKI intervention is increased to a ≥ 40% reduction in AKI
risks (SA4) and when ≥ 50% of FP test results are assumed to have actually been TP test results (SA7).
Multiway incremental analysis
Base case (adult intensive care unit all-comers)
The results of the multiway incremental analysis for the base case are presented in Table 62 (the ICER for
each strategy compared with standard care is shown in the last column for reference). After ranking all
strategies in order of increasing costs, cystatin C (urine), cystatin C (plasma), NGAL (urine) and NGAL
(plasma) were found to be dominated by cystatin C (serum), producing fewer QALYs for a greater cost.
After removal of all dominated options, cystatin C (serum), NGAL (serum) and Nephrocheck remained,
with ICERs of £11,476, £25,492 and £12,855,101 per additional QALY respectively. Based on this analysis,
NGAL (serum) and Nephrocheck are no longer expected to be cost-effective, assuming a willingness-to-pay
threshold of £20,000 per additional QALY.
The CEAF including all available strategies is shown in Figure 41a. Above a threshold value of £11,400,
cystatin C (serum) testing is expected to be the most cost-effective strategy (based on the expected mean
net benefit values, indicated by the cost-effectiveness frontier), with a probability of cost-effectiveness of
27%, falling to 23% at a £20,000 per QALY threshold. Above a threshold of £25,400, NGAL (serum)
testing is expected to be the most cost-effective strategy, with a probability of cost-effectiveness of 20%,
rising to 26% at a £50,000 per QALY threshold.
Secondary analysis (post-cardiac surgery subgroup)
The results of the multiway incremental analysis for the secondary analysis (post-cardiac surgery subgroup)
are presented in Table 63 (the ICER for each strategy compared with standard care is shown in the last
column for reference). After ranking all strategies in order of increasing costs, NGAL (serum) testing was
found to dominate all other alternative strategies. Cystatin C (urine) and NGAL (plasma) testing are both
extendedly dominated by NGAL (serum) testing, having higher ICERs, whereas the remaining tests are all
strongly dominated, producing fewer QALYs at a greater cost than NGAL (serum) testing.
The CEAF including all available strategies is shown in Figure 41b. Above a threshold value of £13,100,
NGAL serum is expected to be the most cost-effective strategy (based on the expected mean net benefit
values, indicated by the cost-effectiveness frontier), with a probability of cost-effectiveness of 31%, rising
to 34% at a £20,000 per QALY threshold.
Summary
An economic evaluation was conducted to assess the cost-effectiveness of biomarkers compared with
standard care for the early identification of AKI in the ICU. Three tests were assessed: Nephrocheck,
cystatin C and NGAL. Cystatin C and NGAL tests are currently available across three alternative media
(plasma, urine and serum); each of these was considered as a separate test in the analysis, resulting in a
total of seven testing strategies together with Nephrocheck. The evaluation consisted of an economic
decision model, in which cost-effectiveness was assessed over a lifetime horizon from a UK NHS and PSS
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TABLE 61 One-way sensitivity analyses: cystatin C (serum) vs. standard care
Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
Base-case analysis (for comparison)
Cystatin C (serum) base case 32,744 5.62 149 0.013 11,476 3.986 0.006 0.56 0.42 0.54
SA1: time horizon (base case: lifetime, i.e. approximately 40 years)
90 days 13,789 0.05 71 0.000 713,786 –0.63 –0.003 0.53 0.40 0.40
1 year (+90 days) 17,486 0.52 92 0.001 71,008 –0.35 –0.003 0.57 0.39 0.38
5 years (+90 days) 25,587 2.02 118 0.005 23,397 0.74 –0.001 0.57 0.40 0.45
10 years (+90 days) 29,477 3.38 134 0.009 15,710 1.90 0.002 0.57 0.40 0.51
20 years (+90 days) 31,708 5.04 150 0.013 11,926 3.45 0.005 0.56 0.40 0.53
SA2: cystatin C test cost (base case cost £4.26)
Test cost × 0.25= £1.065 32,795 5.62 157 0.014 11,070 3.98 0.006 0.56 0.40 0.53
Test cost × 0.50= £2.13 32,796 5.62 158 0.014 11,140 3.98 0.006 0.56 0.40 0.53
Test cost × 1.50= £6.39 32,800 5.62 162 0.014 11,422 3.98 0.006 0.56 0.40 0.53
Test cost × 2.0 = £8.52 32,802 5.62 163 0.014 11,563 3.98 0.006 0.56 0.40 0.53
Test cost × 5.0 = £21.30 32,814 5.62 175 0.014 12,408 3.98 0.005 0.56 0.39 0.52
SA3: ICU AKI incidence (base case: mean 0.317, SD 0.018)
AKI incidence= 0.10 32,395 6.26 74 0.00 17,035 4.64 0.001 0.58 0.35 0.50
AKI incidence= 0.20 32,608 5.96 114 0.009 13,048 4.33 0.003 0.58 0.38 0.53
AKI incidence= 0.40 33,033 5.38 192 0.017 11,055 3.73 0.008 0.58 0.40 0.54
AKI incidence= 0.50 33,246 5.09 232 0.022 10,656 3.43 0.010 0.58 0.40 0.55
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TABLE 61 One-way sensitivity analyses: cystatin C (serum) vs. standard care (continued )
Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
SA4: impact of early AKI intervention on AKI risks (base case: RR 0.78, SD 0.25)
RR= 0.20 (i.e. 80% reduced risks) 32,984 5.65 345 0.043 7958 3.999 0.026 0.67 0.33 0.62
RR= 0.40 (60% reduced risks) 32,945 5.64 307 0.037 8237 3.994 0.022 0.66 0.34 0.62
RR= 0.60 (40% reduced risks) 32,883 5.63 244 0.027 8911 3.988 0.015 0.63 0.35 0.60
RR= 0.70 (30% reduced risks) 32,844 5.63 205 0.021 9610 3.984 0.011 0.61 0.37 0.57
RR= 0.90 (10% reduced risks) 32,753 5.61 115 0.007 15,339 3.974 0.002 0.54 0.42 0.50
RR= 0.95 (5% reduced risks) 32,728 5.61 89 0.004 24,435 3.972 –0.001 0.52 0.44 0.48
RR values > 1 reset to 1 32,816 5.62 178 0.017 10,346 3.981 0.008 0.58 0.39 0.54
RR SD reduced to 0.06 32,808 5.62 170 0.016 10,699 3.980 0.007 0.58 0.39 0.55
SA5: cost of early AKI intervention (base case: mean cost £205, SD £279)
Cost of early AKI treatment = £50 32,748 5.62 109 0.014 7740 3.981 0.009 0.56 0.43 0.56
Cost of early AKI treatment = £100 32,761 5.62 122 0.014 8643 3.981 0.008 0.56 0.42 0.55
Cost of early AKI treatment = £500 32,863 5.62 224 0.014 15,860 3.976 0.003 0.56 0.36 0.50
Cost of early AKI treatment = £800 32,939 5.62 301 0.014 21,273 3.972 –0.001 0.56 0.32 0.46
SA6: ICU utility (base case: mean –0.402, SD 0.201)
ICU utility = 0.00 32,795 5.63 157 0.014 11,202 3.987 0.006 0.56 0.40 0.53
ICU utility = 0.20 32,795 5.63 157 0.014 11,194 3.992 0.006 0.56 0.40 0.53
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Sensitivity analysis
Total
cost (£)
Total
QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
Net benefit
(QALYs) INB
P(more
effective)
P(cost
saving)
P(cost-
effective)
SA7: test accuracy adjustment (FPs reset to TPs and overall incidence of AKI increased)
10% of FP results recoded as TPs and overall
incidence of AKI increased to 32.5%
32,893 5.60 194 0.020 9770 3.958 0.010 0.60 0.38 0.56
25% of FP results recoded as TPs and overall
incidence of AKI increased to 33.8%
32,887 5.57 236 0.026 8897 3.924 0.015 0.62 0.36 0.59
50% of FP results recoded as TPs and overall
incidence of AKI increased to 35.8%
33,029 5.52 278 0.035 7831 3.870 0.022 0.66 0.35 0.63
100% of FP results recoded as TPs and overall
incidence of AKI increased to 39.9%
33,206 5.42 382 0.055 6945 3.760 0.036 0.72 0.31 0.70
SA8: increased mortality for FP results
5% increased ICU mortality for FPs 32,780 5.62 142 0.011 12,822 3.977 0.004 0.55 0.41 0.51
10% increased ICU mortality for FPs 32,763 5.61 124 0.008 15,539 3.974 0.002 0.53 0.42 0.50
30% increased ICU mortality for FPs 32,693 5.60 55 –0.004 Dominated 3.966 –0.007 0.46 0.47 0.43
50% increased ICU mortality for FPs 32,624 5.59 –14 –0.016 886a 3.957 –0.016 0.41 0.52 0.37
SA9: impact of negative test results (reduction in monitoring leading to cost saving + increased mortality risk for FNs)
One-off cost saving (–£100) + 10% increased
ICU mortality for FNs
31,881 5.53 –758 –0.072 10,471a 3.938 –0.034 0.21 0.85 0.31
a Cost saved per QALY lost: in these cases the ICER must be > £20,000 (i.e. > £20,000 saved per QALY lost) to be considered cost-effective. In these instances Nephrocheck testing is
therefore not cost-effective.
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TABLE 62 Multiway incremental cost-effectiveness results (primary analysis)
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI) Comparatora
Incremental cost
(95% CI) (£)
Incremental
QALYs (95% CI) ICER (£) Exclusion reason
ICER vs. standard
care (£)
Standard care 32,596
(24,320 to 43,145)
5.6092
(0.46 to 9.09)
– – – – – –
Cystatin C (serum) 32,744
(24,320 to 43,340)
5.6221
(0.46 to 9.11)
Standard care 149 (–1201 to 1496) 0.013
(–0.16 to 0.19)
11,476 – 11,476
Cystatin C (urine) 32,751
(24,524 to 43,347)
5.6207
(0.46 to 9.11)
Cystatin C (serum) 6 (–111 to 114) –0.0014
(–0.01 to 0.01)
–4405 Dominated by
cystatin C (serum)
13,449
NGAL (urine) 32,759
(24,521 to 43,351)
5.6211
(0.46 to 9.11)
Cystatin C (serum) 15 (–65 to 84) –0.0011
(–0.01 to 0.01)
–13,927 13,742
NGAL (plasma) 32,759
(24,516 to 43,339)
5.6214
(0.46 to 9.11)
Cystatin C (serum) 15 (–55 to 80) –0.0007
(–0.01 to 0.01)
–20,733 13,372
Cystatin C (plasma) 32,761
(24,546 to 43,355)
5.6214
(0.46 to 9.11)
Cystatin C (serum) 17 (–59 to 106) –0.0007
(–0.01 to 0.02)
–23,801 13,504
NGAL (serum) 32,811
(24,587 to 43,427)
5.6247
(0.46 to 9.11)
Cystatin C (serum) 67 (–39 to 257) 0.0026
(–0.01 to 0.02)
25,492 – 13,828
Nephrocheck 32,897
(24,662 to 43,484)
5.6248
(0.46 to 9.12)
NGAL (serum) 86 (9 to 227) 0.000007
(–0.01 to 0.01)
12,855,101 – 19,324
a In the multiway incremental analysis, for each test, after ranking strategies in order of increasing costs, the incremental cost and QALYs are calculated based on a comparison with the
next best strategy, excluding any dominated or extendedly dominated options (i.e. excluding the shaded rows).
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perspective using individual patient trial data and information from the current literature. The primary
analysis concerned the use of the tests in an all-comer ICU population; a secondary analysis was conducted
to explore the impact of the tests on a subgroup of patients in the ICU post cardiac surgery.
In the primary analysis, based on the mean expected cost and QALY results only, each of the tests was
cost-effective when compared in two-way analyses against standard care. Lifetime incremental QALYs
ranged from 0.0115 [cystatin C (urine)] to 0.016 (Nephrocheck) and additional costs ranged from £149
[cystatin C (urine)] to £301 (Nephrocheck). The ICERs ranged from £11,476 to £13,504 per additional
QALY for the cystatin C tests and from £13,372 to £13,828 for the NGAL tests; for Nephrocheck the ICER
was £19,324. The corresponding INB values ranged from 0.001 QALYs for Nephrocheck to 0.006 QALYs
for cystatin C (serum).
There is significant uncertainty around both the incremental cost results and the QALY results, leading to
large uncertainty around the expected cost-effectiveness of the tests. For the incremental costs, all of the
testing strategies had 95% CIs ranging from –£1000 to +£1400 and, for the incremental QALYs, all of the
results ranged from –0.16 to +0.19 or +0.20. Compared with standard care alone, the probability that
the tests are more effective than standard care was 56% for the cystatin C tests, 56–57% for the NGAL tests
and 57% for Nephrocheck. The probability that the tests would be cost saving was 32% for Nephrocheck,
37–40% for the NGAL tests and 40–42% for the cystatin C tests. At a £20,000 per QALY threshold, the
overall probability that the tests are cost-effective compared with standard care was 48% for Nephrocheck,
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FIGURE 41 Cost-effectiveness acceptability frontier: (a) multiway base-case analysis; (b) multiway secondary analysis
(post cardiac surgery).
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TABLE 63 Multiway incremental cost-effectiveness results (secondary analysis)
Strategy
Total cost
(95% CI) (£)
Total QALYs
(95% CI) Comparatora
Incremental cost
(95% CI) (£)
Incremental
QALYs (95% CI) ICER (£) Exclusion reason
ICER vs. standard
care (£)
Standard care 29,959
(22,738 to 37,726)
6.5048
(0.56 to 10.20)
– – – – – –
Cystatin C (urine) 30,082
(22,816 to 37,856)
6.5116
(0.56 to 10.21)
Standard care 124 (–908 to 1162) 0.0068
(–0.13 to 0.14)
18,076 Extendedly
dominated by
NGAL (serum)
18,076
NGAL (plasma) 30,096
(22,836 to 37,867)
6.513
(0.56 to 10.21)
Standard care 137 (–895 to 1178) 0.0082
(–0.13 to 0.14)
16,709 16,709
NGAL (serum) 30,108
(22,845 to 37,892)
6.5163
(0.56 to 10.22)
Standard care 149 (–905 to 1204) 0.0115
(–0.13 to 0.15)
13,051 – 13,051
Cystatin C (serum) 30,111
(22,847 to 37,869)
6.5148
(0.56 to 10.21)
NGAL (serum) 3 (–110 to 129) –0.0015
(–0.01 to 0.01)
–2145 Dominated by
NGAL (serum)
15,337
Cystatin C (plasma) 30,125
(22,879 to 37,889)
6.5129
(0.56 to 10.21)
NGAL (serum) 17 (–138 to 205) –0.0033
(–0.02 to 0.01)
–5120 20,435
NGAL (urine) 30,131
(22,885 to 37,900)
6.5137
(0.56 to 10.21)
NGAL (serum) 23 (–116 to 194) –0.0025
(–0.02 to 0.01)
–9050 19,287
Nephrocheck 30,163
(22,893 to 37,942)
6.5158
(0.56 to 10.20)
NGAL (serum) 55 (–43 to 154) –0.0004
(–0.01 to 0.01)
–123,202 18,617
a In the multiway incremental analysis, for each test, after ranking strategies in order of increasing costs, the incremental cost and QALYs are calculated based on a comparison with the
next best strategy, excluding any dominated or extendedly dominated options (i.e. excluding the shaded rows).
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51–52% for the NGAL tests and 52–54% for the cystatin C tests. Raising the threshold value to £50,000 per
QALY only slightly increased these probabilities.
The results of the multiway analysis indicate that, in the base case, between a threshold of £11,400 and a
threshold of £25,400, cystatin C (serum) is the most cost-effective strategy, with a probability of cost-
effectiveness of 23% at a £20,000 per QALY threshold. Above a £25,400 per QALY threshold, NGAL
(serum) is expected to be the most cost-effective strategy, with a probability of cost-effectiveness of 20%.
All other strategies either are found to be dominated by cystatin C (serum) or, in the case of Nephrocheck,
have an ICER well above £20,000 per QALY [£12,855,101 compared with the next best alternative of
NGAL (serum)]. This analysis suggests that, when taking into account the additional health impact that
alternative tests could provide, several of the tests may no longer be cost-effective options.
Similar results were observed in the secondary analysis (i.e. in the post-cardiac surgery subgroup). All of the
incremental costs and QALYs were slightly reduced compared with the base case, with incremental QALYs
ranging from 0.007 [cystatin C (urine)] to 0.012 [NGAL (serum)] and additional costs ranging from £124
[cystatin C (urine)] to £205 (Nephrocheck). The ICERs were £13,051–19,287 per additional QALY for the
cystatin C tests, £15,337–20,435 for the NGAL tests and £18,617 for Nephrocheck, with INB values
ranging from –0.0002 to 0.004 QALYs. Again, there was substantial uncertainty around these results; at a
£20,000 per QALY threshold there was a 48–52% probability that the tests would be cost-effective. In the
multiway incremental analysis, only NGAL (serum) remained after removal of dominated or extendedly
dominated alternatives (ICER £13,051 vs. standard care; probability of cost-effectiveness 35% at a £20,000
per QALY threshold).
The base-case results were highly sensitive to changes in key model parameters. Scenarios that lead to the
tests becoming non-cost-effective (ICER > £20,000 per QALY) included shortening the time horizon of the
analysis, reducing the incidence of AKI in the ICU, decreasing the impact or increasing the cost of early AKI
intervention, applying a mortality risk for patients with FP test results, applying a cost saving for patients
with negative test results and increased mortality for FN cases and increasing the cost of the Nephrocheck
test. The only scenarios in which the probability that the tests were cost-effective increased to > 60% were
increasing the impact of early AKI intervention to ≥ 40% and ≥ 60% risk reductions for cystatin C and
NGAL respectively and assuming that at least 25%, 25% or 50% of FP test results were in fact TP test
results for Nephrocheck, NGAL and cystatin C respectively.
Discussion
Interpretation of results
The results of the economic evaluation require careful interpretation. When analysed individually against
standard care, all of the tests appear to be cost-effective in the base case and all except cystatin C (plasma)
are cost-effective in the secondary analysis, based on an analysis of the overall expected costs and QALYs.
However, the differences in each of the expected costs and QALYs are small and largely uncertain, resulting
in probabilities of cost-effectiveness around 50%. Such uncertainty strongly indicates that further research
is required before an informed adoption decision can be made. Furthermore, it necessitates a cautious
interpretation of the subsequent multiway analysis, in which all tests are considered within the same
evaluation; because the differences in the expected costs and QALYs across each of the tests are small and
uncertain, marginal changes in any of these values could result in different test rankings, rendering these
results potentially spurious. Perhaps the only exception to this is the Nephrocheck test, which is associated
with extremely large ICERs compared with the alternative testing strategies because it has similar expected
QALY outcomes but relatively higher costs. Assuming that the accuracy of the Nephrocheck test is not
expected to improve significantly compared with the alternative tests, then the only way that this test is
likely to represent a cost-effective strategy is if the cost of the test (currently estimated at > £70) is reduced
to be in line with that of other competitor tests (i.e. £14.98 for NGAL and £4.26 for cystatin C).
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Sensitivity analyses
The cost-effectiveness results are sensitive to changes in key parameters in the model. Most notably, all of
the tests were sensitive to parameters related to the expected change in patient management and
outcomes resulting from a positive or negative test result:
l The cost and impact of early AKI intervention resulting from a TP test result. It is assumed that patients
with a TP test result can benefit from some form of early AKI intervention; however, the exact nature of
this intervention is unclear because of the fact that treatment for AKI currently relies on a heterogeneous
and non-specific bundle of interventions. No diagnostic outcome studies that could inform an estimation
of the impact of such early intervention on patient outcomes have yet been conducted. As such, data
on the impact of early nephrologist consultation on AKI incidence in a population of Mexican patients
treated post cardiac surgery were used as a proxy.464 The appropriateness of this estimation is unclear and
the model results were highly sensitive to both the expected impact of treatment on AKI risks and the
cost of the intervention. Reducing the impact of early AKI intervention to a 10% AKI risk reduction
or increasing the cost of the intervention to £500 (around the 90th percentile of the base-case cost
distribution) results in the Nephrocheck test no longer being cost-effective, whereas reducing the risk
reduction to 5% or increasing the cost to £800 (around the 95th percentile) results in all tests no longer
being cost-effective. In contrast, increasing the risk reduction or reducing the intervention cost leads to
significant increases in expected cost-effectiveness and the probability of cost-effectiveness of all of
the tests.
l The impact of a FP test result. In the base case it was assumed that no harm would result from
a FP test result. Assuming instead that patients with a FP test result would incur a mortality impact
(e.g. as a result of delayed access to necessary nephrotoxic agents) leads to reductions in the expected
cost-effectiveness of the tests: a ≥ 5% mortality impact results in the Nephrocheck test no longer being
cost-effective, a ≥ 10% mortality impact results in NGAL testing no longer being cost-effective and a
≥ 30% mortality impact results in cystatin C testing no longer being cost-effective.
l The impact of a negative test result. In the base case it was assumed that a negative test result (either
TN or FN) would have no impact on baseline treatment costs or QALYs. However, it is reasonable to
assume that this may not be the case: a negative result may lead to reduced costs as a result of reduced
patient monitoring and/or may result in harm for FN cases because of that same reduced monitoring.
Sensitivity analysis indicates that if a one-off cost saving of £100 is applied to all negative results,
and a 10% increased ICU mortality rate is applied to FN results, this would lead to all testing strategies
becoming cost saving at the expense of producing fewer QALYs, resulting in all strategies no longer
being cost-effective. Note that, in the absence of any data, these values were chosen purely arbitrarily.
Other parameters that were found to be influential in the sensitivity analysis include:
l The time horizon of the analysis. Nephrocheck becomes cost-effective only if using a ≥ 20 year time
horizon and cystatin C and NGAL become cost-effective only when using a ≥ 10-year time horizon.
This indicates the importance of downstream health impacts (as a result of reduced CKD incidence and
increased survival) relative to the short-term costs and health impacts in the model.
l The incidence of AKI in the ICU. Reducing the incidence of AKI diminishes the opportunity for tests to
improve patient outcomes (as the absolute proportion of TP cases is reduced) while at the same time
increasing the relative cost of unnecessary testing. The impact of this appears to be greatest for the
two most expensive tests: decreasing the AKI incidence to ≤ 20% results in Nephrocheck no longer
being cost-effective, whereas decreasing the AKI incidence to 10% results in NGAL testing no longer
being cost-effective (in contrast, cystatin C testing remains cost-effective throughout). Thus, the tests
are less likely to be cost-effective when few cases of AKI are expected. This may not be a common
occurrence within the UK ICU setting, where recorded rates of AKI are generally high. It may be more
relevant in settings in which patients entering ICU may be less acutely ill because of higher critical care
capacities, resulting in patients having an overall lower risk of AKI.
l Adjusting the test accuracy to account for the imperfect reference test. Assuming that a proportion of
FP test results are actually TP cases has a huge impact on the results. For example, recoding 10% of FP
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cases in NGAL and cystatin C testing, or 25% of FP cases in Nephrocheck testing, leads to ICERs of
< £10,000; recoding 25% of FP cases results in all tests having a ≥ 60% probability of being cost-
effective. The interpretation of this analysis depends on how much we are willing to believe that FP
cases may actually be TP cases, as a result of the known deficiencies in standard care testing. We are
not aware of any current evidence that could inform this expectation, thus this analysis should be
considered purely exploratory. It does, however, highlight the importance of the methodological issue
of how to account for bias in estimates of diagnostic accuracy resulting from the use of imperfect
reference tests; although there is a growing body of methodological research in this area, the focus to
date has been on methods that require access to individual-level data (which have limited application in
this kind of study in which the main source of evidence is aggregate secondary data), and we are not
aware of any work that has been conducted from a health economic perspective. This is, therefore, a
key area for future research.
In general, of the three tests evaluated in the sensitivity analyses, Nephrocheck was the most sensitive to changes
in key parameters, whereas cystatin C testing was the most resilient to parameter changes. Nevertheless, all of
the tests were found to be sensitive to the key parameters listed above, indicating the need for further research
across these areas. As the results of the VOI analysis provide further insight into the relative importance of the
different areas of uncertainty, full research recommendations are discussed in Chapter 6.
Previous economic evaluations
Our review of economic decision models identified two previous economic evaluations of biomarkers for
the early identification of AKI in the critical care setting. Both of these studies found that testing strategies
were a cost-effective addition to standard care. However, there are notable differences in the overall and
incremental cost and QALY outcomes between these studies and our analysis. In the study by Shaw
et al.205 (the most comparable study, which also considered a UK adult ICU population), the authors
reported a mean lifetime cost of £4672 and 11.79 QALYs for standard care in a post-cardiac surgery
population, whereas, in the current equivalent analysis, we expect a mean lifetime cost of £29,959 and
6.50 QALYs. A key reason for the lower cost in the study by Shaw et al.205 is because the authors did not
include any follow-up costs for patients post hospital discharge, which are expected to be significant
(starting at > £6000 per year) based on a recent large cohort study.457 Other key differences include the
fact that the previous analysis assumed lower ICU length of stays and mortality, did not account for utility
in the ICU (which was negative in the current model) or hospital, did not include a follow-up mortality risk
post ICU discharge and did not include an elevated cost for ESRD (separate from that for CKD). We
therefore believe that it is highly likely that previous assessments of the long-term costs and QALYs for
patients treated in the ICU have been under- and overestimated respectively.
Shaw et al.205 found that urinary NGAL testing dominated standard care, being more effective and less
costly. This is in contrast to the current analysis in which the same test was associated with an additional
cost of £172 and an increase in QALYs of 0.009, resulting in an ICER of £19,287 and a 48% probability of
being cost-effective. Again, there are key differences between the studies that we believe are driving these
alternative results. In particular, the analysis in the study by Shaw et al.205 considered four sequential NGAL
tests and assumed that test accuracy was independent of the sequence of the tests, which is likely to
increase the overall accuracy of the tests. In addition, it appears that all patients with TP results were
assumed to benefit from early AKI treatment, regardless of the concurrent standard care test results (in
contrast we assumed that only patients without a concurrent diagnosis of moderate/severe AKI would be
able to benefit from early AKI treatment in the testing strategies). Finally, Shaw et al.205 reported limited
details of the distributional assumptions applied in their probabilistic analysis and so it is unclear if
uncertainty in the model parameters has been fully captured.
Overall, although all three economic evaluations of biomarkers for the early diagnosis of AKI in the ICU to
date indicate that tests may be cost-effective, we believe that our analysis more accurately reflects the
expected costs and QALYs associated with these strategies and, most importantly, more accurately depicts
the level of uncertainty around these decisions.
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Generalisability
This study has evaluated Nephrocheck, NGAL and cystatin C tests for the early identification of AKI within
both a general all-comers ICU population and a post-cardiac surgery subgroup population. Based on the
fact that this is an early analysis, with the results of the sensitivity analysis indicating that the results are
sensitive to changes in key parameters including the incidence of AKI and the impact of early treatment, it
is unlikely that these results can be extrapolated to the use of tests across other settings (e.g. the hospital
ward or the community). In addition, as many of the costs are specific to the UK NHS, generalisability
beyond the UK should also be considered with caution.
Although each of the three tests was shown to be cost-effective compared with standard care, there is
significant uncertainty around the results, as highlighted by the wide distribution of the incremental costs
and QALYs, the relatively low probabilities of cost-effectiveness and the sensitivity of the results to changes
in key parameters. The potential value of future research as a means of reducing this uncertainty is
explored further in Chapter 6.
It should be noted that combining CKD stages 1–4 was considered to be a necessary simplification within
the model. The key objective of the model was to capture any impacts related to the intervention (i.e. in
this case, the tests). Based on expert consultation, it was not apparent that the tests and resulting
treatments would have any significant impact on patient outcomes once CKD has developed. The CKD
portion of the model therefore aimed to capture the most significant cost and QALY impacts associated
with CKD, which were assumed to be the use of dialysis, the risk of ESRD and transplantation. This
simplification is in line with previous models outlined in the review of AKI models.
ECONOMIC EVALUATION
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Chapter 6 Research prioritisation
Introduction
A key objective of the AKI-Diagnostics project was to inform a strategy towards the generation of evidence
leading to the adoption of diagnostics tests in critical care in a manner that maximises patient benefit and
value for the NHS. Subject to demonstration of clinical efficacy, the final step of any diagnostic test towards
adoption is a reimbursement decision based on cost-effectiveness. As such, a specific metric – VOI – has
been chosen as the main determinant of research recommendations arising from the AKI-Diagnostics project.
Value of information analysis provides a pertinent framework for setting priorities for further research.
This approach relies on the fact that resources that are spent on a new intervention will not be available
to spend on alternative interventions: if we invest in a new intervention that is not the most cost-effective
option, we could lose health (or money) that could have been gained if we had invested in a more
cost-effective intervention. Research (i.e. the gain of more information) therefore has value if it reduces the
risk of adopting an intervention that is not cost-effective. This value can be quantified as either lost health
(measured in QALYs) or lost health-care resources (measured in monetary units) within the VOI framework.
This chapter outlines the methods and findings of the VOI analysis conducted as part of the AKI-Diagnostics
economic evaluation.
It is important to note that the VOI analysis presented here relies on multiple two-way comparisons
between standard care and specific tests. This is on the grounds that the decision problem, in reality,
includes more than just the three tests subjected to detailed study within the project. As such, a four-way
comparison such as that presented in Chapter 5 would be incomplete.
Methods
Value of information analysis
Value of information analysis was conducted for each of the shortlisted tests using the economic decision
model outlined in Chapter 5. For the cystatin C and NGAL tests, which are available across multiple media
(i.e. plasma, urine and serum), VOI analysis was conducted only for the individual test found to have the
highest probability of being cost-effective based on the results of the CEA. This analysis therefore includes
Nephrocheck, NGAL (plasma) and cystatin C (serum).
Within the VOI framework, several measures can be obtained to explore the impact of reducing
uncertainty on the expected cost-effectiveness. The focus of this analysis was on the following measures:
l Expected value of perfect information (EVPI). The EVPI represents the overall burden of uncertainty on
the decision-maker for a defined decision. The economic model is used to determine the difference
between the expected net benefit when a decision is made assuming perfect knowledge of all model
parameters (estimated via model simulations assuming fixed input parameters sampling across the
range of expected parameter values) and the net benefit under current uncertain information. The
resulting EVPI provides an upper bound on the total amount that the decision-maker should be willing
to invest in further research to eliminate all parameter uncertainty. A positive EVPI provides a necessary
but not sufficient condition for the decision to invest in further research: a positive EVPI indicates that
further research may be warranted; however, additional information including the expected cost of
research, the likely reduction in uncertainty as a result of research and the opportunity cost of delayed
adoption is required to make a definitive decision regarding future research requirements.
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
153
l Expected value of perfect parameter information (EVPPI). The EVPPI is an extension of the EVPI in which
the burden of uncertainty around particular individual parameters, or groups of parameters, is
quantified.480 The EVPPI indicates the maximum value that the decision-maker should be willing to
invest to reduce all uncertainty around a specific parameter or group of parameters. As for the EVPI,
the EVPPI presents a necessary but not sufficient condition for conducting further research. However,
the EVPPI enables exploration of the key parameters driving the uncertainty, which can be used to
inform the direction of further research.
Calculation of the VOI was conducted using non-parametric regression modelling approaches.481,482 For
single parameter EVPPI estimates and for groups of up to four parameters, regression was conducted using
the generalised additive model. For parameter groups of five or above, the R ‘earth’ package was used,
which utilises multivariate adaptive regression splines.483
To estimate the VOI for the total population of patients expected to be affected by an adoption decision, a
baseline population of 258,956 was assumed, based on the reported number of critical care records in the
2014–15 Hospital Episodes Statistics report (adult critical care).484 An annual discount rate of 3.5% was
applied to this number over a 10-year time period, assuming that this is the time over which the decision
would remain relevant (e.g. before a comparator intervention would be adopted). This results in a total
10-year discounted population of 2,229,012. All VOI statistics are expressed in monetary terms using the
net monetary benefit statistic.
Results
Expected value of perfect information
The distribution of the EVPI across different willingness-to-pay thresholds for the Nephrocheck, cystatin C
(serum) and NGAL (plasma) tests is shown in Figures 42–44 respectively. At a willingness-to-pay threshold
of £20,000 per QALY, the per-patient EVPI is £430 for Nephrocheck, £371 for NGAL (plasma) and £362
for cystatin C (serum). For the total 10-year discounted population of patients expected to be affected by
this decision (n = 2,229,012), the corresponding 10-year population EVPI is £958M, £827M and £807M
respectively. Population EVPPI for single model parameters, showing top ranked parameters only, is shown
in Figure 45.
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FIGURE 42 Expected value of perfect information: Nephrocheck vs. standard care.
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FIGURE 43 Expected value of perfect information: cystatin C (serum) vs. standard care.
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FIGURE 44 Expected value of perfect information: NGAL (plasma) vs. standard care.
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FIGURE 45 Population EVPPI for single model parameters (showing top ranked parameters only).
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Expected value of perfect parameter information
The population EVPPIs for single model parameters are provided in Figure 46. For all tests the majority of
top-ranked individual parameters relate to the proportion of patients arriving in the ICU with AKI, the
proportion being diagnosed with AKI on the first day, the distribution of patients across health states at
the end of the hospital period of the model and the impact of early AKI intervention on future AKI risks.
Across all of the top ranked parameters shown, the Nephrocheck test is associated with the highest EVPPI,
followed by the NGAL (plasma) test and the cystatin C (serum) test.
The population EVPPIs for groups of parameters are presented in Figure 47. The most influential groups of
parameters are the incidence and starting stages of AKI, followed by the test parameters (test accuracy
and impact and cost of early AKI intervention), and the starting distributions of patients entering the
follow-up model (which are drawn from the end-state distribution of patients in the hospital period of the
model). For all of the top-ranked parameter groups, the Nephrocheck test is associated with the highest
VOI, followed by the NGAL (plasma) test and cystatin C (serum) test. The only parameter group for which
this is not the case is ward mortality and discharge rates, for which NGAL (plasma) and cystatin C (serum)
have positive EVPPIs (£1.53M and £0.48M respectively) and Nephrocheck has a zero value.
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FIGURE 46 Population EVPPIs for single model parameters (showing top-ranked parameters only). FUP, follow-up
period; Tp, transition probability.
RESEARCH PRIORITISATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
Summary
A VOI analysis was conducted to (1) inform a stop–go decision on further research into AKI diagnostic tests
for the DEC programme and (2) guide the design of further research to ensure that it provides information
that will reduce decision uncertainty in a targeted manner. Both the EVPI and the EVPPI metric were used
to characterise the burden of decision uncertainty across and between the model parameters.
For the total 10-year discounted population of patients expected to be affected by this decision
(n = 2,229,012), the 10-year population EVPIs are £958M, £827M and £807M for Nephrocheck, NGAL
and cystatin C respectively. A positive EVPI is a necessary condition for further research being worthwhile,
which has therefore been met for all three tests considered. Furthermore, the magnitude of these
estimates suggests that the current burden of uncertainty puts us at significant risk of population health
loss through an incorrect adoption decision.
When considering individual parameters, the top-ranked parameters in terms of population EVPPIs were
the proportion of patients arriving in the ICU with pre-existing AKI, the proportion being diagnosed with
AKI on the first day, the distribution of patients across health states at the end of the hospital period of
the model and the cost and impact of early AKI intervention. Many of these values were > £100M.
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FIGURE 47 Population EVPPIs for parameter groups.
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When considering groups of parameters, the top-ranked EVPPIs (all also > £100M) were:
l the incidence and starting stages of AKI
l the impact and cost of early AKI intervention.
Discussion
Interpretation of the results and future research recommendations
The results of the VOI analysis indicate that there is a large population burden of decision uncertainty
around the decision to reimburse the three tests that have been studied in detail. Conducting further
research to reduce uncertainty around this decision problem is likely to be of high population value. In
particular, two key areas for future research are highlighted as being particularly worthwhile: (1) the
incidence and progression of AKI in the ICU and (2) the impact and cost of early AKI intervention. In the
grouped EVPPI analysis, both of these parameter groups had values of > £100M across all three tests and
ranked much higher than other parameters. This indicates that an investment of up to £100M would be
worthwhile if it is able to eliminate uncertainty around these parameters. Although the test parameters
grouping (composed of the test accuracy in addition to the impact and cost of early AKI intervention) also
scored highly, it appears that this value is driven by the early AKI intervention parameters rather than the
accuracy of the tests as these two group values are almost identical and the test accuracy parameters do
not feature in the top-ranked single EVPPIs. It is also interesting to note that most of the top-ranked
parameters relate to the short-term patient outcomes, suggesting that the downstream parameters are of
less importance from the perspective of further research.
Although a formal RCT comparing a testing strategy with standard care would be necessary to provide
definitive evidence for the clinical effectiveness and cost-effectiveness of the tests, these results suggest
that expensive long-term follow-up may not be necessary. It may also be entirely possible to reduce our
decision uncertainty substantially by undertaking some observational research to better understand the
rates and trajectory of AKI in the ICU prior to undertaking a trial. It may even be possible to gain useful
data from an observational study that looks at the use of the tests in real-world practice. This would
enable valuable data to be gathered on how the tests may impact on clinical decision-making and change
in the standard care pathway. It appears that, if knowledge is gained about these parameters, prominent
sources of decision uncertainty could be addressed.
A single-centre study485 in patients after cardiac surgery using the Nephrocheck test has recently been
reported, indicating that such studies are feasible. Further multicentre studies, ideally evaluating multiple
tests, will be required to inform a robust assessment of the long-term health economic impact of such
tests. These could be cluster or individually randomised interventions based on the complexities of the final
study protocols and any concerns about contamination. Appropriate arguments would also need to be
developed for the rationale of consenting patients (or not) in this setting.
It should be noted that the EVPPI results provide an upper bound on the amount that a decision-maker
should be willing to spend on this research; additional factors need to be considered such as the cost of
research; to what extent uncertainty would be diminished; the impact of treating patients in a research
setting; and the impact of delaying access to treatment for NHS patients not taking part in a study. To
make more precise statements about the value of research, a calculation of the expected value of sample
information (EVSI) would be necessary, which has not been undertaken within the constraints of this
project. Nevertheless, the magnitude of the VOI estimates observed strongly indicates that the required
research would be achievable within this maximum budget (i.e. £100M). In addition to this form of study,
better data on the incidence and progression of AKI in the ICU will continually become available from the
AKI registry (see Chapter 5) and could be used to update the current evaluation, with a likely significant
impact on uncertainty.
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The results from the sensitivity analyses in Chapter 5 support these findings. In addition, the results of
the sensitivity analyses also highlight the need for further evidence on the specific types of clinical
management changes that would be implemented as a result of a positive or negative test result and the
impact that they would have on patient short-term outcomes (i.e. not just limited to the impact of early
AKI intervention for TPs). It appears that either a clinical consensus needs to be obtained here or the
impact of alternative courses of action needs to be explored within a clinical study, which could be a fairly
simple observational study. In addition, the meta-analysis of diagnostic studies could be extended to
include a sensitivity analysis in which studies at high risk of bias are excluded. This would provide further
information with respect to the robustness of estimates that are included in the economic evaluation.
Limitations
A key limitation of this analysis is the fact that the daily AKI transition probabilities could not be included
as parameters of interest in the EVPPI analysis because of the size of these parameter matrices (which
results in the VOI analysis taking an impractical amount of time to run, even using substantial parallel
computing resources). However, the incidence of AKI, the proportion of patients with pre-existing AKI, the
distribution of AKI on the first day and the end-state distribution of patients in the hospital period of the
model all feature highly in the single- and grouped-parameter EVPPI analyses. It appears safe therefore to
assume that the daily transitions between AKI states would similarly feature in the top-ranked parameters.
In addition to the EVPI and the EVPPI, the EVSI can be computed to determine the value of a defined
research proposal, that is, a clinical trial of specified length and size that would provide information on
specific parameters. EVSI calculation remains computationally expensive and was therefore not explored in
this analysis but would be a useful addition if specific future study designs are proposed.
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Chapter 7 Discussion
The AKI-Diagnostics project had the ambitious goal of establishing a recommended research anddevelopment strategy for diagnostic tests for AKI in critical care in the UK. This was undertaken within
the NIHR DEC programme in acknowledgement that this is an area of significant health burden and is
significantly underdeveloped as an area of technological application. As the first FDA-approved test, there
was a risk that the Nephrocheck test would undergo widespread adoption without consideration of a
robust evidence development strategy comparing it with other testing options and without it going
through the necessary safeguard of a national health technology assessment.
The key clinical message from the project is that diagnostic tests for AKI in critical care patients who do
not have AKI on admission have the potential to provide a meaningful albeit small benefit to patients.
Although the number of studies supporting the Nephrocheck test is considerably smaller than those
supporting the NGAL and cystatin C tests, the quality of these studies does appear to be high when faced
with formal critical appraisal, particularly with regard to aspects of analytical validity.
All tests may represent strategies that may be cost-effective, but this is subject to uncertainty, which is
particularly driven by assumptions regarding the impact of a diagnostic test on clinical care and the
resulting change in clinical outcomes. Although these factors are both modelled in detail in the economic
model, observational or experimental studies are required to ratify the link between possible care process
changes and AKI rates and their longer-term implications.
The results of this project may be interpreted by some as providing sufficient evidence for adoption of the
tests in the NHS; however, we would recommend that this is undertaken only within the framework of
careful observational study, audit and an exit strategy at the point of evidence re-evaluation. Such an
approach would allow many of the assumptions on which the economic model relies to be tested or better
informed by data. There is interest by national reimbursement decision-makers such as NICE in new
models of reimbursement that introduce conditionality on a positive reimbursement decision. We consider
AKI diagnostic tests to be an ideal test case for such a model. There is interest by national reimbursement
decision-makers such as NICE in new models of reimbursement that introduce conditionality on a positive
reimbursement decision. We consider AKI diagnostic tests to be a suitable test case for such a model. This
could be achieved by clearly defining the indication and putting in place a prospective audit framework
that captures key data items that are currently uncertain or absent from the economic model.
The methods for quantitatively establishing an evidence-based and value-based research and development
strategy for diagnostic testing are not established in a universally accepted or methodologically adequate
manner. As such, the AKI-Diagnostics project represents a methods experiment that brings together
many evaluation components. The structure of this report is intended to separate these components into
their own sections for clarity, while acknowledging that they are interlinked and co-dependent. Most
components ultimately feed into the economic model and this can be considered the summarising output
from the project. The limitations of the individual components are discussed in detail in the individual
chapters. It should be noted that, although our consideration of analytical validity goes further than what
is normally required by health technology assessment authorities, the uncertainties around analytical
validity parameters are not captured within the economic model and, therefore, do not feature in the VOI
analysis. Development of improved methods for the incorporation of analytical validity in economic models
should be considered an additional priority for further research.
Many learning points have emerged and will inform the design and conduct of similar attempts to map
out a research strategy for the DECs and the wider NIHR in other diseases or scientific areas of study. The
horizon scan identified a very large long list of candidate biomarkers and tests. We employed a ranking
system based on numbers of publications, the combined sample size and mechanism of action, combined
with expert opinion, using this as a surrogate for trajectory and novelty. Based on this ranking, we focused
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on three tests for detailed study, consuming the remaining resources available within the AKI-Diagnostics
project. It is unknown to us whether these three tests represent the best options for further research
investment compared with the many other putative tests that also require detailed study. Indeed, our
relatively crude ranking strategy may specifically have missed novel or upcoming tests that have appeared
only recently in the literature. We feel that further investment in methodology research to improve the
methods for horizon scanning and the ranking of new technologies for public sector research investment
would be very worthwhile.
There were two important limitations in the meta-analysis of sensitivity and specificity, the most important
of which was the issue of an imperfect reference standard for an AKI definition based on urine output and
serum creatinine; the other limitation was the issue of heterogeneity between studies, particularly with
regard to the choice of case definition threshold. Our ability to explore both of these issues was severely
hampered by a lack of data, particularly for NGAL and cystatin C, for which, despite a large volume of
published studies, reporting standards were simply inadequate in the large majority for this purpose. We
attempted to look at the potential impact of an imperfect reference standard in a fairly crude way using the
economic model. In this analysis we showed that, if it is assumed that ≥ 25% of the FP results are actually
TP results, tests have the potential to be notably more cost-effective (ICERs of <£10,000 per QALY and
> 60% probability of being cost-effective). There should therefore be a strong incentive for researchers
and manufacturers to study this further.
Several issues emerged during the construction and analysis of the economic model and the establishment
of the clinical pathway on which it relies. A key challenge for the project was modelling the clinical impact
and consequent outcomes from the results of the diagnostic tests. In the AKI-Diagnostics economic model
these were derived from the confusion matrix, which allocates simulated patients as TPs, TNs, FPs and FNs.
For the TP results we assumed that, for patients with early AKI, patients will benefit from some form of
early AKI intervention, but the exact nature of this intervention is unclear because treatment for AKI
currently relies on a non-specific bundle of ‘treatments’. No studies were available to inform the nature or
impact of such early intervention on patient outcomes and as such we have had to use data on early
nephrologist consultation as a proxy, with substantial uncertainty around the impact and cost of this
intervention. All of the sensitivity and VOI analyses strongly indicate that the results are highly sensitive to
changes in these parameters. Furthermore, we do not know what impact this early intervention would have
on FP cases. It is also unclear if any management changes will result from a negative test result. In the
base-case analysis we assumed no impact for FP or for all negative test results; however, it is completely
reasonable to assume that this may not be the case. For example, FP results may result in harm because of
delayed access to necessary treatments, whereas negative results may result in cost savings because of
reduced monitoring costs and FN results may result in harm because of that same reduced monitoring.
Again, the sensitivity analyses indicate that uncertainty in the impact of early intervention would have a
significant impact. More information on all of these factors is needed if we want to make an informed
adoption decision. In the face of emerging pharmaceutical treatments, further analysis could use the
AKI-Diagnostics model to evaluate the potential cost-effectiveness of new drugs for AKI in light of
hypothesised treatment effect sizes.
Uncertainty around the incidence and movement of patients between AKI stages in the model is another
key driver of uncertainty. Our decision to model the transition of patients between AKI stages on a daily
basis is data intensive, but we consider this level of detail to be necessary because of the importance of
this time period in the natural history of AKI in a critical care setting. At the time of analysis, data from
only 60 patients were available from the AKI registry. As time passes, a greater number of data will
become available from the AKI registry and should help resolve much of this uncertainty.
A number of future research recommendations may build on or expand the work of the AKI-Diagnostics
project. These include (1) a repeat meta-analysis excluding studies at high risk of bias and (2) testing the
reliability and validity of the framework for assessing the quality of analytical validity studies.
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We propose that biomarkers will help us stratify the many different types of AKI and better understand the
underlying pathophysiology. A better understanding of the pathophysiology and the identification of the
progression of functional AKI, in which there is no tubular damage, to tubular damage will further our
ability to target therapies appropriately. We propose that we already have the capacity to introduce care
pathways for patients with AKI and that some of the significant issues that we experience with this patient
group relate to the delay in recognition of the condition. With regard to elevated creatinine values, some
of this delay is associated with the transfer of data from the laboratory to the practitioner. However, even
if the time delay associated with this pathway was reduced to a minimum the serum creatinine level would
still represent a delayed marker that does not distinguish between functional AKI and damage AKI and
does not indicate the severity of the damage. The early recognition by a biomarker of damage occurring in
the kidney will trigger a clinical review for signs of sepsis, the avoidance of toxins, for example intravenous
iodinated contrast and non-steroidal anti-inflammatory drugs, and a more robust response in terms of
volume assessment, fluid replacement and consideration for the use of vasopressors. This would represent
a personalised approach to a patient identified as developing AKI and it would be anticipated that this
would reduce the injury and the chances of progression from early injury to more severe injury, with the
associated increased risks of morbidity and mortality. Looking to the future it is hoped that, through the
identification of new biomarkers that are able to distinguish tubular injury in the kidneys from functional
AKI without kidney injury having yet occurred, therapies could be studied that target the underlying
pathophysiological processes.
It may be considered that there will be no immediate added value to clinical practice from the AKI-Diagnostics
project; however, this project has provided a comprehensive overview of work that has already been performed
on biomarkers and, importantly, what work needs to be carried out going forward for them to be of clinical
utility. There is a great deal of literature on these biomarkers and there is much confusion about their applicability
in the NHS and outside in the global health-care community. This report has provided a summary of what is
currently understood about the clinical utility of three high-profile biomarkers. We are regularly asked by clinical
colleagues if and how we should utilise biomarkers in the critical care unit. We think that this report urges
caution in investing in new biomarkers until the correct studies have been carried out that link the use of a
particular biomarker with a clinical care pathway, so that its effect on patient outcomes through a plausible
mechanism of clinical impact can be investigated.
Going forward, the development of a fit-for-purpose economic decision model in the AKI-Diagnostics
project has provided a platform for the DECs and the NIHR to further develop a UK research strategy in
this area. With relatively little funding, extra tests or biomarkers could be reviewed and evaluated in the
economic model. It would also be possible to investigate tests used in settings beyond the immediate
admission period to look at risk stratification or sequential monitoring. It is entirely possible that companies
or academic institutions that wish to further evaluate in-development tests may take advantage of the
opportunity presented by building on the work of the AKI-Diagnostics project or it may be that NICE or
other national decision-makers wish to fund the evaluation of tests when they emerge from their
respective pipelines.
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Appendix 1 AKI-Diagnostics search strategies:
search 1 – horizon scanning
ClinicalTrials.gov (via the US National Institutes of Health)
Searched 29 September 2014.
1. biomarker* or marker* | acute kidney injury (89)
2. identify | acute kidney injury (20)
3. diagnose | acute kidney injury (70)
4. prognosis | acute kidney injury (15)
5. detect | acute kidney injury OR acute renal injury (15)
6. predict | acute kidney injury OR acute renal injury (27)
7. monitor | acute kidney injury OR acute renal injury (2)
8. stratify | acute kidney injury OR acute renal injury (2)
9. accuracy | acute kidney injury OR acute renal injury (12)
10. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9
Cochrane Central Register of Controlled Trials (via Wiley Online Library)
(Issue 9 of 12, September 2014)
Searched 29 September 2014.
Search strategy
#1 Biomarker* or ‘bio* marker*’ or test or tests or factor or diagnostic*:ti,ab,kw (Word variations have
been searched)
#2 MeSH descriptor: [Biological Markers] explode all trees
#3 MeSH descriptor: [Acute Kidney Injury] explode all trees and with qualifier(s): [Diagnosis - DI]
#4 MeSH descriptor: [Acute-Phase Proteins] explode all trees and with qualifier(s): [Diagnostic use - DU]
#5 MeSH descriptor: [Insulin-Like Growth Factor Binding Proteins] explode all trees and with qualifier(s):
[Diagnostic use - DU]
#6 (NGAL or ‘Neutrophil gelatinase-associated lipocalin’ or ‘lipocalin 2’ or lcn2 or ‘TIMP-2’ or ‘TIMP 2’ or
‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-2’ or KIM-1 or TIMD1 or ‘TIM-1’ or
‘Hepatitis A virus cellular receptor 1’ or ‘kidney injury molecule 1’ or Cystatin C or ‘Cystatin C’ or L-FABP or
(Liver near/2 ‘Fatty acid-binding protein’) or ‘IL-18’ or ‘IL 18’ or Interleukin-18 or ‘Interleukin 18’ or MIOX
or ‘myo-inositol oxygenase’ or NTN1 or ‘netrin-1’ or IGFBP7 or IBP-7 or ‘IGF-binding protein 7’ or ‘Insulin-
like growth factor-binding protein 7’ or potassium or Creat or Crea or creatinine or ‘T Prot’ or ‘Total
Protein’ or ‘Acute-Phase Protein*’ or Alb or Albumin or BUN or ‘Blood Urea Nitrogen’ or AAP or ‘AP-N’ or
hAPN or AP-M or ‘EC=3.4.11.2’ or ‘microsomal aminopeptidase’ or ‘Alanine aminopeptidase’ or ‘ALP-1’ or
GCAP or ‘PLAP-like’ or ‘Alkaline phosphatase’ or ‘Alkaline phosphatase’ or ‘placental-like’ or GST or
‘glutathione transferase’ or ‘glutathione-S-transferase’ or ‘Glutathione S-transferase A2’ or ‘EC = 2.5.1.18’
or ‘GGT 5’ or GGT5 or ‘gamma glutamyltransferase’ or ‘gamma glutamyl transferase’ or ‘glutamyl
transpeptidase’ or (‘N-acetyl’ near/2 glucosaminidase) or ‘n acetylglucosaminyltransferase’ or ‘n
acetylglucosamine’ or ‘histone acetyltransferase’ or ‘Bifunctional protein*’ or ncoat* or NAG or OGA or
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microglobulin or AMBP or ‘retinol binding protein 4’ or ‘plasma retinol binding protein’ or microalbumin or
clusterin or ‘Apo-J’ or ‘TRPM-2’ or ‘Cysteine-rich protein’ or ‘Cysteine-rich motor neuron 1 protein’ or
‘CYR-61’ or ‘CRIM-1’ or ‘SPP-1’ or Osteopontin or NHE3 or NHE or ‘exchanger 9B2’ or ‘exchanger isoform’
or ‘proton sodium exchange’ or ‘sodium proton exchange protein 3’ or ‘Alpha-2-HS-glycoprotein’ or
‘fetuin A’ or Klotho or CALB1 or calbindin or ‘h-FABP’ or MDGI or ‘M-FABP’ or ‘Fatty acid-binding protein’
or renin or ‘ec=3.4.23.15’):ti,ab,kw
#7 {or #1-#6}
#8 MeSH descriptor: [Acute Kidney Injury] explode all trees
#9 MeSH descriptor: [Kidney Tubular Necrosis, Acute] explode all trees
#10 MeSH descriptor: [Acute Disease] explode all trees
#11 MeSH descriptor: [Kidney Diseases] explode all trees
#12 #10 and #11
#13 (Acute near/3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)):ti,ab,kw (Word
variations have been searched)
#14 (Acute near/3 (renal disease* or renal injury or renal failure or renal dysfunction)):ti,ab,kw
#15 ((Acute near/3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’):ti,ab,kw
#16 (AKI):ti,ab,kw
#17 (‘contrast induced nephropathy’):ti,ab,kw
#18 (renal or kidney* or nephr*):ti,ab,kw or {or #8-#17}
#19 (reperfusion near/5 (injur* or isch?emi*)):ti,ab,kw
#20 MeSH descriptor: [Reperfusion Injury] explode all trees
#21 (‘delayed graft function*’):ti,ab,kw
#22 MeSH descriptor: [Delayed Graft Function] explode all trees
#23 {or #19-#22} and #18
#24 #23 or {or #8-#17} Publication Year from 2004 to 2014
#25 Sera or Serum or Serologic* or urine or urinary:ti (Word variations have been searched)
#26 sample* or specimen*:ti,ab,kw (Word variations have been searched)
#27 MeSH descriptor: [Analytic Sample Preparation Methods] explode all trees
#28 MeSH descriptor: [Blood Specimen Collection] explode all trees
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#29 MeSH descriptor: [Urine Specimen Collection] explode all trees
#30 MeSH descriptor: [Specimen Handling] explode all trees
#31 plasma or blood or urine or urinary:ti,ab,kw (Word variations have been searched)
#32 MeSH descriptor: [Blood] explode all trees
#33 MeSH descriptor: [Blood] this term only
#34 MeSH descriptor: [Plasma] explode all trees
#35 MeSH descriptor: [Serum] explode all trees
#36 MeSH descriptor: [Urine] this term only
#37 ({or #31-#36} and {or #26-#30}) or #25
#38 MeSH descriptor: [Acute Kidney Injury] explode all trees and with qualifier(s): [Blood - BL, Urine - UR]
#39 MeSH descriptor: [Kidney Tubular Necrosis, Acute] explode all trees and with qualifier(s): [Blood - BL,
Urine - UR]
#40 Any MeSH descriptor with qualifier(s): [Blood - BL, Urine - UR]
#41 #23 and #40
#42 {or #37-#39} or #41
#43 #42 and #24
#44 MeSH descriptor: [Biological Markers] explode all trees
#45 (discriminat* or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict* or
subclinical or detect* or monitor* or stratif* or accura* or marker* or biomarker* or sensitivity):ti,ab,kw
(Word variations have been searched)
#46 {or #44-#45} and #43
#47 MeSH descriptor: [Animals] explode all trees
#48 MeSH descriptor: [Veterinary Medicine] explode all trees
#49 MeSH descriptor: [Animal Experimentation] explode all trees
#50 MeSH descriptor: [Humans] explode all trees
#51 {or #47-#49} not #50
#52 #7 and #46
#53 #52 not #51
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Cochrane Database of Systematic Reviews (via Wiley Online Library)
(Issue 9 of 12, September 2014)
Searched 29 September 2014.
Same search as for Cochrane Central Register of Controlled Trials.
Conference Proceedings Citation Index – Science (via Thomson Reuters’
Web of Science) (2008–present)
Searched 29 September 2014.
Search strategy
1. TS=(‘acute kidney injury’ or AKI) OR TS=((Acute NEAR/3 (‘kidney disease*’ or ‘kidney injury’ or ‘kidney
failure’ or ‘kidney dysfunction’))) OR TS=((Acute NEAR/3 (‘renal disease*’ or ‘renal injury’ or ‘renal
failure’ or ‘renal dysfunction’))) OR TS=(((Acute NEAR/3 (‘Tubular Necrosis’ or nephrotoxic*)) or
‘nephrotoxic injur*’)) OR TS=(‘contrast induced nephropath*’) OR TS=((reperfusion NEAR/5 (injur* or
isch?emi*)) AND (renal or kidney* or nephr*)) OR TS=((‘Delayed Graft Function’) AND (renal or
kidney* or nephr*))
2. TI=((Sera or Serum or Serologic* or urine or urinary)) OR TS=((sample* or specimen*) AND (plasma or
blood or urine or urinary or serum or sera or serologic)) OR TS=(Urinalysis)
3. #2 AND #1
4. TS=(discriminat* or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict*
or subclinical or detect* or monitor* or stratif* or accura* or marker* or biomarker* or sensitivity).
5. TS=(NGAL or ‘Neutrophil gelatinase-associated lipocalin’ or ‘lipocalin 2’ or lcn2 or ‘TIMP-2’ or ‘TIMP 2’
or ‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-2’ or KIM-1 or TIMD1 or
‘TIM-1’ or ‘Hepatitis A virus cellular receptor 1’ or ‘kidney injury molecule 1’ or Cystatin C or ‘Cystatin
C’ or L-FABP or (Liver NEAR/2 ‘Fatty acid-binding protein’) or ‘IL-18’ or ‘IL 18’ or Interleukin-18 or
‘Interleukin 18’ or MIOX or ‘myo-inositol oxygenase’ or NTN1 or ‘netrin-1’ or IGFBP7 or IBP-7 or ‘IGF-
binding protein 7’ or ‘Insulin-like growth factor-binding protein 7’ or potassium or Creat or Crea or
creatinine or ‘T Prot’ or ‘Total Protein’ or ‘Acute-Phase Protein*’ or Alb or Albumin or BUN or ‘Blood
Urea Nitrogen’ or AAP or ‘AP-N’ or hAPN or AP-M or ‘EC=3.4.11.2’ or ‘microsomal aminopeptidase’
or ‘Alanine aminopeptidase’ or ‘ALP-1’ or GCAP or ‘PLAP-like’ or ‘Alkaline phosphatase’ or ‘Alkaline
phosphatase’ or ‘placental-like’ or GST or ‘glutathione transferase’ or ‘glutathione-S-transferase’ or
‘Glutathione S-transferase A2’ or ‘EC=2.5.1.18’ or ‘GGT 5’ or GGT5 or ‘gamma glutamyltransferase’
or ‘gamma glutamyl transferase’ or ‘glutamyl transpeptidase’ or (‘N-acetyl’ NEAR/2 glucosaminidase) or
‘n acetylglucosaminyltransferase’ or ‘n acetylglucosamine’ or ‘histone acetyltransferase’ or ‘Bifunctional
protein*’ or ncoat* or NAG or OGA or microglobulin or AMBP or ‘retinol binding protein 4’ or ‘plasma
retinol binding protein’ or microalbumin or clusterin or ‘Apo-J’ or ‘TRPM-2’ or ‘Cysteine-rich protein’ or
‘Cysteine-rich motor neuron 1 protein’ or ‘CYR-61’ or ‘CRIM-1’ or ‘SPP-1’ or Osteopontin or NHE3 or
NHE or ‘exchanger 9B2’ or ‘exchanger isoform’ or ‘proton sodium exchange’ or ‘sodium proton
exchange protein 3’ or ‘Alpha-2-HS-glycoprotein’ or ‘fetuin A’ or Klotho or CALB1 or calbindin or
‘h-FABP’ or MDGI or ‘M-FABP’ or ‘Fatty acid-binding protein’ or renin or ‘ec=3.4.23.15’)
6. TS=(biomarker* or ‘bio* marker*’ or ‘marker*’) OR TS=(diagnostic or test or tests or factor)
7. #4 AND #3
8. #6 OR #5
9. #8 AND #7
10. TS= (rat or rats or swine or pigs or pig or mice or mouse) NOT TS=(human* or patient* or neonate*
or child*or woman or women or men or man or adolescen*)
11. #9 NOT #10
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12. TITLE: (((‘case stud*’ or ‘a case of’ or ‘case report*’ or ‘in a patient’ or girl or woman or man or boy or
child or female or male or ‘a patient of’) not ‘case control’))
13. #11 NOT #12
Database of Abstracts of Reviews of Effect (via Wiley Online Library)
(Issue 3 of 4, July 2014)
Searched 29 September 2014.
Same search as for Cochrane Central Register of Controlled Trials.
EMBASE Classic + EMBASE (via Ovid) (1947 to 25 September 2014)
Searched 26 September 2014.
Search strategy
1. exp *acute kidney failure/ (25,170)
2. exp *kidney tubule necrosis/ (1745)
3. exp acute disease/ and exp *kidney disease/ (2964)
4. exp *kidney injury/ (9663)
5. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (11,879)
6. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (30,030)
7. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (4742)
8. aki.tw. (6336)
9. ‘contrast induced nephropathy’.tw. (1830)
10. exp *contrast induced nephropathy/ (1310)
11. exp *reperfusion injury/ (20,312)
12. (reperfusion adj5 (injur* or isch?emi*)).tw. (53,348)
13. exp *delayed graft function/ or ‘delayed graft function*’.tw. (3768)
14. ((renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. or (or/1-10)) and (11 or 12 or 13) (9795)
15. or/1-10,14 (70,674)
16. limit 15 to yr=‘2004 -Current’ (37,141)
17. (Sera or Serum or Serologic* or urine or urinary).ti. (492,367)
18. (sample* or specimen*).tw. (1,773,754)
19. (Sera or Serum or Serologic*).tw. (1,231,104)
20. plasma.tw. (883,935)
21. blood.tw. (1,964,937)
22. (Urine or Urinary).tw. (527,090)
23. exp blood/ (2,032,361)
24. exp plasma/ (150,511)
25. exp serum/ (238,704)
26. exp urine/ (175,881)
27. (18 and (or/19-26)) or 17 (971,361)
28. exp blood analysis/ (120,308)
29. exp urinalysis/ (73,802)
30. 27 or 28 or 29 [ serum blood urine sample or analysis ] (1,096,197)
31. (NGAL or ‘Neutrophil gelatinase-associated lipocalin’ or ‘lipocalin 2’ or lcn2).tw. (3221)
32. exp neutrophil gelatinase associated lipocalin/ (3536)
33. (TIMP-2 or ‘TIMP 2’ or ‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-2’).tw. (4071)
34. exp ‘tissue inhibitor of metalloproteinase 2’/ (4696)
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35. exp kidney injury molecule 1/ [ used for tim-1 / kim 1 ] (1011)
36. (KIM-1 or TIMD1 or TIM-1 or ‘Hepatitis A virus cellular receptor 1’).tw. (965)
37. (Cystatin C or ‘Cystatin C’).tw. (4931)
38. exp cystatin C/ (6100)
39. (L-FABP or (Liver adj2 ‘Fatty acid-binding protein’)).tw. (962)
40. exp fatty acid binding protein/ (5723)
41. (IL-18 or ‘IL 18’ or Interleukin-18 or ‘Interleukin 18’).tw. (7934)
42. exp interleukin 18/ (9525)
43. (MIOX or ‘myo-inositol oxygenase’).tw. (75)
44. exp inositol oxygenase/ (74)
45. (NTN1 or netrin-1).tw. (717)
46. exp netrin 1/ (743)
47. (IGFBP7 or IBP-7 or ‘IGF-binding protein 7’ or ‘Insulin-like growth factor-binding protein 7’).tw. (274)
48. exp somatomedin binding protein/ [ synonym for Insulin-Like Growth Factor Binding Proteins?] (5151)
49. exp potassium/ or exp potassium blood level/ (111,615)
50. potassium.tw. (144,039)
51. exp creatinine blood level/ or exp creatinine urine level/ or exp creatinine/ [11] (127,699)
52. (Creat or Crea or creatinine).tw. (116,882)
53. (‘T Prot’ or ‘Total Protein’).tw. (29,574)
54. exp protein/ [12] (408,671)
55. (Alb or Albumin).tw. (156,441)
56. exp serum albumin/ or exp albumin blood level/ or exp human albumin/ or exp albumin/ or exp
human serum albumin/ (124,522)
57. exp acute phase protein/ [ broader than albumin and includes more such as retinol binding protein] (7283)
58. exp urea nitrogen blood level/ (21,193)
59. (BUN or Blood Urea Nitrogen).tw. (15,003)
60. (AAP or AP-N or hAPN orAP-M or ‘EC=3.4.11.2’ or ‘Alanine aminopeptidase’).tw. (3381)
61. exp microsomal aminopeptidase/ [Alanine aminopeptidase] (4941)
62. (ALP-1 or GCAP or PLAP-like or Alkaline phosphatase or Alkaline phosphatase or placental-like).tw. (72,967)
63. exp alkaline phosphatase/ [17 emtree only] (84,260)
64. (GST or glutathione-S-transferase or ‘Glutathione S-transferase A2’ or ‘EC=2.5.1.18’).tw. [18] (32,592)
65. exp glutathione transferase/ (30,078)
66. exp gamma glutamyltransferase/ or exp gamma glutamyl transferase blood level/ [20] (22,684)
67. (‘GGT 5’ or GGT5 or ‘gamma glutamyltransferase 5’ or ‘glutamyl transpeptidase’).tw. (5744)
68. ((‘N-acetyl’ adj2 glucosaminidase) or ‘Bifunctional protein*’ or ncoat* or NAG or OGA).tw. (6637)
69. exp acetylglucosaminidase/ [21] (2190)
70. ‘glucosaminidase’.tw. (5217)
71. exp n acetylglucosaminyltransferase/ or exp n acetylglucosamine/ or exp histone acetyltransferase/ (12,481)
72. exp beta 2 microglobulin/ [22] (13,632)
73. (microglobulin or AMBP).tw. (14,268)
74. exp alpha 1 microglobulin/ [23] (1314)
75. exp retinol binding protein/ [24] (3435)
76. ‘retinol binding protein 4’.tw. (800)
77. microalbumin.tw. [25] (974)
78. exp microalbuminuria/ (12,250)
79. (clusterin or ‘Apo-J’ or ‘TRPM-2’).tw. or exp clusterin/ (3246)
80. (‘CYR-61’ or ‘CRIM-1’ or ‘Cysteine-rich protein’ or ‘Cysteine-rich motor neuron 1 protein’).tw. or exp
cysteine rich protein 61/ [27] (1377)
81. (‘SPP-1’ or Osteopontin).tw. or exp osteopontin/ (10,784)
82. (NHE3 or NHE or ‘exchanger 9B2’ or ‘exchanger isoform’).tw. or exp proton sodium exchange/ or exp
sodium proton exchange protein 3/ [29] (6082)
83. ‘Alpha-2-HS-glycoprotein’.tw. or exp fetuin A/ (1182)
84. Klotho.tw. or exp Klotho protein/ (1512)
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85. exp calbindin 1/ or exp calbindin/ or (CALB1 or calbindin).tw. [32] (5621)
86. exp fatty acid binding protein/ or (h-FABP or MDGI or M-FABP or ‘Fatty acid-binding protein’).tw.
[33] (7116)
87. (renin or ‘ec=3.4.23.15’).tw. [34] (54,978)
88. exp kidney injury/di [Diagnosis] (1567)
89. exp acute kidney failure/di [Diagnosis] (3599)
90. (biomarker* or ‘bio* marker*’ or marker*).tw. (770,398)
91. diagnostic*.tw. (718,123)
92. factor.tw. (1,463,890)
93. (test or tests).tw. (1,841,173)
94. exp biological marker/ (131,802)
95. or/31-94 [ specific biomarkers SHs, txtwords, and biomarker general terms ] (5,223,158)
96. exp biological marker/ (131,802)
97. (discriminat* or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict*
or subclinical or detect* or monitor* or stratif* or accura* or marker* or biomarker* or
sensitivity).tw. (10,694,092)
98. 96 or 97 [ detect filter ] (10,708,959)
99. (exp animals/ or exp nonhuman/ or animal experiment/ or exp veterinary medicine/ or exp
experimental animal/) not exp human/ (5,908,462)
100. (16 and 30 and 95 and 98) not 99 (2664)
101. 100 not ((‘case stud*’ or ‘a case of’ or ‘case report*’ or ‘in a patient’ or girl or woman or man or boy
or child or female or male or ‘a patient of’) not ‘case control’).ti. (2502)
International Clinical Trials Registry Platform (via the World
Health Organization)
Searched 29 September 2014.
Search strategy
1. (acute kidney injury OR AKI) AND biomarker* [standard search] (282 results)
2. (acute kidney injury OR AKI OR Acute renal failure) AND (identif* OR recogni* OR diagnos* OR indicat*
OR correlat* OR prognosis OR predict* OR subclinical OR detect* OR monitor* OR stratif* OR accuracy
OR sensitivity) [Advanced search] (49 results)
MEDLINE (via Ovid) (1946 to week 3 September 2014)
Searched 26 September 2014.
Search strategy
1. acute kidney injury/ or kidney tubular necrosis, acute/ (34,230)
2. Acute Disease/ and exp Kidney Diseases/ (7675)
3. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (6635)
4. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (21,345)
5. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3418)
6. aki.tw. (3076)
7. ‘contrast induced nephropathy’.tw. (944)
8. (reperfusion adj5 (injur* or isch?emi*)).tw. or reperfusion injury/ or reperfusion/ (46,033)
9. exp Delayed Graft Function/ or ‘delayed graft function*’.tw. (2299)
10. ((renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. or (or/1-7)) and (8 or 9) (7053)
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11. or/1-7,10 [AKI] (56,812)
12. limit 11 to yr=‘2004 -Current’ (22,491)
13. (Sera or Serum or Serologic* or urine or urinary).ti. (366,534)
14. (sample* or specimen*).tw. (1,272,203)
15. exp Analytic Sample Preparation Methods/ or exp Blood Specimen Collection/ or exp Urine Specimen
Collection/ or exp Specimen Handling/ or exp Specimen Handling/ (281,322)
16. (Sera or Serum or Serologic*).tw. (877,395)
17. plasma.tw. (675,552)
18. blood.tw. (1,343,744)
19. (Urine or Urinary).tw. (352,430)
20. blood/ (48,286)
21. exp plasma/ (16,374)
22. exp serum/ (61,384)
23. urine/ (33,925)
24. or/14-23 [ broadest search ] (3,896,894)
25. ((or/16-23) and (or/14-15)) or 13 [refined search] (702,912)
26. exp Acute Kidney Injury/bl, ur or kidney tubular necrosis, acute/bl, ur (2902)
27. (bl or ur).fs. and (10 or 9) (1624)
28. exp Urinalysis/ (4768)
29. or/25-28 [refined search OR subheading bl ur] (708,078)
30. biomarker*.tw. (87,588)
31. ‘bio* marker*’.tw. (18,195)
32. exp Biological Markers/ (646,975)
33. marker*.tw. (480,182)
34. diagnostic*.tw. (479,993)
35. factor.tw. (1,110,955)
36. (test or tests).tw. (1227167)
37. exp Acute Kidney Injury/di [Diagnosis] (3604)
38. Acute-Phase Proteins/du [Diagnostic Use] (19)
39. Insulin-Like Growth Factor Binding Proteins/du (3)
40. (NGAL or ‘Neutrophil gelatinase-associated lipocalin’ or ‘lipocalin 2’ or lcn2).tw. (1694)
41. (TIMP-2 or ‘TIMP 2’ or ‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-
2’).tw. (3387)
42. (KIM-1 or TIMD1 or TIM-1 or ‘Hepatitis A virus cellular receptor 1’ or ‘kidney injury molecule
1’).tw. (670)
43. (Cystatin C or ‘Cystatin C’).tw. (3195)
44. (L-FABP or (Liver adj2 ‘Fatty acid-binding protein’)).tw. (769)
45. (IL-18 or ‘IL 18’ or Interleukin-18 or ‘Interleukin 18’).tw. (5940)
46. (MIOX or ‘myo-inositol oxygenase’).tw. (61)
47. (NTN1 or netrin-1).tw. (575)
48. (IGFBP7 or IBP-7 or ‘IGF-binding protein 7’ or ‘Insulin-like growth factor-binding protein 7’).tw. (170)
49. potassium.tw. or exp Potassium/ (160,692)
50. (Creat or Crea or creatinine).tw. (75,931)
51. (‘T Prot’ or ‘Total Protein’).tw. (20,553)
52. (Alb or Albumin).tw. (109,497)
53. (BUN or Blood Urea Nitrogen).tw. (9374)
54. (AAP or AP-N or hAPN orAP-M or ‘EC=3.4.11.2’ or ‘Alanine aminopeptidase’).tw. (2431)
55. (ALP-1 or GCAP or PLAP-like or Alkaline phosphatase or Alkaline phosphatase or placental-
like).tw. (52,614)
56. (GST or glutathione-S-transferase or ‘Glutathione S-transferase A2’ or ‘EC=2.5.1.18’).tw. (27,618)
57. ((‘N-acetyl’ adj2 glucosaminidase) or ‘Bifunctional protein*’ or ncoat* or NAG or OGA).tw. (5209)
58. ((alpha* adj2 microglobulin) or AMBP).tw. (1206)
59. clusterin.tw. (1491)
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60. (‘Apo-J’ or ‘TRPM-2’).tw. (185)
61. (‘Cysteine-rich protein’ or ‘Cysteine-rich motor neuron 1 protein’).tw. (640)
62. (‘CYR-61’ or ‘CRIM-1’).tw. (17)
63. (SPP-1 or Osteopontin).tw. (6369)
64. (NHE3 or NHE or ‘exchanger 9B2’ or ‘exchanger isoform’).tw. (2922)
65. ‘Alpha-2-HS-glycoprotein’.tw. (231)
66. Klotho.tw. (832)
67. (CALB1 or calbindin).tw. (4203)
68. (h-FABP or MDGI or M-FABP or ‘Fatty acid-binding protein’).tw. (3785)
69. (renin or ‘ec=3.4.23.15’).tw. (42,939)
70. or/30-69 [additional biomarkers] (3,740,487)
71. (exp animals/ or exp Veterinary Medicine/ or exp Animal Experimentation/) not exp
humans/ (4,020,113)
72. (discriminat* or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict*
or subclinical or detect* or monitor* or stratif* or accura* or marker* or biomarker* or
sensitivity).tw. (7,855,298)
73. exp Biological Markers/ (646,975)
74. 72 or 73 [predict / diagnose filter] (8,047,219)
75. 12 and 29 and 70 and 74 [ all concepts] (2309)
76. 75 not 71 [ not animal studies ] (1830)
77. limit 76 to case reports (159)
78. 76 not 77 [not case studies] (1671)
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
(25 September 2014)
Searched 26 September 2014.
Search strategy
1. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (1403)
2. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (1002)
3. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (144)
4. aki.tw. (741)
5. ‘contrast induced nephropathy’.tw. (144)
6. ((reperfusion adj5 (injur* or isch?emi*)) or ‘delayed graft function*’).tw. (2530)
7. (renal or kidney* or nephr*).tw. or (or/1-5) (36,995)
8. 6 and 7 (476)
9. or/1-5,8 [AKI] (2887)
10. limit 9 to yr=‘2004 -Current’ (2719)
11. (sample* or specimen*).tw. (139,336)
12. (Sera or Serum or Serologic*).tw. (45,535)
13. plasma.tw. (39,175)
14. blood.tw. (74,094)
15. (Urine or Urinary).tw. (18,581)
16. (or/11-15) or biomarker*.tw. [ broadest search, also biomarker*.tw added ] (272,537)
17. biomarker*.tw. (15,361)
18. ‘bio* marker*’.tw. (1368)
19. marker*.tw. (38,812)
20. diagnostic*.tw. (39,369)
21. factor.tw. (85,140)
22. (test or tests).tw. (109,362)
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23. (NGAL or ‘Neutrophil gelatinase-associated lipocalin’ or ‘lipocalin 2’ or lcn2).tw. (330)
24. (TIMP-2 or ‘TIMP 2’ or ‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-
2’).tw. (172)
25. (KIM-1 or TIMD1 or TIM-1 or ‘Hepatitis A virus cellular receptor 1’ or ‘kidney injury molecule
1’).tw. (115)
26. (Cystatin C or ‘Cystatin C’).tw. (363)
27. (L-FABP or (Liver adj2 ‘Fatty acid-binding protein’)).tw. (53)
28. (IL-18 or ‘IL 18’ or Interleukin-18 or ‘Interleukin 18’).tw. (417)
29. (MIOX or ‘myo-inositol oxygenase’).tw. (4)
30. (NTN1 or netrin-1).tw. (48)
31. (IGFBP7 or IBP-7 or ‘IGF-binding protein 7’ or ‘Insulin-like growth factor-binding protein 7’).tw. (32)
32. potassium.tw. (8454)
33. (Creat or Crea or creatinine).tw. (5047)
34. (‘T Prot’ or ‘Total Protein’).tw. (1430)
35. (Alb or Albumin).tw. (6036)
36. (BUN or Blood Urea Nitrogen).tw. (818)
37. (AAP or AP-N or hAPN orAP-M or ‘EC=3.4.11.2’ or ‘Alanine aminopeptidase’).tw. (173)
38. (ALP-1 or GCAP or PLAP-like or Alkaline phosphatase or Alkaline phosphatase or placental-
like).tw. (2787)
39. (GST or glutathione-S-transferase or ‘Glutathione S-transferase A2’ or ‘EC=2.5.1.18’).tw. (1498)
40. (‘GGT 5’ or GGT5 or (‘gamma glutamyltransferase 5’ or ‘glutamyl transpeptidase’)).tw. (205)
41. ((‘N-acetyl’ adj2 glucosaminidase) or ‘Bifunctional protein*’ or ncoat* or NAG or OGA).tw. (229)
42. (microglobulin or AMBP).tw. (329)
43. (‘retinol binding protein 4’ or ‘plasma retinol binding protein’).tw. (93)
44. microalbumin.tw. (55)
45. clusterin.tw. (105)
46. (‘Apo-J’ or ‘TRPM-2’).tw. (5)
47. (‘Cysteine-rich protein’ or ‘Cysteine-rich motor neuron 1 protein’).tw. (34)
48. (‘CYR-61’ or ‘CRIM-1’).tw. (1)
49. (SPP-1 or Osteopontin).tw. (516)
50. (NHE3 or NHE or ‘exchanger 9B2’ or ‘exchanger isoform’).tw. (164)
51. ‘Alpha-2-HS-glycoprotein’.tw. (10)
52. Klotho.tw. (117)
53. (CALB1 or calbindin).tw. (146)
54. (h-FABP or MDGI or M-FABP or ‘Fatty acid-binding protein’).tw. (301)
55. (renin or ‘ec=3.4.23.15’).tw. (1387)
56. or/17-55 [biomarkers] (273,001)
57. (discriminat* or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict*
or subclinical or detect* or monitor* or stratif* or accura* or marker* or biomarker* or
sensitivity).tw. (725,049)
58. 10 and 16 and 56 and 57 (704)
59. ((rat or rats or swine or pigs or pig or mice or mouse) not (human* or patient*)).tw. (63,154)
60. ((‘case stud*’ or ‘a case of’ or ‘case report*’ or ‘in a patient’ or girl or woman or man or boy or child
or female or male or ‘a patient of’) not ‘case control’).ti. (57,135)
61. 58 not (59 or 60) (578)
62. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction) adj3 (discriminat*
or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict* or subclinical or
detect* or monitor* or stratif*)).ti. (68)
63. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction) adj3 (discriminat* or
identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or predict* or subclinical or
detect* or monitor* or stratif*)).ti. (6)
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64. (((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’) adj3 (discriminat* or identif*
or recogni* or diagnos* or indicat* or correlat* or prognos* or predict* or subclinical or detect* or
monitor* or stratif*)).ti. (0)
65. (aki adj3 (discriminat* or identif* or recogni* or diagnos* or indicat* or correlat* or prognos* or
predict* or subclinical or detect* or monitor* or stratif*)).ti. (6)
66. (or/62-65) not (59 or 60) (77)
67. 66 not 61 (25)
68. 61 or 67 (603)
metaRegister of Controlled Trials (mRCT)
Searched 29 September 2014.
Search strategy
1. ‘Acute kidney’ (161)
2. ‘acute renal’ AND biomarker (6)
3. ‘acute renal’ AND detect (10)
4. 1 OR 2 OR 3
PubMed (via the US National Library of Medicine) (1946 to September 2014)
Searched 29 September 2014.
Search strategy
1. #1 (((‘acute kidney[Title] OR ‘acute renal’[Title] OR ‘acute tubular necrosis’[Title] OR ‘aki’[Title] OR
‘delayed graft function’[Title] OR ‘reperfusion injur*’[Title]))) (17,542)
2. #2 ((discriminat*[Title] OR identif*[Title] OR recogni*[Title] OR diagnos*[Title] OR indicat*[Title] OR
correlate*[Title] OR prognot*[Title] OR predict*[Title] OR subclinical[Title] OR detect*[Title] OR monitor*
[Title] OR stratif*[Title] OR accura*[Title] OR marker*[Title] OR biomarker*[Title] OR sensitivity
[Title])) (1,769,745)
3. #3 ((pubstatusaheadofprint[sb] OR publisher[sb] OR pubmednotmedline[sb])) (1,826,775)
4. #4 #1 AND #2 AND #3 (111)
Science Citation Index (via Thomson Reuters’ Web of Science)
(2008 to present)
Searched 29 September 2014.
Same search as for Conference Proceedings Citation Index – Science.
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Appendix 2 AKI-Diagnostics horizon-scanning
biomarker longlist
Biomarker Number of papers Timescale
NGAL 241 2005–14
Cystatin C 115 2004–14
IL-18 73 2005–14
KIM-1 72 2006–14
L-FABP 39 2006–14
NAG 37 2004–14
B2M 16 2006–14
IL-6 11 2007–14
α1-microglobulin 10 2005–14
GST 8 2010–13
IGFBP-7 (Nephrocheck) 8 2013–14
FENa 7 2005–14
BNP 7 2012–14
TIMP-2 (Nephrocheck) 6 2013–14
TNF-α 6 2012–14
CRP 5 2013–14
FEUrea 5 2006–14
GGT 5 2006–13
IL-10 4 2009–14
Procalcitonin 4 2009–14
HGF 4 2008–10
MCP-1 4 2008–13
IL-8 4 2009–12
Lactate dehydrogenase 4 2013–14
AAP 3 2012–14
AP 3 2006–14
Hepcidin 3 2011–13
H-FABP 3 2013–14
hsCRP 3 2011–14
Renin 3 2013–14
SAA 3 2011–13
ADMA 3 2012–13
Angiotensinogen 3 2013
VEGF 3 2008–14
Adiponectin 2 2013–14
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Biomarker Number of papers Timescale
α-GST 2 2013
AOPP 2 2010–12
CXCR1 2 2012–14
EPO 2 2013–14
F2-isoprostanes 2 2011–12
FB 2 2012–13
GT 2 2011–14
HDL 2 2013
LDH 2 2013–14
LVEF 2 2013
MMP-9 2 2009
Osteopontin 2 2009–10
sRAGE 2 2012–13
SUA 2 2012–13
Vitamin D 2 2012–13
vWF 2 2014
Clusterin 2 2013
EGF 2 2013
FLC 2 2013
PAI-1 2 2012
pi-GST 2 2013
Semaphorin 3A 2 2014
AGP 1 2009
ALP 1 2013
Angiopoietin-1 1 2014
Angiopoietin-2 1 2014
Apolipoprotein M 1 2014
Aprotinin 1 2008
AQP 1 1 2006
AQP 2 1 2006
ARC 1 2012
CD14 1 2009
CXCL10 1 2008
D-dimer 1 2014
Dihydroneopterin 1 2010
EA 1 2013
ELA-2 1 2014
enRAGE 1 2013
EO 1 2014
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Biomarker Number of papers Timescale
EPC 1 2014
ESAM 1 2014
E-selectin 1 2014
esRAGE 1 2012
FEK 1 2005
FEMg 1 2005
FGF 1 2009
FGF-2 1 2013
FGF-23 1 2013
FST 1 2014
GA 1 2012
Hb 1 2013
HMGB-1 1 2013
HO-1 1 2014
Hyaluronic acid 1 2014
ICAM-1 1 2014
IL-19 1 2011
Kynurenine 1 2014
LDL 1 2013
MicroRNA-21 1 2013
MIOX 1 2014
MMP-8 1 2014
Neopterin 1 2010
Netrin-1 1 2014
NT-ProBNP 1 2014
PAPP-A 1 2013
PDGF 1 2009
PGF2alpha 1 2011
PIGF 1 2013
Plasma homocysteine 1 2005
ProANP 1 2014
Pro-ENK 1 2013
RBP 1 2013
RCG-32 1 2014
s2-microglobulin 1 2013
sCD25 1 2014
SDMA 1 2012
Serum uric acid 1 2012
TGF-β1 1 2012
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Biomarker Number of papers Timescale
Thrombomodulin 1 2014
TIE-2 1 2014
TIMP-1 1 2013
TLR4 1 2012
Uric acid 1 2011
Urinary glutamyl 1 2014
Vancomycin trough 1 2013
VCAM-1 1 2014
α1-antitrypsin 1 2010
α1-GST 1 2010
AAP, alanine aminopeptidase; ADMA, asymmetric dimethylarginine; AGP, alpha-1-acid glycoprotein; ALP, alkaline phosphatase;
AOPP, advanced oxidation protein products; AP, alkaline phosphatase; AQP, aquaporin; ARC, activity-regulated cytoskeleton-
associated protein; B2M, beta-2-microglobulin; CD14, monocyte differentiation antigen CD14; CRP, C-reactive protein;
CXCL10, C-X-C motif chemokine 10; CXCR1, C-X-C chemokine receptor type 1; EA, endotoxin activity; EGF, epidermal growth
factor; ELA-2, neutrophil elastase-2; enRAGE, extracellular newly identified receptor for advanced glycation end products;
EO, endogenous ouabain; EPC, endothelial progenitor cell; EPO, erythropoietin; ESAM, endothelial cell-selective adhesion molecule;
esRAGE, endogenous secretory receptor for advanced glycation end products; FB, fluid balance; FEK, fractional excretion of
potassium; FEMg, fractional excretion of magnesium; FENa, fractional excretion of sodium; FEUrea, fractional excretion of urea;
FGF, fibroblast growth factor; FLC, free light chain; FST, furosemide stress test; GA, glycated albumin; GGT, gamma-glutamyl
transferase; GST, glutathione-S-transferase; GT, glutamyl transpeptidase; Hb, haemaglobin; HDL, high-density lipoprotein;
H-FABP, heart-type fatty acid-binding protein; HGF, hepatocyte growth factor; HMGB-1, high moblity group box 1; HO-1, heme
oxygenase-1; hsCRP, high-sensitivity C-reactive protein; ICAM-1, intercellular adhesion molecule-1; LDH, lactate dehydrogenase;
LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; MCP-1, monocyte chemoattractant protein-1; microRNA-21,
micro ribonucleic acid-21; MIOX, myo-inositol oxygenase; MMP-8, matrix metallopeptidase-8; MMP-9, matrix metallopeptidase-9;
NT-ProBNP, N-terminal pro-brain natriuretic peptide; PAI-1, plasminogen activator inhibitor 1; PAPP-A, pregnancy-associated plasma
protein A; PDGF, platelet-derived growth factor; PGF2alpha, prostaglandin F2-alpha; PIGF, placental growth factor; proANP,
pro-atrial natriuretic peptide; pro-ENK, pro-encephalin A; RBP, retinal binding protein; RCG-32, response gene to complement 32;
SAA, serum amyloid A; sCD25, soluble monocyte differentiation antigen CD25; SDMA, symmetric dimethylarginine; sRAGE, soluble
isoform of a receptor for advanced glycation end products; SUA, serum uric acid; TGF-1, transforming growth factor-beta-1;
TIE-2, tyrosine kinase with immunoglobulin-like and EGF-like domains 2; TLR4, Toll-like receptor 4; VCAM-1, vascular cell adhesion
molecule-1; vWF, von Willebrand factor.
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Appendix 3 AKI-Diagnostics sample search
strategy: search 2 – evidence for candidate tests
ClinicalTrials.gov (via the US National Institutes of Health; Advanced
Search Interface)
Searched 30 November 2015.
Search strategy
1. Search Terms: NGAL OR Lipocalin OR LCN2 OR uNGAL OR sNGAL OR siderocalin OR ‘oncogene 24p3’
OR ‘cystatin c’ OR ‘gamma trace’ OR ‘Neuroendocrine basic polypeptide’ OR ‘Post-gamma-globulin’
2. Search Terms: ‘IL 18’ OR ‘Interleukin 18’ OR ‘Iboctadekin’ OR ‘Interferon gamma-inducing factor’ OR
‘Interleukin-1 gamma’ OR KIM-1 OR TIMD1 OR TIM-1 OR ‘Hepatitis A virus cellular receptor 1’ OR
‘kidney injury molecule 1’
3. Search Terms: L-FABP OR ‘Fatty acid-binding protein 1’ OR (Liver AND Fatty acid-binding protein) OR
NAG OR ‘Bifunctional protein’ OR ncoat OR (‘N-acetyl’ AND glucosaminidase) OR OGA OR
O-GlcNAcase OR ‘Meningioma-expressed antigen 5’ OR MGEA5 OR ‘Hexosaminidase C’
4. Search Terms: ‘Interleukin 6’ OR IL-6 OR BSF-2 OR IFN-beta-2 OR ‘B-cell stimulatory factor 2’ OR ‘CTL
differentiation factor’ OR ‘Hybridoma growth factor’ OR ‘Interferon beta-2’ OR BNP OR ‘B-type
natriuretic peptide’
5. Search Terms: nephrocheck OR ‘Metalloproteinase inhibitor 2’ OR ‘tissue inhibitor of metalloproteinase-2’
OR timp-2 OR IGFBP7 OR IBP-7 OR IGFBP-rP1 OR ‘IGF-binding protein 7’ OR ‘MAC25 protein’ OR
‘PGI2-stimulating factor’ OR ‘Prostacyclin-stimulating factor’
6. Search Terms: ‘Tumor-derived adhesion factor’ OR ‘Tumour-derived adhesion factor’ OR ‘Tissue Necrosis
Factor’ OR ‘Tumor necrosis factor’ OR ‘Tumour necrosis factor’ OR ‘TNF-alpha’ OR ‘TNF-a’
7. 1 or 2 or 3 or 4 or 5 or 6
8. Conditions: Acute AND (renal OR kidney OR ‘tubular necrosis’)
9. 7 AND 8
Cochrane Central Register of Controlled Trials (via Wiley Online Library)
(Issue 10 of 12, October 2015)
Searched 30 November 2015.
Search strategy
#1 MeSH descriptor: [Acute Kidney Injury] explode all trees
#2 MeSH descriptor: [Acute Disease] explode all trees
#3 MeSH descriptor: [Kidney Diseases] explode all trees
#4 #2 and #3
#5 (Acute near/3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)):ti,ab
#6 (Acute near/3 (renal disease* or renal injury or renal failure or renal dysfunction)):ti,ab
#7 ((Acute near/3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’):ti,ab
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#8 (AKI):ti,ab
#9 (‘contrast induced nephropathy’):ti,ab
#10 {or #1, #4-#9}
#11 (renal or kidney* or nephr*):ti,ab
#12 #1 or #4
#13 #11 or #12
#14 (reperfusion near/5 (injur* or isch?emi*)):ti,ab
#15 MeSH descriptor: [Reperfusion Injury] explode all trees
#16 (‘delayed graft function*’):ti,ab
#17 MeSH descriptor: [Delayed Graft Function] explode all trees
#18 {or #14-#17} and #13
#19 #10 or #18 Publication Year from 2004 to 2014
#20 MeSH descriptor: [Lipocalins] this term only
#21 (NGAL or uNGAL or sNGAL or ‘Neutrophil gelatinase-associated lipocalin’ or ‘neutrophil gelatinase
lipocalin’ or ‘lipocalin 2’ or lcn2 or ‘Oncogene 24p3’ or siderocalin):ti,ab
#22 MeSH descriptor: [Cystatin C] this term only
#23 (‘cystatin c’ or ‘Gamma trace’ or ‘Neuroendocrine basic polypeptide’ or ‘Post-gamma-globulin’):ti,ab
#24 MeSH descriptor: [Interleukin-18] this term only
#25 (‘IL 18’ or ‘Interleukin 18’ or ‘Iboctadekin’ or ‘Interferon gamma-inducing factor’ or ‘Interleukin-1
gamma’):ti,ab
#26 (KIM-1 or TIMD1 or TIM-1 or ‘Hepatitis A virus cellular receptor 1’ or ‘kidney injury molecule 1’):ti,ab
#27 MeSH descriptor: [Fatty Acid-Binding Proteins] explode all trees
#28 (L-FABP or ‘Fatty acid-binding protein 1’ or (Liver near/2 (‘Fatty acid-binding protein’))):ti,ab
#29 MeSH descriptor: [Acetylglucosaminidase] this term only
#30 (NAG or ‘Bifunctional protein*’ or ncoat* or ((‘N-acetyl’) near/3 (glucosaminidase)) or OGA or
O-GlcNAcase or ‘Meningioma-expressed antigen 5’ or MGEA5 or ‘Hexosaminidase C’ or ‘Histone
acetyltransferase’):ti,ab
#31 MeSH descriptor: [Interleukin-6] this term only
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#32 (‘Interleukin 6’ or IL-6 or BSF-2 or IFN-beta-2 or ‘B-cell stimulatory factor 2’ or ‘CTL differentiation
factor’ or ‘Hybridoma growth factor’ or ‘Interferon beta-2’):ti,ab
#33 MeSH descriptor: [Natriuretic Peptide, Brain] this term only
#34 (‘B-type natriuretic peptide*’ or BNP):ti,ab
#35 MeSH descriptor: [Tissue Inhibitor of Metalloproteinase-2] this term only
#36 (nephrocheck or ‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-2’ or timp-2 or
IGFBP7 or IBP-7 or IGFBP-rP1 or ‘IGF-binding protein 7’ or ‘MAC25 protein’ or ‘PGI2-stimulating factor’ or
‘Prostacyclin-stimulating factor’ or ‘Tumo*r-derived adhesion factor’):ti,ab
#37 MeSH descriptor: [Tumor Necrosis Factor-alpha] explode all trees
#38 (‘Tissue Necrosis Factor’ or ‘Tumo*r necrosis factor’ or ‘TNF-alpha’ or ‘TNF-a’):ti,ab
#39 {or #20-#38}
#40 #19 and #39
#41 MeSH descriptor: [Animals] explode all trees
#42 MeSH descriptor: [Veterinary Medicine] explode all trees
#43 MeSH descriptor: [Animal Experimentation] explode all trees
#44 MeSH descriptor: [Humans] explode all trees
#45 {or #41-#43} not #44
#46 #40 not #45
Cochrane Database of Systematic Reviews (via Wiley Online Library)
(Issue 11 of 12, November 2015)
Searched 30 November 2015.
Same search as for Cochrane Central Register of Controlled Trials.
Database of Abstracts of Reviews of Effects (via Wiley Online Library)
(Issue 2 of 4, April 2015)
Searched 30 November 2015.
Same search as for Cochrane Database of Systematic Reviews.
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EMBASE Classic + EMBASE (via Ovid) (1947 to 24 November 2015)
Searched 29 November 2015.
Search strategy
1. exp *acute kidney failure/ (25,748)
2. exp *kidney tubule necrosis/ (1746)
3. exp acute disease/ and exp *kidney disease/ (2978)
4. exp *kidney injury/ (9863)
5. exp *contrast induced nephropathy/ (1397)
6. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (13,009)
7. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (30,609)
8. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (4801)
9. aki.tw. (7002)
10. ‘contrast induced nephropathy’.tw. (1935)
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (65,453)
12. exp *reperfusion injury/ (20910)
13. (reperfusion adj5 (injur* or isch?emi*)).tw. (55,051)
14. exp *delayed graft function/ (526)
15. ‘delayed graft function*’.tw. (3794)
16. or/13-15 (58,543)
17. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (1,017,273)
18. 1 or 2 or 3 or 4 or 5 or 17 (1,020,779)
19. 16 and 18 (9998)
20. 11 or 19 (72,803)
21. 11 or 19 [AKI] (72,803)
22. neutrophil gelatinase associated lipocalin/ (3844)
23. (NGAL or uNGAL or sNGAL).tw. (2362)
24. (‘Neutrophil gelatinase-associated lipocalin’ or ‘neutrophil gelatinase lipocalin’ or ‘lipocalin 2’ or
lcn2).tw,tn. (2938)
25. Oncogene 24p3.tw,tn. (5)
26. siderocalin.tw,tn. (51)
27. or/22-26 [NGAL] (4430)
28. cystatin C/ (6428)
29. cystatin c.tw. (5201)
30. Gamma trace.tw. (20)
31. Neuroendocrine basic polypeptide.tw. (0)
32. Post-gamma-globulin.tw. (7)
33. or/30-34 [Cystatin C] (6843)
34. interleukin 18/ (9916)
35. IL 18.tw. (7741)
36. Interleukin 18.tw. (2711)
37. Iboctadekin.tw. (3)
38. Interferon gamma-inducing factor.tw. (28)
39. Interleukin-1 gamma.tw. (2)
40. or/38-43 [IL-18] (12,384)
41. kidney injury molecule 1/ (1117)
42. (KIM-1 or TIMD1 or TIM-1).tw. (1045)
43. Hepatitis A virus cellular receptor 1.tw. (20)
44. kidney injury molecule 1.tw. (653)
45. ‘T-cell immunoglobulin and mucin domain-containing protein 1’.tw. (0)
46. ‘T-cell immunoglobulin mucin receptor 1’.tw. (0)
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47. ‘T-cell membrane protein 1’.tw. (0)
48. or/47-53 [KIM-1] (1689)
49. fatty acid binding protein/ (5893)
50. L-FABP.tw. (662)
51. Fatty acid-binding protein 1.tw. (42)
52. (Liver adj2 ‘Fatty acid-binding protein’).tw. (782)
53. or/58-61 [L-FABP] (6065)
54. n acetyl beta glucosaminidase/ (4605)
55. Bifunctional protein*.tw. (836)
56. ncoat*.tw. (8)
57. NAG.tw. (4070)
58. (‘N-acetyl’ adj3 glucosaminidase).tw. (4830)
59. OGA.tw. (365)
60. O-GlcNAcase.tw. (408)
61. Meningioma-expressed antigen 5.tw. (2)
62. MGEA5.tw. (34)
63. Hexosaminidase C.tw. (24)
64. ‘EC=3.2.1.169’.tw. (0)
65. ‘EC=2.3.1.48’.tw. (0)
66. Histone acetyltransferase.tw. (2444)
67. or/65-77 [NAG] (12,925)
68. interleukin 6/ (136,429)
69. Interleukin 6.tw. (40,597)
70. IL-6.tw. (94,548)
71. BSF-2.tw. (102)
72. IFN-beta-2.tw. (21)
73. B-cell stimulatory factor 2.tw. (86)
74. CTL differentiation factor.tw. (4)
75. Hybridoma growth factor.tw. (55)
76. Interferon beta-2.tw. (30)
77. or/81-89 [IL-6] (149,048)
78. brain natriuretic peptide/ (17,988)
79. B-type natriuretic peptide*.tw. (6572)
80. BNP.tw. (13,985)
81. or/93-95 [BNP] (24,772)
82. nephrocheck.tw. (2)
83. ‘tissue inhibitor of metalloproteinase 2’/ (4826)
84. Metalloproteinase inhibitor 2.tw. (15)
85. tissue inhibitor of metalloproteinase-2.tw. (609)
86. TIMP 2.tw. (3952)
87. somatomedin binding protein/ (5232)
88. (IGFBP7 or IBP-7 or IGFBP-rP1).tw. (330)
89. IGF-binding protein 7.tw. (12)
90. Insulin-like growth factor-binding protein 7.tw. (146)
91. MAC25 protein.tw. (5)
92. PGI2-stimulating factor.tw. (8)
93. Prostacyclin-stimulating factor.tw. (30)
94. or/99-110 [Nephrocheck TIMP-2 IGFBP7] (11,601)
95. tumor necrosis factor alpha/ (159,697)
96. Tissue Necrosis Factor.tw. (150)
97. Tumo?r necrosis factor.tw. (116,825)
98. TNF-alpha.tw. (103,358)
99. TNF-a.tw. (5983)
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100. Tumour necrosis factor.tw. (19,564)
101. or/116-121 [TNF-a] (227,621)
102. 27 or 35 or 44 or 54 or 62 or 78 or 90 or 96 or 111 or 122 (374,119)
103. 21 and 125 (5514)
104. limit 126 to yr=‘2004 -Current’ (4843)
105. (exp animals/ or exp nonhuman/ or animal experiment/ or exp veterinary medicine/ or exp
experimental animal/) not exp human/ (5,985,269)
106. 127 not 131 (3236)
Health Technology Assessment database (via Wiley Online Library)
(Issue 4 of 4, October 2015)
Searched 30 November 2015.
Same search as for Cochrane Database of Systematic Reviews.
Health Management Information Consortium (HMIC)
(1983 to November 2015)
Searched 30 November 2015.
Same search as for MEDLINE In-Process & Other Non-Indexed Citations (via Ovid).
International Clinical Trials Registry Platform (via the World Health
Organization, Advanced Search)
Searched 30 November 2015.
Search strategy
1. Title: NGAL OR Lipocalin OR LCN2 OR uNGAL OR sNGAL OR siderocalin OR ‘oncogene 24p3’ OR
‘cystatin c’ OR ‘gamma trace’ OR ‘Neuroendocrine basic polypeptide’ OR ‘Post-gamma-globulin’
2. Title: ‘IL 18’ OR ‘Interleukin 18’ OR ‘Iboctadekin’ OR ‘Interferon gamma-inducing factor’ OR ‘Interleukin-
1 gamma’ OR KIM-1 OR TIMD1 OR TIM-1 OR ‘Hepatitis A virus cellular receptor 1’ OR ‘kidney injury
molecule 1’
3. Title: L-FABP OR ‘Fatty acid-binding protein’ OR NAG OR ‘Bifunctional protein’ OR ncoat OR (‘N-acetyl’
AND glucosaminidase) OR O-GlcNAcase OR ‘Meningioma-expressed antigen 5’ OR MGEA5 OR
‘Hexosaminidase C’
4. Title: ‘Interleukin 6’ OR IL-6 OR BSF-2 OR IFN-beta-2 OR ‘B-cell stimulatory factor 2’ OR ‘CTL differentiation
factor’ OR ‘Hybridoma growth factor’ OR ‘Interferon beta-2’ OR BNP OR ‘B-type natriuretic peptide’
5. Title: nephrocheck OR ‘Metalloproteinase inhibitor 2’ OR ‘tissue inhibitor of metalloproteinase-2’ OR
timp-2 OR IGFBP7 OR IBP-7 OR IGFBP-rP1 OR ‘IGF-binding protein 7’ OR ‘MAC25 protein’ OR
‘PGI2-stimulating factor’ OR ‘Prostacyclin-stimulating factor’
6. Title: ‘Tumor-derived adhesion factor’ OR ‘Tumour-derived adhesion factor’ OR ‘Tissue Necrosis Factor’
OR ‘Tumor necrosis factor’ OR ‘Tumour necrosis factor’ OR ‘TNF-alpha’ OR ‘TNF-a’
7. 1 or 2 or 3 or 4 or 5 or 6
8. Condition: acute kidney OR acute renal OR acute tubular necrosis OR AKI
9. 7 and 8
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MEDLINE (via Ovid) (1946 to November Week 2 2015)
Searched 29 November 2015.
Search strategy
1. Acute Disease/ and exp Kidney Diseases/ (7632)
2. acute kidney injury/ (32,719)
3. kidney tubular necrosis, acute/ (2173)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (6843)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (21,178)
6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3393)
7. aki.tw. (3147)
8. ‘contrast induced nephropathy’.tw. (971)
9. or/1-8 (51,426)
10. reperfusion injury/ (20,176)
11. reperfusion/ (4154)
12. exp Delayed Graft Function/ (663)
13. ‘delayed graft function*’.tw. (2118)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (39,781)
15. or/10-14 (48,027)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (689,988)
17. 1 or 2 or 3 or 16 (697,761)
18. 15 and 17 (7094)
19. 9 or 18 [AKI] (56,709)
20. Lipocalins/ (2456)
21. (NGAL or uNGAL or sNGAL).tw. (1018)
22. (‘Neutrophil gelatinase-associated lipocalin’ or ‘neutrophil gelatinase lipocalin’ or ‘lipocalin 2’ or
lcn2).tw,nm. (1885)
23. Oncogene 24p3.tw,nm. (4)
24. siderocalin.tw,nm. (42)
25. or/20-24 [NGAL] (2982)
26. Cystatin C/ (2620)
27. cystatin c.tw,nm. (3499)
28. Gamma trace.tw,nm. (56)
29. Neuroendocrine basic polypeptide.tw,nm. (0)
30. Post-gamma-globulin.tw,nm. (11)
31. or/26-30 [Cystatin C] (3531)
32. Interleukin-18/ (3995)
33. IL 18.tw,nm. (5449)
34. Interleukin 18.tw,nm. (4423)
35. Iboctadekin.tw,nm. (0)
36. Interferon gamma-inducing factor.tw,nm. (72)
37. Interleukin-1 gamma.tw,nm. (6)
38. or/32-37 [IL 18] (6372)
39. Hepatitis A virus cellular receptor 1.tw,nm. (19)
40. (KIM-1 or TIMD1 or TIM-1).tw,nm. (539)
41. kidney injury molecule 1.tw,nm. (381)
42. ‘T-cell immunoglobulin and mucin domain-containing protein 1’.tw,nm. (0)
43. ‘T-cell immunoglobulin mucin receptor 1’.tw,nm. (0)
44. ‘T-cell membrane protein 1’.tw,nm. (0)
45. or/39-44 [KIM-1] (700)
46. fatty acid-binding proteins/ or myelin p2 protein/ (4046)
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47. L-FABP.tw. (499)
48. Fatty acid-binding protein 1.tw,nm. (30)
49. (Liver adj2 ‘Fatty acid-binding protein’).tw,nm. (621)
50. or/46-49 [L-FABP] (4232)
51. Acetylglucosaminidase/ (4857)
52. Bifunctional protein*.tw,nm. (770)
53. ncoat*.tw,nm. (7)
54. NAG.tw. (2998)
55. (‘N-acetyl’ adj3 glucosaminidase).tw,nm. (4250)
56. OGA.tw. (194)
57. O-GlcNAcase.tw,nm. (242)
58. Meningioma-expressed antigen 5.tw,nm. (1)
59. MGEA5.tw. (21)
60. Hexosaminidase C.tw,nm. (163)
61. ‘EC=3.2.1.169’.tw,nm. (0)
62. ‘EC=2.3.1.48’.tw,nm. (0)
63. Histone acetyltransferase.tw,nm. (2068)
64. or/51-63 [NAG] (11,007)
65. Interleukin-6/ (46701)
66. Interleukin 6.tw,nm. (57,499)
67. IL-6.tw. (63,124)
68. BSF-2.tw. (101)
69. IFN-beta-2.tw,nm. (103)
70. B-cell stimulatory factor 2.tw,nm. (82)
71. CTL differentiation factor.tw,nm. (5)
72. Hybridoma growth factor.tw,nm. (55)
73. Interferon beta-2.tw,nm. (80)
74. or/65-73 [IL-6] (82,477)
75. Natriuretic Peptide, Brain/ (10,025)
76. B-type natriuretic peptide*.tw,nm. (4073)
77. BNP.tw. (6475)
78. or/75-77 [BNP] (12,102)
79. nephrocheck.tw,nm. (0)
80. Metalloproteinase inhibitor 2.tw,nm. (8)
81. ‘Tissue Inhibitor of Metalloproteinase-2’/ (2890)
82. tissue inhibitor of metalloproteinase-2.tw,nm. (3043)
83. TIMP 2.tw. (3181)
84. (IGFBP7 or IBP-7 or IGFBP-rP1).tw. (208)
85. IGF-binding protein 7.tw,nm. (10)
86. Insulin-like growth factor-binding protein 7.tw,nm. (84)
87. MAC25 protein.tw,nm. (5)
88. PGI2-stimulating factor.tw,nm. (6)
89. Prostacyclin-stimulating factor.tw,nm. (28)
90. Tumor-derived adhesion factor.tw,nm. (14)
91. or/79-90 [Nephrocheck TIMP 2 IGFBP7] (4440)
92. Tumor Necrosis Factor-alpha/ (97,576)
93. Tissue Necrosis Factor.tw,nm. (115)
94. ‘Tumor necrosis factor’.tw,nm. (136,471)
95. TNF-alpha.tw. (79,914)
96. TNF-a.tw. (1226)
97. or/92-96 [TNF-a] (156,262)
98. 25 or 31 or 38 or 45 or 50 or 64 or 74 or 78 or 91 or 97 [10 Selected Biomarkers] (242,639)
99. 19 and 98 (2776)
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100. limit 99 to yr=‘2004 -Current’ (2219)
101. (exp animals/ or exp Veterinary Medicine/ or exp Animal Experimentation/) not exp humans/ (3,990,735)
102. 100 not 101 [10 Biomarkers and AKI, 2004+, not animals studies] (1383)
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
(24 November 2015)
Searched 29 November 2015.
Search strategy
1. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (1612)
2. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (1032)
3. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (150)
4. aki.tw. (872)
5. ‘contrast induced nephropathy’.tw. (147)
6. or/1-5 (2805)
7. ‘delayed graft function*’.tw. (169)
8. (reperfusion adj5 (injur* or isch?emi*)).tw. (2578)
9. 7 or 8 (2733)
10. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (39,482)
11. 9 and 10 (526)
12. 6 or 11 [AKI] (3193)
13. (NGAL or uNGAL or sNGAL).tw. (235)
14. (‘Neutrophil gelatinase-associated lipocalin’ or ‘neutrophil gelatinase lipocalin’ or ‘lipocalin 2’ or
lcn2).tw,nm. (312)
15. Oncogene 24p3.tw,nm. (0)
16. siderocalin.tw,nm. (2)
17. or/13-16 [NGAL] (351)
18. cystatin c.tw,nm. (397)
19. Gamma trace.tw,nm. (0)
20. Neuroendocrine basic polypeptide.tw,nm. (0)
21. Post-gamma-globulin.tw,nm. (0)
22. or/18-21 [Cystatin C] (397)
23. IL 18.tw,nm. (419)
24. Interleukin 18.tw,nm. (134)
25. Iboctadekin.tw,nm. (0)
26. Interferon gamma-inducing factor.tw,nm. (1)
27. Interleukin-1 gamma.tw,nm. (0)
28. or/23-27 [IL-18] (455)
29. Hepatitis A virus cellular receptor 1.tw,nm. (0)
30. (KIM-1 or TIMD1 or TIM-1).tw,nm. (95)
31. kidney injury molecule 1.tw,nm. (73)
32. ‘T-cell immunoglobulin and mucin domain-containing protein 1’.tw,nm. (0)
33. ‘T-cell immunoglobulin mucin receptor 1’.tw,nm. (0)
34. ‘T-cell membrane protein 1’.tw,nm. (0)
35. or/29-34 [KIM-1] (122)
36. L-FABP.tw. (39)
37. Fatty acid-binding protein 1.tw,nm. (2)
38. (Liver adj2 ‘Fatty acid-binding protein’).tw,nm. (41)
39. or/36-38 [L-FABP] (59)
40. Bifunctional protein*.tw,nm. (19)
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41. ncoat*.tw,nm. (0)
42. NAG.tw. (171)
43. (‘N-acetyl’ adj3 glucosaminidase).tw,nm. (133)
44. OGA.tw. (25)
45. O-GlcNAcase.tw,nm. (25)
46. Meningioma-expressed antigen 5.tw,nm. (0)
47. MGEA5.tw. (1)
48. Hexosaminidase C.tw,nm. (0)
49. ‘EC=3.2.1.169’.tw,nm. (0)
50. ‘EC=2.3.1.48’.tw,nm. (0)
51. Histone acetyltransferase.tw,nm. (132)
52. or/40-51 [NAG] (417)
53. Interleukin 6.tw,nm. (2351)
54. IL-6.tw. (5580)
55. BSF-2.tw. (0)
56. IFN-beta-2.tw,nm. (1)
57. B-cell stimulatory factor 2.tw,nm. (1)
58. CTL differentiation factor.tw,nm. (0)
59. Hybridoma growth factor.tw,nm. (1)
60. Interferon beta-2.tw,nm. (1)
61. or/53-60 [IL-6] (6473)
62. B-type natriuretic peptide*.tw,nm. (433)
63. BNP.tw. (572)
64. or/62-63 [BNP] (800)
65. nephrocheck.tw,nm. (0)
66. Metalloproteinase inhibitor 2.tw,nm. (2)
67. tissue inhibitor of metalloproteinase-2.tw,nm. (24)
68. TIMP 2.tw. (168)
69. (IGFBP7 or IBP-7 or IGFBP-rP1).tw. (29)
70. IGF-binding protein 7.tw,nm. (1)
71. Insulin-like growth factor-binding protein 7.tw,nm. (14)
72. MAC25 protein.tw,nm. (0)
73. PGI2-stimulating factor.tw,nm. (0)
74. Prostacyclin-stimulating factor.tw,nm. (0)
75. Tumo?r-derived adhesion factor.tw,nm. (1)
76. or/65-75 [Nephrocheck TIMP-2 IGFBP7] (206)
77. Tissue Necrosis Factor.tw,nm. (15)
78. ‘Tumo?r necrosis factor’.tw,nm. (5964)
79. TNF-alpha.tw. (6211)
80. TNF-a.tw. (108)
81. or/77-80 [TNF-a] (9432)
82. 17 or 22 or 28 or 35 or 39 or 52 or 61 or 64 or 76 or 81 [10 biomarkers] (15,155)
83. 12 and 82 [AKI and Biomarkers] (319)
84. ((rat or rats or swine or pigs or pig or mice or mouse) not (human* or patient*)).tw. (66,543)
85. 83 not 84 (230)
86. limit 85 to yr=‘2004 -Current’ [10 biomarkes and AKI, 2004+, not animals] (227)
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NHS Economic Evaluation Database (via Wiley Online Library)
(Issue 2 of 4, April 2015)
Searched 30 November 2015.
Same search as for Cochrane Database of Systematic Reviews.
PubMed (via the US National Library of Medicine) (1946 to November 2015)
Searched 30 November 2015.
Search strategy
#1 Search (‘acute kidney’[Title] OR ‘acute renal’[Title] OR ‘acute tubular necrosis’[Title] OR ‘aki’[Title] OR
‘delayed graft function’[Title] OR ‘reperfusion injur*’[Title]) 18,005
#2 Search (((((NGAL[Title] OR Lipocalin[Title] OR LCN2[Title] OR uNGAL[Title] OR sNGAL[Title] OR siderocalin
[Title] OR ‘oncogene 24p3’[Title] OR ‘cystatin c’[Title] OR ‘gamma trace’[Title] OR ‘Neuroendocrine basic
polypeptide’[Title] OR ‘Post-gamma-globulin’[Title] OR ‘IL 18’[Title] OR ‘Interleukin 18’[Title] OR
‘Iboctadekin’[Title] OR ‘Interferon gamma-inducing factor’[Title] OR ‘Interleukin-1 gamma’[Title] OR KIM-1
[Title] OR TIMD1[Title] OR TIM-1[Title] OR ‘Hepatitis A virus cellular receptor 1’[Title] OR ‘kidney injury
molecule 1’[Title])) OR (L-FABP[Title] OR ‘Fatty acid-binding protein 1’[Title] OR (Liver[Title] AND Fatty
acid-binding protein)[Title] OR NAG[Title] OR ‘Bifunctional protein’[Title] OR ncoat[Title] OR (‘N-acetyl’[Title]
AND glucosaminidase)[Title] OR OGA[Title] OR O-GlcNAcase[Title] OR ‘Meningioma-expressed antigen
5’[Title] OR MGEA5[Title] OR ‘Hexosaminidase C’[Title])) OR (‘Interleukin 6’[Title] OR IL-6[Title] OR BSF-2
[Title] OR IFN-beta-2[Title] OR ‘B-cell stimulatory factor 2’[Title] OR ‘CTL differentiation factor’[Title]
OR ‘Hybridoma growth factor’[Title] OR ‘Interferon beta-2’[Title] OR BNP[Title] OR ‘B-type natriuretic
peptide’[Title])) OR (nephrocheck[Title] OR ‘Metalloproteinase inhibitor 2’[Title] OR ‘tissue inhibitor of
metalloproteinase-2’[Title] OR timp-2[Title] OR IGFBP7[Title] OR IBP-7[Title] OR IGFBP-rP1[Title] OR
‘IGF-binding protein 7’[Title] OR ‘MAC25 protein’[Title] OR ‘PGI2-stimulating factor’[Title] OR ‘Prostacyclin-
stimulating factor’[Title])) OR (‘Tumor-derived adhesion factor’[Title] OR ‘Tumour-derived adhesion
factor’[Title] OR ‘Tissue Necrosis Factor’[Title] OR ‘Tumor necrosis factor’[Title] OR ‘Tumour necrosis
factor’[Title] OR ‘TNF-alpha’[Title] OR ‘TNF-a’[Title]) 59,070
#3 Search (pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]) 1,881,815
#4 Search (#1 and #2 and #4) 45
Science Citation Index (via Thomson Reuters’ Web of Science)
(1900 to November 2015)
Searched 30 November 2015.
Search strategy
#1 TS=(‘acute kidney injury’ or AKI) OR TS=((Acute NEAR/3 (‘kidney disease*’ or ‘kidney injury’ or ‘kidney
failure’ or ‘kidney dysfunction’))) OR TS=((Acute NEAR/3 (‘renal disease*’ or ‘renal injury’ or ‘renal failure’
or ‘renal dysfunction’))) OR TS=(((Acute NEAR/3 (‘Tubular Necrosis’ or nephrotoxic*)) or ‘nephrotoxic
injur*’)) OR TS=(‘contrast induced nephropath*’) OR TS=((reperfusion NEAR/5 (injur* or isch?emi*)) AND
(renal or kidney* or nephr*)) OR TS=((‘Delayed Graft Function’) AND (renal or kidney* or nephr*))
#2 TS=(NGAL or uNGAL or sNGAL or ‘Oncogene 24p3’ or siderocalin or ‘Neutrophil gelatinase-associated
lipocalin’ or ‘neutrophil gelatinase lipocalin’ or ‘lipocalin 2’ or lcn2)
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#3 TOPIC: (‘cystatin c’ or ‘Gamma trace’ or ‘Neuroendocrine basic polypeptide’ or ‘Post-gamma-globulin’)
#4 TOPIC: (‘IL 18’ or ‘Interleukin 18’ or ‘Iboctadekin’ or ‘Interferon gamma-inducing factor’ or ‘Interleukin-1
gamma’)
#5 TOPIC: (KIM-1 or TIMD1 or TIM-1 or ‘Hepatitis A virus cellular receptor 1’ or ‘kidney injury molecule 1’)
#6 TOPIC: (L-FABP or ‘Fatty acid-binding protein 1’ or ((Liver near/2 (‘Fatty acid-binding protein’))))
#7 TOPIC: (NAG or ‘Bifunctional protein*’ or ncoat* or ((‘N-acetyl’) near/3 (glucosaminidase)) or OGA or
O-GlcNAcase or ‘Meningioma-expressed antigen 5’ or MGEA5 or ‘Hexosaminidase C’ or ‘Histone
acetyltransferase’)
#8 TOPIC: (‘Interleukin 6’ or IL-6 or BSF-2 or IFN-beta-2 or ‘B-cell stimulatory factor 2’ or ‘CTL
differentiation factor’ or ‘Hybridoma growth factor’ or ‘Interferon beta-2’)
#9 TOPIC: (‘B-type natriuretic peptide*’ or BNP)
#10 TS=(nephrocheck or ‘Metalloproteinase inhibitor 2’ or ‘tissue inhibitor of metalloproteinase-2’ or
timp-2 or IGFBP7 or IBP-7 or IGFBP-rP1 or ‘IGF-binding protein 7’ or ‘MAC25 protein’ or ‘PGI2-stimulating
factor’ or ‘Prostacyclin-stimulating factor’ or ‘Tumo#r-derived adhesion factor’)
#11 TOPIC: (‘Tissue Necrosis Factor’ or ‘Tumo#r necrosis factor’ or ‘TNF-alpha’ or ‘TNF-a’)
#12 #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
#13 #12 AND #1
#14 TS= (mice or mouse or rat or rats or hamster* or sheep or animal* or rabbit* or dog or dogs or cat or
cats or chicken* or poultry or pig or pigs or swine or swines or horse or horses or cow or cows or bovine*)
NOT TS=(human* or patient* or neonate* or child*or woman or women or men or man or adolescen*)
#15 TI= (mice or mouse or rat or rats or hamster* or sheep or animal* or rabbit* or dog or dogs or cat or
cats or chicken* or poultry or pig or pigs or swine or swines or horse or horses or cow or cows or bovine*)
#16 #15 OR #14
#17 #13 not #16
Conference Proceedings Citation Index – Science (via Thomson Reuters’
Web of Science) (1990 to November 2015)
Searched 30 November 2015.
Same as search for Science Citation Index.
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Appendix 4 AKI-Diagnostics systematic review
data extraction proforma
Ref ID: Reviewer initials: Data entered:
Citation
Authors:
Title:
Journal: Year: Pages:
Vol:
Study
Design:a Aim:
Location:b
Funding: Industry Charity Conflict of
interest declared:
Yes
Government Other No
Research council Not reported
Reporting standard: REMARK STARD Other (detail)
STROBE TRIPOD Not reported
Population
Setting: Critical care unit Single site Area evaluated: Clinical validity/
utility
Emergency dept. Multisited Analytical validity
Cardiac surgery n Cost-effectiveness
Laboratoryc Other (specify)
Other (specify)
Study duration (months): Inclusion criteria:
Recruitment period:
Recruitment method
(consecutive, random,
matched, retro or
prospective, matched, etc.):
Exclusion criteria:
Details of study throughput: CONSORT diagram Sample size/power
calculation reported:
Yes
Written statement No
Other (detail)
Not reported
a Complete page 6 if trial design.
b Country (or countries) of study.
c Studies of analytical validity only.
d Include laboratories only if entirely laboratory-based.
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
229
Characteristics Group 1 Group 2 Group 3
Patient group (detail)
Total number
Number (%) with previous AKI
Age range
Mean (SD)
Median (IQR)
Number male (%)
Number female (%)
Ethnicity (%)
White
Asian
Black
Other
Comorbidities
Relevant lifestyle factors
Between group
difference at baseline:
Yes Baseline difference adjusted: Yes Follow-up duration:
No No
Unclear Unclear Median follow-up:
Record any key differences in the Notes section on page 5.
Biomarker details
Features Biomarker 1 Biomarker 2 Biomarker 3
Reference method
or comparator test
Name of analyte
Test name
Manufacturer
Sample matrix used [e.g. urine, serum, plasma (incl. type)]
Collection timing and frequency (e.g. on admission,
every 2 hours)
Test platform/method used
Test purpose (e.g. diagnosis, prognosis, risk prediction)
Cut-off threshold applied
Prespecified threshold (e.g. reported in methods) Y/N Y/N Y/N Y/N
Method to determine cut-off (e.g. level recommended
for assay)
Time between index and reference tests
Assessor blind to reference test results Y/N Y/N Y/N Y/N
Number of samples per patient
Number of laboratoriess used
Test timing to AKI diagnosis
If reference method, enter name of classification system only. If comparator biomarker, enter relevant details.
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Main findings
Study endpoints:
Patient outcomesa Biomarker 1b Biomarker 2b Biomarker 3b
Reference
method/
comparatorb
Patient group (detail)
Baseline kidney function
Classification system used: (RIFLE, AKIN, KDIGO or
details if other method used)
Number (%) diagnosed with AKI
Cause(s) of AKI [e.g. cardiac surgery (specify if
on- or off-pump), low blood pressure, etc.]
Number (%) patients at (from classification above):
1
2
3
Other (as above)
Number (%) of patients with:
Recovery of kidney function
Chronic kidney disease
Renal replacement therapy
Re-admission
Death
Average length of stay
Related costing data (incl. cost of biomarker,
laboratory costs, staff time, QALY data, etc.).
If unsure, add page reference
a If individual results given for adults and children, report these separately.
b Replace with relevant biomarker name.
Test validity Biomarker 1a Biomarker 2a Biomarker 3a
Reference
method/
comparatora
Total number of tests
Test failure rate
Distribution of analyte (across the population):
Mean
SD
CV%
Range
Median
Interquartile range
DOI: 10.3310/hta22320 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 32
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
231
Test validity Biomarker 1a Biomarker 2a Biomarker 3a
Reference
method/
comparatora
True positive (TP), false positive, true negative (TN), false negative (FN) vs. gold standard (or comparator)
GS + GS – GS + GS – GS + GS – Include only if table presented
Test + TP FP TP FP TP FP
Test – FN TN FN TN FN TN
Test validity Biomarker 1a Biomarker 2a Biomarker 3a
Reference
method/
comparatora
Sensitivity, 95% CIb
Specificity, 95% CIb
Likelihood ratios, 95% CIb
ROC curve present Y/N Y/N Y/N Y/N
AUC and 95% CIb
Univariate analysis:
Odds/hazard ratios, 95% CIb
Dichotomised or continuous D/C D/C D/C D/C
Multivariate analysis:
Odds/hazard ratios, 95% CIb
Dichotomised or continuous D/C D/C D/C D/C
Variables adjusted for (detail)
CV%, coefficient of variation; ROC, receiver operating characteristic.
a Replace with relevant biomarker name.
b Document if confidence intervals are not provided.
Brief summary of key findings Notes (incl. key limitation of study)
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Appendix 5 QUADAS-2 assessment
Phase 1: state the review question
Patients (setting, intended use of index test, presentation,
prior testing):
ICU/ED/cardiac surgery; adult and child populations; diagnosis
or prognosis of acute kidney injury
Index test(s): Nephrocheck; NGAL; cystatin C
Reference standard and target condition: AKI diagnosed on the basis of creatinine/urine output
criteria → classification systems: KDIGO, AKIN, RIFLE
Phase 2: draw a flow diagram for the primary study
Phase 3: risk of bias and applicability judgments
QUADAS-2 is structured so that four key domains are each rated in terms of the risk of bias and the
concern regarding applicability to the research question (as defined above). Each key domain has a set of
signalling questions to help reach the judgments regarding bias and applicability.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
l Was a consecutive or random sample of patients enrolled? Yes/no/unclear
l Was a case–control design avoided? Yes/no/unclear
l Did the study avoid inappropriate exclusions? Yes/no/unclear
Could the selection of patients have introduced bias? Risk: low/high/unclear
B. Concerns regarding applicability
Describe included patients (prior testing, presentation, intended use of index test and setting):
Is there concern that the included patients do not match the review question? Concern: low/high/unclear
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Domain 2: index test(s)
If more than one index test was used, please complete for each test.
A. Risk of bias
Describe the index test and how it was conducted and interpreted:
l Were the index test results interpreted without knowledge of the results of the reference
standard? Yes/no/unclear
l If a threshold applicability was used, was it prespecified? Yes/no/unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: low/high/unclear
B. Concerns regarding applicability
Is there concern that the index test, its conduct or interpretation differ from the review
question? Concern: low/high/unclear
Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
l Is the reference standard likely to correctly classify the target condition? Yes/no/unclear
l Were the reference standard results interpreted without knowledge of the results of the index
test? Yes/no/unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: low/high/
unclear
B. Concerns regarding applicability
Is there concern that the target condition as defined by the reference standard does not match the review
question? Concern: low/high/unclear
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test(s) and/or reference standard or who were
excluded from the 2 × 2 table (refer to flow diagram):
Describe the time interval and any interventions between the index test(s) and the reference standard:
l Was there an appropriate interval between the index test(s) and the reference standard?
Yes/no/unclear
l Did all patients receive a reference standard? Yes/no/unclear
l Did patients receive the same reference standard? Yes/no/unclear
l Were all patients included in the analysis? Yes/no/unclear
Could the patient flow have introduced bias? Risk: low/high/unclear
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Appendix 6 Characteristics of eligible studies
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
524 Adademir 201273 Turkey Clinical Cardiac (single) Adults Other NGAL (urine) 55 N/N
983 Aghel 201074 USA, Belgium Clinical Unclear (single) Adults Other NGAL (serum) 91 Y/Y
1390 Åhlström 200475 Finland Clinical Critical care (single) Adults ADQI Group
consensus
Cystatin C (serum) 202 N/N
7818 Al-Beladi 201476 Saudi Arabia Clinical Critical care (single) Adults RIFLE Cystatin C (serum) 84 N/N
117 Alcaraz 201477 Spain Clinical/analytical Critical care (single) Children RIFLE NGAL (urine) 106 Y/Y
125 Alharazy 201478 Malaysia Clinical/analytical Cardiac: contrast
(single)
Adults Other NGAL (serum) 100 Y/Y
122 Arthur 201479 USA Clinical Cardiac (multisite,
n= 4)
Adults AKIN Cystatin C (urine)/
NGAL (urine)
105 N/N
149 Ataei 201480 Iran Clinical/analytical Critical care (single) Children RIFLE Cystatin C (serum) 107 Y/Y
349 Aydogdu 201332 Turkey Clinical Critical care (single) Adults RIFLE Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
151 Y/Y
982 Bagshaw 201081 Australia Clinical Critical care (multisite,
n= 2)
Adults RIFLE NGAL (plasma, urine) 83 Y/Y
5501 Bargnoux 201382 France Analytical Laboratory (multisite,
n= 2)
Not
specified
– NGAL (urine) 100 N/N
20 Basu 201483 USA Clinical Critical care (multisite,
n= 17)
Children KDIGO NGAL (plasma) 214 Y/Y
1030 Bell 200984 Sweden Clinical Critical care (single) Adults RIFLE Cystatin C (serum) 271 N/N
11252 Bell 201585 Sweden Clinical Critical care (single) Adults KDIGO Nephrocheck (urine)/
NGAL (urine)/cystatin C
(urine)
94 N/N
1170 Bennett 200886 USA Clinical/analytical Cardiac (single) Children Other NGAL (urine) 196 Y/Y
82 Bihorac 201433 USA Clinical Critical care (multisite,
n= 23)
Adults KDIGO Nephrocheck (urine) 408 Y/Y
112 Bojan 201487 France Clinical Cardiac (single) Children AKIN NGAL (urine) 200 Y/Y
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
11386 Bojic 201588 Serbia Clinical Critical care (single) Adults KDIGO NGAL (serum, urine) 103 N/N
532 Breidthardt 201289 Switzerland Clinical Emergency department
(multisite, n = 3)
Adults AKIN NGAL (plasma) 207 Y/Y
926 Briguori 201090 Italy Clinical Cardiac: contrast
(single)
Adults AKIN Cystatin C (serum) 410 Y/Y
826 Cai 201091 Sweden Analytical Laboratory (single) Not
specified
– NGAL (urine) 38 N/N
450 Cantinotti 201292 Italy Clinical Cardiac (single) Children RIFLE NGAL (urine) 135 Y/Y
52 Cemil 201493 Turkey Clinical Emergency department
(single)
Adults Not reported NGAL (serum) 60 Y/Y
597 Chen 201234 Taiwan Clinical Critical care (single) Adults AKIN Cystatin C (serum,
urine)/NGAL (serum,
urine)
150 Y/Y
390 Cho 201335 South Korea Clinical Critical care (single) Adults AKIN NGAL (urine) 145 Y/Y
23 Cho 201494 South Korea Clinical Critical care (single) Adults RIFLE NGAL (serum, urine) 82 N/N
11582 Chung 201595 Sri Lanka, USA Analytical Laboratory (multisite,
n= 2)
Adults – Cystatin C (urine) 42 N/N
967 Constantin 201036 France Clinical Critical care (single) Adults RIFLE NGAL (plasma) 88 Y/Y
981 Cruz 201096 Italy Clinical Critical care (single) Adults RIFLE NGAL (plasma) 301 Y/Y
599 Cullen 201297 Ireland Analytical Laboratory (single) Adults – NGAL (urine) 174 N/N
11388 Dai 201598 China Clinical Critical care (single) Adults KDIGO Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
112 N/N
11338 De Berardinis 201599 USA, Italy, France Clinical/analytical Emergency department
(multisite, n = 3)
Adults RIFLE NGAL (plasma) 530 Y/Y
1645 de Geus 201137 The Netherlands Clinical Critical care (single) Adults RIFLE Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
510 N/N
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
768 de Geus 2011100 The Netherlands Clinical Critical care (single) Adults RIFLE NGAL (plasma, urine) 632 Y/Y
302 de Geus 2013101 The Netherlands Clinical Critical care (single) Adults AKIN NGAL (plasma) 663 Y/Y
179 de Geus 2013102 The Netherlands Clinical/analytical Critical care (single) Adults AKIN NGAL (urine) 481 N/N
139 Delanaye 2014103 France, Belgium Clinical Critical care (multisite,
n= 3)
Adults KDIGO Cystatin C (serum) 51 N/N
1611 Delcroix 2013104 Belgium Clinical Cardiac (single) Adults KDIGO NGAL (plasma, urine) 50 Y/Y
1624 Demirtas 2013105 Turkey Clinical Cardiac (single) Adults Not reported NGAL (not specified) 72 N/N
1219 Dent 2007106 USA Clinical/analytical Cardiac (single) Children RIFLE NGAL (plasma) 120 Y/Y
1600 Di Somma 2013107 Italy Clinical Emergency department
(multisite, n = 3)
Adults AKIN/RIFLE NGAL (plasma) 665 Y/Y
669 Doi 2011108 Japan Clinical Critical care (single) Adults RIFLE NGAL (urine) 339 N/N
1594 Doi 2013109 Japan Clinical Cardiac (multisite,
n= 2)
Adults AKIN NGAL (plasma) 146 Y/Y
141 Doi 2014110 Japan Clinical Critical care (single) Adults RIFLE NGAL (urine) 339 N/N
525 Ejaz 2012111 USA Clinical Cardiac (single) Adults AKIN NGAL (urine) 100 N/N
408 El-Farghali 2012112 Egypt Clinical Critical care (single) Children AKIN NGAL (serum) 60 Y/Y
1511 Fan 2014113 China Clinical Critical care (single) Adults RIFLE NGAL (urine) 126 Y/Y
11667 Fanning 2015114 New Zealand Clinical Cardiac (single) Adults KDIGO NGAL (serum, urine) 50 N/N
997 Felicio 2009115 Brazil Clinical Cardiac (single) Adults Not reported Cystatin C (serum) 50 N/N
393 Fouad 2013116 Egypt Clinical Critical care (single) Adults AKIN/RIFLE Cystatin C (serum) 100 N/N
1432 Gaipov 2015117 Turkey Clinical Cardiac (single) Adults KDIGO NGAL (serum, urine) 60 Y/Y
75 Ghonemy 201438 Egypt Clinical Cardiac (single) Adults RIFLE Cystatin C (serum)/
NGAL (serum)
50 Y/Y
242 Glassford 2013118 Australia Clinical/analytical Critical care (single) Adults RIFLE NGAL (plasma, urine) 102 N/N
11804 Gocze 2015119 Germany Clinical Critical care (single) Adults OTHER Nephrocheck (urine) 107 N/N
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
961 Grenier 2010120 USA, Canada, the
Netherlands
Analytical Laboratory (multisite,
n= 3)
Adults – NGAL (urine) Unclear N/N
4025 Guo 2011121 China Clinical Critical care (multisite,
no numbers reported)
Adults RIFLE NGAL (urine) 92 N/N
1049 Haase 200931 Australia Clinical Cardiac (single) Adults AKIN Cystatin C (plasma)/
NGAL (urine)
100 Y/Y
1072 Haase-Fielitz 200939 Australia Clinical/analytical Cardiac (single) Adults RIFLE Cystatin C (plasma)/
NGAL (urine)
100 Y/Y
1020 Haase-Fielitz 200940 Australia Clinical/analytical Cardiac (single) Adults AKIN/RIFLE NGAL (plasma) 100 Y/Y
1622 Hamed 2013122 Egypt Clinical Critical care (single) Children RIFLE Cystatin C (serum) 62 Y/Y
1062 Han 200941 USA Clinical/analytical Cardiac (single) Adults AKIN
(modified)
NGAL (urine) 90 Y/Y
142 Hansen 2014123 Denmark Analytical Laboratory (multisite,
n= 2)
Adults – NGAL (plasma, urine) 68 N/N
526 Hassinger 2012124 USA Clinical Cardiac (single) Children RIFLE Cystatin C (serum) 100 N/N
1059 Heise 2009125 Germany Clinical Cardiac (single) Adults National Kidney
Foundation
guideline
Cystatin C (serum) 50 N/N
1403 Herget-Rosenthal
200442
Germany Clinical/analytical Critical care (single) Adults RIFLE Cystatin C (serum) 85 Y/Y
1236 Hirsch 2007126 USA Clinical/analytical Cardiac (single) Children Other NGAL (plasma, urine) 91 Y/Y
1440 Hjortrup 201543 Denmark Clinical Critical care (multisite,
n= 3)
Adults KDIGO NGAL (plasma, urine) 222 Y/Y
225 Hoffman 2013127 USA Clinical/analytical Critical care (single) Children Other NGAL (urine) 62 Y/Y
207 Hong 2013128 South Korea Clinical/analytical Emergency
department/critical care
(single)
Adults RIFLE NGAL (plasma) 45 Y/Y
1488 Hoste 201444 USA, Canada,
Europea
Clinical Critical care (multisite,
n= 35)
Adults KDIGO Nephrocheck (urine) 153 Y/Y
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
1574 In 2014129 South Korea Clinical Critical care (single) Adults RIFLE NGAL (plasma) 126 Y/Y
1587 Jayaraman 2014130 India Clinical Cardiac (single) Adults RIFLE NGAL (urine) 100 N/N
1531 Johansson 2014131 Sweden Clinical Cardiac (single) Adults RIFLE Cystatin C (serum) 64 N/N
247 Kambhampati 2013132 USA Clinical Cardiac (single) Adults AKIN NGAL (urine) 100 N/N
1601 Kashani 201345 USA, Europea Clinical Critical care (multisite,
n= 35)
Adults KDIGO Nephrocheck (urine) 728 N/N
1139 Kato 200846 Japan Clinical Critical care (single) Adults Other Cystatin C (serum) 87 Y/Y
1609 Khosravi 2013133 Iran Clinical Critical care (single) Adults RIFLE NGAL (serum) 90 Y/Y
67 Kidher 201447 UK Clinical/analytical Cardiac (single) Adults RIFLE NGAL (plasma) 53 Y/Y
137 Kiessling 2014134 Germany Clinical/analytical Cardiac (single) Adults AKIN Cystatin C (serum) 70 N/N
296 Kift 2013135 UK Analytical Laboratory (single) Adults AKIN NGAL (urine) 78 N/N
2189 Kim 2012136 South Korea Clinical Cardiac: contrast
(single)
Adults Other Cystatin C (serum) 89 Y/Y
232 Kim 2013137 South Korea Clinical Emergency
department/critical care
(single)
Adults/
children
AKIN NGAL (plasma) 231 N/N
720 Koch 2011138 Germany Clinical Cardiac (single) Children RIFLE NGAL (plasma) 218 N/N
1889 Koeijers 2012139 Curaçao Clinical Critical care (single) Adults AKIN NGAL (urine) 88 Y/Y
473 Kokkoris 201248 Greece Clinical Critical care (single) Adults RIFLE Cystatin C (plasma)/
NGAL (plasma, urine)
100 Y/Y
1127 Koyner 2008140 USA Clinical Cardiac (single) Adults Other Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
72 Y/Y
827 Koyner 2010141 USA Clinical Cardiac (single) Adults AKIN Cystatin C (urine)/
NGAL (urine)
123 N/N
2483 Koyner 2012142 USA Clinical Cardiac (multisite,
n= 6)
Adults AKIN NGAL (plasma, urine) 380 N/N
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
341 Koyner 2013143 USA Clinical Cardiac (multisite,
n= 8)
Adults/
children
AKIN/RIFLE Cystatin C (urine) 1502 N/N
3999 Koyner 2014144 USA, Europea Clinical Critical care (multisite,
n= 35)
Adults KDIGO Nephrocheck (urine) 692 N/N
11469 Koyner 2015145 USA Clinical Critical care (unclear) Adults AKIN Nephrocheck (urine)/
NGAL (plasma, urine)
77 N/N
871 Krawczeski 2010146 USA Clinical Cardiac (single) Children RIFLE Cystatin C (serum) 374 Y/Y
657 Krawczeski 2011147 USA Clinical Cardiac (single) Children AKIN/RIFLE NGAL (urine) 220 N/N
745 Krawczeski 2011148 USA Clinical/analytical Cardiac (single) Children AKIN/RIFLE NGAL (plasma, urine) 373 Y/Y
1961 Lacquaniti 2013149 Italy Clinical Cardiac: contrast
(single)
Adults Other NGAL (serum, urine) 120 Y/Y
4002 Lagos-Arevalo 2014150 Canada Clinical/analytical Critical care (single) Children KDIGO Cystatin C (serum,
urine)/NGAL (urine)
160 Y/Y
840 Lassus 2010151 Finland Clinical Emergency department
(multisite, n = 14)
Adults AKIN/RIFLE Cystatin C (serum) 292 Y/Y
5108 Legrand 2014152 USA, Italy Clinical Emergency department
(multisite, n = 2)
Adults RIFLE Cystatin C (urine)/
NGAL (plasma)
87 N/N
5087 Legrand 201549 France Clinical Critical care (single) Adults KDIGO Cystatin C (plasma)/
NGAL (plasma, urine)
111 Y/Y
1500 Lewandowska 2014153 Poland Clinical/analytical Critical care (single) Adults RIFLE NGAL (urine) 63 Y/Y
1650 Li 2010154 China Clinical Emergency department
(single)
Adults RIFLE Cystatin C (serum) 71 N/N
1607 Li 2013155 China Clinical Critical care (single) Adults AKIN NGAL (urine) 55 Y/Y
1035 Liangos 200950 USA Clinical/analytical Cardiac (multisite,
n= 2)
Adults AKIN
(modified)
Cystatin C (urine)/
NGAL (urine)
103 Y/Y
263 Liebetrau 2013156 Germany Clinical/analytical Cardiac (single) Adults KDIGO Cystatin C (plasma)/
NGAL (urine)
141 N/N
97 Liebetrau 2014157 Germany Clinical/analytical Cardiac: contrast
(single)
Adults KDIGO Cystatin C (plasma)/
NGAL (urine)
128 N/N
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
283 Linko 201351 Finland Clinical Critical care (multisite,
n= 25)
Adults RIFLE NGAL (plasma) 369 Y/Y
392 Liu 201352 China Clinical/analytical Cardiac (single) Adults AKIN NGAL (urine) 109 Y/Y
591 Macdonald 2012158 Australia Clinical/analytical Emergency department
(multisite, n = 2)
Adults RIFLE NGAL (plasma) 102 Y/Y
237 Magro 2013159 Brazil Clinical Critical care (single) Adults AKIN/RIFLE Cystatin C (serum) 121 N/N
275 Makris 2013160 Greece Analytical Laboratory (single) Adults – Cystatin C (urine) 130 N/N
1434 Malyszko 2015161 Poland Clinical Cardiac: contrast
(single)
Adults Other Cystatin C (serum)/
NGAL (serum, urine)
89 N/N
793 Manzano-Fernandez
2011162
Spain Clinical/analytical Unclear (single) Adults Other Cystatin C (plasma) 20 Y/Y
1528 Marcelino 2014163 Portugal Clinical Critical care (single) Adults AKIN NGAL (urine) 61 Y/Y
607 Martensson 2012164 Sweden Clinical Critical care (single) Adults RIFLE Cystatin C (serum) 327 N/N
4001 Martensson 2014165 Australia Clinical Critical care (single) Adults RIFLE NGAL (urine) 102 N/N
1519 Matsa 2014166 UK Clinical Critical care (single) Adults RIFLE NGAL (plasma, urine) 194 Y/Y
534 McCullough 2012167 USA Clinical Cardiac: contrast
(multisite, n = 3)
Adults Other NGAL (plasma) 63 N/N
979 McIlroy 201053 USA Clinical Cardiac (single) Adults AKIN NGAL (urine) 426 Y/Y
11593 McIlroy 2015168 USA Clinical Cardiac (single) Adults KDIGO NGAL (urine) 603 Y/Y
1568 Meersch 201454 Germany Clinical Cardiac (single) Adults KDIGO Nephrocheck (urine)/
NGAL (urine)
50 Y/Y
1485 Meersch 201455 Germany Clinical Cardiac (single) Children RIFLE Nephrocheck (urine)/
NGAL (urine)
51 Y/Y
1592 Merrikhi 2014169 Iran Clinical Critical care (single) Children RIFLE NGAL (plasma, urine) 50 Y/Y
1369 Mishra 2005170 USA Clinical Cardiac (single) Children Other NGAL (serum, urine) 71 Y/Y
5578 Mortara 2013171 Italy Clinical/analytical Emergency department
(single)
Adults Other NGAL (serum) 30 Y/Y
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
381 Munir 201356 Pakistan Clinical Cardiac (single) Adults AKIN NGAL (urine) 88 Y/Y
1628 Murty 2013172 India Clinical Unclear (single) Adults RIFLE Cystatin C (serum) 330 N/N
1058 Naruse 2009173 Japan Clinical/analytical Unclear (single) Adults K/DOQI Cystatin C (serum) 328 N/N
864 Nejat 201057 New Zealand Clinical/analytical Critical care (multisite,
n= 2)
Adults AKIN Cystatin C (plasma) 444 N/N
885 Nejat 2010174 New Zealand Clinical/analytical Critical care (multisite,
n= 2)
Adults AKIN Cystatin C (plasma,
urine)
444 Y/Y
544 Nejat 2012175 Australia Clinical Critical care (multisite,
n= 2)
Adults AKIN Cystatin C (urine)/
NGAL (urine)
489 N/N
6561 Nemes 2010176 Hungary Clinical Critical care (single) Adults Other Cystatin C (serum) 105 Y/Y
1166 Nickolas 2008177 USA Clinical/analytical Emergency department
(single)
Adults RIFLE NGAL (urine) 635 Y/Y
624 Nickolas 2012178 USA, Germany Clinical/analytical Emergency department
(multisite, n = 3)
Adults RIFLE Cystatin C (urine)/
NGAL (urine)
1635 Y/Y
64 Nisula 2014179 Finland Clinical Critical care (multisite,
no numbers reported)
Adults KDIGO NGAL (urine) 1042 Y/Y
554 Oh 201258 South Korea Clinical Cardiac (single) Adults Other NGAL (urine) 71 Y/Y
72 Omerika 2014180 Bosnia
Herzegovina
Clinical Cardiac (single) Adults RIFLE NGAL (urine) 150 N/N
4004 Ortuno-Anderiz
2015181
Spain Clinical Critical care (single) Adults RIFLE Cystatin C (plasma) 50 N/N
1578 Ozkan 2014182 Turkey Clinical Emergency department
(single)
Adults Not reported NGAL (serum) 100 N/N
11344 Palazzuoli 201559 Italy Clinical Unclear (single) Adults AKIN Cystatin C (plasma)/
NGAL (plasma)
203 Y/Y
695 Parikh 201160 USA, Canada Clinical Cardiac (multisite,
n= 6)
Adults RIFLE NGAL (plasma, urine) 1219 Y/Y
348 Park 2013183 South Korea Clinical Unclear (single) Adults AKIN Cystatin C (plasma,
urine)
213 Y/Y
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
1453 Park 201561 South Korea Clinical Cardiac (single) Adults RIFLE NGAL (plasma) 189 Y/Y
252 Peco-Antic 2013184 Serbia Clinical Cardiac (single) Children RIFLE Cystatin C (serum)/
NGAL (serum, urine)
112 N/N
875 Pedersen 2010185 Denmark Analytical Cardiac (single) Adults/
children
– NGAL (plasma, urine) 17 N/N
1004 Perianayagam 2009186 USA Clinical/analytical Critical care (multisite,
n= 2)
Adults Other Cystatin C (serum) 200 N/N
3997 Perrotti 201562 France Clinical Cardiac (single) Adults Other NGAL (plasma) 166 Y/Y
921 Perry 201063 USA Clinical Cardiac (multisite,
n= 2)
Adults ADQI Group
consensus
NGAL (plasma) 879 Y/Y
11359 Petrovic 2015187 Serbia CEA Cardiac (single) Children RIFLE Cystatin C (serum)/
NGAL (urine)
112 Y/Y
260 Pickering 2013188 New Zealand Clinical Critical care (multisite,
n= 2)
Adults KDIGO Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
528 N/N
13 Pipili 2014189 Greece Clinical Critical care (single) Adults RIFLE Cystatin C (serum)/
NGAL (urine)
106 N/N
11327 Prowle 201564 Australia Clinical Cardiac (single) Adults RIFLE Cystatin C (serum)/
NGAL (urine)
93 Y/Y
11325 Ralib 2014190 New Zealand Clinical Emergency department
(single)
Adults KDIGO Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
77 N/N
11863 Rewa 2015191 Canada Clinical Critical care (multisite,
n= 5)
Adults KDIGO
(modified)
NGAL (whole blood) 227 Y/Y
615 Ribichini 2012192 Italy Clinical/analytical Cardiac: contrast
(single)
Adults Other Cystatin C (serum) 166 Y/Y
442 Ricci 2012193 Italy Clinical Cardiac (single) Children RIFLE NGAL (whole blood) 160 Y/Y
978 Ristikankare 2010194 Finland Clinical Cardiac (single) Adults RIFLE Cystatin C (serum) 110 N/N
790 Royakkers 2011195 The Netherlands Clinical Critical care (multisite,
n= 5)
Adults RIFLE Cystatin C (serum,
urine)
151 N/N
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
1638 Royakkers 2012196 The Netherlands Clinical Critical care (multisite,
n= 5)
Adults RIFLE NGAL (serum, urine) 140 N/N
11514 Ruf 2015197 Germany Clinical Cardiac (single) Children RIFLE Cystatin C (serum)/
NGAL (plasma, urine)
59 N/N
5666 Rybi-Szuminska
2013198
Poland Analytical Laboratory (multisite,
no numbers reported)
Children – NGAL (urine) 172 N/N
10309 Sagheb 2014199 Iran Clinical Critical care (single) Adults Other Cystatin C (serum) 80 N/N
465 Sargentini 201265 Italy Clinical Cardiac (single) Adults AKIN NGAL (urine) 52 Y/Y
11626 Schaub 2015200 USA, Canada Clinical Cardiac (multisite,
n= 6)
Adults AKIN NGAL (urine) 959 N/N
316 Schinstock 2013201 USA Clinical/analytical Emergency department
(single)
Adults AKIN NGAL (urine) 363 Y/Y
432 Schnell 2012202 France Clinical Critical care (multisite,
n= 2)
Adults AKIN Cystatin C (serum,
urine)
58 N/N
386 Seitz 2013203 Germany Clinical Cardiac (single) Children RIFLE Cystatin C (serum)/
NGAL (urine)
139 Y/Y
899 Shapiro 2010204 USA Clinical Emergency department
(multisite, n = 10)
Adults RIFLE NGAL (plasma) 661 Y/Y
654 Shaw 2011205 USA CEA Cardiac (unclear) Adults RIFLE NGAL (urine) Unclear Y/Y
1649 Shi 2010206 China Clinical Critical care (multisite,
n= 2)
Adults AKIN Cystatin C (serum) 98 N/N
705 Shlipak 2011207 USA Clinical Cardiac (multisite,
n= 6)
Adults AKIN Cystatin C (serum) 1147 N/N
463 Shrestha 2012207 USA Clinical Critical care (single) Adults AKIN/RIFLE
(simplified)
NGAL (serum, urine) 93 Y/Y
3995 Shum 201566 China Clinical Critical care (single) Adults AKIN NGAL (plasma) 151 Y/Y
1040 Siew 2009209 USA Clinical Critical care (single) Adults AKIN NGAL (urine) 391 N/N
230 Siew 2013210 USA Clinical/analytical Critical care (single) Adults AKIN Cystatin C (urine)/
NGAL (urine)
352 N/N
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
598 Sohrabian 2012211 Sweden Analytical Laboratory (single) Adults – Cystatin C (urine) 41 N/N
857 Soto 2010212 Portugal Clinical Emergency department
(single)
Adults AKIN/RIFLE Cystatin C (plasma,
urine)
616 Y/Y
187 Soto 2013213 Portugal Clinical Emergency department
(single)
Adults AKIN/RIFLE Cystatin C (serum)/
NGAL (plasma)
616 Y/Y
11842 Soyler 2015214 Turkey Clinical Emergency department
(single)
Adults AKIN NGAL (urine) 100 Y/Y
439 Spahillari 2012215 USA Clinical Cardiac (multisite,
n= 6)
Adults Other Cystatin C (plasma) 1150 N/N
750 Svenmarker 2011216 Sweden Clinical Cardiac (unclear) Adults Other Cystatin C (serum) 98 N/N
185 Tasanarong 2013217 Thailand Clinical Cardiac: contrast
(single)
Adults KDIGO NGAL (urine) 130 Y/Y
613 Torregrosa 2012218 Spain Clinical/analytical Critical care (single) Adults RIFLE Cystatin C (urine)/
NGAL (urine)
135 Y/Y
1080 Tuladhar 200967 UK Clinical Cardiac (single) Adults ADQI Group
consensus
NGAL (plasma, urine) 50 Y/Y
11329 Tung 201568 Taiwan Clinical Cardiac (single) Adults AKIN Cystatin C (serum)/
NGAL (serum)
189 Y/Y
11765 Tziakas 201569 Greece Clinical/analytical Cardiac (multisite,
n= 3)
Adults AKIN/RIFLE/
KDIGO
Cystatin C (plasma,
urine)/NGAL (plasma,
urine)
805 Y/Y
11253 Varela 201570 Argentina Clinical Cardiac (single) Adults AKIN NGAL (urine) 66 Y/Y
1371 Villa 200571 Spain Clinical Critical care (single) Adults Other Cystatin C (serum) 50 N/N
11382 Volpon 2015219 Brazil Clinical Critical care (single) Children RIFLE Cystatin C (serum) 122 Y/Y
136 Wacker-Gusmann
2014220
Germany Clinical Cardiac: contrast
(unclear)
Adults AKIN/RIFLE Cystatin C (serum) 373 N/N
1307 Wagener 2006221 USA Clinical Cardiac (single) Adults ADQI Group
consensus
NGAL (urine) 81 Y/Y
1138 Wagener 200872 USA Clinical Cardiac (single) Adults AKIN NGAL (urine) 426 Y/Y
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Study Population Biomarker
ID First author Location Outcome area Setting (sites) Population Classification Analyte
Subjects
(AKI)
Sensitivity/
specificity
224 Wai 2013222 USA Clinical Critical care (single) Children RIFLE NGAL (urine) 60 Y/Y
882 Wald 2010223 USA, Canada Clinical/analytical Cardiac (multisite,
n= 3)
Adults AKIN
(modified)
Cystatin C (plasma) 150 N/N
6718 Wang 2009224 China Clinical/analytical Cardiac (single) Adults Other Cystatin C (serum) 61 Y/Y
1486 Wang 2014225 China Clinical Cardiac (single) Adults AKIN Cystatin C (serum) 616 N/N
1548 Wang 2014226 China Clinical/analytical Critical care (single) Adults AKIN Cystatin C (serum) 446 Y/Y
11832 Westhoff 2015227 Germany Clinical Critical care (single) Children RIFLE Nephrocheck (urine) 133 Y/Y
1183 Wheeler 2008228 USA Clinical Critical care (multisite,
no numbers reported)
Children Other NGAL (serum) 143 Y/Y
218 Xiang 2013229 China Analytical Laboratory (single) Adults – NGAL (serum) 454 N/N
291 Yin 2013230 China Clinical Cardiac (single) Adults Other Cystatin C (serum) 204 Y/Y
1619 Yoon 2013231 South Korea Clinical Cardiac: contrast
(single)
Adults Other Cystatin C
(not specified)
723 Y/Y
1613 Youssef 2013232 Egypt Clinical Critical care (single) Children RIFLE NGAL (serum) 75 Y/Y
1222 Zappitelli 2007233 USA Clinical Critical care (single) Children RIFLE NGAL (urine) 140 Y/Y
700 Zappitelli 2011234 USA, Canada Clinical/analytical Cardiac (multisite,
n= 3)
Children AKIN Cystatin C (plasma) 288 N/N
11263 Zappitelli 2015235 USA, Canada Clinical/analytical Critical care (multisite,
n= 3)
Children KDIGO Cystatin C (serum)/
NGAL (urine)
287 N/N
243 Zheng 2013236 China Clinical/analytical Cardiac (single) Children AKIN
(modified)
Cystatin C (serum) 43 Y/Y
11825 Zwiers 2015237 The Netherlands Clinical/analytical Critical care (single) Children RIFLE NGAL (urine) 100 Y/Y
–, not applicable; ADQI, Acute Dialysis Quality Initiative; K/DOQI, Kidney Disease Outcomes Quality Initiative (of the National Kidney Foundation); N, no; Y, yes.
a Austria, Belgium, France, Germany, Spain, Sweden and the UK.
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Appendix 7 Full performance measures quality
assessment forms for the Nephrocheck case studies
Bihorac et al.33
Reference ID: 82 Reviewer initials: MM/BK Data entered: 23 May 2016
Citation
Authors: Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, DeMuth GE, et al.
Title: Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication
Journal: American Journal of Respiratory
and Critical Care Medicine
Year: 2014 Pages: 932–9
Vol.: 189(8)
Description of the measurement procedure
Features Index Reference
Name of analyte Nephrocheck Creatinine
Test name Nephrocheck Jaffe method
Test platform/method used Astute 140 Meter Roche COBAS Modular D
Manufacturer Astute Medical Roche
Sample matrix used [e.g. urine, serum, plasma
(including type)]
Urine Serum
Pre-analytical biological
Patient state (e.g. fed/fasted, sitting/
standing, rested)
Not described Not described
Patient preparation The presence of an indwelling
urinary catheter was also a
prerequisite
Not described
Anatomical site and/or mechanism Catheter and urometer Direct venepuncture via other
available venous access or via an
indwelling arterial line
Timing of sampling (e.g. before 0900) Within 60 minutes of serum sample Not described
Pre-analytical technical
Sample collection (mechanism and use of
stabilisation)
Urine samples were collected in
standard (non-coated) specimen
cups
Blood was collected in clot
activator blood collection tubes
(for serum)
Preprocessing handling, temperature,
transport and time
For subjects with indwelling bladder
catheters, the collection bag was
first emptied and then a fresh
sample of urine was collected;
alternatively, the sample could be
taken from a urometer, if present
Not described
Sample processing (e.g. preservation,
centrifugation conditions, timings and
temperature)
Urine was centrifuged (10 minutes
at 1000g) to remove any cells
or other debris and was then
aliquoted and frozen
Serum was prepared by
centrifugation for 10 minutes at
a minimum of 1300g after
clotting and was then aliquoted
and frozen
Storage (e.g. volume, temperature,
duration, freeze–thaw cycles)
Frozen (on dry ice or liquid
nitrogen) ≤ 2 hours from collection
and stored at ≤ –70 °C
Frozen (on dry ice or liquid
nitrogen) ≤ 2 hours from
collection and stored at ≤ –70 °C
Postprocessing handling and transport Samples were shipped on dry ice.
Samples were thawed immediately
prior to analysis
Samples were shipped on dry
ice. Samples were thawed
immediately prior to analysis
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Description of the measurement procedure
Features Index Reference
Consideration of differences between groups All samples were collected through
the same prospective collection. No
obvious difference between AKI
and non-AKI
All samples were collected
through the same prospective
collection. No obvious difference
between AKI and non-AKI
Standard operating procedures or quality
assurance
Samples were excluded if they were
not collected within 60 minutes of
the blood sample, they were not
processed and frozen within
2 hours, < 15ml of urine was
collected, they were not properly
labelled or they were not properly
frozen
Samples were excluded if they
were of insufficient volume, the
wrong collection tube was used,
they were haemolysed, they
were incorrectly labelled, they
were not collected within
60 minutes of the urine samples,
they were not processed within
2 hours or they were not
properly frozen
Other Sponsor banked samples; shipped
to laboratories for analysis
Sponsor banked samples;
shipped to laboratories for
analysis
Analytical factors
Sample blinding procedure Technicians masked to clinical data Not described
Sample randomisation procedure Not described Not described
Batching Not described Not described
Reference control materials Traceable to reference standard
solutions that contain defined mass
(concentration) of TIMP-2 and
IGFBP-7 in accordance with EN ISO
17511
IDMS-traceable calibration
Quality assurance procedures Two internal controls (one positive
and one negative) were run
automatically with every sample.
If the automatic check of these
internal controls showed that the
control value results were not
within predefined limits, the metre
displayed an error message and
the test result was not reported.
These controls were in addition to
external liquid controls (traceable
to the same reference standard
solutions as the test), which were
run to verify test performance and
operator proficiency
Not described
Patient inclusion/exclusion criteria Critically ill adult patients within
24 hours of admission to an ICU.
The presence of an indwelling
urinary catheter was also a
prerequisite for inclusion. Patients
with documented AKI at the time of
enrolment were excluded
Critically ill adult patients within
24 hours of admission to an ICU.
The presence of an indwelling
urinary catheter was also a
prerequisite for inclusion.
Patients with documented AKI at
the time of enrolment were
excluded
Test failure rate and reasons for test failure 2.9% (12/420): eight invalid or
missing test results, four sample
processing deviations
Not described
Technical replication Urine from each subject was
analysed at each of the three
testing sites, producing triplicate
test values for each sample
Serum samples were analysed
for creatinine at a central
laboratory
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Performance evaluation
Performance goals (for precision and bias
including method of calculation)
Not described Not described
Within-individual biological variation Not described Not described
Pre-analytical factors Not described Not described
Total measurement uncertainty Not described Not described
Analytical verification or full validation Not described – manufacturer’s
data reported
Not described
Analytical sensitivity
Method (brief description) Manufacturer’s data reported Not described
Limit of blank (LOB) Manufacturer’s data reported Not described
Limit of detection (LOD) Manufacturer’s data reported Not described
Limit of quantitation (LOQ) Manufacturer’s data reported Not described
Analytical selectivity
Method (brief description) Not described Not described
Cross-reactivity Not described Not described
Interference Not described Not described
Carry-over Not described Not described
Trueness
Method (brief description) Not described Not described
Bias Not described Not described
Precision
Method (brief description including
M-Factors: time, calibration, operator
and equipment)
Manufacturer’s data reported Not described
Repeatability (range), CV% Not described Not described
Intermediate Imprecision (range), CV% Not described Not described
Reproducibility (range), CV% Manufacturer’s data reported Not described
Linearity and working range Manufacturer’s data reported Not described
Method (brief description) Manufacturer’s data reported Not described
Other (e.g. lot to lot, antibody validation
profile)
Not described Not described
Signalling questions
Were measurement procedures different between groups?
l No, but it is not clear whether samples were measured randomly or in batches, which may have introduced a
systematic bias
Were measurement procedures described in enough detail to be repeated?
l The urinary Nephrocheck test was generally reported in enough detail to be repeated
l However, several parameters required to repeat the serum creatinine reference test were not described
Were measurement factors appropriately controlled for?
l No; the manufacturer’s kit insert identifies albumin and bilirubin as interferents and recommends ‘caution in interpreting
Nephrocheck results in patients with significant proteinuria or severe hyperbilirubinuria’. Albumin (proteinuria and haematuria)
and bilirubin (to a lesser extent) are associated with AKI. No attempt was made to identify and exclude these samples
l Quality control procedures were not reported for the creatinine reference test
l No validation or verification of the measurement systems was reported
l No performance goals were reported
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Signalling questions
Were measurement procedures applicable to the final clinical setting?
l No, measurements were conducted at three sites and the median of three measurements was used to determine
diagnostic accuracy. Only a single measurement at a single site would be used in clinical practice, which may lead to
less precise measurements
Samples were freeze–thawed prior to measurement in the study, whereas samples are likely to be analysed immediately
(fresh) in the acute clinical context. No data were available on freeze–thaw cycles, but the manufacturer suggests avoiding
repeated freezing and thawing
Risk of bias (yes, no, uncertain)
Unclear
Risk of irreproducibility (yes, no, uncertain)
High
Risk of inapplicability (yes, no, uncertain)
High
CV%, coefficient of variation; IDMS, isotope dilution mass spectrometry.
Meersch et al.
Reference ID: 1485 Reviewer initials: BK/MM Data entered: 13 May 2016
Citation
Authors: Meersch M, Schmidt C, Van Aken H, Rossaint J, Görlich D, Stege D, et al.
Title: Validation of cell-cycle arrest biomarkers for acute kidney injury after pediatric cardiac surgery
Journal PLOS ONE Year: 2014 Pages: e110865
Vol: 9 (10)
Description of the measurement procedure
Name of analyte Nephrocheck Creatinine
Test name Nephrocheck
Test platform/method used Astute 140 Meter
Manufacturer Astute Medical
Sample matrix used [e.g. urine, serum,
plasma (including type)]
Urine Serum
Pre-analytical biological
Patient state (e.g. fed/fasted, sitting/
standing, rested)
Not described Not described
Patient preparation Not described Not described
Anatomical site and/or mechanism Not described Not described
Time of sampling (e.g. before 0900) Immediately before and at 4 and
24 hours post CPB
Routinely measured before
surgery, immediately after surgery
and at least daily in the
postoperative period
Pre-analytical technical
Sample collection (mechanism and
use of stabilisation)
Not described Not described
Preprocessing handling, temperature,
transport and time
Not described Not described
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Description of the measurement procedure
Sample processing (e.g. preservation,
centrifugation conditions, timings
and temperature)
Not described Not described
Storage (e.g. volume, temperature,
duration, freeze–thaw cycles)
Stored in aliquots at –80 °C. Length of
storage not described
Not described
Postprocessing handling and
transport
Not described Not described
Consideration of differences between
groups
Nephrocheck and creatinine tests not
performed at the same time
Nephrocheck and creatinine tests
not performed at the same time
Standard operating procedures or
quality assurance
Not described Not described
Other
Analytical factors
Sample blinding Laboratory investigators blinded to clinical
outcomes
Laboratory investigators blinded to
clinical outcomes
Sample randomisation Not described Not described
Batching Not described Not described
Reference control materials Not described Not described
Quality assurance procedures Not described Not described
Patient inclusion/exclusion criteria All patients aged < 18 years undergoing
cardiac surgery with CPB at the authors’
centre between July 2013 and December
2013 were approached for study inclusion.
Patients with severe pre-existing renal
insufficiency (serum creatinine two times
the age-adjusted normal range) were
excluded
All patients aged < 18 years
undergoing cardiac surgery with
CPB at the authors’ centre
between July 2013 and December
2013 were approached for study
inclusion. Patients with severe
pre-existing renal insufficiency
(serum creatinine two times the
age-adjusted normal range) were
excluded
Test failure rate and reasons for test
failure
Not described Not described
Performance evaluation
Performance goals (for precision and
bias including method of calculation)
Not described Not described
Within-individual biological variation Not described Not described
Pre-analytical factors Not described Not described
Total measurement uncertainty Not described Not described
Analytical verification or full validation Not described Not described
Analytical sensitivity
Method (brief description) Not described Not described
Limit of blank (LOB) Not described Not described
Limit of detection (LOD) Not described Not described
Limit of quantitation (LOQ) Not described Not described
Analytical specificity
Method (brief description) Not described Not described
Cross-reactivity Not described Not described
Interference Not described Not described
Carry-over Not described Not described
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Performance evaluation
Trueness
Method (brief description) Not described Not described
Bias Not described Not described
Precision
Method (brief description
including M-factors: time,
calibration, operator and
equipment)
Not described Not described
Repeatability (range), CV% Not described Not described
Intermediate imprecision (range),
CV%
Not described Not described
Reproducibility (range), CV% Not described Not described
Linearity and working range Not described Not described
Method (brief description) Not described Not described
Other (e.g. lot to lot, antibody validation
profile)
Not described Not described
Signalling questions
Were measurement procedures different between groups?
l Uncertain. Pre-analytical and analytical study procedures were not reported in enough detail to be confident that
systematic bias between the groups had been avoided, for example no details were reported concerning sample
randomisation and batching. However, laboratory investigators were blinded to clinical outcomes
l Index and reference test samples were collected at different times. It is unclear whether this may have introduced a bias
Were measurement procedures described in enough detail to be repeated?
l No; very limited data were provided concerning the Nephrocheck test and only the analyte name, matrix and time
points were provided for creatinine
Were measurement factors appropriately controlled for?
l No. Albumin, bilirubin and methylene blue are known Nephrocheck interferents that were not controlled for in the
urine samples
l Quality control procedures were not reported for either the index test or the reference test
l The method for and traceability of the reference test were not described
l The performance characteristics of the index test and reference test were not described
l It is unclear whether the measurement systems were performing as specified by the manufacturer as no internal
verification was performed
l No performance goals were reported
Were measurement procedures applicable to the final clinical setting?
l No. The test was performed in patients aged < 18 years of age, which contradicts the instructions for use
l Samples were frozen and thawed prior to measurement in the study, whereas samples are likely to be analysed
immediately (fresh) in the acute clinical context. No data were available on freeze–thaw cycles, but the manufacturer
suggests avoiding repeated freezing and thawing
Risk of bias (high, low, unclear)
Unclear
Risk of irreproducibility (high, low, unclear)
High
Risk of inapplicability (high, low, unclear)
High
CV%, coefficient of variation.
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Hoste et al.44
Reference ID: 1488 Reviewer initials: MM/BK Data entered: 18 May 2016
Citation
Authors: Hoste EAJ, McCullough PA, Kashani K, Chawla LS, Joannidis M, Shaw AD, et al.
Title: Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers
Journal: Nephrology Dialysis
Transplantation
Year: 2014 Pages: 2054–61
Vol: 29
Description of the measurement procedure
Features Index Reference
Name of analyte Nephrocheck Creatinine
Test name Nephrocheck
Test platform/method used Astute 140 Meter Not described
Manufacturer Astute Medical Not described
Sample matrix used [e.g. urine, serum,
plasma (including type)]
Urine Serum
Pre-analytical biological
Patient state (e.g. fed/fasted,
sitting/standing, rested)
Not described Not described
Patient preparation Urinary catheter Not described
Anatomical site and/or mechanism Urinary catheter Not described
Time of sampling (e.g. before
0900)
‘At enrolment’ (unclear if within 1 hour) Not described
Pre-analytical technical
Sample collection (mechanism and
use of stabilisation)
‘Standard methods’ Not described
Preprocessing handling,
temperature, transport and time
Collected either directly from catheter or
from collection bag (emptied first)
Not described
Sample processing (e.g.
preservation, centrifugation
conditions, timings and
temperature)
Centrifugation (10 minutes at 1000g) Not described
Storage (e.g. volume, temperature,
duration, freeze–thaw cycles)
Frozen within 2 hours of collection, stored
at ≤ 70 °C (length of storage not
described)
Not described
Postprocessing handling and
transport
Transport not described. Thawed
immediately prior to analysis
Not described
Consideration of differences between
groups
Prospective data used for Nephrocheck,
sometimes retrospective data used for
creatinine
In some patients the baseline
creatinine value was used (two
different methods for determining
baseline) rather than the creatinine
value at the time of enrolment
Standard operating procedures or
quality assurance
Operators required to complete proficiency
training using control samples. No other
quality assurance described
Not described
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Description of the measurement procedure
Features Index Reference
Other
Analytical factors
Sample blinding Technicians blinded to clinical data Blinded to final determination of
AKI status
Sample randomisation Not described Not described
Batching Not described Not described
Reference control materials Traceable to reference standard solutions
in accordance with ISO 17511
Not described
Quality assurance procedures Two detection zones used as internal
controls (one positive and one negative
control) and run automatically with every
sample, in addition to external liquid
controls (traceable to the same reference
standard solutions as the test), which are
run to verify test performance and
operator proficiency
Not described
Patient inclusion/exclusion criteria
Test failure rate and reasons for
test failure
n= 7/744 Sapphire patients with invalid or
missing test results
Not described
Performance evaluation
Performance goals (for precision and
bias including method of calculation)
Not described Not described
Within-individual biological variation Not described Not described
Pre-analytical factors Not described Not described
Total measurement uncertainty Not described Not described
Analytical verification or full validation Not described – manufacturer’s data
reported
Not described
Analytical sensitivity
Method (brief description) Not described Not described
Limit of blank (LOB) Manufacturer’s data reported Not described
Limit of detection (LOD) Manufacturer’s data reported Not described
Limit of quantitation (LOQ) Manufacturer’s data reported Not described
Analytical specificity
Method (brief description) Not described Not described
Cross-reactivity Not described Not described
Interference Not described Not described
Carry-over Not described Not described
Trueness
Method (brief description) Not described Not described
Bias Not described Not described
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Performance evaluation
Precision
Method (brief description
including M-factors: time,
calibration, operator and
equipment)
Manufacturer’s data reported Not described
Repeatability (range), CV% Not described Not described
Intermediate Imprecision
(range), CV%
Not described Not described
Reproducibility (range), CV% Manufacturer’s data reported Not described
Linearity and working range Manufacturer’s data reported Not described
Method (brief description) Manufacturer’s data reported Not described
Other (e.g. lot to lot, antibody
validation profile)
Not described Not described
Signalling questions
Were measurement procedures different between groups?
l Pre-analytical procedures were described in adequate detail and did not appear to differ between patient groups
l Although laboratory investigators were blinded to clinical outcomes, it is unclear whether samples were batched or
randomised for analysis
l The index and reference test samples were collected at different times. It is unclear whether this may have introduced a bias
Were measurement procedures described in enough detail to be repeated?
l The urinary Nephrocheck test was reported in enough detail to be repeated, although it is not clear whether the
measurements were performed in a single batch and randomised
l In addition, it is not clear how long the samples were frozen for
l Several parameters required to repeat the serum creatinine reference test were not described
Were measurement factors appropriately controlled for?
l No; albumin, bilirubin and methylene blue are known Nephrocheck interferents that were not controlled for in the
urine samples. The manufacturer’s kit insert recommends ‘caution in interpreting Nephrocheck results in patients with
significant proteinuria or severe hyperbilirubinuria’304
l Quality control procedures were not reported for the creatinine reference test. The method for and traceability of the
reference test were not described
l It is unclear whether the measurement systems were performing as specified by the manufacturer as no internal
verification was performed
l It is also not clear whether the samples were processed within 1 hour of collection
l The performance characteristics and goals of the reference test and index test were not described
Were measurement procedures applicable to the final clinical setting?
l Unclear. Samples were freeze–thawed prior to measurement in the study, whereas samples are likely to be analysed
immediately (fresh) in the acute clinical context. No data were available on freeze–thaw cycles but the manufacturer
suggests avoiding repeated freezing and thawing
Risk of bias (high, low, unclear)
Unclear
Risk of irreproducibility (high, low, unclear)
High
Risk of inapplicability (high, low, unclear)
Unclear
CV%, coefficient of variation.
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Meersch et al.54
Reference ID: 1568 Reviewer initials: MM/BK Data entered: 19 May 2016
Citation
Authors: Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, et al.
Title: Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following
cardiac surgery
Journal: PLOS ONE Year: 2014 Pages: e93460
Vol: 9
Description of the measurement procedure
Features Index Reference
Name of analyte Nephrocheck Creatinine
Test name Nephrocheck
Test platform/method used Astute 140 Meter
Manufacturer Astute Medical
Sample matrix used [e.g. urine, serum, plasma
(including type)]
Urine Serum
Pre-analytical biological
Patient state (e.g. fed/fasted, sitting/standing,
rested)
Not described Not described
Patient preparation Not described Not described
Anatomical site and/or mechanism Not described Not described
Time of sampling (e.g. before 0900) Pre CPB and 4, 12 and 24 hours
after CPB
Pre CPB and 4, 12, 24, 48 and
72 hours post CPB and at time
of discharge
Pre-analytical technical
Sample collection (mechanism and use of
stabilisation)
Not described Not described
Preprocessing handling, temperature, transport
and time
Not described Not described
Sample processing (e.g. preservation,
centrifugation conditions, timings and
temperature)
Centrifuged immediately (further
details not given)
Not described
Storage (e.g. volume, temperature, duration,
freeze–thaw cycles)
Stored at ≤ –70 °C (duration not
stated)
Not described
Postprocessing handling and transport Thawed immediately prior to
analysis
Not described
Consideration of differences between groups Prospective data used for
Nephrocheck, sometimes
retrospective data used for
creatinine
In some patients the baseline
creatinine value was used rather
than the creatinine value at the
time of enrolment
Standard operating procedures or quality
assurance
Not described Not described
Other
Analytical factors
Sample blinding Not described Not described
Sample randomisation Not described Not described
Batching Not described Not described
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Description of the measurement procedure
Features Index Reference
Reference control materials Not described Not described
Quality assurance procedures Not described Not described
Patient inclusion/exclusion criteria Those with a Cleveland Clinic
Foundation Score of ≥ 6 were
eligible for enrolment. Exclusion
criteria included:
1. pregnancy
2. post-renal transplantation,
3. immunosuppressive therapy
and
4. patients receiving
corticosteroid therapy with a
change in their dose within
the past 2 weeks
Those with a Cleveland Clinic
Foundation Score of ≥ 6 were
eligible for enrolment. Exclusion
criteria included:
1. pregnancy,
2. post-renal transplantation,
3. immunosuppressive therapy
and
4. patients receiving
corticosteroid therapy with a
change in their dose within
the past 2 weeks
Test failure rate and reasons for test failure Not described Not described
Performance evaluation
Performance goals (for precision and bias including
method of calculation)
Not described Not described
Within-individual biological variation Not described Not described
Pre-analytical factors Not described Not described
Total measurement uncertainty Not described Not described
Analytical verification or full validation Not described Not described
Analytical sensitivity
Method (brief description) Not described Not described
Limit of blank (LOB) Not described Not described
Limit of detection (LOD) Not described Not described
Limit of quantitation (LOQ) Not described Not described
Analytical specificity
Method (brief description) Not described Not described
Cross-reactivity Not described Not described
Interference Not described Not described
Carry-over Not described Not described
Trueness
Method (brief description) Not described Not described
Bias Not described Not described
Precision
Method (brief description including
M-factors: time, calibration, operator
and equipment)
Not described Not described
Repeatability (range), CV% Not described Not described
Intermediate Imprecision (range), CV% Not described Not described
Reproducibility (range), CV% Not described Not described
Linearity and working range Not described Not described
Method (brief description) Not described Not described
Other (e.g. lot to lot, antibody validation
profile)
Not described Not described
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Signalling questions
Were measurement procedures different between groups?
l Uncertain. Pre-analytical and analytical study procedures were not reported in enough detail to be confident that bias
had been avoided, for example no details were reported concerning sample blinding, randomisation and batching
l In some patients the baseline creatinine value was used rather than the creatinine value at the time of enrolment.
It is not clear if this was systematically different between the patient groups
Were measurement procedures described in enough detail to be repeated?
l Limited details were provided concerning the Nephrocheck test; not enough details were provided to repeat the study
l Almost all parameters required to repeat the serum creatinine reference test were not described, not even the name
and manufacturer of the assay
Were measurement factors appropriately controlled for?
l No. Albumin, bilirubin and methylene blue are known Nephrocheck interferents that were not controlled for in the
urine samples
l Quality control procedures were not reported for Nephrocheck or for the creatinine reference test
l The method for and traceability of the reference test were not described
l The performance characteristics of the reference test and the index test were not described
l It is unclear whether the measurement systems were performing as specified by the manufacturer as no internal
verification was reported
l No performance goals were reported
Were measurement procedures applicable to the final clinical setting?
l Unclear as the study procedures not described in enough detail
l Samples were frozen and thawed prior to measurement in the study whereas samples are likely to be analysed
immediately (fresh) in the acute clinical context. No data were provided on freeze–thaw cycles but the manufacturer
suggests avoiding repeated freezing and thawing
Risk of bias (high, low, unclear)
Unclear
Risk of irreproducibility (high, low, unclear)
High
Risk of inapplicability (high, low, unclear)
High
CV%, coefficient of variation.
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Appendix 8 Search methods for the
AKI-Diagnostics economic model literature review
Databases searched
l Cochrane Central Register of Controlled Trials (via Wiley Online Library) (Issue 2 of 12, February 2016)
l Database of Abstracts of Reviews of Effect (Wiley Online Library) (Issue 2 of 4, April 2015)
l EMBASE Classic + EMBASE (via Ovid) (1947 to 26 February 2015)
l Ovid MEDLINE (1946 to March Week 2 2016)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (23 March 2016)
l NHS Economic Evaluation Database (Wiley Online Library) (Issue 2 of 4, April 2015).
Example MEDLINE search
(Full search strategies used in all databases are available from the authors on request.)
Search strategy
1. Acute Disease/ and exp Kidney Diseases/ (8114)
2. acute kidney injury/ (35,209)
3. kidney tubular necrosis, acute/ (2292)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (8613)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (21,799)
6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3501)
7. aki.tw. (4196)
8. ‘contrast induced nephropathy’.tw. (1099)
9. or/1-8 (55,186)
10. reperfusion injury/ (21,566)
11. reperfusion/ (4317)
12. exp Delayed Graft Function/ (832)
13. ‘delayed graft function*’.tw. (2349)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (42,376)
15. or/10-14 (51,149)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (725,426)
17. 1 or 2 or 3 or 16 (733,668)
18. 15 and 17 (7807)
19. 9 or 18 [AKI] (60,934)
20. models, economic/ or models, econometric/ (11,379)
21. markov chain/ (10,943)
22. Decision Trees/ (9378)
23. decision support techniques/ (14,411)
24. microsimulat*.tw. (484)
25. (patient level adj8 simulat*).tw. (44)
26. (simulat* adj3 model*).tw. and decision*.mp. (1428)
27. (discrete event* adj5 simulat*).tw. (429)
28. (discrete event* adj8 model*).tw. (346)
29. (decision* adj5 model*).tw. (9343)
30. (model* adj5 markov*).tw. (8445)
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31. ((econom* or cost or costs) adj6 model*).tw. (14,201)
32. ‘state transition model*’.tw. (294)
33. (‘transition probabilit*’ and (state or states or model*)).tw. (1097)
34. or/20-33 [Econ models] (61,100)
35. 19 and 34 (118)
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Appendix 9 Search methods for the
AKI-Diagnostics economic model parameters
literature review
Databases searched
Searches Databases
AKI costs l Cochrane Database of Systematic Reviews (via Wiley Online Library) (Issue 7 of 12, July 2015)
l Database of Abstracts of Reviews of Effect (via Wiley Online Library) (Issue 2 of 4, April 2015)
l EMBASE Classic + EMBASE (via Ovid) (1947 to 15 July 2015)
l Ovid MEDLINE (1946 to July Week 2 2015)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (16 July 2015)
AKI utilities l EMBASE Classic + EMBASE (via Ovid) (1947 to 27 July 2015)
l Ovid MEDLINE (1946 to July Week 2 2015)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (16 July 2015)
AKI risks l Cochrane Central Register of Controlled Trials (via Wiley Online Library) (Issue 7 of 12, July 2015)
l EMBASE Classic + EMBASE (via Ovid) (1947 to 30 July 2015)
l Ovid MEDLINE (1946 to July Week 4 2015)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (30 July 2015)
CKD costs l Cochrane Database of Systematic Reviews (via Wiley Online Library) (Issue 8 of 12, August 2015)
l Database of Abstracts of Reviews of Effect (via Wiley Online Library) (Issue 2 of 4, April 2015)
l EMBASE Classic + EMBASE (via Ovid) (1947 to 14 August 2015)
l Ovid MEDLINE (1946 to August Week 1 2015)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (14 August 2015)
l NHS Economic Evaluation Database (via Wiley Online Library) (Issue 2 of 4, April 2015)
CKD utilities l Cochrane Database of Systematic Reviews (via Wiley Online Library) (Issue 8 of 12, August 2015)
l Database of Abstracts of Reviews of Effect (via Wiley Online Library) (Issue 2 of 4, April 2015)
l EMBASE Classic + EMBASE (via Ovid) (1947 to 17 August 2015)
l Ovid MEDLINE (1946 to August Week 1 2015)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (August 17, 2015)
l NHS Economic Evaluation Database (via Wiley Online Library) (Issue 2 of 4, April 2015)
CKD risks l Cochrane Central Register of Controlled Trials (via Wiley Online Library) (Issue 8 of 12, August 2015)
l EMBASE Classic + EMBASE (via Ovid) (1947 to 2 September 2015)
l Ovid MEDLINE (1946 to August Week 2 2015)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (25 August 2015)
l NHS Economic Evaluation Database (via Wiley Online Library) (Issue 2 of 4, April 2015)
Example MEDLINE searches
(Full search strategies used in all databases are available from the authors on request.)
Acute kidney injury costs
Search strategy
1. Acute Disease/ and exp Kidney Diseases/ (7907)
2. acute kidney injury/ (34,725)
3. kidney tubular necrosis, acute/ (2253)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (7745)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (22,094)
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6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3518)
7. aki.tw. (3679)
8. ‘contrast induced nephropathy’.tw. (1025)
9. or/1-8 (54,260)
10. reperfusion injury/ (21,127)
11. reperfusion/ (4276)
12. exp Delayed Graft Function/ (713)
13. ‘delayed graft function*’.tw. (2205)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (41,542)
15. or/10-14 (50,057)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (715,951)
17. 1 or 2 or 3 or 16 (724,030)
18. 15 and 17 (7499)
19. 9 or 18 [AKI] (59,776)
20. exp Hospitalization/ (172,146)
21. Inpatients/ (14,321)
22. (ward or wards).tw. (39,848)
23. exp Hospitals/ (215,221)
24. hospital units/ or exp intensive care units/ (70,023)
25. hospital*.tw. (826,340)
26. ‘high dependency’.tw. (785)
27. (critical adj2 care).tw. (17,692)
28. (intensive adj2 care).tw. (91,081)
29. (inpatient or inpatients).tw. (64,890)
30. or/20-29 [Hospital Wards] (1,093,337)
31. exp great britain/ (322,784)
32. (‘united king*’ or uk or ‘U.K.’ or ‘UK.’ or ‘U.K’ or britain).in,ti. (843,719)
33. (british or english or scottish or welsh or irish).in,ti. (81,221)
34. (scotland or ireland).in,ti. (85,992)
35. (england not ‘new england’).in,ti. (53,958)
36. (wales not ‘new south wales’).in,ti. (32,677)
37. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).in,ti. (680,616)
38. ((london adj2 ontario) or (london adj on) or new london).in,ti. (20,486)
39. (manchester adj3 (USA or massach*)).in,ti. (328)
40. (newcastle adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (6218)
41. (liverpool adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (1167)
42. or/38-41 (28,187)
43. 37 not 42 (652,429)
44. (nhs or ‘national health service’).in,ti. (78,445)
45. or/31-36,43-44 (1,323,915)
46. 19 and 30 and 45 (503)
47. exp ‘Costs and Cost Analysis’/ (191,630)
48. cost*.tw. (352,643)
49. budget*.tw. (18,103)
50. (price or prices or pricing).tw. (23,573)
51. (financial* adj4 burden*).tw. (2622)
52. (economic* adj4 burden*).tw. (5378)
53. expenditure*.tw. (36,926)
54. or/47-53 [Costs] (492,123)
55. 19 and 30 and 45 and 54 [AKI Wards UK Costs] (49)
56. limit 55 to yr=‘2010 -Current’ (28)
57. 19 and 30 and 54 (479)
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58. limit 57 to ‘reviews (maximizes specificity)’ (20)
59. 56 or 58 (48)
Acute kidney injury utilities
Search strategy
1. Acute Disease/ and exp Kidney Diseases/ (7907)
2. acute kidney injury/ (34,725)
3. kidney tubular necrosis, acute/ (2253)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (7745)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (22,094)
6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3518)
7. aki.tw. (3679)
8. ‘contrast induced nephropathy’.tw. (1025)
9. or/1-8 (54,260)
10. reperfusion injury/ (21,127)
11. reperfusion/ (4276)
12. exp Delayed Graft Function/ (713)
13. ‘delayed graft function*’.tw. (2205)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (41,542)
15. or/10-14 (50,057)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (715,951)
17. 1 or 2 or 3 or 16 (724,030)
18. 15 and 17 (7499)
19. 9 or 18 [AKI] (59,776)
20. exp great britain/ (322,784)
21. (‘united king*’ or uk or ‘U.K.’ or ‘UK.’ or ‘U.K’ or britain).in,ti. (843,719)
22. (british or english or scottish or welsh or irish).in,ti. (81,221)
23. (scotland or ireland).in,ti. (85,992)
24. (england not ‘new england’).in,ti. (53,958)
25. (wales not ‘new south wales’).in,ti. (32,677)
26. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).in,ti. (680,616)
27. ((london adj2 ontario) or (london adj on) or new london).in,ti. (20,486)
28. (manchester adj3 (USA or massach*)).in,ti. (328)
29. (newcastle adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (6218)
30. (liverpool adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (1167)
31. or/27-30 (28,187)
32. 26 not 31 (652,429)
33. (nhs or ‘national health service’).in,ti. (78,445)
34. or/20-25,32-33 [UK] (1,323,915)
35. exp Health Status/ (113,246)
36. ‘health status’.tw. (37,086)
37. ‘Quality of Life’/ (128,885)
38. (hql or hqol or h qol or hrqol or hr qol).tw. (8334)
39. ‘quality of life’.tw. (149,495)
40. ‘questionnaire*’.tw. (301,418)
41. or/35-40 (558,180)
42. (utility or utilities).ti. (18,669)
43. (qaly or ‘quality adjusted life year*’).tw. (7053)
44. 42 or 43 (25,018)
45. 41 and 44 (8176)
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46. ((utility or utilities) adj5 (hql or hqol or h qol or hrqol or hr qol or ‘quality of life’ or health* or score*
or weight*)).ab. (4351)
47. (preference* adj5 (hql or hqol or h qol or hrqol or hr qol or ‘quality of life’ or health* or score* or
weight*)).tw. (3981)
48. (sf6d or sf 6d or short form 6d or shortform 6d or sf sixd or sf six d).tw. (466)
49. (hui or hui1 or hui2 or hui3).tw. (904)
50. ‘health utilities index*’.tw. (542)
51. *quality-adjusted life years/ (1625)
52. ‘health related quality of life’.tw. (22,714)
53. quality-adjusted life years/ (7808)
54. QALY.tw. (4335)
55. (eq-5d* or eq5d* or euroqol*).tw. (4329)
56. or/45-55 [Utilities] (41,087)
57. 19 and 34 and 56 [AKI and UK and Utilities] (9)
58. 19 and 56 [AKI and Utilities] (54)
59. limit 58 to ‘reviews (best balance of sensitivity and specificity)’ (11)
60. limit 57 to yr=‘2010 -Current’ (3)
61. 59 or 60 (14)
Acute kidney injury risks
Search strategy
1. Acute Disease/ and exp *Kidney Diseases/ (6067)
2. *acute kidney injury/ (26,477)
3. *kidney tubular necrosis, acute/ (1197)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (7787)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (22,104)
6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3519)
7. aki.tw. (3705)
8. ‘contrast induced nephropathy’.tw. (1027)
9. or/1-8 (46,556)
10. *reperfusion injury/ (16,238)
11. *reperfusion/ (1132)
12. exp *Delayed Graft Function/ (373)
13. ‘delayed graft function*’.tw. (2207)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (41,592)
15. or/10-14 (46,283)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (716,822)
17. 1 or 2 or 3 or 16 (720,726)
18. 15 and 17 (7033)
19. 9 or 18 [AKI] (51,801)
20. ‘high dependency’.tw. (785)
21. (critical adj2 care).tw. (17,716)
22. (intensive adj2 care).tw. (91,210)
23. (inpatient or inpatients).tw. (65,020)
24. critical care/ (25,394)
25. critical illness/ (18,693)
26. Intensive Care/ (16,540)
27. exp intensive care units/ (61,237)
28. critical illness*.tw. (4877)
29. ICU.tw. (29,797)
30. 20 or 21 or 22 or 24 or 25 or 26 or 27 or 28 or 29 [ICU] (160,191)
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31. likelihood functions/ (18,212)
32. markov chains/ (10,701)
33. odds ratio/ (66,036)
34. proportional hazards models/ (51,090)
35. risk/ (103,777)
36. logistic models/ (99,887)
37. risk assessment/ (189,789)
38. risk factors/ (612,509)
39. ((risk or risks or odds or proportion*) adj5 (mortality or death or stage*)).ti. (9334)
40. ((incidence or prevalen*) adj5 (mortality or death or stage*)).ti. (3039)
41. or/31-40 [Risks Odds Likelihood studies] (976,879)
42. meta-analysis/ (58,183)
43. sn.fs. (564,719)
44. 42 or 43 [Data set cohort or meta analysis studies] (617,723)
45. *hospitalization/ or *’length of stay’/ or *patient admission/ or *patient discharge/ or *patient
readmission/ or *patient transfer/ (58,042)
46. ((risk or risks or odds or proportion* or incidence or prevalen*) adj8 (aki or ‘acute kidney*’)).ti. (394)
47. ((risk or risks or odds or proportion* or incidence or prevalen*) adj8 (‘acute kidney*’ or ‘acute renal*’
or ‘acute nephr*’ or ‘acute tubular necrosis*’)).ti. (603)
48. 46 or 47 [AKI Risks Title search] (634)
49. exp great britain/ (323,050)
50. (‘united king*’ or uk or ‘U.K.’ or ‘UK.’ or ‘U.K’ or britain).in,ti. (845,318)
51. (british or english or scottish or welsh or irish).in,ti. (81,404)
52. (scotland or ireland).in,ti. (86,152)
53. (england not ‘new england’).in,ti. (54,012)
54. (wales not ‘new south wales’).in,ti. (32,731)
55. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).in,ti. (681,856)
56. ((london adj2 ontario) or (london adj on) or new london).in,ti. (20,549)
57. (manchester adj3 (USA or massach*)).in,ti. (330)
58. (newcastle adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (6251)
59. (liverpool adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (1172)
60. or/56-59 (28,287)
61. 55 not 60 (653,569)
62. (nhs or ‘national health service’).in,ti. (78,681)
63. or/49-54,61-62 [UK Filter] (1,326,014)
64. 9 and 30 and 41 and 44 and 63 [AKI ICU Risks Data sets UK] (12)
65. 19 and 30 and 45 and 63 [AKI ICU and Length of stay Discharged UK] (8)
66. 48 and 63 [AKI Risks UK Titles] (34)
67. 67 or/64–66 [Final AKI ICU Risks] (47)
Chronic kidney disease costs
Search strategy
1. Acute Disease/and exp Kidney Diseases/ (7918)
2. acute kidney injury/ (34,881)
3. kidney tubular necrosis, acute/ (2256)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (7865)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (22,132)
6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3525)
7. aki.tw. (3750)
8. ‘contrast induced nephropathy’.tw. (1033)
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9. or/1–8 (54,483)
10. reperfusion injury/ (21,228)
11. reperfusion/ (4287)
12. exp Delayed Graft Function/ (724)
13. ‘delayed graft function*’.tw. (2217)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (41,727)
15. or/10–14 (50,280)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (718,566)
17. 1 or 2 or 3 or 16 (726,662)
18. 15 and 17 (7538)
19. 9 or 18 [AKI] (60,029)
20. exp Hospitalisation/ (173,062)
21. Inpatients/ (14,410)
22. (ward or wards).tw. (39,983)
23. exp Hospitals/ (215,922)
24. hospital units/or exp intensive care units/ (70,293)
25. hospital*.tw. (830,289)
26. ‘high dependency’.tw. (789)
27. (critical adj2 care).tw. (17,765)
28. (intensive adj2 care).tw. (91,464)
29. (inpatient or inpatients).tw. (65,272)
30. or/20–29 [Hospital Wards] (1,098,124)
31. exp great britain/ (323,690)
32. (‘united king*’ or uk or ‘U.K.’ or ‘UK.’ or ‘U.K’ or britain).in,ti. (850,035)
33. (british or english or scottish or welsh or irish).in,ti. (81,795)
34. (scotland or ireland).in,ti. (86,568)
35. (england not ‘new england’).in,ti. (54,183)
36. (wales not ‘new south wales’).in,ti. (32,822)
37. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).in,ti. (685,504)
38. ((london adj2 ontario) or (london adj on) or new london).in,ti. (20,635)
39. (manchester adj3 (USA or massach*)).in,ti. (339)
40. (newcastle adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (6295)
41. (liverpool adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (1182)
42. or/38–41 (28,436)
43. 37 not 42 (657,068)
44. (nhs or ‘national health service’).in,ti. (79,247)
45. or/31–36,43–44 (1,331,854)
46. 19 and 30 and 45 (513)
47. exp ‘Costs and Cost Analysis’/ (192,502)
48. cost*.tw. (354,814)
49. budget*.tw. (18,180)
50. (price or prices or pricing).tw. (23,711)
51. (financial* adj4 burden*).tw. (2651)
52. (economic* adj4 burden*).tw. (5444)
53. expenditure*.tw. (37,118)
54. or/47–53 [Costs] (494,870)
55. 19 and 30 and 45 and 54 [AKI Wards UK Costs] (49)
56. limit 55 to yr = ’2010 -Current’ (28)
57. 19 and 30 and 54 (479)
58. limit 57 to ‘reviews (maximises specificity)’ (20)
59. 56 or 58 (48)
60. renal insufficiency, chronic/or exp kidney failure, chronic/ (90,923)
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61. Chronic Disease/and exp Kidney Diseases/ (13,363)
62. (chronic kidney or chronic renal).tw. (50,765)
63. CKD.tw. (12,350)
64. (end stage renal or end stage kidney or endstage renal or endstage kidney).tw. (27,376)
65. (ESRF or ESKF or ESRD or ESKD).tw. (11,389)
66. exp Dialysis/ (22,640)
67. renal dialysis/or hemodiafiltration/or exp peritoneal dialysis/ (98,191)
68. renal replacement therapy/ (3833)
69. h?emodialysis.tw. (59,032)
70. peritonealdialysis.tw. (8)
71. dialysis.tw. (83,548)
72. (CAPD or CCPD).tw. (6461)
73. Kidney Transplantation/ (83,562)
74. ((renal or kidney*) adj3 transplant*).tw. (65,170)
75. or/60–74 [CKD or End stage or dialysis or transplants] (299,294)
76. exp *’Costs and Cost Analysis’/ (50,115)
77. cost*.ti. (81,585)
78. budget*.ti. (4877)
79. (price or prices or pricing).ti. (6778)
80. financ*.ti. (12,421)
81. economic*.ti. (30,984)
82. expenditure*.ti. (7616)
83. or/76–82 [Cost Specific] (159,833)
84. 45 and 83 and 75 (210)
85. limit 84 to yr = ’2010 -Current’ (69)
86. 83 and 75 (2194)
87. limit 86 to ‘reviews (maximises specificity)’ (52)
88. 85 or 87 [CKD Costs Reviews or Recent UK studies] (117)
89. 88 not 59 [CKD not AKI costs] (112)
Chronic kidney disease utilities
Search strategy
1. exp great britain/ (323,690)
2. (‘united king*’ or uk or ‘U.K.’ or ‘UK.’ or ‘U.K’ or britain).in,ti. (850,035)
3. (british or english or scottish or welsh or irish).in,ti. (81,795)
4. (scotland or ireland).in,ti. (86,568)
5. (england not ‘new england’).in,ti. (54,183)
6. (wales not ‘new south wales’).in,ti. (32,822)
7. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).in,ti. (685,504)
8. ((london adj2 ontario) or (london adj on) or new london).in,ti. (20,635)
9. (manchester adj3 (USA or massach*)).in,ti. (339)
10. (newcastle adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (6295)
11. (liverpool adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (1182)
12. or/8–11 (28,436)
13. 7 not 12 (657,068)
14. (nhs or ‘national health service’).in,ti. (79,247)
15. or/1–6,13–14 (1,331,854)
16. renal insufficiency, chronic/or exp kidney failure, chronic/ (90,923)
17. Chronic Disease/and exp Kidney Diseases/ (13,363)
18. (chronic kidney or chronic renal).tw. (50,765)
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19. CKD.tw. (12,350)
20. (end stage renal or end stage kidney or endstage renal or endstage kidney).tw. (27,376)
21. (ESRF or ESKF or ESRD or ESKD).tw. (11,389)
22. exp Dialysis/ (22,640)
23. renal dialysis/or hemodiafiltration/or exp peritoneal dialysis/ (98,191)
24. renal replacement therapy/ (3833)
25. h?emodialysis.tw. (59,032)
26. peritonealdialysis.tw. (8)
27. dialysis.tw. (83,548)
28. (CAPD or CCPD).tw. (6461)
29. Kidney Transplantation/ (83,562)
30. ((renal or kidney*) adj3 transplant*).tw. (65,170)
31. or/16–30 [CKD or End stage or dialysis or transplants] (299,294)
32. exp Health Status/ (113,928)
33. ‘Quality of Life’/ (129,941)
34. ‘health status’.tw. (37,306)
35. (hql or hqol or h qol or hrqol or hr qol).tw. (8435)
36. ‘quality of life’.tw. (150,784)
37. ‘questionnaire*’.tw. (303,559)
38. or/32–37 (562,053)
39. (utility or utilities).ti. (18,818)
40. 38 and 39 (2240)
41. ((utility or utilities) adj5 (hql or hqol or h qol or hrqol or hr qol or ‘quality of life’ or health* or score*
or weight*)).ab. (4399)
42. (preference* adj5 (hql or hqol or h qol or hrqol or hr qol or ‘quality of life’ or health* or score* or
weight*)).tw. (4018)
43. (sf6d or sf 6d or short form 6d or shortform 6d or sf sixd or sf six d).tw. (477)
44. (hui or hui1 or hui2 or hui3).tw. (913)
45. ‘health utilities index*’.tw. (546)
46. quality-adjusted life-years/ (7915)
47. (qaly or ‘quality-adjusted life-year*’).tw. (7153)
48. ‘health related quality of life’.tw. (22,942)
49. (eq-5d* or eq5d* or euroqol*).tw. (4398)
50. or/40–49 [Health Utilities] (41,544)
51. 15 and 31 and 50 (98)
52. limit 51 to yr = ’2010 -Current’ (51)
53. 31 and 50 (1140)
54. limit 53 to ‘reviews (maximises specificity)’ (52)
55. 52 or 54 [CKD Health Utilities Search] (98)
56. Acute Disease/and exp Kidney Diseases/ (7918)
57. acute kidney injury/ (34,881)
58. kidney tubular necrosis, acute/ (2256)
59. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (7865)
60. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (22,132)
61. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3525)
62. aki.tw. (3750)
63. ‘contrast induced nephropathy’.tw. (1033)
64. or/56–63 (54,483)
65. reperfusion injury/ (21,228)
66. reperfusion/(4287)
67. exp Delayed Graft Function/ (724)
68. ‘delayed graft function*’.tw. (2217)
69. (reperfusion adj5 (injur* or isch?emi*)).tw. (41,727)
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70. or/65–69 (50,280)
71. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (718,566)
72. 56 or 57 or 58 or 71 (726,662)
73. 70 and 72 (7538)
74. 64 or 73 [AKI] (60,029)
75. 15 and 50 and 74 (9)
76. 50 and 74 (54)
77. limit 76 to ‘reviews (best balance of sensitivity and specificity)’ (11)
78. 75 or 77 (19)
79. 55 not 78 (96)
Chronic kidney disease risks
Search strategy
1. likelihood functions/ (18,331)
2. markov chains/ (10,769)
3. odds ratio/ (66,504)
4. proportional hazards models/ (51,509)
5. risk/ (104,119)
6. logistic models/ (100,507)
7. risk assessment/ (190,924)
8. risk factors/ (615,846)
9. ((risk or risks or odds or proportion*) adj5 (mortality or death or stage*)).ti. (9407)
10. ((incidence or prevalen*) adj5 (mortality or death or stage*)).ti. (3063)
11. or/1–10 [Risks Odds Likelihood studies] (982,161)
12. meta-analysis/ (58,864)
13. sn.fs. (568,088)
14. 12 or 13 [Data set cohort or meta analysis studies] (621,726)
15. exp great britain/ (324,006)
16. (‘united king*’ or uk or ‘U.K.’ or ‘UK.’ or ‘U.K’ or britain).in,ti. (850,727)
17. (british or english or scottish or welsh or irish).in,ti. (81,862)
18. (scotland or ireland).in,ti. (86,638)
19. (england not ‘new england’).in,ti. (54,221)
20. (wales not ‘new south wales’).in,ti. (32,839)
21. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).in,ti. (686,055)
22. ((london adj2 ontario) or (london adj on) or new london).in,ti. (20,654)
23. (manchester adj3 (USA or massach*)).in,ti. (339)
24. (newcastle adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (6308)
25. (liverpool adj4 (australia* or ‘new south wales’ or nsw)).in,ti. (1187)
26. or/22–25 (28,473)
27. 21 not 26 (657,582)
28. (nhs or ‘national health service’).in,ti. (79,391)
29. or/15–20,27–28 [UK Filter] (1,332,939)
30. renal insufficiency, chronic/or exp kidney failure, chronic/ (90,965)
31. Chronic Disease/and exp Kidney Diseases/ (13,364)
32. (chronic kidney or chronic renal).tw. (50,799)
33. CKD.tw. (12,359)
34. (end stage renal or end stage kidney or endstage renal or endstage kidney).tw. (27,394)
35. (ESRF or ESKF or ESRD or ESKD).tw. (11,393)
36. exp Dialysis/ (22,644)
37. renal dialysis/or hemodiafiltration/or exp peritoneal dialysis/ (98,226)
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38. renal replacement therapy/ (3840)
39. h?emodialysis.tw. (59,057)
40. peritonealdialysis.tw. (8)
41. dialysis.tw. (83,581)
42. (CAPD or CCPD).tw. (6461)
43. Kidney Transplantation/ (83,595)
44. ((renal or kidney*) adj3 transplant*).tw. (65,203)
45. or/30–44 [CKD] (299,421)
46. 45 and 11 and 14 and 29 [CKD and risks and data set and UK] (259)
47. ((risk or risks or odds or proportion* or incidence or prevalen*) adj8 (ckd or ‘chronic kidney’ or
‘chronic renal’)).ti. (1377)
48. ((risk or risks or odds or proportion* or incidence or prevalen*) adj8 (end stage renal or end stage
kidney or ESRF or ESKF or ESRD or ESKD)).ti. (599)
49. ((risk or risks or odds or proportion* or incidence or prevalen*) adj8 (h?emodialysis or
peritonealdialysis or dialysis or CAPD or CCPD)).ti. (1714)
50. ((risk or risks or odds or proportion* or incidence or prevalen*) adj8 (renal or kidney*) adj3
transplant*).ti. (1572)
51. or/47–50 [CKD Risks Title search] (5157)
52. 46 and 51 (29)
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Appendix 10 Search methods for early
treatment/preventative strategies for acute kidney
injury in the intensive care unit
Databases searched
l Cochrane Database of Systematic Reviews (via Wiley Online Library) (Issue 3 of 12, March 2016)
l Cochrane Central Register of Controlled Trials (via Wiley Online Library) (Issue 2 of 12, February 2016)
l EMBASE Classic+EMBASE (via Ovid) (1947 to 14 March 2016)
l Ovid MEDLINE (1946 to March Week 1 2016)
l Ovid MEDLINE In-Process & Other Non-Indexed Citations (14 March 2016).
Example MEDLINE search
(Full search strategies used in all databases are available from the authors on request.)
Search strategy
1. Acute Disease/and exp *Kidney Diseases/ (6286)
2. *acute kidney injury/ (26,908)
3. *kidney tubular necrosis, acute/ (1263)
4. (Acute adj3 (kidney disease* or kidney injury or kidney failure or kidney dysfunction)).tw. (8577)
5. (Acute adj3 (renal disease* or renal injury or renal failure or renal dysfunction)).tw. (21,792)
6. ((Acute adj3 (Tubular Necrosis or nephrotoxic*)) or ‘nephrotoxic injur*’).tw. (3501)
7. aki.tw. (4174)
8. ‘contrast induced nephropathy’.tw. (1095)
9. or/1–8 (47,456)
10. *reperfusion injury/ (16,539)
11. *reperfusion/(1162)
12. exp *Delayed Graft Function/ (429)
13. ‘delayed graft function*’.tw. (2348)
14. (reperfusion adj5 (injur* or isch?emi*)).tw. (42,315)
15. or/10–14 (47,193)
16. (renal or kidney* or nephr* or ‘tubular necrosis’ or aki).tw. (724,886)
17. 1 or 2 or 3 or 16 (729,011)
18. 15 and 17 (7293)
19. 9 or 18 [AKI] (52,903)
20. (HDU or ‘high dependency’).tw. (874)
21. (critical adj2 care).tw. (18,319)
22. (intensive adj2 care).tw. (93,030)
23. (inpatient or inpatients).tw. (66,467)
24. critical care/ (42,427)
25. critical illness/ (19,515)
26. Intensive Care/ (42,427)
27. exp intensive care units/ (62,277)
28. critical* ill*.tw. (31,178)
29. ICU.tw. (31,036)
30. or/20–29 [ICU] (235,133)
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31. early diagnosis/ (18,720)
32. (early adj3 (treatment* or intervention* or involv*)).tw. (71,209)
33. (early adj3 onset).tw. (28,860)
34. (early adj3 (therapy or therapies)).tw. (12,709)
35. (early adj4 management).tw. (10,464)
36. early initiation.tw. (2380)
37. pre-emptive.tw. (1823)
38. or/31–37 [Early treatment] (138,435)
39. 19 and 30 and 38 (232)
40. (prevent* adj3 (‘acute kidney injury’ or ‘acute kidney failure’ or ‘acute kidney disease’ or
AKI)).tw. (406)
41. acute kidney injury/pc (2634)
42. 40 or 41 [AKI prevention] (2824)
43. 30 and 42 (299)
44. 39 or 43 (505)
45. exp treatment outcome/ (738,812)
46. exp clinical trial/ (726,655)
47. effect*.ti. (1,483,694)
48. or/45–47 [Treatment effect] (2,629,847)
49. 44 and 48 [AKI ICU Early intervention or Prevention Treatment Effect] (125)
50. limit 44 to ‘reviews (best balance of sensitivity and specificity)’ (213)
51. 49 or 50 (310)
52. exp animals/not exp humans/ (4,201,019)
53. preconditioning.ti. (5874)
54. perioperative*.ti. (13,889)
55. or/52–54 [studies to remove] (4,216,305)
56. 51 not 55 (296)
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